smiles,MW,LogP,HBD,HBA,TPSA,RotBonds,AromaticRings,QED,Lipinski_Violations,scaffold,molecule_chembl_id,standard_type,standard_value,standard_units,pchembl_value,assay_chembl_id,target_chembl_id,document_chembl_id,type1_confidence,type1_reasoning
Brc1cc2c(NCc3ccccn3)ncnc2s1,321.2029999999998,3.4609000000000005,1,5,50.7,3,3,0.8025223631913365,0,c1ccc(CNc2ncnc3sccc23)nc1,CHEMBL3416616,IC50,7904.0,nM,5.1,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cc2c(NCc3cccnc3)ncnc2s1,321.2029999999998,3.4609000000000005,1,5,50.7,3,3,0.8025223631913365,0,c1cncc(CNc2ncnc3sccc23)c1,CHEMBL3416615,IC50,10000.0,nM,,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cc2c(NCc3ccncc3)ncnc2s1,321.2029999999998,3.4609000000000005,1,5,50.7,3,3,0.8025223631913365,0,c1cc(CNc2ncnc3sccc23)ccn1,CHEMBL3416614,IC50,3883.0,nM,5.41,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3[nH]ccc23)c1,289.13599999999985,3.4640000000000004,2,3,53.6,2,3,0.7592316613598842,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL5181237,IC50,3.76,nM,8.43,CHEMBL5231460,CHEMBL203,CHEMBL5230115,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Brc1cccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)c1,429.32199999999983,3.2750000000000012,2,7,75.2,6,3,0.6231140863863043,0,c1ccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)cc1,CHEMBL128987,IC50,3.2,nM,8.49,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3cc4[nH]nnc4cc23)c1,341.1719999999999,3.4072000000000005,2,5,79.38000000000001,2,4,0.5841120308083241,0,c1ccc(Nc2ncnc3cc4[nH]nnc4cc23)cc1,CHEMBL172652,IC50,4.1,nM,8.39,CHEMBL679548,CHEMBL203,CHEMBL1129035,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3cccnc23)c1,301.1469999999998,3.530900000000001,1,4,50.7,2,3,0.7864226288611571,0,c1ccc(Nc2ncnc3cccnc23)cc1,CHEMBL54805,IC50,34.0,nM,7.47,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3ccncc23)c1,301.1469999999999,3.530900000000001,1,4,50.7,2,3,0.7864226288611571,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL52665,IC50,35.0,nM,7.46,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3ccncc23)c1NCCN1CCOCC1,429.32199999999983,3.2750000000000004,2,7,75.2,6,3,0.6231140863863042,0,c1ccc(Nc2ncnc3ccncc23)c(NCCN2CCOCC2)c1,CHEMBL405398,IC50,3.236,nM,8.49,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)nc23)c1,444.3369999999998,3.0601000000000003,2,8,88.09,7,3,0.5380965898414123,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)nc23)cc1,CHEMBL417420,IC50,2.9,nM,8.54,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,429.32199999999983,3.2750000000000012,2,7,75.2,6,3,0.6231140863863042,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1,CHEMBL162622,IC50,0.65,nM,9.19,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)c1,430.30999999999983,2.67,2,8,88.09,6,3,0.6174903737511086,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)cc1,CHEMBL294475,IC50,0.81,nM,9.09,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)c1,411.2669999999999,3.3035999999999994,3,7,104.30000000000001,6,4,0.44725881605236345,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)cc1,CHEMBL53426,IC50,0.25,nM,9.6,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Brc1cccc(Nc2ncnc3cnc(NCCn4ccnc4)nc23)c1,411.2669999999999,3.2344999999999997,2,8,93.44,6,4,0.5032385939614786,0,c1ccc(Nc2ncnc3cnc(NCCn4ccnc4)nc23)cc1,CHEMBL271328,IC50,2.344,nM,8.63,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3cnccc23)c1,301.1469999999999,3.530900000000001,1,4,50.7,2,3,0.7864226288611571,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL51265,IC50,51.0,nM,7.29,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2ncnc3ncccc23)c1,301.1469999999999,3.530900000000001,1,4,50.7,2,3,0.7864226288611571,0,c1ccc(Nc2ncnc3ncccc23)cc1,CHEMBL54475,IC50,688.0,nM,6.16,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Brc1cccc(Nc2nnnc3ccccc23)c1,301.1469999999999,3.530900000000001,1,4,50.7,2,3,0.7864226288611571,0,c1ccc(Nc2nnnc3ccccc23)cc1,CHEMBL119758,IC50,1000.0,nM,,CHEMBL677204,CHEMBL203,CHEMBL1128536,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1,455.4739999999999,2.7882000000000007,2,6,114.94999999999999,7,4,0.4340502672809981,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CNC5)c4[nH]3)cc2)cc1,CHEMBL4867893,IC50,88.3,nM,7.05,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1,425.44799999999987,2.779600000000001,2,5,105.72,5,4,0.4797299100942174,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CNC5)c4[nH]3)cc2)cc1,CHEMBL4863088,IC50,33.8,nM,7.47,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1,457.46499999999986,3.3088000000000015,2,5,105.72,5,4,0.44867164059769554,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1,CHEMBL4852264,IC50,38.6,nM,7.41,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)CC1,483.52799999999985,3.5684000000000022,2,6,114.94999999999999,7,4,0.40706427045626475,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1,CHEMBL4856592,IC50,50.8,nM,7.29,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1,439.47499999999985,3.1697000000000015,2,5,105.72,5,4,0.4660327838267861,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1,CHEMBL4875332,IC50,29.7,nM,7.53,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1,453.50199999999984,3.559800000000002,2,5,105.72,5,4,0.4508201409129321,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1,CHEMBL4871192,IC50,30.8,nM,7.51,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)C1,469.50099999999986,3.178300000000001,2,6,114.94999999999999,7,4,0.42108998781563867,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1,CHEMBL4873984,IC50,104.0,nM,6.98,CHEMBL4843876,CHEMBL203,CHEMBL4842353,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,368.1939999999999,3.1026000000000016,2,5,79.8,3,3,0.694863572755517,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL378144,IC50,0.6,nM,9.22,CHEMBL862512,CHEMBL203,CHEMBL1138126,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#CCCn1cc(Nc2nc(OC[C@H]3CN(C(=O)C=C)C[C@@H]3OC)c3c(Cl)c[nH]c3n2)cn1,469.93299999999977,2.6129,2,8,110.19,10,3,0.3658328805466014,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786812,Ki,10.0,nM,8.0,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1F,323.32699999999977,3.511000000000002,1,5,56.27000000000001,6,3,0.744696458691166,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL65250,IC50,4.0,nM,8.4,CHEMBL678292,CHEMBL203,CHEMBL1135760,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2,312.3319999999998,2.9044800000000004,1,4,74.59,3,3,0.5775163837196398,0,c1cncc(-c2n[nH]c3c2Cc2ccccc2-3)c1,CHEMBL1972250,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(-n2ccc3cc(OC)cc(O)c3c2=O)c1,291.30599999999976,2.6862000000000013,1,4,51.46,4,3,0.7385528683433785,0,O=c1c2ccccc2ccn1-c1ccccc1,CHEMBL2442327,IC50,3060.0,nM,5.51,CHEMBL2446217,CHEMBL203,CHEMBL2440093,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(-n2ccc3cc(OC)cc(OC)c3c2=O)c1,305.33299999999974,2.989200000000001,0,4,40.46,5,3,0.6984943156984673,0,O=c1c2ccccc2ccn1-c1ccccc1,CHEMBL2442319,IC50,3510.0,nM,5.46,CHEMBL2446217,CHEMBL203,CHEMBL2440093,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C#Cc1cccc(Nc2nc(C)nc3oc(C)cc23)c1,263.2999999999999,3.564540000000002,1,4,50.95,4,3,0.7180811574505639,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL3297892,IC50,30.0,nM,7.52,CHEMBL3299340,CHEMBL203,CHEMBL3297731,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2nc(N)nc3[nH]c(CCc4ccccn4)cc23)c1,354.4169999999998,3.4452000000000016,3,5,92.51,6,4,0.47748618029442474,0,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1,CHEMBL2335379,IC50,19900.0,nM,4.7,CHEMBL2343569,CHEMBL203,CHEMBL2331499,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC(C)COC)c4c(c23)OCCO4)c1,391.4269999999998,3.539600000000002,1,7,74.73000000000002,8,3,0.6443458926588158,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805584,IC50,76.1,nM,7.12,CHEMBL3807187,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1,305.33699999999976,3.371900000000002,1,5,56.27000000000001,6,3,0.7489468819361764,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL304929,Kd,0.55,nM,9.26,CHEMBL4394506,CHEMBL203,CHEMBL4393671,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC)c(OCC(=O)NO)cc23)c1,364.3609999999998,2.2475000000000005,3,7,105.60000000000001,8,3,0.34988152031200914,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3896110,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCC(=O)NO)cc23)c1,378.3879999999998,2.6376,3,7,105.60000000000001,9,3,0.32964858041912204,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3976436,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCN4CCOCC4)cc23)c1,418.49699999999973,3.464400000000002,1,7,68.74000000000001,9,3,0.4437567149339546,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1,CHEMBL5281903,IC50,0.81,nM,9.09,CHEMBL5230898,CHEMBL203,CHEMBL5230100,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC)c4c(c23)OCCO4)c1,333.3469999999998,3.134500000000002,1,6,65.50000000000001,4,3,0.7430098989992114,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805236,IC50,10.9,nM,7.96,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)c1,389.41099999999983,3.2936000000000014,1,7,74.73000000000002,4,3,0.6864585684338103,0,c1ccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)cc1,CHEMBL3806170,IC50,16.7,nM,7.78,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OCC)c4c(c23)OCCO4)c1,347.3739999999998,3.524600000000002,1,6,65.50000000000001,5,3,0.7286030310120791,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805039,IC50,9.2,nM,8.04,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc(OCCO)c(OCCOC)cc23)c1,379.41599999999977,2.7510000000000012,2,7,85.73000000000002,11,3,0.43668147159238385,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3741490,IC50,1.0,nM,9.0,CHEMBL3745491,CHEMBL203,CHEMBL3739340,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(NC(=O)C=C)cc23)c1,388.4269999999998,3.504400000000002,2,6,85.37,9,3,0.3489879013981771,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3622617,IC50,1.8,nM,8.74,CHEMBL3625155,CHEMBL203,CHEMBL3621102,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,393.44299999999976,3.405100000000002,1,7,74.73000000000002,12,3,0.4178840975839869,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL553,IC50,0.029,nM,10.54,CHEMBL5260455,CHEMBL203,CHEMBL5257147,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c4c(c23)OCCO4)c1,377.3999999999998,3.1511000000000013,1,7,74.73000000000002,7,3,0.5223856081627517,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805461,IC50,8.1,nM,8.09,CHEMBL3807187,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,457.53399999999976,3.578700000000002,2,7,88.61,10,3,0.3948337610217401,0,c1ccc(Nc2ncnc3cc(OC4CCOC4)ccc23)cc1,CHEMBL3622645,IC50,1.2,nM,8.92,CHEMBL3625155,CHEMBL203,CHEMBL3621102,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(C)C)CCCO4)c1,427.50799999999975,3.5880000000000027,1,6,70.59,7,3,0.4957558737690949,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCCO4)cc1,CHEMBL3114698,IC50,10000.0,nM,,CHEMBL3118715,CHEMBL203,CHEMBL3112407,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(C)C)CCO4)c1,413.48099999999977,3.1979000000000024,1,6,70.59,7,3,0.5117397632987148,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1,CHEMBL3114690,IC50,3.0,nM,8.52,CHEMBL3118714,CHEMBL203,CHEMBL3112407,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCN(C)CC2)CCCO4)c1,482.58799999999974,3.2738000000000023,1,7,73.83000000000001,6,3,0.4419950526954336,0,O=C(/C=C/CN1CCNCC1)N1CCCOc2cc3ncnc(Nc4ccccc4)c3cc21,CHEMBL3114692,IC50,10000.0,nM,,CHEMBL3118715,CHEMBL203,CHEMBL3112407,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCN(C)CC2)CCO4)c1,468.56099999999975,2.883700000000002,1,7,73.83000000000001,6,3,0.45598049240227534,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21,CHEMBL3114689,IC50,16.0,nM,7.8,CHEMBL3118714,CHEMBL203,CHEMBL3112407,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCOCC2)CCCO4)c1,469.5449999999998,3.3586000000000027,1,7,79.82000000000001,5,3,0.4534308037858204,0,O=C(/C=C/CN1CCOCC1)N1CCCOc2cc3ncnc(Nc4ccccc4)c3cc21,CHEMBL3114691,IC50,10000.0,nM,,CHEMBL3118715,CHEMBL203,CHEMBL3112407,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCOCC2)CCO4)c1,455.5179999999998,2.9685000000000015,1,7,79.82000000000001,5,3,0.46805814369874327,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21,CHEMBL3114699,IC50,12.0,nM,7.92,CHEMBL3118714,CHEMBL203,CHEMBL3112407,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)c1,443.5069999999998,2.8024000000000013,1,7,79.82000000000001,6,3,0.5870697506280481,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774926,IC50,139.0,nM,6.86,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,303.3209999999998,3.1259000000000015,1,5,56.27000000000001,2,3,0.7371467439211692,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1,CHEMBL4453068,IC50,48.7,nM,7.31,CHEMBL4730561,CHEMBL203,CHEMBL4725422,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,321.3109999999998,3.2650000000000015,1,5,56.27000000000001,2,3,0.7342836144965219,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1,CHEMBL4750375,IC50,19.7,nM,7.71,CHEMBL4730561,CHEMBL203,CHEMBL4725422,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,391.4269999999998,3.1591000000000014,1,7,74.73000000000002,2,3,0.6727670764195051,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1,CHEMBL2087361,IC50,2.0,nM,8.7,CHEMBL2090277,CHEMBL203,CHEMBL2086389,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,429.47999999999985,2.9849000000000014,1,8,85.42000000000002,6,4,0.47176473734718594,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064373,IC50,380.0,nM,6.42,CHEMBL2066000,CHEMBL203,CHEMBL2062376,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCOC)c4cc23)c1,360.3729999999999,2.9090000000000007,1,7,82.18000000000002,6,4,0.5512278621533081,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612562,IC50,190.0,nM,6.72,CHEMBL3614855,CHEMBL203,CHEMBL3611993,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3ccc(NC(C)=O)cc23)c1,302.33699999999976,3.3131000000000013,2,4,66.91,4,3,0.7284032109884782,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3815074,IC50,2.04,nM,8.69,CHEMBL3815405,CHEMBL203,CHEMBL3813636,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3ccc(NC(N)=O)cc23)c1,303.3249999999998,2.8453,3,4,92.93,3,3,0.6485795975637998,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3814447,IC50,2.22,nM,8.65,CHEMBL3815405,CHEMBL203,CHEMBL3813636,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3ccc(OCC(=O)NO)cc23)c1,334.3349999999998,2.2388999999999992,3,6,96.37000000000002,6,3,0.37612339441072723,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3959855,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1,438.5529999999997,3.1479000000000017,2,7,93.21000000000001,12,3,0.35085031786826787,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL517907,IC50,10.96,nM,7.96,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)c1,346.4379999999997,2.377300000000001,2,6,71.48,5,3,0.7098859212371298,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645466,IC50,10.0,nM,8.0,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1cccc(Nc2ncnn3ccc(COC[C@@H]4CNCCO4)c23)c1,363.4209999999997,1.9591999999999998,2,7,72.71000000000001,6,3,0.6525484113515188,0,c1ccc(Nc2ncnn3ccc(COCC4CNCCO4)c23)cc1,CHEMBL1645465,IC50,670.0,nM,6.17,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C#Cc1nn([C@@H]2CCCN(C(=O)C=C)C2)c2ncnc(N)c12,296.33399999999966,0.7393000000000001,1,6,89.93,3,2,0.6518313410568409,0,c1ncc2cnn(C3CCCNC3)c2n1,CHEMBL4071151,IC50,690.0,nM,6.16,CHEMBL4041414,CHEMBL203,CHEMBL4038351,0.7,Activity in Type 1 range; Activity in typical Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)N(C)C)cc2)cc1.Cl,452.95999999999975,2.8784000000000023,0,6,83.99,12,2,0.34764882242672274,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL552634,IC50,700.0,nM,6.16,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)O)c(O)c2)cc1,405.4279999999998,2.1586,2,8,121.21000000000001,11,2,0.3892922398258367,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL310580,IC50,470.0,nM,6.33,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)O)cc2)cc1,389.4289999999998,2.4530000000000003,1,7,100.98,10,2,0.42032345885441846,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL80030,IC50,230.0,nM,6.64,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=C(CN1CCNCC1)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,372.89599999999956,3.3315000000000023,1,4,41.57000000000001,7,2,0.5975994126246481,0,C=C(CN1CCNCC1)C(=O)c1ccc(OCc2ccccc2)cc1,CHEMBL544538,IC50,1500.0,nM,5.82,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N(C)CCOc1c(N)ncnc1-c1ccc(CN2CCN(CC(C)C)CC2=O)c(C)c1,480.61299999999966,2.35762,1,7,104.88999999999999,15,2,0.5206143961687842,0,O=C1CNCCN1Cc1ccc(-c2ccncn2)cc1,CHEMBL5188786,Kd,30000.0,nM,4.52,CHEMBL5133814,CHEMBL203,CHEMBL5131445,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,414.4689999999997,3.512200000000001,1,7,99.16,9,4,0.46472973378772864,0,c1ccc(Oc2ccc(-c3n[nH]c4ncncc34)cc2)cc1,CHEMBL3921017,IC50,28.22,nM,7.55,CHEMBL3888240,CHEMBL203,CHEMBL3886627,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1,443.5069999999997,3.442400000000002,2,6,102.48000000000002,6,3,0.5683830521183324,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CNC3)CCN4)cc2)cc1,CHEMBL3965549,IC50,2.1,nM,8.68,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC(Oc2cc3c(N[C@H](C)c4ccccc4)ncnc3cc2OC)C1,404.4699999999997,3.587100000000002,1,6,76.58,9,3,0.606739434178486,0,c1ccc(CNc2ncnc3ccc(OC4CNC4)cc23)cc1,CHEMBL3926558,IC50,6.0,nM,8.22,CHEMBL3882125,CHEMBL203,CHEMBL3881529,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(C)c(C)c(C)c4)nn32)CC1,421.5449999999996,3.3555600000000023,2,5,93.25,7,2,0.7405569485369381,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5265797,IC50,2458.0,nM,5.61,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(Br)c(OC)c4)nn32)CC1,518.412,3.2100000000000017,2,7,111.71000000000001,8,2,0.5685905103551407,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5286702,IC50,1999.0,nM,5.7,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(C(C)C)c(OC)c4)nn32)CC1,481.59699999999964,3.5709000000000026,2,7,111.71000000000001,11,2,0.5850024756338598,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5278071,IC50,1000.0,nM,,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,453.54299999999967,2.7559200000000015,2,7,111.71000000000001,9,2,0.650793253178239,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5266481,IC50,3326.0,nM,5.48,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(C5CC5)c(OC)c4)nn32)CC1,479.5809999999997,3.324900000000002,2,7,111.71000000000001,9,2,0.5894843546605542,0,c1cc(C2CC2)ccc1-c1cc2n(n1)C(C1CCNCC1)CCN2,CHEMBL5267491,IC50,1000.0,nM,,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(CC)c(OC)c4)nn32)CC1,467.56999999999965,3.009900000000002,2,7,111.71000000000001,10,2,0.6057157778234471,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5269683,IC50,1000.0,nM,,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(CCC)c(OC)c4)nn32)CC1,481.59699999999964,3.400000000000002,2,7,111.71000000000001,11,2,0.5591812162245903,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5271932,IC50,1000.0,nM,,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(Cl)c(OC)c4)nn32)CC1,473.96099999999973,3.100900000000002,2,7,111.71000000000001,8,2,0.6233442286918083,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5289250,IC50,1760.0,nM,5.75,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5c(c4)OCC5(C)C)nn32)CC1,479.5809999999997,3.108900000000002,2,7,111.71000000000001,8,2,0.637664889960597,0,c1cc2c(cc1-c1cc3n(n1)C(C1CCNCC1)CCN3)OCC2,CHEMBL5268388,IC50,129.0,nM,6.89,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5ccoc5c4)nn32)CC1,449.51099999999974,3.185100000000002,2,7,115.62,6,3,0.5782199823924515,0,c1cc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2o1,CHEMBL5288582,IC50,271.0,nM,6.57,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Cn2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,517.634,2.638420000000001,1,9,95.83,10,3,0.47821125548145343,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1CC1CCNC1,CHEMBL4099008,IC50,63.8,nM,7.2,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1,405.4579999999997,2.833800000000001,1,7,95.5,5,3,0.6708634703512238,0,c1ncc2c(-c3ccc4c(c3)OCO4)cn(CC3CCNCC3)c2n1,CHEMBL4755698,IC50,10000.0,nM,,CHEMBL4720222,CHEMBL203,CHEMBL4715815,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N(C)CCN(C)C)cc3OC)nc3[nH]ccc23)CC1,493.6119999999997,3.263700000000001,2,8,98.85000000000002,14,3,0.4154765794114129,0,c1ccc(Nc2nc(OC3CCNCC3)c3cc[nH]c3n2)cc1,CHEMBL5198920,IC50,7.696,nM,8.11,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)nc3[nH]ccc23)CC1,519.6060000000002,2.9344,2,8,115.92000000000002,9,3,0.45805178992183443,1,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1,CHEMBL5189711,IC50,31.35,nM,7.5,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)CC1,479.5599999999997,3.148200000000001,2,7,89.62,7,3,0.5252246899647924,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1,CHEMBL5192155,IC50,13.42,nM,7.87,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)ncc2Cl)CC1,474.96799999999973,3.3203000000000022,1,7,73.83000000000001,7,2,0.6435963307998741,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1,CHEMBL5203195,IC50,9.6,nM,8.02,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3[nH]ccc23)CC1,461.5699999999997,3.009100000000001,2,7,89.62,7,3,0.5456348750438323,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1,CHEMBL5208416,IC50,5.681,nM,8.25,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)CC1,456.97799999999967,3.1812000000000014,1,7,73.83000000000001,7,2,0.6689220324418644,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1,CHEMBL5183664,IC50,20.1,nM,7.7,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc3[nH]ccc23)CC1,491.5959999999997,3.0177000000000005,2,8,98.85000000000002,9,3,0.48694979387021103,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1,CHEMBL5205097,IC50,12.32,nM,7.91,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(CCO)CC4)cc3)ncc2Cl)CC1,487.00399999999973,2.5437000000000003,2,8,94.06000000000002,9,2,0.5497074524543631,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1,CHEMBL5199354,IC50,42.06,nM,7.38,CHEMBL5099547,CHEMBL203,CHEMBL5096223,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(Oc2nc(Nc3ccn(C)n3)nc3ccsc23)CC1,384.46499999999975,2.7242000000000006,1,8,85.17,6,3,0.6810376619277926,0,c1cc(Nc2nc(OC3CCNCC3)c3sccc3n2)n[nH]1,CHEMBL5184048,IC50,126.0,nM,6.9,CHEMBL5099547,CHEMBL203,CHEMBL5096223,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(Oc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)CC1,367.4129999999997,1.9907999999999995,2,7,100.96000000000001,6,3,0.6690190779887693,0,c1cc2c(OC3CCNCC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL5208549,IC50,203.8,nM,6.69,CHEMBL5099547,CHEMBL203,CHEMBL5096223,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(Oc2nc(Nc3cnn(C)c3)nc3ccsc23)CC1,384.46499999999975,2.7242000000000006,1,8,85.17,6,3,0.6810376619277926,0,c1cc2nc(Nc3cn[nH]c3)nc(OC3CCNCC3)c2s1,CHEMBL5171318,IC50,135.0,nM,6.87,CHEMBL5099547,CHEMBL203,CHEMBL5096223,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC([C@@H]2CCNC3C(C(N)=O)C(c4ccc(Oc5ccccc5)cc4)=NN32)CC1,473.5769999999997,2.7127000000000008,2,6,100.26,6,2,0.6286835231771484,0,c1ccc(Oc2ccc(C3=NN4C(C3)NCCC4C3CCNCC3)cc2)cc1,CHEMBL5193128,IC50,21.0,nM,7.68,CHEMBL5127259,CHEMBL203,CHEMBL5126513,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(Br)c(OC)c4)nn32)CC1,518.412,3.2100000000000017,2,7,111.71000000000001,8,2,0.5685905103551407,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5275348,IC50,1092.0,nM,5.96,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,453.54299999999967,2.7559200000000015,2,7,111.71000000000001,9,2,0.650793253178239,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1,CHEMBL5276374,IC50,621.0,nM,6.21,CHEMBL5251914,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C5CC5)c(OC)c4)nn32)CC1,479.5809999999997,3.324900000000002,2,7,111.71000000000001,9,2,0.5894843546605542,0,c1cc(C2CC2)ccc1-c1cc2n(n1)C(C1CCNCC1)CCN2,CHEMBL5288751,IC50,450.0,nM,6.35,CHEMBL5251900,CHEMBL203,CHEMBL5247657,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(C)c3)c(C(N)=O)nc2CC)CC1,574.774000000002,3.2981200000000026,2,8,110.93000000000002,11,2,0.4624218226121199,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1,CHEMBL3663925,IC50,1.1,nM,8.96,CHEMBL3705896,CHEMBL203,CHEMBL3638445,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)CC1,560.747000000002,2.989700000000002,2,8,110.93000000000002,10,2,0.474416259030911,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1,CHEMBL3663933,IC50,1.3,nM,8.89,CHEMBL3705896,CHEMBL203,CHEMBL3638445,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC(n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)CC1,517.634,2.9534200000000013,1,9,95.83,9,3,0.4989633156292973,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCNCC1,CHEMBL4101484,IC50,1000.0,nM,,CHEMBL4001767,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CCC(n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,384.44299999999976,3.1881000000000004,1,6,89.93,4,4,0.5480229427026876,0,c1ccc2ncc(-c3cn(C4CCNC4)c4ncncc34)cc2c1,CHEMBL5265881,IC50,1.2,nM,8.92,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(-c4ccc5c(c4)OCO5)n3)[nH]c12,457.4899999999998,2.657,2,6,109.44,3,3,0.5855442730575131,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(-c4ccc5c(c4)OCO5)n3)cc21,CHEMBL5085136,IC50,6.5,nM,8.19,CHEMBL5029924,CHEMBL203,CHEMBL5029169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(-c4cccc(OC)c4)n3)[nH]c12,443.5069999999997,2.9369000000000005,2,5,100.21000000000001,5,3,0.6041835139452211,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(-c4ccccc4)n3)cc21,CHEMBL5083976,IC50,9.6,nM,8.02,CHEMBL5029924,CHEMBL203,CHEMBL5029169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(Nc4ccccc4OC)n3)[nH]c12,458.5219999999997,3.0135000000000005,3,6,112.24000000000001,6,3,0.5069447899349374,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21,CHEMBL5077776,IC50,0.4,nM,9.4,CHEMBL5029925,CHEMBL203,CHEMBL5029169,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3nc(Nc4ccccc4OC)ncc3C)[nH]c12,472.54899999999975,3.3219200000000013,3,6,112.24000000000001,7,3,0.49134433323029975,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21,CHEMBL5085118,IC50,1.2,nM,8.92,CHEMBL5029924,CHEMBL203,CHEMBL5029169,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCCC(n2nc(-c3ccc4ccccc4c3)c3c(N)ncnc32)C1,398.4699999999997,3.5782000000000016,1,6,89.93,4,4,0.5329021216600256,0,c1ccc2cc(-c3nn(C4CCCNC4)c4ncncc34)ccc2c1,CHEMBL5203640,IC50,88.0,nM,7.06,CHEMBL5097728,CHEMBL203,CHEMBL5096180,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Br)ccn3)cc2)c(C(N)=O)n1N,538.4060000000011,3.012199999999999,3,7,149.23000000000002,7,3,0.324576242255069,1,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4878421,IC50,578.0,nM,6.24,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N,527.5070000000006,3.2685000000000013,3,7,149.23000000000002,7,3,0.3309161170948711,1,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4864983,IC50,433.0,nM,6.36,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Cl)ccn3)cc2)c(C(N)=O)n1N,493.9549999999998,2.9030999999999993,3,7,149.23000000000002,7,3,0.3547222894549624,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4860527,IC50,176.0,nM,6.75,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(OC)ccn3)cc2)c(C(N)=O)n1N,489.5359999999998,2.2582999999999998,3,8,158.46,9,3,0.3390244804013255,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4874550,IC50,450.0,nM,6.35,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(C)c3)c(C(N)=O)nc2CC)C1,590.7730000000021,2.961920000000002,2,9,120.16000000000001,12,2,0.4249232230485927,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(OC2CCCNC2)n1,CHEMBL3663936,IC50,1.2,nM,8.92,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,576.746000000002,2.653500000000002,2,9,120.16000000000001,11,2,0.4342839283105772,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(OC2CCCNC2)n1,CHEMBL3663935,IC50,1.3,nM,8.89,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(C(F)(F)F)cc3)c3c(N)ncnc32)C1,416.40699999999975,3.4438000000000013,1,6,89.93,4,3,0.6608856734582172,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL2180203,IC50,60.0,nM,7.22,CHEMBL4041412,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(F)cc3)c3c(N)ncnc32)C1,366.3999999999997,2.5641,1,6,89.93,4,3,0.7197084247985834,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4062509,IC50,30.0,nM,7.52,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O)cc3)c3c(N)ncnc32)C1,364.40899999999965,2.1305999999999994,2,7,110.16,5,3,0.6890368531613745,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4072299,IC50,3.0,nM,8.52,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc4ccccc4c3)c3c(N)ncnc32)C1,398.4699999999997,3.5782000000000016,1,6,89.93,4,4,0.5329021216600256,0,c1ccc2cc(-c3nn(C4CCCNC4)c4ncncc34)ccc2c1,CHEMBL4090601,IC50,1.0,nM,9.0,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(F)(F)F)c3)c3c(N)ncnc32)C1,416.40699999999975,3.4438000000000013,1,6,89.93,4,3,0.6608856734582172,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL2180204,IC50,30.0,nM,7.52,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(F)c3)c3c(N)ncnc32)C1,366.3999999999997,2.5641,1,6,89.93,4,3,0.7197084247985834,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4100655,IC50,10.0,nM,8.0,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc4ccccc34)c3c(N)ncnc32)C1,398.4699999999997,3.5782000000000016,1,6,89.93,4,4,0.5329021216600256,0,c1ccc2c(-c3nn(C4CCCNC4)c4ncncc34)cccc2c1,CHEMBL4095447,IC50,1.0,nM,9.0,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,348.4099999999996,2.4250000000000007,1,6,89.93,4,3,0.7342877988013325,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4099713,IC50,10.0,nM,8.0,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4ccc(C(C)=O)cc4)nn3)c3c(N)ncnc32)C1,457.49799999999976,2.2083000000000004,1,10,137.71,7,4,0.35557531405017345,0,c1ccc(-n2cc(-c3nn(C4CCCNC4)c4ncncc34)nn2)cc1,CHEMBL4581088,IC50,1000.0,nM,5.1,CHEMBL4481538,CHEMBL203,CHEMBL4480410,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(C)c4ccccc34)c3c(N)ncnc32)C1,401.4739999999997,2.9167000000000005,1,7,94.86,5,4,0.5327667111401849,0,c1ccc2c(-c3nn(C4CCCNC4)c4ncncc34)c[nH]c2c1,CHEMBL4094959,IC50,1.9,nM,8.72,CHEMBL5243475,CHEMBL203,CHEMBL5241118,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)C1,388.4349999999997,2.3013000000000003,2,7,118.61,4,4,0.5199502700398929,0,c1ncc2c(-c3cnc4[nH]ccc4c3)nn(C3CCCNC3)c2n1,CHEMBL4103201,IC50,2.0,nM,8.7,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(C#CC3CCCC3)c3c(N)ncnc32)C1,364.4529999999996,2.2997000000000005,1,6,89.93,3,2,0.652233595465767,0,C(#CC1CCCC1)c1nn(C2CCCNC2)c2ncncc12,CHEMBL4082783,IC50,60.0,nM,7.22,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(C#CCC3CCCC3)c3c(N)ncnc32)C1,378.47999999999956,2.689800000000001,1,6,89.93,4,2,0.6550407293680363,0,C(#Cc1nn(C2CCCNC2)c2ncncc12)CC1CCCC1,CHEMBL4069586,IC50,120.0,nM,6.92,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(C3CC3)c3c(N)ncnc32)C1,312.3769999999996,1.6354,1,6,89.93,4,2,0.8700949242459614,0,c1ncc2c(C3CC3)nn(C3CCCNC3)c2n1,CHEMBL4099254,IC50,110.0,nM,6.96,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(Cc3ccccc3)c3c(N)ncnc32)C1,362.4369999999996,2.3488000000000007,1,6,89.93,5,3,0.7196805654670293,0,c1ccc(Cc2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4060919,IC50,3.0,nM,8.52,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCC[C@@H](n2nc(I)c3c(N)ncnc32)C1,398.2079999999998,1.3626,1,6,89.93,3,2,0.6097633001574244,0,c1ncc2cnn(C3CCCNC3)c2n1,CHEMBL4091966,IC50,20.0,nM,7.7,CHEMBL4041414,CHEMBL203,CHEMBL4038351,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@@H](n2ncc3c(N)ncnc32)C1,272.31199999999967,0.7579999999999997,1,6,89.93,3,2,0.8149832454485963,0,c1ncc2cnn(C3CCCNC3)c2n1,CHEMBL4094527,IC50,1600.0,nM,5.8,CHEMBL4041414,CHEMBL203,CHEMBL4038351,0.5,Activity in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,456.5059999999998,3.3062000000000014,1,8,108.27,6,4,0.4617792234701749,0,O=c1n(-c2ccc(Oc3ccccc3)cc2)c2cncnc2n1C1CCCNC1,CHEMBL3991931,Kd,19.0,nM,7.72,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCC[C@H](n2nc(C(=O)c3ccc(CC(=O)N(C)C)c(C)c3C)c3c(N)ncnc32)C1,489.57999999999964,2.2365399999999998,1,8,127.31,11,3,0.4154212853964886,0,O=C(c1ccccc1)c1nn(C2CCCNC2)c2ncncc12,CHEMBL5286014,IC50,65.0,nM,7.19,CHEMBL5243471,CHEMBL203,CHEMBL5241118,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C1,401.8579999999997,2.5016999999999996,2,7,100.96000000000001,7,3,0.6152753082763192,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786858,Ki,8.0,nM,8.1,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)C1,367.4129999999997,1.8482999999999994,2,7,100.96000000000001,7,3,0.6449934709879654,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3787327,Ki,590.0,nM,6.23,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@@H](Nc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,489.62799999999964,3.101400000000001,2,9,94.45,10,3,0.4892150732962437,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(NC3CCNC3)nc2[nH]1,CHEMBL4206312,IC50,29.0,nM,7.54,CHEMBL4178351,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@@H](Nc2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C1,395.4709999999997,2.083099999999999,2,9,105.79,9,3,0.6156472729568838,0,c1nc2c(Nc3cn[nH]c3)nc(NC3CCNC3)nc2[nH]1,CHEMBL4209368,Ki,105.0,nM,6.98,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@@H](Nc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C1,386.8469999999998,2.2871999999999995,3,7,103.76000000000002,6,3,0.5810845513602282,0,c1cc2c(NC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL4206481,Ki,4.0,nM,8.4,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,562.719000000002,2.2634000000000016,2,9,120.16000000000001,11,2,0.4436135841954446,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(OC2CCNC2)n1,CHEMBL3663929,IC50,1.7,nM,8.77,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@@H](n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,503.60699999999974,2.56332,1,9,95.83,9,3,0.5131228882201051,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCNC1,CHEMBL4073062,IC50,436.3,nM,6.36,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@@H](n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,384.44299999999976,3.1881000000000004,1,6,89.93,4,4,0.5480229427026876,0,c1ccc2ncc(-c3cn(C4CCNC4)c4ncncc34)cc2c1,CHEMBL5291403,IC50,0.4,nM,9.4,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@@H](n2nc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,385.43099999999976,2.5831,1,7,102.82000000000001,4,4,0.5438754060502426,0,c1ccc2ncc(-c3nn(C4CCNC4)c4ncncc34)cc2c1,CHEMBL5291034,IC50,5.4,nM,8.27,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@H](N2C(=O)N(C(C)C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,534.665000000001,2.9179000000000013,1,8,97.38,11,2,0.5419769281187289,1,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1C1CCNC1,CHEMBL3087201,IC50,864.0,nM,6.06,CHEMBL3088813,CHEMBL203,CHEMBL3085739,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@H](N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,506.6109999999997,2.1393000000000004,1,8,97.38,9,2,0.5956101658784271,1,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1C1CCNC1,CHEMBL3087202,IC50,525.0,nM,6.28,CHEMBL3088813,CHEMBL203,CHEMBL3085739,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@H](N2C(=O)N(C3CCCC3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,560.7030000000019,3.4521000000000015,1,8,97.38,9,2,0.5147175454707673,1,O=C1N(C2CCCC2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1C1CCNC1,CHEMBL3087199,IC50,58.7,nM,7.23,CHEMBL3088813,CHEMBL203,CHEMBL3085739,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@H](Nc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,489.62799999999964,3.101400000000001,2,9,94.45,10,3,0.4892150732962437,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(NC3CCNC3)nc2[nH]1,CHEMBL4213741,Ki,164.0,nM,6.79,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@H](n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,503.60699999999974,2.56332,1,9,95.83,9,3,0.5131228882201051,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCNC1,CHEMBL4093766,IC50,91.8,nM,7.04,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@H](n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,384.44299999999976,3.1881000000000004,1,6,89.93,4,4,0.5480229427026876,0,c1ccc2ncc(-c3cn(C4CCNC4)c4ncncc34)cc2c1,CHEMBL5289003,IC50,111.0,nM,6.96,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@H](n2nc(-c3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,394.4349999999997,2.0520999999999994,1,8,108.39,8,3,0.659834319768646,0,c1ccc(-c2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL5284165,IC50,5000.0,nM,,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@H](n2nc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,385.43099999999976,2.5831,1,7,102.82000000000001,4,4,0.5438754060502426,0,c1ccc2ncc(-c3nn(C4CCNC4)c4ncncc34)cc2c1,CHEMBL5272088,IC50,741.0,nM,6.13,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,418.4569999999997,1.7849,1,8,108.39,7,3,0.5081726960704563,0,C(#Cc1nn(C2CCNC2)c2ncncc12)c1ccccc1,CHEMBL3701238,IC50,5000.0,nM,,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CC[C@H](n2nc(C(=O)Nc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,437.45999999999975,1.6373999999999995,2,9,137.49,9,3,0.5552913664362631,0,O=C(Nc1ccccc1)c1nn(C2CCNC2)c2ncncc12,CHEMBL5275918,IC50,5000.0,nM,,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1CC[C@H](n2nc(CCc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,422.48899999999963,2.1703,1,8,108.39,10,3,0.5813773919398204,0,c1ccc(CCc2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL5273555,IC50,5000.0,nM,,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1,427.4639999999998,3.2913000000000023,2,5,105.72,5,4,0.47682773263833544,0,c1ccc(Oc2ccc(-c3cc4[nH]c5c(n4n3)CNCC5)cc2)cc1,CHEMBL3968222,IC50,0.25,nM,,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2CC1,441.4909999999998,3.333800000000002,2,5,105.72,5,4,0.46347860060506085,0,c1ccc(Oc2ccc(-c3cc4[nH]c5c(n4n3)CCNCC5)cc2)cc1,CHEMBL3913116,IC50,0.25,nM,,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCc2c([nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)C1,427.46399999999977,3.2913000000000023,2,5,105.72,5,4,0.47682773263833544,0,c1ccc(Oc2ccc(-c3cc4[nH]c5c(n4n3)CCNC5)cc2)cc1,CHEMBL3962133,IC50,0.25,nM,,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCc2c(sc3ncnc(NC4CCCCC4)c23)C1,342.4679999999997,3.5066000000000024,1,5,58.120000000000005,3,2,0.8674221017887345,0,c1nc(NC2CCCCC2)c2c3c(sc2n1)CNCC3,CHEMBL3133900,IC50,5000.0,nM,,CHEMBL3137113,CHEMBL203,CHEMBL3132827,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1CCc2c(sc3ncnc(N[C@@H](CO)c4ccccc4)c23)C1,380.4729999999998,2.9075000000000015,2,6,78.35000000000001,6,3,0.6656671241880388,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272168,IC50,3057.0,nM,5.51,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,380.4729999999998,2.9075000000000015,2,6,78.35000000000001,6,3,0.6656671241880388,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272061,IC50,8.0,nM,8.1,CHEMBL5358605,CHEMBL203,CHEMBL5356985,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1C[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@H](OC)C1,431.8839999999998,2.126599999999999,2,8,110.19000000000001,9,3,0.5511036552632873,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3787132,Ki,32.0,nM,7.5,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1C[C@@H]2CN(c3nc(Nc4ccc(N5CCN(C)CC5)cc4)c4ncn(C(C)C)c4n3)C[C@@H]2C1,515.6659999999998,2.983200000000001,1,9,85.66000000000001,9,3,0.5018416854628761,1,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CC4CNCC4C3)nc2[nH]1,CHEMBL3608430,IC50,8.0,nM,8.1,CHEMBL3609989,CHEMBL203,CHEMBL3608213,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1C[C@@H]2CN(c3nc(Nc4cnn(C)c4)c4ncn(C(C)C)c4n3)C[C@@H]2C1,421.50899999999973,1.9648999999999992,1,9,97.00000000000001,8,3,0.629184164168355,0,c1nc2c(Nc3cn[nH]c3)nc(N3CC4CNCC4C3)nc2[nH]1,CHEMBL4207951,IC50,49.0,nM,7.31,CHEMBL4178351,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1C[C@H](CO)[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C1,431.8839999999998,1.720099999999999,3,8,121.19000000000003,9,3,0.48675361961436886,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786647,Ki,15.0,nM,7.82,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1C[C@H](COC)[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C1,445.9109999999997,2.374199999999999,2,8,110.19000000000003,10,3,0.5119275627273236,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786523,Ki,4.0,nM,8.4,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](C(F)(F)F)C1,469.8549999999998,3.2901000000000007,2,7,100.96000000000001,7,3,0.5372150001723393,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786802,Ki,3.0,nM,8.52,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](F)C1,419.8479999999998,2.4497,2,7,100.96000000000001,7,3,0.5950452768362468,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3787220,Ki,3.0,nM,8.52,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](O)C1,417.8569999999998,1.4724999999999988,3,8,121.19000000000001,8,3,0.5190527930470996,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786220,Ki,8.0,nM,8.1,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,431.8839999999998,2.126599999999999,2,8,110.19000000000001,9,3,0.5511036552632873,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3786098,Ki,4.0,nM,8.4,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)[C@@H](C(F)(F)F)C1,435.40999999999974,2.6367000000000003,2,7,100.96000000000001,7,3,0.5776509271612033,0,c1cc2c(OCC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL3785393,Ki,35.0,nM,7.46,CHEMBL3790712,CHEMBL203,CHEMBL3785081,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1C[C@H](Nc2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)[C@@H](F)C1,413.4609999999997,2.031099999999999,2,9,105.79,9,3,0.5957839082833802,0,c1nc2c(Nc3cn[nH]c3)nc(NC3CCNC3)nc2[nH]1,CHEMBL4204498,Ki,56.0,nM,7.25,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N1C[C@H](Nc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](F)C1,404.83699999999976,2.235199999999999,3,7,103.76000000000002,6,3,0.5633024922660592,0,c1cc2c(NC3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1,CHEMBL4211367,Ki,3.0,nM,8.52,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,285.3509999999996,1.9352999999999994,2,4,73.91,4,2,0.8451673485107614,0,c1nc(NC2CCCNC2)c2cc[nH]c2n1,CHEMBL4085457,IC50,50000.0,nM,,CHEMBL4005782,CHEMBL203,CHEMBL4004825,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)NC1=CC=C2N=CN=C(Nc3cccc(C(F)(F)F)c3)C21,346.3119999999997,3.257500000000001,2,4,65.85,3,1,0.825307569866595,0,C1=CC2C(=C1)N=CN=C2Nc1ccccc1,CHEMBL474342,IC50,0.912,nM,9.04,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.85,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
C=CC(=O)NC1=CC=C2N=CN=C(Nc3cccc(C)c3)C21,292.3419999999997,2.5471200000000005,2,4,65.85,4,1,0.8407986245812334,0,C1=CC2C(=C1)N=CN=C2Nc1ccccc1,CHEMBL474147,IC50,0.4169,nM,9.38,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
C=CC(=O)NC1=CC=C2N=CN=C(Nc3cccc(Cl)c3)C21,312.75999999999976,2.892100000000001,2,4,65.85,3,1,0.8428180821604455,0,C1=CC2C(=C1)N=CN=C2Nc1ccccc1,CHEMBL460735,IC50,1.585,nM,8.8,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
C=CC(=O)NC1=NC=C2N=CN=C(Nc3ccc(F)c(Br)c3)C21,376.1889999999998,2.612400000000001,2,5,78.21000000000001,2,1,0.7788345040932567,0,C1=NC=C2N=CN=C(Nc3ccccc3)C12,CHEMBL474141,IC50,0.7244,nM,9.14,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.85,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
C=CC(=O)NC1=NC=C2N=CN=C(Nc3ccc(F)c(Cl)c3)C21,331.7379999999998,2.5033000000000003,2,5,78.21000000000001,2,1,0.8166739212657403,0,C1=NC=C2N=CN=C(Nc3ccccc3)C12,CHEMBL516373,IC50,0.7762,nM,9.11,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.85,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
C=CC(=O)NC1=NC=C2N=CN=C(Nc3cccc(C)c3)C21,293.3299999999997,2.01922,2,5,78.21000000000001,3,1,0.8182257163781242,0,C1=NC=C2N=CN=C(Nc3ccccc3)C12,CHEMBL516022,IC50,0.4786,nM,9.32,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
C=CC(=O)NC1CCCN(C(=O)Nc2ccnc(Nc3ccc(N4CCN(C)CC4)cc3OC)n2)C1,494.5999999999997,2.2790999999999997,3,8,114.96000000000001,9,2,0.5025107204744766,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)N1CCCCC1,CHEMBL4228216,IC50,1000.0,nM,,CHEMBL4222199,CHEMBL203,CHEMBL4219138,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21,417.4689999999997,3.100200000000001,3,6,111.27000000000001,7,3,0.5116942257476255,0,c1ccc(Oc2ccc(-c3cc4n(n3)CCCN4)cc2)cc1,CHEMBL3977729,IC50,0.72,nM,9.14,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)NCCN1C(=O)N(Cc2ccccc2)Cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc21,556.6710000000018,3.2250000000000014,2,8,106.17,12,3,0.366967071305529,1,O=C1Nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2CN1Cc1ccccc1,CHEMBL3087203,IC50,1000.0,nM,,CHEMBL3088813,CHEMBL203,CHEMBL3085739,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)NCCn1c(-c2nc(-c3cnn(C4CCN(C)CC4)c3)cnc2N)nc2ccccc21,471.56899999999973,2.5078999999999994,2,9,119.78,9,4,0.39748070385914686,0,c1ccc2[nH]c(-c3cncc(-c4cnn(C5CCNCC5)c4)n3)nc2c1,CHEMBL3813746,IC50,2200.0,nM,5.66,CHEMBL3817134,CHEMBL203,CHEMBL3813644,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)NCCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,400.4419999999998,3.170000000000001,2,7,107.95,8,4,0.4614602250556494,0,c1ccc(Oc2ccc(-c3n[nH]c4ncncc34)cc2)cc1,CHEMBL3894938,IC50,70.49,nM,7.15,CHEMBL3887533,CHEMBL203,CHEMBL3886356,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)NCc1ccc(-n2nc3c(=O)[nH]nc(N)c3c2-c2oc3ccc(C)cc3c2C)cc1,454.4899999999999,3.523240000000002,3,7,131.82999999999998,8,5,0.34823268134544566,0,O=c1[nH]ncc2c(-c3cc4ccccc4o3)n(-c3ccccc3)nc12,CHEMBL4541330,IC50,1000.0,nM,,CHEMBL4313078,CHEMBL203,CHEMBL4311952,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
C=CC(=O)N[C@@H]1CCN(c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,489.62799999999964,2.783500000000001,2,9,94.45,10,3,0.48957226349715277,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CCCC3)nc2[nH]1,CHEMBL4207425,Ki,161.0,nM,6.79,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CCN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C1,395.4709999999997,1.765199999999999,2,9,105.79,9,3,0.6127703124359648,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4203072,Ki,183.0,nM,6.74,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3C)c3ncn(C(C)C)c3n2)C[C@H]1F,427.48799999999966,2.0216199999999995,2,9,105.79,10,3,0.5799257769485733,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL3608432,IC50,4.0,nM,8.4,CHEMBL4178360,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3CC)c3ncn(C(C)C)c3n2)C[C@H]1F,441.51499999999965,2.2756,2,9,105.79,11,3,0.5419845310104411,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4218154,IC50,3.0,nM,8.52,CHEMBL4178360,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3nc[nH]c3n2)C[C@H]1F,401.4059999999997,0.6674999999999993,3,9,125.88000000000001,8,3,0.5147068330783696,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4213609,IC50,675.0,nM,6.17,CHEMBL4178351,CHEMBL203,CHEMBL4177539,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C(C)(C)C)c3n2)C[C@H]1F,457.51399999999967,1.8958999999999993,2,10,115.02000000000002,8,3,0.5395868132113286,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4208829,IC50,17.0,nM,7.77,CHEMBL4178351,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C(C)C)c3n2)C[C@H]1F,443.4869999999997,1.721799999999999,2,10,115.02000000000002,11,3,0.5307146457365192,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4216679,IC50,1.0,nM,9.0,CHEMBL4178360,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,415.4329999999997,0.6778999999999995,2,10,115.02000000000002,9,3,0.5650301203796078,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL3989970,IC50,3.0,nM,8.52,CHEMBL4178360,CHEMBL203,CHEMBL4177539,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(CC)c3n2)C[C@H]1F,429.4599999999997,1.1607999999999992,2,10,115.02000000000002,10,3,0.5379568334530174,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4205392,Ki,6.0,nM,8.22,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(CC)nc3OC)c3ncn(C)c3n2)C[C@H]1F,429.4599999999997,1.1607999999999992,2,10,115.02000000000002,10,3,0.5379568334530174,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL3608434,IC50,1.0,nM,9.0,CHEMBL3609990,CHEMBL203,CHEMBL3608213,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C[C@H]1F,413.4609999999997,1.7131999999999992,2,9,105.79,9,3,0.5928064226499049,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL3608429,IC50,2.0,nM,8.7,CHEMBL3609990,CHEMBL203,CHEMBL3608213,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1,396.4539999999997,3.3164000000000007,2,6,98.72,5,4,0.5177712309188474,0,C1=Cc2c(-c3cnc4ccccc4c3)c3cncnc3n2CC1,CHEMBL4650281,IC50,1.1,nM,8.96,CHEMBL5243469,CHEMBL203,CHEMBL5241118,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,489.62799999999964,2.783500000000001,2,9,94.45,10,3,0.48957226349715277,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CCCC3)nc2[nH]1,CHEMBL4208811,Ki,9.0,nM,8.05,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(CCO)c3n2)C1,491.5999999999997,1.1949000000000003,3,10,114.68,10,3,0.39991466536160325,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CCCC3)nc2[nH]1,CHEMBL3608431,IC50,7.0,nM,8.15,CHEMBL3609989,CHEMBL203,CHEMBL3608213,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@H]1CCN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C1,395.4709999999997,1.765199999999999,2,9,105.79,9,3,0.6127703124359648,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4212326,Ki,36.0,nM,7.44,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@H]1CN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C[C@@H]1F,413.4609999999997,1.7131999999999992,2,9,105.79,9,3,0.5928064226499049,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1,CHEMBL4204566,Ki,152.0,nM,6.82,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1,436.4149999999998,1.8324999999999991,2,8,103.83000000000001,11,2,0.5742234970821537,0,c1ccc(COc2cnc(NC3CCOC3)nc2)cc1,CHEMBL4077859,IC50,10000.0,nM,,CHEMBL4018334,CHEMBL203,CHEMBL4017480,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cc(-c2cn(C)c3ccccc23)ccn1,277.32699999999966,3.3648000000000016,1,3,46.92,4,3,0.7460923911925248,0,c1ccc2c(-c3ccncc3)c[nH]c2c1,CHEMBL5420997,IC50,9000.0,nM,5.05,CHEMBL5330922,CHEMBL203,CHEMBL5329221,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(-c2cn(C)c3ccccc23)ncn1,278.31499999999966,2.7598000000000003,1,4,59.81,4,3,0.7493444197485748,0,c1ccc2c(-c3ccncn3)c[nH]c2c1,CHEMBL5400930,IC50,150.0,nM,6.82,CHEMBL5330930,CHEMBL203,CHEMBL5329221,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2cc[nH]n2)nc(-c2ccccc2)n1,306.3289999999998,2.734800000000001,3,5,95.59,5,3,0.6298911374478489,0,c1ccc(-c2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL3604917,IC50,300.0,nM,6.52,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cc(Nc2n[nH]c3ccccc23)c(OC)cc1N(C)CCN(C)C,408.5059999999997,3.437400000000002,3,6,85.52,13,3,0.47049166005513265,0,c1ccc(Nc2n[nH]c3ccccc23)cc1,CHEMBL4074766,IC50,462.0,nM,6.33,CHEMBL4009508,CHEMBL203,CHEMBL4007434,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cc(Nc2n[nH]c3ccccc23)ccc1N(C)CCN(C)C,378.4799999999996,3.4288000000000016,3,5,76.28999999999999,11,3,0.5237257913951862,0,c1ccc(Nc2n[nH]c3ccccc23)cc1,CHEMBL4090330,IC50,2626.0,nM,5.58,CHEMBL4009508,CHEMBL203,CHEMBL4007434,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cc(Nc2nccc(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,484.5639999999998,3.4198000000000013,2,9,99.91999999999999,9,4,0.3851460971093518,0,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1,CHEMBL2424676,IC50,71.0,nM,7.15,CHEMBL2427158,CHEMBL203,CHEMBL2424560,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(OC)c(OC)c3)n2)c(OC)cc1N1CCN(C)CC1,547.6160000000017,3.374600000000002,3,10,130.18,14,3,0.3248834357948879,1,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1,CHEMBL4587847,IC50,12.57,nM,7.9,CHEMBL4384381,CHEMBL203,CHEMBL4382243,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3cccc(OC)c3)n2)c(OC)cc1N1CCN(C)CC1,517.5900000000001,3.3660000000000023,3,9,120.95,12,3,0.3669458149393961,1,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1,CHEMBL4451619,IC50,54.99,nM,7.26,CHEMBL4384381,CHEMBL203,CHEMBL4382243,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N1CCC(C(N)=O)CC1,515.5740000000001,3.3073000000000006,4,8,151.57,10,3,0.3169195779660906,1,O=C(Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1)c1ccccc1,CHEMBL4454516,IC50,0.5872,nM,9.23,CHEMBL4384381,CHEMBL203,CHEMBL4382243,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N1CCN(C)CC1,487.5639999999998,3.357400000000002,3,8,111.72,10,3,0.4149706265654017,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1,CHEMBL4456234,IC50,120.7,nM,6.92,CHEMBL4384381,CHEMBL203,CHEMBL4382243,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C,465.56199999999967,2.8282000000000007,3,10,112.46999999999998,16,3,0.36800274925444343,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL5088907,IC50,6.198,nM,8.21,CHEMBL5046854,CHEMBL203,CHEMBL5046228,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)nc3C)n2)c(OC)cc1N(C)CCN(C)C,479.58899999999966,3.1366200000000015,3,10,112.46999999999998,17,3,0.3570728606820661,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1,CHEMBL5080676,IC50,5.654,nM,8.25,CHEMBL5046854,CHEMBL203,CHEMBL5046228,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(C)c3)n2)c(OC)cc1N(C)CCN(C)C,465.5619999999997,2.8282000000000007,3,10,112.47,16,3,0.36800274925444343,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1,CHEMBL5071181,IC50,21.43,nM,7.67,CHEMBL5046854,CHEMBL203,CHEMBL5046228,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(CC)c3)n2)c(OC)cc1N(C)CCN(C)C,479.5889999999997,3.3111000000000015,3,10,112.47,17,3,0.3368063735961447,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1,CHEMBL5094406,IC50,8.023,nM,8.1,CHEMBL5046854,CHEMBL203,CHEMBL5046228,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cc2c(Nc3ccc(F)c(C#N)c3)ncnc2cc1OCCOC,407.4049999999998,3.5338800000000017,2,7,109.16000000000001,9,3,0.4341708535568533,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3622620,IC50,195.8,nM,6.71,CHEMBL3625155,CHEMBL203,CHEMBL3621102,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cc2c(Nc3ccc(F)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,470.4799999999998,2.8327,3,7,108.48,12,3,0.3088958336092876,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3671540,IC50,156.0,nM,6.81,CHEMBL3705421,CHEMBL203,CHEMBL3638799,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cn1,305.3409999999997,3.201320000000001,2,5,79.8,5,3,0.723537026971941,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL54088,IC50,0.48,nM,9.32,CHEMBL674018,CHEMBL203,CHEMBL1132213,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2[nH]1,358.1989999999998,3.5885000000000007,3,4,82.69999999999999,4,3,0.6227568841218871,0,c1ccc(Nc2ncnc3cc[nH]c23)cc1,CHEMBL474142,IC50,1.096,nM,8.96,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cc2ncnc(Nc3cccc(Cl)c3)c2cn1,325.75899999999984,3.5463000000000013,2,5,79.8,4,3,0.7170400593259514,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL446019,IC50,0.537,nM,9.27,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc(-n2c(=O)c(C)nc3cnc(Nc4ccc(OC)cc4)nc32)cc1,428.4519999999998,3.3608200000000013,2,8,111.03,8,4,0.45308823981092317,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437470,IC50,7167.0,nM,5.14,CHEMBL2439335,CHEMBL203,CHEMBL2434822,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)cc1,482.54799999999983,2.7956000000000003,2,9,108.27999999999999,7,4,0.40412915874848737,0,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437461,IC50,691.0,nM,6.16,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)cc1,512.5739999999998,2.8042000000000007,2,10,117.50999999999999,9,4,0.36053336252286416,1,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437468,IC50,272.0,nM,6.57,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)cc1,469.5049999999999,2.8804000000000007,2,9,114.27,6,4,0.4145496172938205,0,O=c1cnc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437459,IC50,3456.0,nM,5.46,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(OC)cc4)nc32)cc1,414.4249999999999,3.0524000000000013,2,8,111.03,7,4,0.466566814742607,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437478,IC50,4802.0,nM,5.32,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc(Nc2ncc3ncc(=O)n(-c4ccc(OC)cc4)c3n2)cc1,414.4249999999999,3.0524000000000013,2,8,111.03,7,4,0.466566814742607,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437477,IC50,33885.0,nM,4.47,CHEMBL2439336,CHEMBL203,CHEMBL2434822,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OCCN4CCOCC4)cc23)cc1,449.51099999999974,3.217500000000001,2,8,97.84,10,3,0.48081849626457346,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1,CHEMBL4516586,IC50,4.3,nM,8.37,CHEMBL4342912,CHEMBL203,CHEMBL4342409,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc(Oc2nc(Nc3cc(C)[nH]n3)cc(N3CCN(C)CC3)n2)cc1,434.50399999999973,2.920320000000001,3,8,111.29999999999998,9,3,0.4869418653800376,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604922,IC50,1800.0,nM,5.75,CHEMBL3606404,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc2ncc(NC(=O)Nc3ccccc3)nc2c1,333.3509999999998,3.3983000000000008,3,4,96.01,4,3,0.6376176286571941,0,O=C(Nc1ccccc1)Nc1cnc2ccccc2n1,CHEMBL5272590,IC50,18.0,nM,7.75,CHEMBL5230829,CHEMBL203,CHEMBL5230100,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains quinazoline core; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccc2ncnc(Cc3ccc(F)c(Cl)c3)c2n1,342.7609999999998,3.532600000000002,1,4,67.77000000000001,4,3,0.7363813361816426,0,c1ccc(Cc2ncnc3cccnc23)cc1,CHEMBL524117,IC50,0.7586,nM,9.12,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc2ncnc(NC3CCCCC3)c2c1,296.3739999999996,3.4989000000000026,2,4,66.91,4,2,0.8474172319065916,0,c1ccc2c(NC3CCCCC3)ncnc2c1,CHEMBL3133894,IC50,2800.0,nM,5.55,CHEMBL3137113,CHEMBL203,CHEMBL3132827,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OC)cc3OC)c2c1,350.37799999999976,3.515100000000002,2,6,85.37,8,3,0.6618132745326429,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3133906,IC50,931.0,nM,6.03,CHEMBL3137113,CHEMBL203,CHEMBL3132827,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccc2ncnc(Nc3ccc(S(N)(=O)=O)cc3)c2c1,369.40599999999984,2.1452999999999998,3,6,127.07,6,3,0.5914251850281845,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3133910,IC50,76500.0,nM,4.12,CHEMBL3134707,CHEMBL203,CHEMBL3132827,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
C=CC(=O)Nc1ccc2ncnc(Nc3ccccc3)c2c1,290.32599999999974,3.4979000000000013,2,4,66.91,4,3,0.7216672848207403,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL1221699,IC50,1.0,nM,,CHEMBL1226208,CHEMBL203,CHEMBL1221199,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-c2nccc(Nc3cc(C)[nH]n3)n2)c1,320.3559999999997,3.04322,3,5,95.59,6,3,0.6279915336225997,0,c1ccc(-c2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL3604919,IC50,2500.0,nM,5.6,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cccc(-c2noc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,401.4259999999999,3.554800000000002,3,7,113.17000000000002,8,4,0.40587598199393066,0,c1ccc(CNc2ncnc3onc(-c4ccccc4)c23)cc1,CHEMBL4447289,IC50,416.0,nM,6.38,CHEMBL4416105,CHEMBL203,CHEMBL4414600,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(-c3nc(-c4cnn(C)c4)cnc3N)nc3ccccc32)c1,436.4789999999998,3.5897000000000014,2,8,116.54,7,5,0.406814003738144,0,c1ccc(-n2c(-c3cncc(-c4cn[nH]c4)n3)nc3ccccc32)cc1,CHEMBL3813947,EC50,9.0,nM,8.05,CHEMBL3817138,CHEMBL203,CHEMBL3813644,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
C=CC(=O)Nc1cccc(-n2c(-c3nc(-c4cnn(CCO)c4)cnc3N)nc3ccccc32)c1,466.5049999999998,3.045,3,9,136.77,9,5,0.31359015611177504,0,c1ccc(-n2c(-c3cncc(-c4cn[nH]c4)n3)nc3ccccc32)cc1,CHEMBL3813817,EC50,8.0,nM,8.1,CHEMBL3817138,CHEMBL203,CHEMBL3813644,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
C=CC(=O)Nc1cccc(-n2c(=O)c(C)nc3cnc(Nc4ccc(OC)cc4)nc32)c1,428.4519999999998,3.3608200000000013,2,8,111.03,8,4,0.45308823981092317,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437471,IC50,5.29,nM,8.28,CHEMBL2439336,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)nc4)nc32)c1,496.5749999999997,3.104020000000001,2,9,108.27999999999999,8,4,0.3922614911847938,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)nc3)nc2n1-c1ccccc1,CHEMBL4086000,IC50,1.4,nM,8.85,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4cnn(C5CCN(C)CC5)c4)nc32)c1,484.5639999999997,3.420420000000002,2,9,109.97,8,4,0.40364292755494063,0,O=c1ccc2cnc(Nc3cnn(C4CCNCC4)c3)nc2n1-c1ccccc1,CHEMBL4064475,IC50,1.8,nM,8.74,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4cnn(CCN(C)C)c4)nc32)c1,458.52599999999967,2.71532,2,9,109.97,11,4,0.3907646887661021,0,O=c1ccc2cnc(Nc3cn[nH]c3)nc2n1-c1ccccc1,CHEMBL4082515,IC50,4.2,nM,8.38,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4nc5c(s4)CN(C)CC5)nc32)c1,473.5619999999997,3.401620000000001,2,9,105.03999999999999,7,4,0.4281362655338355,0,O=c1ccc2cnc(Nc3nc4c(s3)CNCC4)nc2n1-c1ccccc1,CHEMBL4063421,IC50,2.5,nM,8.6,CHEMBL4001768,CHEMBL203,CHEMBL4000215,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cc(N(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,554.6550000000016,3.475200000000002,2,10,107.86,12,4,0.3166651887056535,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL3752139,IC50,95.0,nM,7.02,CHEMBL3755797,CHEMBL203,CHEMBL3751728,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)ccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,511.5859999999998,3.409200000000002,2,9,104.61999999999999,9,4,0.36400044089239336,1,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL3633142,Kd,0.43,nM,9.37,CHEMBL3755962,CHEMBL203,CHEMBL3751728,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(C(N)=O)cc4)nc32)c1,427.42399999999986,2.1426999999999996,3,8,144.89,6,4,0.399765921998372,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437467,IC50,3.97,nM,8.4,CHEMBL2439334,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1,482.5479999999998,2.7956000000000003,2,9,108.27999999999999,7,4,0.40412915874848737,0,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437462,IC50,0.677,nM,9.17,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,512.5739999999998,2.8042000000000007,2,10,117.50999999999999,9,4,0.36053336252286416,1,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437469,IC50,1.07,nM,8.97,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)c1,469.5049999999998,2.8804000000000007,2,9,114.27,6,4,0.4145496172938205,0,O=c1cnc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccccc1,CHEMBL2437460,IC50,2.86,nM,8.54,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(NC(C)=O)cc4)nc32)c1,441.45099999999985,3.0022,3,8,130.89999999999998,7,4,0.392084525070397,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437466,IC50,4.53,nM,8.34,CHEMBL2439334,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(OC)cc4)nc32)c1,414.42499999999984,3.0524000000000013,2,8,111.03,7,4,0.466566814742607,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437479,IC50,5.6,nM,8.25,CHEMBL2439334,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccccc4)nc32)c1,384.39899999999983,3.043800000000001,2,7,101.8,5,4,0.5129644677407557,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437488,IC50,4.94,nM,8.31,CHEMBL2439334,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1,554.6550000000017,3.451620000000002,2,10,117.38999999999999,11,4,0.33382728687339747,1,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,CHEMBL4126630,IC50,1.0,nM,9.0,CHEMBL4125335,CHEMBL203,CHEMBL4118273,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccccc4)nc32)c1,414.42499999999984,2.3475,2,8,110.91,6,4,0.48516972053580987,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc12,CHEMBL4128726,IC50,68.0,nM,7.17,CHEMBL4125335,CHEMBL203,CHEMBL4118273,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Cn2c(=O)ccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1,495.58699999999976,3.4597000000000024,2,8,95.38999999999999,8,4,0.37928183351626726,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1Cc1ccccc1,CHEMBL5194482,IC50,216.3,nM,6.67,CHEMBL5146950,CHEMBL203,CHEMBL5143636,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(N2C(=O)C(C)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,570.6540000000016,3.243900000000002,2,9,123.24,11,3,0.41226180798715256,1,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21,CHEMBL3219128,IC50,6.02,nM,8.22,CHEMBL3223694,CHEMBL203,CHEMBL3217539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(N2C(=O)C3CCCN3C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,582.6650000000016,3.3880000000000017,2,9,123.24,9,3,0.40374276161341416,1,O=C1C2CCCN2C(=O)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1,CHEMBL3219126,IC50,1000.0,nM,,CHEMBL3223695,CHEMBL203,CHEMBL3217539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(N2C(=O)CN(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,556.6270000000015,2.8554000000000004,2,9,123.24,10,3,0.4230428293927373,1,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21,CHEMBL3219125,IC50,9.14,nM,8.04,CHEMBL3223691,CHEMBL203,CHEMBL3217539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(NC)nc32)c1,338.3709999999997,2.3463000000000003,2,5,90.46000000000001,6,2,0.8352599864263275,0,O=C1NCc2cncnc2N1c1ccccc1,CHEMBL2029427,IC50,837.1,nM,6.08,CHEMBL2033654,CHEMBL203,CHEMBL2029259,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3OC)n2)c1,530.5890000000009,3.384900000000002,4,8,140.82,10,3,0.32502327364346345,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(C(=O)N3CCNCC3)cc2)n1,CHEMBL4226177,IC50,215.0,nM,6.67,CHEMBL4222199,CHEMBL203,CHEMBL4219138,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(C(=O)N4CCOCC4)cc3OC)n2)c1,517.5460000000002,3.4697000000000013,4,8,146.81,9,3,0.33229876913073186,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1,CHEMBL4228848,IC50,128.0,nM,6.89,CHEMBL4222199,CHEMBL203,CHEMBL4219138,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2Cl)c1,538.0080000000012,3.3912000000000013,4,9,131.95,11,3,0.3031183094179512,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3699590,IC50,1.0,nM,7.7,CHEMBL3706050,CHEMBL203,CHEMBL3639181,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OCCN4CCOCC4)cc23)c1,449.51099999999974,3.217500000000001,2,8,97.84,10,3,0.48081849626457346,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1,CHEMBL4436337,IC50,4.3,nM,8.37,CHEMBL4342766,CHEMBL203,CHEMBL4342406,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2cnc(C(N)=O)c(Nc3ccc(N4CCN(C)CC4)cc3)n2)c1,473.53699999999975,2.987700000000001,3,8,125.71,9,3,0.4265013838354496,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3663926,IC50,0.92,nM,9.04,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3cc(C)[nH]n3)cc(N3CCN(C)CC3)n2)c1,434.5039999999997,2.920320000000001,3,8,111.29999999999998,9,3,0.48694186538003775,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604921,Ki,0.64,nM,9.19,CHEMBL3606413,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCN(C)CC3)n2)c1,420.47699999999975,2.6119000000000003,3,8,111.29999999999998,8,3,0.5003822437838286,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604933,IC50,1900.0,nM,5.72,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2Cl)c1,538.9920000000013,3.4399000000000015,3,9,129.14999999999998,11,3,0.35070212121389327,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3699583,IC50,1.0,nM,8.26,CHEMBL3706050,CHEMBL203,CHEMBL3639181,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1,501.5909999999997,3.5501000000000014,3,8,125.71,11,3,0.3802473646798697,1,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3663921,IC50,1.3,nM,8.89,CHEMBL3705896,CHEMBL203,CHEMBL3638445,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(S(N)(=O)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,593.5880000000013,3.4899000000000013,3,9,152.01,11,3,0.31673193057467386,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3699602,IC50,5.5,nM,8.26,CHEMBL3706050,CHEMBL203,CHEMBL3639181,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(N4CCN(C)CC4)c3)c(C(N)=O)nc2CC)c1,531.6170000000009,3.558700000000001,3,9,134.94,13,3,0.3356696408715036,1,c1ccc(Oc2cncc(Nc3cccc(N4CCNCC4)c3)n2)cc1,CHEMBL3663927,IC50,1.2,nM,8.92,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccn(C)n3)nc3[nH]ccc23)c1,375.3919999999998,3.351800000000001,3,7,109.75,7,4,0.4459250248447496,0,c1ccc(Oc2nc(Nc3cc[nH]n3)nc3[nH]ccc23)cc1,CHEMBL3786453,IC50,7.6,nM,8.12,CHEMBL3790960,CHEMBL203,CHEMBL3785081,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)c1,375.3919999999998,3.351800000000001,3,7,109.75,7,4,0.4459250248447496,0,c1ccc(Oc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1,CHEMBL3786962,IC50,1.6,nM,8.8,CHEMBL3790960,CHEMBL203,CHEMBL3785081,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(CCN(C)C)c3)nc3[nH]ccc23)c1,432.4879999999998,3.376400000000001,3,8,112.98999999999998,11,4,0.34758637554898825,0,c1ccc(Oc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1,CHEMBL4211782,Ki,3.0,nM,8.52,CHEMBL4178356,CHEMBL203,CHEMBL4177539,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(CCN(C)C)c3)nc3[nH]ccc23)c1F,450.4779999999998,3.515500000000001,3,8,112.98999999999998,11,4,0.3345225685230118,0,c1ccc(Oc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1,CHEMBL4216749,Ki,2.0,nM,8.7,CHEMBL4178356,CHEMBL203,CHEMBL4177539,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1cccc(Oc2nccc(Nc3cc(C)[nH]n3)n2)c1,336.35499999999973,3.16852,3,6,104.82,7,3,0.5972280054560112,0,c1ccc(Oc2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL3604931,IC50,900.0,nM,6.05,CHEMBL3606405,CHEMBL203,CHEMBL3603765,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(OC)c(C)c(OC)c3)nn21,461.52199999999976,3.504120000000002,3,7,120.5,10,3,0.4633018041505683,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1,CHEMBL5282956,IC50,18.0,nM,7.75,CHEMBL5251900,CHEMBL203,CHEMBL5247657,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)cc3)nn21,401.46999999999974,3.4869200000000014,3,5,102.03999999999999,6,3,0.5696565631400446,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1,CHEMBL3965262,IC50,0.34,nM,9.47,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)cc3)nn21,405.43299999999977,3.3176000000000005,3,5,102.03999999999999,5,3,0.5668585910506969,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1,CHEMBL3908905,IC50,1.2,nM,8.92,CHEMBL4414895,CHEMBL203,CHEMBL4414549,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21,417.46899999999977,3.187100000000001,3,6,111.27000000000001,7,3,0.5335684300411538,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1,CHEMBL3926191,IC50,0.48,nM,9.32,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCCOC)cc3)nn21,461.52199999999976,3.2037000000000013,3,7,120.5,10,3,0.3324512948831592,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1,CHEMBL3890068,IC50,0.63,nM,9.2,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CC(=O)Nc1ccccc1Nc1ncnc2cc(OC)c(OCCN3CCOCC3)cc12,449.5109999999998,3.217500000000001,2,8,97.84,10,3,0.48081849626457346,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1,CHEMBL5283875,IC50,4.3,nM,8.37,CHEMBL5230868,CHEMBL203,CHEMBL5230100,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1ccccc1Oc1nc(Nc2cc(C)[nH]n2)cc(N2CCN(C)CC2)n1,434.5039999999997,2.9203200000000002,3,8,111.29999999999998,9,3,0.4869418653800376,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604920,IC50,600.0,nM,6.22,CHEMBL3606404,CHEMBL203,CHEMBL3603765,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1nc2c(Cc3ccc(F)c(Cl)c3)ncnc2cc1OC,372.78699999999986,3.5412000000000017,1,5,77.00000000000001,6,3,0.6930161654077002,0,c1ccc(Cc2ncnc3cccnc23)cc1,CHEMBL490497,IC50,0.955,nM,9.02,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CC(=O)Nc1nc2c(Cc3ccc(F)c(Cl)c3)ncnc2cc1OCCOC,416.83999999999986,3.557800000000002,1,6,86.23000000000002,9,3,0.44608623722024787,0,c1ccc(Cc2ncnc3cccnc23)cc1,CHEMBL490498,IC50,0.9772,nM,9.01,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)C(O)(CC)CC2,526.6450000000006,3.2024000000000017,2,10,104.34,10,4,0.35403186183049373,1,O=c1[nH]n(-c2ccc3c(n2)CCC3)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,CHEMBL4871593,IC50,60.0,nM,7.22,CHEMBL4844330,CHEMBL203,CHEMBL4842364,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,500.60699999999974,2.8860000000000015,2,10,104.34,11,4,0.37351787019809934,1,O=c1[nH]n(-c2ccccn2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,CHEMBL1976040,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C=CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21,325.3719999999996,2.6688,1,7,88.08,9,3,0.7010253650702456,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242569,IC50,5080.0,nM,5.29,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CS(=O)(=O)N1CCC[C@@H]1Cn1cc(-c2ccc3c(c2)OCO3)c2c(N)ncnc21,427.48599999999976,2.3468999999999998,1,8,112.57000000000001,6,3,0.6649189366277819,0,c1ncc2c(-c3ccc4c(c3)OCO4)cn(CC3CCCN3)c2n1,CHEMBL4095253,IC50,642.7,nM,6.19,CHEMBL4058124,CHEMBL203,CHEMBL4052785,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C=CS(=O)(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,416.52799999999985,2.6682000000000006,2,7,95.42,7,3,0.6414760142237768,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272167,IC50,91.0,nM,7.04,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CS(=O)(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,406.2649999999998,3.416100000000001,2,6,96.87,5,3,0.6742049284000394,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL139095,IC50,0.7586,nM,9.12,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C=CS(=O)(=O)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,391.2499999999999,3.448100000000002,1,6,84.84,4,3,0.7335175970445679,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL336264,IC50,0.4266,nM,9.37,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N,539.518000000001,3.1058000000000003,3,7,149.23000000000002,6,3,0.3351141292634251,1,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4847730,IC50,11802.0,nM,4.93,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Cl)ccn3)cc2)c(C(N)=O)n1N,505.9659999999998,2.7403999999999997,3,7,149.23000000000002,6,3,0.35823597757653186,1,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c(C3CCCCN3)n2)cc1,CHEMBL4852748,IC50,30000.0,nM,,CHEMBL4841672,CHEMBL203,CHEMBL4840351,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N1CCC[C@@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,465.5169999999998,3.3126000000000015,2,7,118.50999999999999,5,4,0.44655122021395893,0,O=C(Nc1ccccn1)c1ccc(-c2nc(C3CCCN3)n3ccncc23)cc1,CHEMBL4747506,IC50,10000.0,nM,,CHEMBL5045467,CHEMBL203,CHEMBL5042540,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,465.5169999999998,3.3126000000000015,2,7,118.50999999999999,5,4,0.44655122021395893,0,O=C(Nc1ccccn1)c1ccc(-c2nc(C3CCCN3)n3ccncc23)cc1,CHEMBL3707348,Kd,170.0,nM,6.77,CHEMBL5133814,CHEMBL203,CHEMBL5131445,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N1CCC[C@H]1n1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)ncnc21,466.5049999999998,2.8670999999999998,2,8,131.92000000000002,5,4,0.44207700323751853,0,O=C(Nc1ccccn1)c1ccc(-c2nn(C3CCCN3)c3ncncc23)cc1,CHEMBL5187554,IC50,1000.0,nM,,CHEMBL5127259,CHEMBL203,CHEMBL5126513,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,454.48999999999984,2.7534,1,8,108.27,5,4,0.4752428318869178,0,O=c1n(-c2ccc(Oc3ccccc3)cc2)c2cncnc2n1C1CCNC1,CHEMBL4071161,IC50,1000.0,nM,,CHEMBL5127259,CHEMBL203,CHEMBL5126513,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC#CC(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,392.4839999999998,2.7448000000000006,2,6,78.35000000000001,5,3,0.6677911891428278,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272113,IC50,1270.0,nM,5.9,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,370.42799999999966,2.1310400000000005,3,3,91.22,5,2,0.7230635014308044,0,c1cc(N2CCCCC2)c2cc[nH]c2c1,CHEMBL4297674,IC50,2000.0,nM,5.7,CHEMBL4616782,CHEMBL203,CHEMBL4616583,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,355.7599999999998,3.5227000000000013,2,5,79.8,3,3,0.7025594995962487,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL203644,IC50,0.3,nM,9.52,CHEMBL862512,CHEMBL203,CHEMBL1138126,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC#CC(=O)Nc1cccc(-c2nccc(-c3cc4c([nH]3)C3(CCNCC3)CNC4=O)n2)c1,440.5069999999997,2.4651000000000005,4,5,111.8,3,3,0.4677136203005445,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(-c4ccccc4)n3)cc21,CHEMBL5082422,IC50,499.0,nM,6.3,CHEMBL5029924,CHEMBL203,CHEMBL5029169,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O,315.37299999999965,2.2087000000000003,1,5,79.37,6,2,0.875104649329547,0,O=c1cc(Nc2ccncc2)c1=O,CHEMBL2005899,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1,369.4289999999997,0.49739999999999984,2,7,119.03,5,2,0.8129684626051042,0,c1nc(NC2CCNCC2)nc2c1CCc1cn[nH]c1-2,CHEMBL599224,IC50,10000.0,nM,,CHEMBL1072198,CHEMBL203,CHEMBL1157561,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)N1CCN(C(=O)Cn2c(-c3ccc(C)cc3)csc2=N)CC1,358.46699999999964,1.6951900000000002,1,5,69.4,5,2,0.9071708390044279,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437294,Ki,6090.0,nM,5.21,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)N1CCN(C(=O)Cn2c(-c3ccc(Cl)cc3)csc2=N)CC1,378.88499999999976,2.04017,1,5,69.4,4,2,0.887461931363522,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437295,Ki,8580.0,nM,5.07,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)N1CCN(C(=O)Cn2c(-c3ccccc3)csc2=N)CC1,344.43999999999966,1.38677,1,5,69.4,4,2,0.9139975079704286,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437297,Ki,16770.0,nM,4.78,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)N1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,522.9970000000005,3.266800000000001,2,9,121.39,10,4,0.34080380368775337,1,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1,CHEMBL258270,IC50,3.0,nM,8.52,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1,508.5979999999997,3.245000000000001,1,8,98.74000000000001,8,3,0.5458117432997912,1,c1cc(OCC2CCCO2)cc(-c2cn(C3CC(N4CCNCC4)C3)c3ncncc23)c1,CHEMBL3785951,IC50,10000.0,nM,,CHEMBL3789980,CHEMBL203,CHEMBL3785066,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OC[C@@H]5CCCO5)c4F)c4c(N)ncnc43)C2)CC1,508.5979999999997,3.245000000000001,1,8,98.74000000000001,8,3,0.5458117432997912,1,c1cc(OCC2CCCO2)cc(-c2cn(C3CC(N4CCNCC4)C3)c3ncncc23)c1,CHEMBL3786167,IC50,10000.0,nM,,CHEMBL3789991,CHEMBL203,CHEMBL3785066,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)N1CC[C@H](Nc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,477.6169999999996,2.9353000000000007,2,9,94.45,10,3,0.5597543863617629,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(NC3CCNC3)nc2[nH]1,CHEMBL4206604,Ki,161.0,nM,6.79,CHEMBL4178356,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)N1CCc2cc(Nc3ncnc4ccc(N)cc34)ccc21,319.3679999999997,2.8646000000000003,2,5,84.14,4,3,0.709588626643355,0,c1ccc2c(Nc3ccc4c(c3)CCN4)ncnc2c1,CHEMBL5194147,IC50,10000.0,nM,,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)NNC(=O)c1csc2ncc(-c3ccc(Br)cc3)n12,379.2389999999998,2.6062000000000003,2,5,75.5,3,3,0.6725205303566023,0,c1ccc(-c2cnc3sccn23)cc1,CHEMBL5204417,IC50,153.0,nM,6.82,CHEMBL5110647,CHEMBL203,CHEMBL5108025,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)Nc1c(Br)cccc1Nc1ncnc2ccncc12,358.1989999999999,3.4893,2,5,79.8,4,3,0.7493212692521575,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270921,IC50,29.51,nM,7.53,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12,303.16999999999985,3.2654000000000005,2,3,72.19,3,2,0.8934121024832659,0,c1ccc2sccc2c1,CHEMBL1973142,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1,252.2770000000001,2.1608799999999997,2,4,91.8,4,2,0.8561982278815581,0,c1ccc(-c2ccccn2)cc1,CHEMBL210032,Ki,1800.0,nM,,CHEMBL860206,CHEMBL203,CHEMBL1148638,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1,258.30600000000004,2.2223799999999994,2,5,91.8,4,2,0.8634714430718463,0,c1ccc(-c2ccsc2)nc1,CHEMBL2006567,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)Nc1cc2ncnc(NCc3ccccc3)c2cn1,293.3299999999997,2.5953,2,5,79.8,5,3,0.772588657006679,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL53404,IC50,100.0,nM,7.0,CHEMBL680021,CHEMBL203,CHEMBL1129564,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,358.19899999999984,3.489300000000001,2,5,79.8,4,3,0.7493212692521575,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL52418,IC50,29.0,nM,7.54,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)Nc1ccc(C)c(Nc2nccc(-c3cccnc3)n2)c1,319.36799999999965,3.5490200000000014,2,5,79.8,6,3,0.7685095433428663,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL423288,IC50,100000.0,nM,,CHEMBL676151,CHEMBL203,CHEMBL1159186,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
CC(=O)Nc1ccc(Nc2ncnc3cc(N)ncc23)cc1,294.3179999999998,2.309,3,6,105.82,5,3,0.6841501629982633,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL122081,IC50,10000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1,375.3879999999998,2.473,4,6,115.97999999999999,7,4,0.38486965512796034,0,O=c1c(NCc2ccccc2)c(Nc2ccc3[nH]ncc3c2)c1=O,CHEMBL1988608,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)Nc1cccc(Nc2ncnc3cc(N)ncc23)c1,294.31799999999976,2.309,3,6,105.82,5,3,0.6841501629982631,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL125983,IC50,10000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCCCC2)cs1,339.42099999999965,0.7384999999999993,3,6,103.42999999999999,6,1,0.6866006138037124,0,O=C(CCN1CCCCC1)NNC(=O)c1cscn1,CHEMBL5282535,IC50,9202.0,nM,5.04,CHEMBL5259434,CHEMBL203,CHEMBL5257091,0.5,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1
CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCN(C)CC2)cs1,354.43599999999964,-0.49999999999999933,3,7,106.66999999999999,7,1,0.6156769071602443,0,O=C(CCN1CCNCC1)NNC(=O)c1cscn1,CHEMBL5276173,IC50,131.0,nM,6.88,CHEMBL5259434,CHEMBL203,CHEMBL5257091,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; H-bond features typical of Type 1
CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCOCC2)cs1,341.3929999999997,-0.4151999999999998,3,7,112.66,6,1,0.6274613005439101,0,O=C(CCN1CCOCC1)NNC(=O)c1cscn1,CHEMBL5269071,IC50,143.0,nM,6.84,CHEMBL5259434,CHEMBL203,CHEMBL5257091,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; H-bond features typical of Type 1
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,447.54299999999967,2.965820000000001,2,9,105.03999999999999,7,3,0.5754108874418277,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL189963,IC50,10000.0,nM,,CHEMBL5481337,CHEMBL203,CHEMBL5465560,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(=O)c1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,295.34599999999966,2.859,1,6,86.69,7,3,0.7506854572436227,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241773,IC50,12000.0,nM,4.92,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)c1ccc(N2CCN(C(=O)CN3CC[C@@H](C(=O)Nc4ccc(O)c(Cl)c4)C3)CC2)cc1,484.98399999999975,2.857400000000001,2,6,93.19000000000001,8,2,0.4835309721901047,0,O=C(Nc1ccccc1)C1CCN(CC(=O)N2CCN(c3ccccc3)CC2)C1,CHEMBL3356117,IC50,50000.0,nM,,CHEMBL3377057,CHEMBL203,CHEMBL3351461,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(=O)c1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,295.34599999999966,2.859,1,6,86.69,7,3,0.7506854572436227,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241946,IC50,2800.0,nM,5.55,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(=O)c1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,447.4949999999998,3.2062000000000017,1,9,102.49000000000001,8,4,0.4310497498844302,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064391,IC50,6800.0,nM,5.17,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,254.28500000000008,3.1057000000000015,1,3,54.37,5,2,0.8528036890699656,0,O=C(c1ccccc1)c1ccccc1,CHEMBL571,IC50,10000.0,nM,,CHEMBL3745491,CHEMBL203,CHEMBL3739340,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)C(=O)N1Cc2c(NC(=O)c3cc(F)cc(F)c3)n[nH]c2C1(C)C,376.40699999999964,3.563600000000002,2,3,78.09,4,2,0.8411897366294981,0,O=C(Nc1n[nH]c2c1CNC2)c1ccccc1,CHEMBL604712,IC50,10000.0,nM,,CHEMBL1074435,CHEMBL203,CHEMBL1157586,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21,345.46799999999956,3.0535000000000014,2,4,63.13,4,2,0.8944646558345623,0,O=C1NCCn2cc(-c3ccsc3)cc21,CHEMBL3298400,IC50,10000.0,nM,,CHEMBL3301281,CHEMBL203,CHEMBL3297733,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(C)NC(=O)Nc1nc2nc(N)ncc2cc1-c1ccccc1,336.3989999999997,3.194000000000001,3,5,105.82,3,3,0.6661860976596552,0,c1ccc(-c2cnc3ncncc3c2)cc1,CHEMBL76599,IC50,5530.0,nM,5.26,CHEMBL675380,CHEMBL203,CHEMBL1130094,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(C)NC(=O)c1ccc(N(CCCl)CCCl)cc1,317.25999999999965,3.4989000000000026,1,2,32.34,6,1,0.8145984051693793,0,c1ccccc1,CHEMBL589259,IC50,31430.0,nM,4.5,CHEMBL1065784,CHEMBL203,CHEMBL1157716,0.4,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
CC(C)(C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,404.4439999999998,3.230000000000002,1,6,115.61000000000001,6,2,0.4488864705845576,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL78206,IC50,1300.0,nM,5.89,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,346.4159999999997,1.4502999999999997,2,7,115.27,4,3,0.7414814883691502,0,c1cncc(-c2ccn3ncnc3c2)c1,CHEMBL2205766,IC50,10000.0,nM,,CHEMBL2211491,CHEMBL203,CHEMBL2203257,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)(C)OC(=O)N1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,395.4629999999997,3.5680000000000014,2,7,106.5,4,3,0.6869777129031971,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL168921,IC50,2200.0,nM,5.66,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)(C)OC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,329.3519999999997,3.509300000000002,3,6,99.35000000000001,6,2,0.4544756930329674,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL355206,IC50,10000.0,nM,,CHEMBL674006,CHEMBL203,CHEMBL1127676,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)(C)OC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,331.36799999999965,3.3708000000000014,4,6,99.02000000000001,7,2,0.5063005237806221,0,c1ccc(CNc2ccccc2)cc1,CHEMBL170111,IC50,1000.0,nM,6.0,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21,497.5329999999999,2.4186000000000005,3,10,162.48,7,4,0.339519027781695,0,O=c1c(NCc2ccccc2)c(Nc2ccc3[nH]ncc3c2)c1=O,CHEMBL1969506,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)ONC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,358.3939999999997,2.9428000000000014,4,6,111.38000000000001,8,2,0.37298247924057243,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL422899,IC50,30000.0,nM,4.52,CHEMBL674006,CHEMBL203,CHEMBL1127676,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)ONC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,360.4099999999997,2.804300000000001,5,6,111.05000000000001,9,2,0.40010530912013575,0,c1ccc(CNc2ccccc2)cc1,CHEMBL168343,IC50,5000.0,nM,5.3,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)ONC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,344.36699999999973,3.013900000000002,4,6,111.38000000000001,7,2,0.38694084980736687,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL353879,IC50,20000.0,nM,,CHEMBL674006,CHEMBL203,CHEMBL1127676,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)ONC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,346.3829999999997,2.8754000000000013,5,6,111.05000000000001,8,2,0.4204502885025739,0,c1ccc(CNc2ccccc2)cc1,CHEMBL170996,IC50,100.0,nM,7.0,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)c1cc(NC(=O)CN2CCN(c3ccccc3)CC2)no1,342.4429999999996,2.732800000000001,1,5,61.61000000000001,4,2,0.9256162450999967,0,O=C(CN1CCN(c2ccccc2)CC1)Nc1ccon1,CHEMBL4755651,IC50,66.0,nM,7.18,CHEMBL4672269,CHEMBL203,CHEMBL4665865,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(C)c1cc(NC(=O)CN2CCOCC2)no1,267.32899999999984,1.2428,1,5,67.60000000000001,3,1,0.8921906646239339,0,O=C(CN1CCOCC1)Nc1ccon1,CHEMBL4787698,IC50,144.0,nM,6.84,CHEMBL4672269,CHEMBL203,CHEMBL4665865,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CC(C)(C)c1cnc(CSc2cnc(NC(=O)Cc3ccc(CNC(CO)CO)cc3)s2)o1,490.6509999999997,3.3449000000000018,4,9,120.51,13,3,0.3021466962408843,0,O=C(Cc1ccccc1)Nc1ncc(SCc2ncco2)s1,CHEMBL300936,IC50,25000.0,nM,,CHEMBL677888,CHEMBL203,CHEMBL1135763,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2,312.3479999999997,3.0644800000000005,2,4,87.72,2,2,0.8468005107431871,0,C1=CC(c2ccccc2)c2cn[nH]c2O1,CHEMBL2004447,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,301.7809999999997,3.483900000000001,1,5,69.62,2,3,0.7467618341433325,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL406845,IC50,480.0,nM,6.32,CHEMBL940057,CHEMBL203,CHEMBL1145498,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1,392.4379999999997,3.4228000000000014,2,7,88.23,9,4,0.5227300222066353,0,c1ccc(-c2nc3cnccn3c2-c2ccncn2)cc1,CHEMBL1991395,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12,410.4279999999997,3.1491000000000007,1,7,81.13,7,4,0.5590560906168078,0,c1ccc(-c2nc3n(c2-c2ccc4nncn4n2)CCC3)cc1,CHEMBL1996587,Ki,1584.89,nM,5.8,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12,410.3839999999998,3.2471000000000014,1,8,93.75,7,5,0.4889077480800075,0,c1ccc(-c2nc3occn3c2-c2ccc3nncn3n2)cc1,CHEMBL1972849,Ki,794.33,nM,6.1,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12,410.3839999999998,3.290600000000002,1,8,93.75,7,5,0.4887151502027425,0,c1ccc(-c2nc3occn3c2-c2ccc3nncn3n2)cc1,CHEMBL1976732,Ki,1258.93,nM,5.9,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CC(C)(O)Cn1/c(=N/C(=O)c2cccc(-c3cccnc3)c2)[nH]c2ccccc21,386.45499999999976,3.543400000000002,2,4,83.26999999999998,7,4,0.5626550130245946,0,O=C(N=c1[nH]c2ccccc2[nH]1)c1cccc(-c2cccnc2)c1,CHEMBL4444231,IC50,173.0,nM,6.76,CHEMBL4324120,CHEMBL203,CHEMBL4321840,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)(O)Cn1/c(=N/C(=O)c2ccnc(-c3ccccc3)c2)[nH]c2ccccc21,386.45499999999976,3.543400000000002,2,4,83.26999999999998,7,4,0.5626550130245946,0,O=C(N=c1[nH]c2ccccc2[nH]1)c1ccnc(-c2ccccc2)c1,CHEMBL4434788,IC50,22.0,nM,7.66,CHEMBL4324122,CHEMBL203,CHEMBL4321840,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)(O)Cn1/c(=N/C(=O)c2ccnc(-c3cccnc3)c2)[nH]c2ccccc21,387.44299999999976,2.9384000000000006,2,5,96.16,7,4,0.5626686495076645,0,O=C(N=c1[nH]c2ccccc2[nH]1)c1ccnc(-c2cccnc2)c1,CHEMBL4449589,IC50,35.0,nM,7.46,CHEMBL4324122,CHEMBL203,CHEMBL4321840,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12,396.4009999999997,3.106600000000001,1,7,81.13,6,4,0.5755564831890257,0,c1ccc(-c2nc3n(c2-c2ccc4nncn4n2)CCC3)cc1,CHEMBL1998551,Ki,1584.89,nM,5.8,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)=CC[C@@H](O)C1=CC(=O)c2c(O)ccc(O)c2C1=O,288.2989999999997,2.1204000000000005,3,5,94.83000000000001,8,1,0.5847074834650013,0,O=C1C=CC(=O)c2ccccc21,CHEMBL9470,IC50,139.2,nM,6.86,CHEMBL4410222,CHEMBL203,CHEMBL4406881,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CC(C)C(CO)Nc1nc(Nc2ccc(N3CCNCC3)cc2)c2ncn(C(C)C)c2n1,438.5799999999996,2.989200000000001,4,9,103.16000000000001,13,3,0.4256553241653006,0,c1nc(Nc2ccc(N3CCNCC3)cc2)c2nc[nH]c2n1,CHEMBL4213400,IC50,78.0,nM,7.11,CHEMBL4178351,CHEMBL203,CHEMBL4177539,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,361.4899999999995,2.3134000000000006,2,4,81.33,9,1,0.8622393374431374,0,O=C(C1CCNCC1)N1Cc2cn[nH]c2C1,CHEMBL1230607,IC50,10000.0,nM,,CHEMBL1074435,CHEMBL203,CHEMBL1157586,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1,256.30900000000014,2.9985999999999997,2,4,80.73,6,3,0.7544262364747091,0,c1cc(-c2ccc3[nH]ncc3c2)on1,CHEMBL1966343,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,374.44799999999975,3.350100000000001,1,5,79.70000000000002,8,4,0.5809052905520269,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1969561,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,390.4169999999998,2.839900000000001,1,6,115.61000000000001,9,2,0.441460320159751,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL490987,IC50,1000.0,nM,6.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12,292.34599999999966,3.092900000000001,2,5,70.9,5,4,0.6084649229748759,0,c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1,CHEMBL1682553,Ki,1800.0,nM,,CHEMBL1685430,CHEMBL203,CHEMBL1681650,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)Nc1ncnn2ccc(CN3CCC(N)CC3)c12,288.39899999999955,1.4727,2,6,71.48,7,2,0.8912699913265424,0,c1ncc2c(CN3CCCCC3)ccn2n1,CHEMBL1645468,IC50,1000.0,nM,,CHEMBL1647391,CHEMBL203,CHEMBL1641446,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12,269.30399999999975,2.419600000000001,2,3,66.47999999999999,4,2,0.8221374222252893,0,O=C1NN=CC1=Cc1c[nH]c2ccccc12,CHEMBL1989029,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cc(/C=C(\C#N)C(N)=O)cc(C(C)C)c1O,272.3479999999997,3.031280000000002,2,3,87.11,9,1,0.6520060271788214,0,c1ccccc1,CHEMBL504173,IC50,1000.0,nM,6.0,CHEMBL941412,CHEMBL203,CHEMBL1150213,0.6,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range
CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,437.5519999999996,3.296000000000001,3,9,111.02999999999999,11,3,0.4886206808210586,0,c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCNCC3)n2)on1,CHEMBL3545085,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1ccc(C2N=C(C(N)=O)c3ncn(-c4ccc(F)cc4)c3N2)cc1,377.4229999999997,3.533500000000002,2,5,85.30000000000001,6,3,0.7292831411701689,0,C1=NC(c2ccccc2)Nc2c1ncn2-c1ccccc1,CHEMBL4795888,IC50,710.0,nM,6.15,CHEMBL4700377,CHEMBL203,CHEMBL4699428,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)c1cnc(N2CC(C#N)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,476.5599999999997,3.5457800000000024,2,9,114.09,9,3,0.5704931780812669,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5169349,IC50,17.0,nM,7.77,CHEMBL5141217,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cnc(N2CC(C(=O)N(C)C)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,522.6290000000002,3.110400000000002,2,9,110.61,12,3,0.5044875710406446,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5170376,IC50,0.9,nM,9.05,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cnc(N2CC(CS(C)(=O)=O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,543.6690000000015,3.0668000000000015,2,10,124.44,12,3,0.4593582180263289,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5173517,IC50,0.1,nM,10.0,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cnc(N2CC(O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,467.54899999999964,2.7669000000000006,3,9,110.53,10,3,0.5215843485085285,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5203267,IC50,3.6,nM,8.44,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cnc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,557.6960000000017,3.455300000000003,2,10,124.44,13,3,0.44625946158057483,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5200991,IC50,0.2,nM,9.7,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1cnc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,481.5759999999996,3.155400000000002,3,9,110.53,11,3,0.506040420691311,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5207390,IC50,0.3,nM,9.52,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1ncc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,481.5759999999996,3.155400000000002,3,9,110.53,11,3,0.506040420691311,0,c1cc(Nc2cc3cncc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5172587,IC50,1.8,nM,8.74,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)c1nnc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,466.5649999999996,3.579600000000002,2,9,103.19000000000001,10,3,0.583851525215384,0,c1cc(Nc2cc3cnnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5184941,IC50,16.0,nM,7.8,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)n1c(CO)nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc21,401.44599999999974,1.9471999999999996,3,9,112.22,9,3,0.5947253142015285,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3734934,Ki,0.53,nM,7.8,CHEMBL3737948,CHEMBL203,CHEMBL3734664,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)n1c(Nc2ccccc2)nc2cnc(Nc3ccc(C(=O)N[N+]4=CCN(C)CC4)cc3)nc21,484.58799999999974,3.5679000000000016,3,8,103.01,10,4,0.34472526118263386,0,O=C(N[N+]1=CCNCC1)c1ccc(Nc2ncc3nc(Nc4ccccc4)[nH]c3n2)cc1,CHEMBL4113919,IC50,3.0,nM,8.52,CHEMBL3706157,CHEMBL203,CHEMBL3638579,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1cc(C(N)=O)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,466.5269999999998,2.453500000000001,2,10,150.68,9,4,0.42143248018263896,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]ccc4cn3)n2)cn1,CHEMBL5274166,Ki,0.35,nM,9.46,CHEMBL5253713,CHEMBL203,CHEMBL5252534,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)n1cnc2cnc(Nc3ccnc(N4CCC(C(N)=O)CC4)n3)cc21,380.4559999999997,2.2475000000000005,2,8,114.85000000000001,7,3,0.6973521000888462,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735410,Ki,151.0,nM,6.82,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1cnnc1-c1cccc(N2Cc3ccccc3C2=O)n1,319.3679999999997,3.0814000000000012,0,5,63.910000000000004,5,3,0.7439973346079563,0,O=C1c2ccccc2CN1c1cccc(-c2nnc[nH]2)n1,CHEMBL3952214,IC50,19952.62,nM,,CHEMBL4727545,CHEMBL203,CHEMBL4725315,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(C)n1cnnc1-c1cccc(NC(=O)C2CCCCO2)n1,315.3769999999996,2.4286000000000003,1,6,81.93,6,2,0.9367483628683798,0,O=C(Nc1cccc(-c2nnc[nH]2)n1)C1CCCCO1,CHEMBL4759397,IC50,19952.62,nM,,CHEMBL4727545,CHEMBL203,CHEMBL4725315,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2cc(C=O)co2)c2c(N)ncnc21,271.27999999999975,2.0618999999999996,1,7,99.83,6,3,0.7317040013224727,0,c1coc(-c2n[nH]c3ncncc23)c1,CHEMBL1241439,IC50,5960.0,nM,5.22,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cc(F)c(C=O)c(F)c2)c2c(N)ncnc21,317.29899999999975,2.7470999999999997,1,6,86.69,6,3,0.7505790869016964,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241861,IC50,10000.0,nM,5.0,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2cc(F)c(O)cc2F)c2c(N)ncnc21,305.2879999999997,2.6402,2,6,89.85,6,3,0.7593504269015655,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242028,IC50,6900.0,nM,5.16,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2cc(F)c3cn[nH]c3c2)c2c(N)ncnc21,311.3239999999997,2.6717999999999993,2,6,98.3,5,4,0.5927847706314311,0,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1,CHEMBL1242573,IC50,1200.0,nM,5.92,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2cc(O)cc(Br)c2)c2c(N)ncnc21,348.2039999999998,3.1245000000000003,2,6,89.85,6,3,0.7426537867997828,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242285,IC50,249.0,nM,6.6,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,287.2979999999997,2.501099999999999,2,6,89.85,6,3,0.7554555039898821,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242198,IC50,576.0,nM,6.24,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,308.3449999999997,2.8432999999999993,3,6,105.64,6,4,0.5277706284055409,0,c1ccc2[nH]c(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1241674,Kd,220.0,nM,6.66,CHEMBL1908694,CHEMBL203,CHEMBL1908390,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,348.2039999999998,3.124500000000001,2,6,89.85,6,3,0.7426537867997828,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241578,IC50,550.0,nM,6.26,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc(C#N)c(F)c2)c2c(N)ncnc21,296.30899999999974,2.66718,1,6,93.41,5,3,0.7842796752208405,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241771,IC50,8900.0,nM,5.05,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(C#N)c(O)c2)c2c(N)ncnc21,294.3179999999997,2.2336799999999997,2,7,113.64,6,3,0.748797000171062,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241944,IC50,2600.0,nM,5.58,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(C=O)c(F)c2)c2c(N)ncnc21,299.30899999999974,2.6079999999999997,1,6,86.69,6,3,0.7511206802202501,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241860,IC50,9000.0,nM,5.05,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(CC#N)cc2)c2c(N)ncnc21,292.34599999999966,2.72248,1,6,93.41,6,3,0.800675815759068,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1240545,IC50,13000.0,nM,4.89,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,303.75299999999976,3.0154000000000005,2,6,89.85,6,3,0.7592199565366481,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241484,IC50,158.0,nM,6.8,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,287.2979999999997,2.501099999999999,2,6,89.85,6,3,0.7554555039898821,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242377,IC50,1400.0,nM,5.85,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(N)c(O)c2)c2c(N)ncnc21,284.3229999999997,1.9442,3,7,115.87,7,3,0.4889457235248862,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242848,IC50,2120.0,nM,5.67,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(NS(C)(=O)=O)cc2)c2c(N)ncnc21,346.4159999999997,2.0279,2,7,115.79,8,3,0.7465059572088026,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242030,IC50,12800.0,nM,4.89,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc(O)c(F)c2)c2c(N)ncnc21,287.2979999999997,2.501099999999999,2,6,89.85,6,3,0.7554555039898821,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241945,IC50,1040.0,nM,5.98,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc(O)cc2)c2c(N)ncnc21,269.3079999999997,2.362,2,6,89.85,6,3,0.7449921529589861,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241241,IC50,922.0,nM,6.04,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3[nH]c(=O)[nH]c3c2)c2c(N)ncnc21,309.33299999999974,1.8259999999999998,3,6,118.27,5,4,0.5217312727104362,0,O=c1[nH]c2ccc(-c3n[nH]c4ncncc34)cc2[nH]1,CHEMBL1241586,IC50,937.0,nM,6.03,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3[nH]c(=O)ccc3c2)c2c(N)ncnc21,320.3559999999997,2.4978999999999996,2,6,102.48,5,4,0.5905065501975338,0,O=c1ccc2cc(-c3n[nH]c4ncncc34)ccc2[nH]1,CHEMBL1241863,IC50,6700.0,nM,5.17,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3[nH]ccc3c2)c2c(N)ncnc21,292.34599999999966,3.1377000000000006,2,5,85.41,5,4,0.5940561618443512,0,c1ncc2c(-c3ccc4[nH]ccc4c3)n[nH]c2n1,CHEMBL1242294,IC50,176.0,nM,6.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3[nH]ncc3c2)c2c(N)ncnc21,293.3339999999997,2.5326999999999993,2,6,98.3,5,4,0.5914659946233978,0,c1ncc2c(-c3ccc4[nH]ncc4c3)n[nH]c2n1,CHEMBL1242386,IC50,1100.0,nM,5.96,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3c(C=O)c[nH]c3c2)c2c(N)ncnc21,320.3559999999997,2.9501999999999997,2,6,102.48,6,4,0.5649321323285218,0,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1,CHEMBL1242666,IC50,638.0,nM,6.2,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3c(N)n[nH]c3c2)c2c(N)ncnc21,308.3489999999997,2.1148999999999996,3,7,124.32000000000001,6,4,0.5206753840264887,0,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1,CHEMBL1242476,IC50,207.0,nM,6.68,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3c(c2)CCO3)c2c(N)ncnc21,295.34599999999966,2.5912999999999995,1,6,78.85000000000001,5,3,0.7858059769755096,0,c1ncc2c(-c3ccc4c(c3)CCO4)n[nH]c2n1,CHEMBL1241587,IC50,5000.0,nM,5.3,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3c(c2)OCCO3)c2c(N)ncnc21,311.3449999999997,2.4276,1,7,88.08,5,3,0.7817045804664382,0,c1ncc2c(-c3ccc4c(c3)OCCO4)n[nH]c2n1,CHEMBL1241588,IC50,15000.0,nM,4.82,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3c(ccn3C)c2)c2c(N)ncnc21,306.37299999999965,3.1481000000000003,1,6,74.55,6,4,0.6170976986244163,0,c1ncc2c(-c3ccc4[nH]ccc4c3)n[nH]c2n1,CHEMBL1242384,IC50,955.0,nM,6.02,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3cc(O)ccc3c2)c2c(N)ncnc21,319.36799999999965,3.515200000000002,2,6,89.85,6,4,0.5898235626156154,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1,CHEMBL1242662,IC50,88.0,nM,7.06,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,292.34599999999966,3.1376999999999997,2,5,85.41,5,4,0.5940561618443512,0,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1,CHEMBL1242574,IC50,220.0,nM,6.66,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21,293.3339999999997,2.5326999999999993,2,6,98.3,5,4,0.5914659946233978,0,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1,CHEMBL1242477,IC50,2500.0,nM,5.6,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3cnccc3c2)c2c(N)ncnc21,304.3569999999997,3.2046,1,6,82.51,5,4,0.6146133900580988,0,c1cc2cc(-c3n[nH]c4ncncc34)ccc2cn1,CHEMBL1242207,IC50,25000.0,nM,4.6,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3nc(N)ccc3c2)c2c(N)ncnc21,319.3719999999997,2.7867999999999995,2,7,108.53,6,4,0.5878286592395792,0,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1241949,IC50,12000.0,nM,4.92,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3nc(NN)ccc3c2)c2c(N)ncnc21,334.38699999999966,2.4901999999999997,3,8,120.56,7,4,0.3885827263729941,0,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1241950,IC50,7000.0,nM,5.16,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3nc[nH]c(=O)c3c2)c2c(N)ncnc21,321.3439999999997,1.8928999999999996,2,7,115.37,5,4,0.5822998722466886,0,O=c1[nH]cnc2ccc(-c3n[nH]c4ncncc34)cc12,CHEMBL1241776,IC50,7400.0,nM,5.13,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,304.3569999999997,3.2046,1,6,82.51,5,4,0.6146133900580988,0,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1233882,IC50,610.0,nM,6.21,CHEMBL3223623,CHEMBL203,CHEMBL3217752,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3nccnc3c2)c2c(N)ncnc21,305.34499999999974,2.5995999999999997,1,7,95.4,5,4,0.6113042520835761,0,c1cnc2cc(-c3n[nH]c4ncncc34)ccc2n1,CHEMBL1241774,IC50,18000.0,nM,4.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.85,Contains quinazoline core; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3nonc3c2)c2c(N)ncnc21,295.30599999999976,2.1925999999999997,1,8,108.54,5,4,0.6033228005706859,0,c1ncc2c(-c3ccc4nonc4c3)n[nH]c2n1,CHEMBL1241492,IC50,8300.0,nM,5.08,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,321.3399999999997,2.7627999999999995,1,7,99.83,5,4,0.6091158648192192,0,O=c1ccoc2ccc(-c3n[nH]c4ncncc34)cc12,CHEMBL1242118,IC50,29000.0,nM,4.54,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(-c2ccc3occc3c2)c2c(N)ncnc21,293.3299999999997,3.4026000000000005,1,6,82.76,5,4,0.6121051766957113,0,c1ncc2c(-c3ccc4occc4c3)n[nH]c2n1,CHEMBL1241490,IC50,964.0,nM,6.02,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cccc(C(=O)NC3=NCCS3)c2)c2c(N)ncnc21,381.46499999999975,2.489,2,8,111.08,6,3,0.7209462291759554,0,O=C(NC1=NCCS1)c1cccc(-c2n[nH]c3ncncc23)c1,CHEMBL1242115,IC50,579.0,nM,6.24,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cccc(CC#N)c2)c2c(N)ncnc21,292.34599999999966,2.72248,1,6,93.41,6,3,0.800675815759068,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241583,IC50,17000.0,nM,4.77,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cccc(NS(C)(=O)=O)c2)c2c(N)ncnc21,346.4159999999997,2.0279,2,7,115.79,8,3,0.7465059572088026,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241948,IC50,100000.0,nM,4.0,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,269.3079999999997,2.362,2,6,89.85,6,3,0.7449921529589861,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1230790,IC50,954.0,nM,6.02,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cccc(O)c2F)c2c(N)ncnc21,287.2979999999997,2.501099999999999,2,6,89.85,6,3,0.7554555039898821,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242110,IC50,3720.0,nM,5.43,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cccc3[nH]ccc23)c2c(N)ncnc21,292.34599999999966,3.1377000000000006,2,5,85.41,5,4,0.5940561618443512,0,c1cc(-c2n[nH]c3ncncc23)c2cc[nH]c2c1,CHEMBL1242757,IC50,4600.0,nM,5.34,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2ccn3ccnc3c2)c2c(N)ncnc21,293.3339999999997,2.3041,1,7,86.92,5,4,0.6124966343214543,0,c1ncc2c(-c3ccn4ccnc4c3)n[nH]c2n1,CHEMBL1242665,IC50,45000.0,nM,4.35,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,293.3339999999997,2.5327,2,6,98.3,5,4,0.5914659946233978,0,c1ncc2c(-c3cnc4[nH]ccc4c3)n[nH]c2n1,CHEMBL1242293,IC50,380.0,nM,6.42,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(C)n1nc(-c2cnc3ccccc3c2)c2c(N)ncnc21,304.3569999999997,3.2046,1,6,82.51,5,4,0.6146133900580988,0,c1ccc2ncc(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1242754,IC50,1000.0,nM,6.0,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(C)n1nc(N)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,439.50499999999977,2.3318000000000003,2,11,146.5,9,4,0.46175724540404456,1,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]ncc4cn3)n2)cn1,CHEMBL5280555,Ki,0.79,nM,9.1,CHEMBL5253712,CHEMBL203,CHEMBL5252534,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,301.38599999999957,2.956800000000002,4,4,72.72,11,2,0.593334886982252,0,c1ccc(CCCNCCc2ccccc2)cc1,CHEMBL926,IC50,5551.0,nM,5.26,CHEMBL1909203,CHEMBL203,CHEMBL1909046,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1,286.37899999999956,2.655000000000001,3,3,83.80000000000001,5,2,0.8107077911896503,0,O=C(Nc1ccnc2[nH]ccc12)C1CCCCC1,CHEMBL2002992,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC(NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,308.3369999999997,2.8821800000000017,3,4,93.35000000000001,7,2,0.459749518897389,0,O=C(/C=C/c1ccccc1)NCc1ccccc1,CHEMBL55979,IC50,400.0,nM,6.4,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C,273.3359999999996,2.2676999999999996,2,5,71.09,5,2,0.8361297705507181,0,O=c1cc(Nc2ccncc2)c1=O,CHEMBL1986186,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC(O)c1ccc(NC(=O)c2cc3ccccc3[nH]2)cc1,280.32699999999966,3.4735000000000014,3,2,65.12,5,3,0.6874344804601497,0,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1,CHEMBL3798556,IC50,35000.0,nM,4.46,CHEMBL3804124,CHEMBL203,CHEMBL3797044,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
CC(O)c1cccc(NC(=O)c2cc3ccccc3[nH]2)c1,280.32699999999966,3.4735000000000005,3,2,65.12,5,3,0.6874344804601497,0,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1,CHEMBL3800448,IC50,34000.0,nM,4.47,CHEMBL3804124,CHEMBL203,CHEMBL3797044,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
CC1(C)OCc2c(C(=O)c3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21,360.3769999999998,2.7393,2,6,109.44000000000001,5,4,0.5437628915885627,0,O=C(c1nc(-c2cn[nH]c2)nc2c1COC2)c1n[nH]c2ccccc12,CHEMBL3759761,Ki,104.0,nM,6.98,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c(Cl)c3Cl)nc(-c3cn[nH]c3)nc21,366.2119999999999,3.405500000000001,3,6,104.39999999999999,5,3,0.6562984247324904,0,c1cc(Nc2nc(-c3cn[nH]c3)nc3c2COC3)n[nH]1,CHEMBL3758646,Ki,389.0,nM,6.41,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4c(F)cc(F)cc34)nc(-c3cn[nH]c3)nc21,383.3619999999998,3.530100000000001,3,6,104.39999999999999,5,4,0.499945973914651,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3760072,Ki,10.4,nM,7.98,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC1(C)OCc2c(Nc3n[nH]c4c(F)cccc34)nc(-c3cn[nH]c3)nc21,365.3719999999998,3.391000000000001,3,6,104.39999999999999,5,4,0.514005466991233,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3759615,Ki,3.0,nM,8.52,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4c3CCCC4)nc(-c3cn[nH]c3)nc21,351.41399999999965,2.977500000000001,3,6,104.39999999999999,5,3,0.6699825968769173,0,c1n[nH]cc1-c1nc2c(c(Nc3n[nH]c4c3CCCC4)n1)COC2,CHEMBL3758959,Ki,2000.0,nM,,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4cc(F)ccc34)nc(-c3cn[nH]c3)nc21,365.3719999999998,3.391000000000001,3,6,104.39999999999999,5,4,0.514005466991233,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3759499,Ki,2.0,nM,8.7,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4ccc(F)cc34)nc(-c3cn[nH]c3)nc21,365.3719999999998,3.391000000000001,3,6,104.39999999999999,5,4,0.514005466991233,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3758283,Ki,8.0,nM,8.1,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4cccc(F)c34)nc(-c3cn[nH]c3)nc21,365.3719999999998,3.391000000000001,3,6,104.39999999999999,5,4,0.514005466991233,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3759935,Ki,17.0,nM,7.77,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3c[nH]nn3)nc21,348.3699999999997,2.6469000000000005,3,7,117.29,5,4,0.5207608974953846,0,c1ccc2c(Nc3nc(-c4c[nH]nn4)nc4c3COC4)n[nH]c2c1,CHEMBL3759696,Ki,732.0,nM,6.13,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cc[nH]n3)nc21,347.3819999999997,3.251900000000001,3,6,104.4,5,4,0.525370454235535,0,c1ccc2c(Nc3nc(-c4cc[nH]n4)nc4c3COC4)n[nH]c2c1,CHEMBL3760058,Ki,175.0,nM,6.76,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21,347.3819999999997,3.251900000000001,3,6,104.39999999999999,5,4,0.525370454235535,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3758502,Ki,0.2,nM,9.7,CHEMBL3762138,CHEMBL203,CHEMBL3758169,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Nc3n[nH]c4ccncc34)nc(-c3cn[nH]c3)nc21,348.3699999999998,2.6468999999999996,3,7,117.29,5,4,0.5207608974953846,0,c1cc2[nH]nc(Nc3nc(-c4cn[nH]c4)nc4c3COC4)c2cn1,CHEMBL3760038,Ki,2000.0,nM,,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1(C)OCc2c(Oc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21,348.36599999999976,3.300600000000001,2,6,101.60000000000001,5,4,0.5888925702746349,0,c1ccc2c(Oc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3759442,Ki,85.0,nM,7.07,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1=NNC2=NC(=O)NC(c3ccccc3Br)C12,307.1509999999998,2.2072000000000003,2,3,65.85,2,1,0.8351607548156395,0,O=C1N=C2NN=CC2C(c2ccccc2)N1,CHEMBL5198368,IC50,90.0,nM,7.05,CHEMBL5097734,CHEMBL203,CHEMBL5096180,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range
CC1=NNC2Oc3ncn(N)c(=N)c3C(c3ccccc3Br)C12,375.22999999999973,1.2845700000000009,3,7,101.31,3,2,0.6539918126506893,0,N=c1[nH]cnc2c1C(c1ccccc1)C1C=NNC1O2,CHEMBL5400975,IC50,60.0,nM,7.22,CHEMBL5347320,CHEMBL203,CHEMBL5346867,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC1CCC(n2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)C1,327.3629999999997,3.2813000000000008,2,6,89.85,5,3,0.7536555699278191,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242656,IC50,366.0,nM,6.44,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12,312.37699999999967,1.5447799999999996,1,5,88.91,5,2,0.9284511020269033,0,c1nc(NC2CCCNC2)c2cc[nH]c2n1,CHEMBL234085,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12,303.36599999999964,0.6233999999999995,2,5,85.35,6,2,0.8681806908244334,0,c1nc(NC2CCCNC2)c2cc[nH]c2n1,CHEMBL1969879,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)N1CCC[C@@H](n2nc(-c3ccc(F)cc3)c3c(N)ncnc32)C1,368.41599999999966,2.7881,1,6,89.93,5,3,0.7676888955776456,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4103121,IC50,5000.0,nM,5.3,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)N1CCC[C@@H](n2nc(-c3cccc(F)c3)c3c(N)ncnc32)C1,368.41599999999966,2.7881,1,6,89.93,5,3,0.7676888955776456,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4084214,IC50,3400.0,nM,5.47,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,350.4259999999996,2.649,1,6,89.93,5,3,0.7841299855474787,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4081698,IC50,4700.0,nM,5.33,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4ccc(C(C)=O)cc4)nn3)c3c(N)ncnc32)C1,459.5139999999997,2.4323000000000006,1,10,137.71,8,4,0.4492164039282949,0,c1ccc(-n2cc(-c3nn(C4CCCNC4)c4ncncc34)nn2)cc1,CHEMBL4588202,IC50,649.0,nM,6.19,CHEMBL4481537,CHEMBL203,CHEMBL4480410,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)C1,481.60099999999966,2.0229999999999997,2,8,116.92,11,2,0.5882449025406087,0,c1cc(N2CCNCC2)ccc1Nc1cncc(OC2CCNC2)n1,CHEMBL3663934,IC50,1.2,nM,8.92,CHEMBL3705896,CHEMBL203,CHEMBL3638445,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,450.4649999999997,2.884500000000002,1,7,83.48,7,2,0.7500668161155856,0,c1cncc(N2CCc3ncnc(NC4CCNC4)c3C2)c1,CHEMBL3643413,IC50,10000.0,nM,,CHEMBL5474412,CHEMBL203,CHEMBL5465560,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,420.4729999999997,2.0089,1,8,108.39,8,3,0.6432804947652428,0,C(#Cc1nn(C2CCNC2)c2ncncc12)c1ccccc1,CHEMBL3701282,IC50,5000.0,nM,,CHEMBL5256648,CHEMBL203,CHEMBL5252660,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,382.48899999999975,3.1315000000000017,2,6,78.35000000000001,7,3,0.7088077437599887,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272112,IC50,20000.0,nM,,CHEMBL1273342,CHEMBL203,CHEMBL1269003,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)NNC(=O)c1csc2ncc(-c3ccc(C)cc3)n12,328.39699999999976,2.5422200000000004,2,5,75.5,5,3,0.7255822897149152,0,c1ccc(-c2cnc3sccn23)cc1,CHEMBL5176561,IC50,450.0,nM,6.35,CHEMBL5110647,CHEMBL203,CHEMBL5108025,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)Nc1cc(Nc2cc[nH]n2)nc(-c2ccccc2)n1,308.34499999999974,2.958800000000001,3,5,95.59,6,3,0.6732155614090053,0,c1ccc(-c2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL3604918,IC50,3400.0,nM,5.47,CHEMBL3606404,CHEMBL203,CHEMBL3603765,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)Nc1cc2c(NCc3ccccc3)ncnc2cc1OC,336.3949999999997,3.599000000000003,2,5,76.14,8,3,0.7191434535046699,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL3934539,IC50,136.0,nM,6.87,CHEMBL3854863,CHEMBL203,CHEMBL3853319,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)Nc1ccc(Oc2nc(Nc3cc(C)[nH]n3)cc(N3CCN(C)CC3)n2)cc1,436.5199999999997,3.1443200000000013,3,8,111.29999999999998,10,3,0.5179837104740181,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604925,IC50,700.0,nM,6.16,CHEMBL3606405,CHEMBL203,CHEMBL3603765,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)Nc1cccc(Oc2nc(Nc3cc(C)[nH]n3)cc(N3CCN(C)CC3)n2)c1,436.51999999999964,3.1443200000000013,3,8,111.29999999999998,10,3,0.5179837104740181,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604924,IC50,1900.0,nM,5.72,CHEMBL3606404,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)Nc1cccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCN(C)CC3)n2)c1,422.4929999999997,2.8359000000000005,3,8,111.29999999999998,9,3,0.5330091890188638,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604934,IC50,10000.0,nM,,CHEMBL3606403,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(=O)Nc1cccc(Oc2nccc(Nc3cc(C)[nH]n3)n2)c1,338.3709999999997,3.39252,3,6,104.82,8,3,0.6361191846525031,0,c1ccc(Oc2nccc(Nc3cc[nH]n3)n2)cc1,CHEMBL3604932,IC50,10000.0,nM,,CHEMBL3606404,CHEMBL203,CHEMBL3603765,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCC(=O)Nc1ccccc1Oc1nc(Nc2cc(C)[nH]n2)cc(N2CCN(C)CC2)n1,436.51999999999964,3.1443200000000004,3,8,111.29999999999998,10,3,0.5179837104740181,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604923,IC50,10000.0,nM,,CHEMBL3606403,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(C)[C@@H]1[C@@](C)(C(=O)/C=C/OC)[C@H]2[C@H](C)C[C@@](C)(O)C[C@]2(O)C(=O)[C@@]1(C)O,396.52399999999943,2.2461000000000007,3,6,104.06000000000002,15,0,0.4863422048410024,0,O=C1CCCC2CCCCC12,CHEMBL498247,IC50,10500.0,nM,4.98,CHEMBL974188,CHEMBL203,CHEMBL1142620,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CCC(C)n1cnc2cnc(Nc3ccnc(N4CCC(OC)CC4)n3)cc21,381.48399999999964,3.5511000000000026,1,8,80.99000000000001,9,3,0.6991118021929329,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735250,Ki,14.0,nM,7.85,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC(C)n1nc(-c2ccc(C)c(O)c2)c2c(N)ncnc21,297.3619999999996,3.0605200000000004,2,6,89.85,8,3,0.7751024887193273,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242109,IC50,1670.0,nM,5.78,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCC1=C2C(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)=NC=NC2N=C1NC(=O)OC[C@@H]1COCCN1,544.5910000000014,3.235400000000001,3,10,126.52000000000001,7,3,0.43752012957282777,1,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCC1COCCN1,CHEMBL583403,IC50,23.0,nM,7.64,CHEMBL1052827,CHEMBL203,CHEMBL1154610,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCN1CCNCC1,539.6440000000013,3.0131000000000006,3,10,120.53,8,3,0.4246390589345884,1,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCN1CCNCC1,CHEMBL565714,IC50,21.0,nM,7.68,CHEMBL1052827,CHEMBL203,CHEMBL1154610,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCN1CCOCC1,540.6280000000014,3.440100000000002,2,10,117.73,8,3,0.47419694255895667,1,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCN1CCOCC1,CHEMBL578255,IC50,111.0,nM,6.96,CHEMBL1052827,CHEMBL203,CHEMBL1154610,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OC[C@@H]1COCCN1,526.6010000000006,3.0963000000000003,3,10,126.52000000000001,7,3,0.4531964786350171,1,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCC1COCCN1,CHEMBL567873,IC50,33.0,nM,7.48,CHEMBL1052827,CHEMBL203,CHEMBL1154610,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,521.6660000000002,3.5568000000000017,2,8,102.92999999999999,11,2,0.5703394097150783,1,O=C1CN(C2CCCC2)c2nc(Nc3ccc(C(=O)NC4CCNCC4)cc3)ncc2N1,CHEMBL1968380,Ki,251.19,nM,6.6,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCCC(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2,362.3889999999997,3.3924000000000003,4,5,102.82,5,2,0.38168061897351807,0,N=C1/C(=C2/C(=O)Nc3ccccc32)Nc2ccccc21,CHEMBL3799585,IC50,8000.0,nM,5.1,CHEMBL3802284,CHEMBL203,CHEMBL3797047,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12,254.29300000000012,2.8497000000000003,2,3,70.67,4,3,0.7545928879364325,0,c1ccc2nc3[nH]ncc3cc2c1,CHEMBL1967564,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12,317.2989999999998,3.0367000000000006,2,4,83.56,5,3,0.7744741041731756,0,c1ccc(-c2cc3cn[nH]c3nn2)cc1,CHEMBL1979970,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12,310.35699999999974,3.373300000000002,1,5,76.88,6,3,0.8011679191087868,0,c1ccc2nc3[nH]ncc3cc2c1,CHEMBL1970913,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCC(Cc1coc2nc(N)nc(N)c12)c1ccccc1OC,326.39999999999964,3.5222000000000016,2,6,100.19,10,3,0.7185565508042809,0,c1ccc(CCc2coc3ncncc23)cc1,CHEMBL605413,IC50,2200.0,nM,5.66,CHEMBL1038898,CHEMBL203,CHEMBL1152608,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCCCCCCCCCCCCCCC[n+]1ccccc1.[Br-],384.44599999999923,3.4594000000000014,0,0,3.88,16,1,0.32213756612662414,0,c1cc[nH+]cc1,CHEMBL334255,IC50,3472.0,nM,5.46,CHEMBL1909203,CHEMBL203,CHEMBL1909046,0.5,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range
CCCCN1C(=O)CS/C1=N/Nc1nncc2ccccc12,315.40199999999976,2.688200000000001,1,6,70.48,6,2,0.8590609015424638,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1,CHEMBL3921710,IC50,23.0,nM,7.64,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCCNC(=O)c1ccc(N(CCCl)CCCl)cc1,317.25999999999965,3.5005000000000024,1,2,32.34,10,1,0.5583465463144338,0,c1ccccc1,CHEMBL590083,IC50,22810.0,nM,4.64,CHEMBL1065784,CHEMBL203,CHEMBL1157716,0.4,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
CCCCNC(=S)NNc1nncc2ccccc12,275.3809999999997,2.2208999999999994,3,4,61.87,6,2,0.44172710662533843,0,c1ccc2cnncc2c1,CHEMBL3905411,IC50,52.0,nM,7.28,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O,355.4379999999996,2.2297000000000007,3,5,81.67000000000002,11,2,0.4746629946063804,0,O=C1NC(=O)c2cccc3cccc1c23,CHEMBL1987359,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1,282.3439999999997,3.2989000000000015,2,5,72.9,7,2,0.6279397020089187,0,c1ccc(Nc2cn[sH+]n2)cc1,CHEMBL1971694,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,330.4129999999997,2.9638,3,4,100.86999999999999,7,3,0.6691730135121757,0,c1ccc(-c2ccc3[nH]ncc3c2)cc1,CHEMBL1992342,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1,372.44999999999976,3.3400000000000016,3,4,103.94999999999999,8,3,0.617112145009576,0,c1ccc(-c2ccc3[nH]ncc3c2)cc1,CHEMBL1973893,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCc1cc(N2CCC(N)CC2)nc2sc(C(N)=O)c(N)c12,333.4609999999996,1.8574000000000002,3,6,111.26,7,2,0.7905084697765767,0,c1cc2ccc(N3CCCCC3)nc2s1,CHEMBL578601,IC50,7000.0,nM,,CHEMBL1049082,CHEMBL203,CHEMBL1156029,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCc1cc(N2CCC(O)CC2)nc2sc(C(N)=O)c(N)c12,334.44499999999965,1.891,3,6,105.46999999999998,7,2,0.791616284469,0,c1cc2ccc(N3CCCCC3)nc2s1,CHEMBL576887,IC50,7000.0,nM,,CHEMBL1049082,CHEMBL203,CHEMBL1156029,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCc1cc(N2CCCC(O)C2)nc2sc(C(N)=O)c(N)c12,334.44499999999965,1.891,3,6,105.46999999999998,7,2,0.791616284469,0,c1cc2ccc(N3CCCCC3)nc2s1,CHEMBL576989,IC50,7000.0,nM,,CHEMBL1049082,CHEMBL203,CHEMBL1156029,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCCc1cc(N2CCNCC2)nc2sc(C(N)=O)c(N)c12,319.4339999999997,1.3395000000000004,3,6,97.27,6,2,0.7899098287248604,0,c1cc2ccc(N3CCNCC3)nc2s1,CHEMBL568922,IC50,7000.0,nM,,CHEMBL1049082,CHEMBL203,CHEMBL1156029,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,398.48199999999963,3.3349400000000013,3,3,77.23,11,2,0.6263032743124629,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL535,IC50,31.8,nM,7.5,CHEMBL4398934,CHEMBL203,CHEMBL4396905,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C,380.4919999999996,3.1958400000000013,3,3,77.23,11,2,0.6457599185457328,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL275117,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,398.48199999999963,3.3349400000000013,3,3,77.23,11,2,0.6263032743124629,0,O=C1Nc2ccccc2C1=Cc1ccc[nH]1,CHEMBL1990885,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1,398.49599999999964,2.44212,3,9,107.25999999999999,11,4,0.41834970358726004,0,c1cc(Nc2nccn3c(-c4cn[nH]c4)cnc23)sn1,CHEMBL4228240,IC50,500.0,nM,,CHEMBL4222457,CHEMBL203,CHEMBL4219148,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCN1C(=O)CS/C1=N/Nc1nncc2ccccc12,287.3479999999998,1.9079999999999997,1,6,70.48,4,2,0.8731687943796813,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1,CHEMBL3893698,IC50,47.0,nM,7.33,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCN1CCN(CC(=O)Nc2cc(C)on2)CC1,252.31800000000015,0.5590199999999994,1,5,61.61,6,1,0.8480705227171326,0,O=C(CN1CCNCC1)Nc1ccon1,CHEMBL1619395,IC50,81.0,nM,7.09,CHEMBL4672269,CHEMBL203,CHEMBL4665865,0.6,Activity in Type 1 range; Activity in typical Type 1 range; H-bond features typical of Type 1
CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,429.47499999999974,2.6543,2,6,90.03999999999999,8,3,0.6002763863443701,0,O=C(CCCN1CCNCC1)Nc1n[nH]c2nnc(-c3ccccc3)cc12,CHEMBL1992740,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCN1CCN(CCCNc2ccc(Oc3nc4ccccc4c4nncn34)cc2)CC1,431.54399999999964,3.5093000000000014,1,8,70.82,9,4,0.4281979873911198,0,c1ccc2c(c1)nc(Oc1ccc(NCCCN3CCNCC3)cc1)n1cnnc21,CHEMBL4649833,IC50,9510.0,nM,5.02,CHEMBL4619916,CHEMBL203,CHEMBL4619706,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCN1CCN(c2nc(Oc3ccc4ccc(=O)[nH]c4c3)c3sccc3n2)CC1,407.49899999999974,3.4670000000000014,1,7,74.35,5,4,0.5584226967472556,0,O=c1ccc2ccc(Oc3nc(N4CCNCC4)nc4ccsc34)cc2[nH]1,CHEMBL4794102,IC50,1000.0,nM,,CHEMBL4770070,CHEMBL203,CHEMBL4765321,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCNC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1,367.40899999999976,3.532000000000002,3,6,97.40000000000002,9,3,0.6165620278897587,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2016600,IC50,10000.0,nM,,CHEMBL2020642,CHEMBL203,CHEMBL2016491,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCNC(=O)c1cnc(Nc2ccnc(-c3cnn(S(=O)(=O)C4CC4)c3)n2)cc1N[C@@H](C)CC,484.58599999999973,2.7791000000000006,3,10,143.79,13,3,0.39549500595309817,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3ccccn3)n2)cn1,CHEMBL5415613,IC50,5.6,nM,8.25,CHEMBL5358074,CHEMBL203,CHEMBL5356962,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,442.27299999999974,3.588700000000001,2,7,106.10000000000001,7,3,0.44402992261166346,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL422292,IC50,1.5,nM,8.82,CHEMBL673925,CHEMBL203,CHEMBL1134843,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(C)ccc2n2nnnc12,495.54299999999984,3.3252200000000016,1,10,128.60000000000002,7,4,0.4239099524105624,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325478,IC50,7000.0,nM,5.16,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,481.51599999999985,3.0168000000000017,1,10,128.60000000000002,6,4,0.4373439252942457,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325477,IC50,90.0,nM,7.05,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1,409.4229999999999,1.0866800000000003,1,9,124.39,6,3,0.6395698439311306,0,O=c1c(=Cc2ccco2)sc2n1C=CC(c1ccco1)C=2,CHEMBL1999112,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)CCC(=O)Nc1cc(Nc2cccc(Br)c2)ncn1,393.2409999999997,3.264500000000001,2,6,93.21000000000001,8,2,0.7018351742887791,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4288761,IC50,933.0,nM,6.03,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOC(=O)CCCC(=O)Nc1cc(Nc2cccc(Cl)c2)ncn1,362.8169999999997,3.5455000000000014,2,6,93.21000000000001,9,2,0.6974228745549078,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4283061,IC50,27.0,nM,7.57,CHEMBL4267255,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOC(=O)CCCn1c(=O)oc2cc3ncnc(NCc4ccccc4)c3cc21,406.4419999999998,3.493100000000002,1,8,99.25,9,4,0.44718454323409657,0,O=c1[nH]c2cc3c(NCc4ccccc4)ncnc3cc2o1,CHEMBL3612577,IC50,10000.0,nM,,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(O)cc4)c3cc21,408.4139999999998,3.3302000000000023,2,9,119.48,9,4,0.35295587997925665,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612594,IC50,20.0,nM,7.7,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(S(N)(=O)=O)cc4)c3cc21,471.49499999999983,2.2720000000000002,2,10,159.41,10,4,0.3674322440909689,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612582,IC50,10000.0,nM,,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc21,432.4399999999998,3.5009000000000015,2,9,127.92999999999999,8,5,0.3740833211469772,0,O=c1[nH]c2cc3c(Nc4ccc5[nH]ncc5c4)ncnc3cc2o1,CHEMBL3612590,IC50,130.0,nM,6.89,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4cccc(O)c4)c3cc21,408.4139999999998,3.3302000000000023,2,9,119.48,9,4,0.4469904659366124,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612595,IC50,8.7,nM,8.06,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,315.3249999999997,2.6596000000000015,3,6,99.35000000000001,9,2,0.4473556728891674,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL168425,IC50,20000.0,nM,4.7,CHEMBL674005,CHEMBL203,CHEMBL1127676,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,317.34099999999967,2.521100000000001,4,6,99.02000000000001,10,2,0.48253422234542653,0,c1ccc(CNc2ccccc2)cc1,CHEMBL171727,IC50,7000.0,nM,5.16,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)[C@@H]1CCCN1CC(=O)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1OC,512.5879999999999,2.5256000000000016,2,9,119.09000000000002,11,3,0.3316922542267855,1,O=C(COc1ccc(-c2nc3ccccc3s2)cc1)NNC(=O)CN1CCCC1,CHEMBL5201110,IC50,109.0,nM,6.96,CHEMBL5133605,CHEMBL203,CHEMBL5131433,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C,310.3529999999997,3.3009400000000015,2,3,71.19,6,2,0.6747222050998686,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL86943,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
CCOC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,301.2979999999997,2.730700000000001,3,6,99.35000000000001,8,2,0.4578862429702947,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL354521,IC50,40000.0,nM,4.4,CHEMBL674006,CHEMBL203,CHEMBL1127676,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,303.3139999999997,2.5922000000000005,4,6,99.02000000000001,9,2,0.5003677995779018,0,c1ccc(CNc2ccccc2)cc1,CHEMBL355857,IC50,400.0,nM,6.4,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)c1ccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)cc1,372.3809999999997,2.5903,3,8,130.51,10,2,0.5725861878062483,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4290750,IC50,21.0,nM,7.68,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOC(=O)c1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,477.5209999999998,3.1803000000000017,1,10,111.72,9,4,0.38245997855346453,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064374,IC50,5800.0,nM,5.24,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)c1ccc(Nc2nncc3ccccc23)cc1,293.3259999999997,3.5501000000000014,1,5,64.11,5,3,0.7451939087476416,0,c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3906533,IC50,4.4,nM,8.36,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOC(=O)c1ccc(O)c(Nc2ncnc3cc4oc(=O)n(CCOC)c4cc23)c1,424.41299999999984,2.8100000000000014,2,10,128.71,10,4,0.3397417033106409,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612573,IC50,440.0,nM,6.36,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O,258.277,1.6304999999999998,2,3,71.19,3,2,0.8041609038136314,0,O=C1NCCc2c1[nH]c1ccccc21,CHEMBL2005528,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOC(=O)c1cccc(Nc2ncnc3[nH]c(C)c(C)c23)c1,310.35699999999974,3.4950400000000013,2,5,79.9,7,3,0.7209870582913267,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL72976,IC50,100000.0,nM,,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CCOC(=O)c1cn2ncnc(NCc3ccccc3)c2c1CC,324.38399999999973,3.0805000000000016,1,6,68.52,8,3,0.7057678404323402,0,c1ccc(CNc2ncnn3cccc23)cc1,CHEMBL371863,IC50,200.0,nM,6.7,CHEMBL881943,CHEMBL203,CHEMBL1140398,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOC(=O)c1cn2ncnc(Nc3ccc4[nH]ncc4c3)c2c1CC,350.38199999999983,3.088300000000001,2,7,97.2,7,4,0.5369205850226693,0,c1cc2c(Nc3ccc4[nH]ncc4c3)ncnn2c1,CHEMBL372112,IC50,50.0,nM,7.3,CHEMBL881943,CHEMBL203,CHEMBL1140398,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOC(C)=O.CN(C)CCNc1[nH]cnc2nc3ccccc3c1-2,343.43099999999964,2.6056,2,6,83.14,9,1,0.6930238413335614,0,c1ccc2c3c[nH]cnc-3nc2c1,CHEMBL357326,IC50,10000.0,nM,,CHEMBL679944,CHEMBL203,CHEMBL1132555,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CCOc1cc(-c2nn(CCO)c3ncnc(N)c23)ccc1OC,329.35999999999973,1.4750999999999999,2,8,108.31,10,3,0.7047153994976786,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242753,IC50,8010.0,nM,5.1,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(O)cc2)c1O,370.42999999999984,3.181080000000001,3,6,116.57,10,2,0.39145113544468174,0,c1ccc(CSc2ccccc2)cc1,CHEMBL483233,IC50,3000.0,nM,5.52,CHEMBL941412,CHEMBL203,CHEMBL1150213,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2cccc(OC)c2)c1O,384.4569999999998,3.484080000000002,2,6,105.57,11,2,0.40997897227965086,0,c1ccc(CSc2ccccc2)cc1,CHEMBL483232,IC50,4000.0,nM,5.4,CHEMBL941412,CHEMBL203,CHEMBL1150213,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,354.4309999999998,3.4754800000000023,2,5,96.33999999999999,9,2,0.45071677739642174,0,c1ccc(CSc2ccccc2)cc1,CHEMBL485070,IC50,400.0,nM,6.4,CHEMBL941412,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,282.29499999999973,3.564300000000002,1,4,59.67,5,3,0.7975171213321737,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL172517,IC50,31800.0,nM,4.5,CHEMBL4231196,CHEMBL203,CHEMBL4229349,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1cc2ncnc(NC3=CC(=O)C(OC(CF)CF)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,515.517,2.740500000000001,2,9,122.75000000000001,15,2,0.324479654374935,1,O=C1C=CC(=O)C(Nc2ncnc3ccccc23)=C1,CHEMBL243410,IC50,283.3,nM,6.55,CHEMBL892951,CHEMBL203,CHEMBL1147965,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOc1cc2ncnc(NC3=CC(=O)C(OC)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,451.4829999999998,2.0626999999999995,2,9,122.75000000000001,13,2,0.43554567052012644,0,O=C1C=CC(=O)C(Nc2ncnc3ccccc23)=C1,CHEMBL428039,IC50,799.3,nM,6.1,CHEMBL892951,CHEMBL203,CHEMBL1147965,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOc1cc2ncnc(N[C@@H](C)c3ccccc3)c2cc1NC(=O)[C@@H]1COC(=O)N1,421.45699999999977,3.2485,3,7,114.47000000000003,9,3,0.5364209967939662,0,O=C1NC(C(=O)Nc2ccc3ncnc(NCc4ccccc4)c3c2)CO1,CHEMBL3818563,IC50,0.71,nM,9.15,CHEMBL3820193,CHEMBL203,CHEMBL3817746,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CO,390.80199999999985,3.4954000000000023,3,6,96.37000000000002,8,3,0.5958266457736722,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL4449681,IC50,0.34,nM,9.47,CHEMBL4384432,CHEMBL203,CHEMBL4382245,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1cc2ncnc(Nc3cccc(OC)c3)c2c2c1OCCO2,353.37799999999976,3.5519000000000016,1,7,74.73000000000002,7,3,0.7515995256302264,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805774,IC50,4.4,nM,8.36,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1cc2ncnc(Nc3cccc([N+](=O)[O-])c3)c2c2c1OCCO2,368.3489999999999,3.451500000000002,1,8,108.64000000000001,6,3,0.5386720565625972,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805238,IC50,9.7,nM,8.01,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1ccc(-c2cc(C(F)(F)F)c(C#N)c(SCC(=O)NCC(=O)O)n2)cc1,439.41499999999985,3.330680000000001,2,7,112.31,9,2,0.6069184571817119,0,c1ccc(-c2ccccn2)cc1,CHEMBL2029694,IC50,8400.0,nM,5.08,CHEMBL2034705,CHEMBL203,CHEMBL2029299,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,327.38799999999964,3.0637000000000008,1,7,88.08,10,3,0.7745831809493207,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242472,IC50,5950.0,nM,5.22,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,339.39899999999966,3.2949000000000015,2,7,99.08,7,3,0.7564728838537961,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242289,IC50,768.0,nM,6.12,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,353.42599999999965,3.597900000000002,1,7,88.08,8,3,0.7538570725827946,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1240554,IC50,1400.0,nM,5.85,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1ccc(C(=O)Nc2nccc(-c3cccnc3)n2)cc1NC(=O)/C=C/CN(C)C,446.5109999999997,3.2459000000000016,2,7,109.33999999999999,12,3,0.48571347031306245,0,O=C(Nc1nccc(-c2cccnc2)n1)c1ccccc1,CHEMBL2385988,IC50,6000.0,nM,5.22,CHEMBL2390159,CHEMBL203,CHEMBL2384937,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,449.51099999999974,3.402300000000002,1,9,94.65,9,4,0.4374148126849475,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064382,IC50,1400.0,nM,5.85,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOc1ccc2cc(-c3nn(C)c4ncnc(N)c34)ccc2c1,319.3679999999997,3.1644000000000005,1,6,78.85,6,4,0.6272694179011019,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1,CHEMBL1242661,IC50,21000.0,nM,4.68,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1ccc2cc(-c3nn(CC4CCNCC4)c4ncnc(N)c34)ccc2n1.Cl,439.95099999999957,3.443800000000001,2,8,103.77,7,4,0.4903981626885349,0,c1cnc2ccc(-c3nn(CC4CCNCC4)c4ncncc34)cc2c1,CHEMBL2070051,IC50,10000.0,nM,,CHEMBL2072949,CHEMBL203,CHEMBL2069256,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1,411.42599999999976,0.9952999999999996,2,11,149.58,9,3,0.4284696068729471,1,O=C(NN=Cc1ccccc1)c1nnn(-c2cnon2)c1N1CCCC1,CHEMBL1992732,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N,374.4219999999998,1.26768,2,7,135.17,9,2,0.7768738013853492,0,O=C(NCc1ccccc1)c1ccccn1,CHEMBL424872,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl,383.85699999999974,2.0494,2,6,111.37999999999998,9,2,0.7891266501926829,0,O=C(NCc1ccccc1)c1ccccn1,CHEMBL377383,Ki,1800.0,nM,,CHEMBL867306,CHEMBL203,CHEMBL1138045,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N,375.40999999999985,0.5115800000000001,3,7,161.19,9,2,0.6623410762515892,0,O=C(NCc1ccccc1)c1ccccn1,CHEMBL2004355,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N,375.4099999999998,0.5115800000000006,3,7,161.19,9,2,0.6623410762515893,0,O=C(NCc1ccccc1)c1ccccn1,CHEMBL377408,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl,384.84499999999974,1.2933000000000003,3,6,137.4,9,2,0.6857127448208695,0,O=C(NCc1ccccc1)c1ccccn1,CHEMBL2006581,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N,297.31799999999976,1.25918,2,6,113.91999999999999,7,2,0.858341736670672,0,O=C(NCc1cccnc1)c1ccccn1,CHEMBL209534,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N,297.31799999999976,1.25918,2,6,113.91999999999999,7,2,0.858341736670672,0,O=C(NCc1ccncc1)c1ccccn1,CHEMBL1984206,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N,434.4739999999998,1.5360799999999997,2,9,153.63,13,2,0.6293082808757999,0,O=C(Cc1ccccc1)Nc1ccccn1,CHEMBL210963,Ki,1800.0,nM,,CHEMBL860206,CHEMBL203,CHEMBL1148638,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl,443.90899999999976,2.3177999999999996,2,8,129.84,13,2,0.6351982895506235,0,O=C(Cc1ccccc1)Nc1ccccn1,CHEMBL210928,Ki,1800.0,nM,,CHEMBL860206,CHEMBL203,CHEMBL1148638,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N,356.3819999999997,2.13258,2,7,119.49000000000001,11,2,0.7795508815441708,0,O=C(Cc1ccccc1)Nc1ccccn1,CHEMBL210618,Ki,1800.0,nM,,CHEMBL860206,CHEMBL203,CHEMBL1148638,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,371.4259999999998,1.09568,1,7,120.55999999999999,6,3,0.7167032115900049,0,c1nc(-c2cnn(C3CNC3)c2)c2cc[nH]c2n1,CHEMBL2105759,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl,482.00999999999965,1.7869000000000006,3,8,133.55,9,2,0.5191860772131784,0,c1cc(NC2CC2)nc(Nc2ccc(N3CCNCC3)cc2)n1,CHEMBL3991929,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,316.38599999999974,2.5737000000000005,3,4,100.86999999999999,6,3,0.6882700414997416,0,c1ccc(-c2ccc3[nH]ncc3c2)cc1,CHEMBL1997597,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1,346.4329999999998,2.8558000000000003,1,5,90.12,5,3,0.7863042361116613,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL2000104,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCS(=O)(=O)c1ccc(S(=O)(=O)NC)cc1Nc1cc(Nc2ccc(Cl)cn2)ncn1,482.9749999999998,2.7139000000000006,3,9,143.04000000000002,10,3,0.44099820104419046,0,c1ccc(Nc2cc(Nc3ccccn3)ncn2)cc1,CHEMBL4094739,IC50,25000.0,nM,,CHEMBL4024628,CHEMBL203,CHEMBL4020849,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCS(=O)(=O)n1cc(-c2ccnc(Nc3ccc4c(cnn4CC(=O)N(C)C)c3)n2)c2ccccc21,503.58799999999985,3.4776000000000025,1,9,115.00999999999999,10,5,0.361551457123466,1,c1ccc2c(-c3ccnc(Nc4ccc5[nH]ncc5c4)n3)c[nH]c2c1,CHEMBL5430401,IC50,38.0,nM,7.42,CHEMBL5341566,CHEMBL203,CHEMBL5338765,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,521.6660000000002,3.5568000000000017,2,8,102.92999999999999,11,2,0.5703394097150783,1,O=C1CN(C2CCCC2)c2nc(Nc3ccc(C(=O)NC4CCNCC4)cc3)ncc2N1,CHEMBL513909,Kd,240.0,nM,6.62,CHEMBL1908701,CHEMBL203,CHEMBL1908390,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,380.37399999999974,2.9079000000000006,2,4,78.32,4,3,0.73344493486508,0,c1cc2c(ncc3ncc(C4CCNC4)n32)[nH]1,CHEMBL3622821,IC50,10000.0,nM,,CHEMBL5471956,CHEMBL203,CHEMBL5465560,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,392.3849999999997,3.279000000000001,3,5,95.59,8,3,0.5984099583581054,0,c1cnc(-c2c[nH]c3ncccc23)nc1,CHEMBL3039513,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC[C@H](C)Nc1cc(Nc2ccnc(-c3cnn(S(=O)(=O)C4CC4)c3)n2)ncc1C(=O)N(C)C,484.5859999999998,2.7312000000000003,2,10,135.0,13,3,0.4697862045532207,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3ccccn3)n2)cn1,CHEMBL5401125,IC50,300.0,nM,6.52,CHEMBL5358074,CHEMBL203,CHEMBL5356962,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC[C@H](C)Nc1cc(Nc2ccnc(-c3cnn(S(=O)(=O)C4CC4)c3)n2)ncc1C(=O)NC,470.5589999999998,2.3890000000000002,3,10,143.79,12,3,0.42917735966137893,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3ccccn3)n2)cn1,CHEMBL5410422,IC50,3.6,nM,8.44,CHEMBL5358074,CHEMBL203,CHEMBL5356962,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC[C@H](C)Nc1cc(Nc2ccnc(-c3cnn(S(=O)(=O)C4CC4)c3)n2)ncc1C(=O)NCCC(F)F,534.5930000000011,3.4144000000000014,3,10,143.79,14,3,0.3183424501889004,1,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3ccccn3)n2)cn1,CHEMBL5405222,IC50,5.6,nM,8.25,CHEMBL5358074,CHEMBL203,CHEMBL5356962,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC[C@H](C)Nc1cc(Nc2ccnc(-c3cnn(S(=O)(=O)C4CC4)c3)n2)ncc1C(=O)NCCCF,516.6030000000001,3.118800000000001,3,10,143.79,14,3,0.30929721515381814,1,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3ccccn3)n2)cn1,CHEMBL5405737,IC50,3.7,nM,8.43,CHEMBL5358074,CHEMBL203,CHEMBL5356962,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,354.4579999999996,3.2021000000000015,3,7,87.89,12,3,0.5756719627819336,0,c1ccc(CNc2ncnc3[nH]cnc23)cc1,CHEMBL14762,Kd,10000.0,nM,,CHEMBL1060182,CHEMBL203,CHEMBL1150977,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CC[C@H]1CN(c2ccc(-c3ccnc(Nc4cc(OC)c(OC)c(OC)c4)n3)cn2)CCN1,450.54299999999967,3.4962000000000018,2,9,93.66000000000001,12,3,0.5347096207053805,0,c1ccc(Nc2nccc(-c3ccc(N4CCNCC4)nc3)n2)cc1,CHEMBL112346,IC50,10000.0,nM,,CHEMBL674700,CHEMBL203,CHEMBL1131898,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12,281.35899999999964,3.4147000000000016,2,3,61.8,7,3,0.772992190695588,0,c1ccc(-c2cc3nccnc3[nH]2)cc1,CHEMBL1976420,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCc1c(C(N)=O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,411.46899999999977,3.5322000000000022,2,7,103.13,7,5,0.44487814431794875,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL194958,IC50,120.0,nM,6.92,CHEMBL881943,CHEMBL203,CHEMBL1140398,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CCc1c(CC(N)=O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,425.49599999999975,3.461100000000002,2,7,103.13,8,5,0.4156433025920515,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL194160,IC50,1100.0,nM,5.96,CHEMBL881943,CHEMBL203,CHEMBL1140398,0.85,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,396.4949999999996,2.2785000000000006,2,7,92.63,9,3,0.47016975266866856,0,c1c[nH+]cc(CNc2cc(N3CCCCC3)nc3ccnn23)c1,CHEMBL2103840,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,552.7240000000019,2.6972000000000014,3,10,121.10999999999999,12,2,0.4281496579360725,1,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(NC2CCOCC2)n1,CHEMBL3301622,Kd,3502.0,nM,5.46,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCc1nc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)nc1Oc1cccc(NC(=O)/C=C/CN(C)C)c1,558.6870000000018,3.481900000000002,3,9,128.95,15,3,0.30301274563370917,1,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3663922,IC50,1.4,nM,8.85,CHEMBL3705896,CHEMBL203,CHEMBL3638445,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O,286.28699999999975,1.6979999999999997,1,5,77.52000000000001,6,2,0.8688679802741013,0,O=C1NC(=O)c2c1ncc1ccccc21,CHEMBL2003524,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1c(-c2nc(-c3cnn(C4CCN(C)CC4)c3)cnc2N)nc2ccccc21,402.50599999999963,3.225600000000001,1,8,90.68,7,4,0.563570173918258,0,c1ccc2[nH]c(-c3cncc(-c4cnn(C5CCNCC5)c4)n3)nc2c1,CHEMBL3815045,IC50,50.0,nM,7.3,CHEMBL3817134,CHEMBL203,CHEMBL3813644,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,425.4929999999997,1.5841999999999998,3,10,137.14000000000001,10,3,0.5202565020980735,0,c1nonc1-c1nc2cncc(OCC3CCCNC3)c2[nH]1,CHEMBL494089,Kd,10000.0,nM,,CHEMBL1908702,CHEMBL203,CHEMBL1908390,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,270.2959999999997,1.0921199999999998,2,6,102.48,5,3,0.7253100324170814,0,O=c1[nH]c2ncncc2cc1-c1cc[nH]n1,CHEMBL3545366,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,432.53199999999964,3.495420000000002,1,8,85.8,10,4,0.5040438668001951,0,O=C(c1cc2c(nc(Nc3cc[nH]n3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1,CHEMBL3545215,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O,342.42399999999964,3.4473200000000013,1,7,69.03999999999999,8,3,0.7689863608129291,0,O=c1[nH]cc(-c2ccnc(Nc3ccccc3)n2)s1,CHEMBL1986263,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21,282.6579999999998,2.2483999999999993,1,4,68.0,2,3,0.7441477920871176,0,O=c1o[nH]c2[nH]c3ccccc3c(=O)c12,CHEMBL468280,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21,280.6669999999998,1.8148999999999995,2,5,88.22999999999999,3,3,0.7114378269783662,0,O=c1o[nH]c2[nH]c3ccccc3c(=O)c12,CHEMBL523823,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1cnc2c(N)nc(N(c3cccc(Cl)c3)[C@@H]3CCCC[C@@H]3N)nc21,385.9029999999997,3.4898000000000007,2,7,98.88000000000001,7,3,0.7127144400625329,0,c1ccc(N(c2ncc3nc[nH]c3n2)C2CCCCC2)cc1,CHEMBL411901,IC50,10000.0,nM,,CHEMBL940057,CHEMBL203,CHEMBL1145498,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCn1cnc2c(Nc3cccc(C#N)c3)nc(NCCN)nc21.Cl,358.8369999999997,2.2538799999999997,3,8,117.47,8,3,0.6180643386739495,0,c1ccc(Nc2ncnc3[nH]cnc23)cc1,CHEMBL557975,IC50,10000.0,nM,,CHEMBL675242,CHEMBL203,CHEMBL1132163,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1cnc2c(Nc3cccc(C(F)(F)F)c3)nc(NCCN)nc21.Cl,401.82399999999967,3.401000000000001,3,7,93.68,8,3,0.585802140215094,0,c1ccc(Nc2ncnc3[nH]cnc23)cc1,CHEMBL534909,IC50,10000.0,nM,,CHEMBL675242,CHEMBL203,CHEMBL1132163,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CCn1cnc2c(Nc3cccc(Cl)c3)nc(NCCN)nc21,331.8109999999997,2.6137999999999995,3,7,93.68,8,3,0.642553172439338,0,c1ccc(Nc2ncnc3[nH]cnc23)cc1,CHEMBL173647,IC50,100000.0,nM,,CHEMBL675242,CHEMBL203,CHEMBL1132163,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CCn1cnc2cnc(Nc3ccnc(N4CCC(OC)CC4)n3)cc21,353.42999999999967,2.6000000000000005,1,8,80.99000000000001,7,3,0.7548664715320663,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736094,Ki,201.0,nM,6.7,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21,285.3069999999997,1.8095999999999999,2,7,99.08,7,3,0.7610432281110134,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242113,IC50,6450.0,nM,5.19,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O,472.54899999999975,3.578780000000001,2,6,134.11,8,3,0.541980627690379,0,O=C(Nc1nc2cc(NC(=O)C3CCCCC3)ccc2[nH]1)c1ccccc1,CHEMBL485556,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,404.45299999999975,3.235000000000002,2,8,97.25,9,4,0.3782608423172447,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL497459,IC50,8.0,nM,8.1,CHEMBL1007322,CHEMBL203,CHEMBL1155952,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,394.4789999999996,2.1111999999999993,2,7,100.51,8,3,0.7029538605742774,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL169920,IC50,500.0,nM,6.3,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C(=O)N1CCC(c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn23)CC1,403.4899999999996,3.320800000000001,2,5,95.55,5,4,0.5366474349470914,0,c1ccc2[nH]c(-c3nc(C4CCNCC4)n4ccncc34)cc2c1,CHEMBL1762114,IC50,10000.0,nM,,CHEMBL1762895,CHEMBL203,CHEMBL1759853,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,346.3939999999998,2.5715000000000003,1,5,79.70000000000002,6,4,0.6158161027435856,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1996111,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,434.5479999999996,2.7964,2,8,91.21000000000001,7,3,0.6380121763709554,0,c1cc(Nc2ncc3ccn(C4CCCC4)c3n2)ncc1N1CCNCC1,CHEMBL3545110,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,524.5720000000005,3.583000000000001,2,7,119.71,11,3,0.4349184674292033,1,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)cc1,CHEMBL4572913,IC50,149.0,nM,6.83,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3cccc(C(F)(F)F)c3)c3c(N)ncnc32)C1,473.50299999999964,3.3756000000000013,1,7,93.17,8,3,0.5714479570238618,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4101735,IC50,1000.0,nM,6.0,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,405.50599999999963,2.3568000000000007,1,7,93.17,8,3,0.6552222368567432,0,c1ccc(-c2nn(C3CCCNC3)c3ncncc23)cc1,CHEMBL4073874,IC50,220.0,nM,6.66,CHEMBL4041413,CHEMBL203,CHEMBL4038351,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1,484.5599999999998,3.2231000000000023,2,6,108.96000000000001,9,4,0.3916801277877009,0,c1ccc(Oc2ccc(-c3cc4[nH]c5c(n4n3)CNCC5)cc2)cc1,CHEMBL3973566,IC50,0.25,nM,,CHEMBL4414895,CHEMBL203,CHEMBL4414549,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(NCCO)c23)C1,361.47099999999966,1.0979999999999996,2,7,81.59,9,2,0.7500919681236058,0,c1ncc2c3c(sc2n1)CNCC3,CHEMBL1271619,IC50,4884.0,nM,5.31,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@@H](CO)c4ccccc4)c23)C1,437.56899999999973,2.8393000000000006,2,7,81.59,10,3,0.5534468274713804,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1271508,IC50,20000.0,nM,,CHEMBL1273342,CHEMBL203,CHEMBL1269003,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@H](CO)Cc4ccccc4)c23)C1,451.5959999999997,2.7093000000000007,2,7,81.59,11,3,0.5127730327611663,0,c1ccc(CCNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1271618,IC50,149.0,nM,6.83,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,437.56899999999973,2.8393000000000006,2,7,81.59,10,3,0.5534468274713804,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272276,IC50,70.0,nM,7.16,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C/C=C/C(=O)Nc1cc2c(N3CCc4ccccc43)ncnc2cc1O[C@@H]1CCOC1,459.54999999999967,3.548000000000002,1,7,79.82000000000001,9,3,0.5414632939640436,0,c1ccc2c(c1)CCN2c1ncnc2cc(OC3CCOC3)ccc12,CHEMBL4168254,IC50,5.0,nM,8.3,CHEMBL4155049,CHEMBL203,CHEMBL4152264,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C/C=C/C(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccccc4)nc32)c1,441.4949999999998,2.975600000000001,2,8,105.04,9,4,0.42491348852029603,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437486,IC50,39.7,nM,7.4,CHEMBL2439334,CHEMBL203,CHEMBL2434822,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,615.7390000000017,3.022000000000001,2,10,128.29,9,3,0.4094623914233721,1,O=C(Nc1ccc(C(=O)N2CCCCC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL592445,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,375.4359999999997,2.3697999999999997,2,6,91.73,8,4,0.5398036755426752,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1965631,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1,361.4009999999997,3.347200000000001,2,4,78.19,7,4,0.3246043033658934,0,O=C(c1cc2ccccc2[nH]1)c1cc2ccccc2[nH]1,CHEMBL7432,IC50,30000.0,nM,,CHEMBL678295,CHEMBL203,CHEMBL1135728,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CC(CNNC(N)=O)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,406.9139999999996,2.220800000000002,3,5,96.68999999999998,12,2,0.41498189183090506,0,c1ccc(COc2ccccc2)cc1,CHEMBL541307,IC50,3900.0,nM,5.41,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCC(=O)c1ccc(OCc2ccccc2)c(O)c1.Cl,335.83099999999956,3.5274000000000023,1,4,49.77,10,2,0.7863822016165214,0,c1ccc(COc2ccccc2)cc1,CHEMBL552860,IC50,360.0,nM,6.44,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12,360.3679999999997,2.5784000000000002,2,5,86.8,8,3,0.7055360868955581,0,c1ccc(-c2cc3cn[nH]c3nn2)cc1,CHEMBL41783,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCCNC(=O)/C=C/C(=O)Cc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,497.39699999999965,3.2666000000000013,2,7,100.11000000000001,12,3,0.3277199471890293,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL460743,IC50,1.096,nM,8.96,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCCNC(=O)/C=C/C(=O)N(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,512.4119999999997,3.117800000000001,2,7,103.35000000000001,12,3,0.33557210322315556,1,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL136102,IC50,1.45,nM,8.84,CHEMBL673925,CHEMBL203,CHEMBL1134843,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCCNC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,498.3849999999997,3.0935000000000006,3,7,112.14,11,3,0.30714918822149617,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL334801,IC50,1.1,nM,8.96,CHEMBL673925,CHEMBL203,CHEMBL1134843,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCN(C)c1c(Br)cccc1Nc1ncnc2ccncc12,401.3119999999997,3.5287000000000015,1,6,57.18,9,3,0.682242131407411,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270966,IC50,40.74,nM,7.39,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,401.31199999999967,3.5287000000000015,1,6,57.18,9,3,0.6822421314074111,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL162053,IC50,8.1,nM,8.09,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,401.3119999999996,3.5287000000000015,1,6,57.18000000000001,9,3,0.6822421314074111,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL126137,IC50,39.81,nM,7.4,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCNc1c(Br)cccc1Nc1ncnc2ccncc12,387.28499999999974,3.5044000000000013,2,6,65.97,8,3,0.6750690396489035,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270713,IC50,45.71,nM,7.34,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,387.28499999999974,3.5044000000000004,2,6,65.97,8,3,0.6750690396489035,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL162034,IC50,1.1,nM,8.96,CHEMBL673924,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,387.2849999999997,3.5044000000000013,2,6,65.97,8,3,0.6750690396489035,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL128432,IC50,44.67,nM,7.35,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCNc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,388.2729999999997,2.8994,2,7,78.86,8,3,0.6723388468844977,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL54067,IC50,35.0,nM,7.46,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)CCNc1ncnc2c1[nH]c1ccccc12,255.32500000000013,2.0846,2,4,56.839999999999996,6,3,0.7491854440101525,0,c1ccc2c(c1)[nH]c1cncnc12,CHEMBL5179320,IC50,10000.0,nM,,CHEMBL5138014,CHEMBL203,CHEMBL5136983,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1,401.46999999999963,3.4240000000000013,2,5,86.89999999999999,9,4,0.4954817600555607,0,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccccc4)c3)cc12,CHEMBL461140,IC50,3300.0,nM,5.48,CHEMBL955786,CHEMBL203,CHEMBL1152141,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,468.55699999999973,3.513700000000002,1,6,68.5,4,4,0.4573972811321401,0,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCOCCn1cc2c2ccccc21,CHEMBL91829,Kd,5100.0,nM,5.29,CHEMBL1908694,CHEMBL203,CHEMBL1908390,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)S(=O)(=O)c1ccc(Nc2ccc(C(=O)c3c(F)cccc3F)c(N)n2)cc1,432.45199999999977,3.166900000000002,2,6,105.39,9,3,0.5799309798172847,0,O=C(c1ccccc1)c1ccc(Nc2ccccc2)nc1,CHEMBL193456,IC50,100000.0,nM,,CHEMBL827663,CHEMBL203,CHEMBL1144370,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CN(C)S(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc4c(cc23)OCO4)cc1,406.85099999999994,3.0058000000000007,1,7,93.65,6,3,0.6653310980793289,0,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1,CHEMBL3098313,IC50,18300.0,nM,4.74,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C)S(=O)(=O)c1ccc(Nc2nc(Cl)nc3ccccc23)cc1,362.84199999999987,3.2771000000000017,1,5,75.19,6,3,0.720713445039315,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098314,IC50,100000.0,nM,,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,344.2159999999998,3.5969000000000015,1,5,53.94,5,3,0.7868681517234083,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL53711,IC50,0.006,nM,8.59,CHEMBL680021,CHEMBL203,CHEMBL1129564,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Extremely potent (less typical for Type 1)
CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,344.2159999999998,3.5969000000000015,1,5,53.940000000000005,5,3,0.7868681517234083,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL53428,IC50,0.08913,nM,10.05,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1cc2sncc2cc1NC(=O)C(=O)O,265.2939999999998,1.3854,2,6,82.53,4,2,0.801632665478394,0,c1ccc2sncc2c1,CHEMBL1997023,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-],407.9889999999996,1.4636000000000002,0,2,9.49,10,2,0.7097759763658067,0,[N+]=C1C=CC(=C(c2ccccc2)c2ccccc2)C=C1,CHEMBL64894,IC50,473.0,nM,6.33,CHEMBL1909203,CHEMBL203,CHEMBL1909046,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN(C)c1ccc(CNc2ncnc3cc(N)ncc23)cc1,294.3619999999997,2.2851,2,6,79.96,7,3,0.7682180294897893,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL121984,IC50,100000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
CN(C)c1ccc(Nc2ncnc3cc(N)ncc23)cc1,280.3349999999997,2.4166,2,6,79.96,6,3,0.7666440196314603,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL341053,IC50,4860.0,nM,5.31,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1ccc(Nc2ncnc3ccncc23)c(N)c1,280.3349999999997,2.4166,2,6,79.96,6,3,0.7171650908515068,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL271540,IC50,4897.79,nM,5.31,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1ccc2c(Nc3cccc(Br)c3)ncnc2n1,344.2159999999998,3.5969000000000024,1,5,53.94,5,3,0.7868681517234083,0,c1ccc(Nc2ncnc3ncccc23)cc1,CHEMBL50245,IC50,324.0,nM,6.49,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1ccc2ncnc(Nc3cccc(Br)c3)c2n1,344.2159999999997,3.5969000000000015,1,5,53.940000000000005,5,3,0.7868681517234083,0,c1ccc(Nc2ncnc3cccnc23)cc1,CHEMBL53796,IC50,9.6,nM,8.02,CHEMBL680030,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1cccc(CNc2ncnc3cc(N)ncc23)c1,294.3619999999997,2.2851,2,6,79.96,7,3,0.7682180294897893,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL333045,IC50,10000.0,nM,5.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1cccc(Nc2ncnc3cc(N)ncc23)c1,280.3349999999997,2.4166,2,6,79.96,6,3,0.7666440196314603,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL125331,IC50,1790.0,nM,5.75,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1cccc(Nc2ncnc3ccncc23)c1N,280.33499999999964,2.4165999999999994,2,6,79.96,6,3,0.7171650908515068,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL406236,IC50,1819.7,nM,5.74,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C)c1ccccc1CNc1ncnc2cc(N)ncc12,294.3619999999997,2.2851,2,6,79.96,7,3,0.7682180294897893,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL419601,IC50,100000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
CN(C)c1ccccc1Nc1ncnc2cc(N)ncc12,280.3349999999997,2.4166,2,6,79.96,6,3,0.7666440196314603,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL123523,IC50,69000.0,nM,4.16,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
CN(C)c1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,349.2209999999998,3.3683000000000023,0,5,51.02,5,3,0.7118867351163339,0,O=c1[nH]c2ncncc2cc1-c1ccccc1,CHEMBL299347,IC50,50000.0,nM,,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN(C)c1ncc2ncnc(Nc3cccc(Br)c3)c2n1,345.2039999999998,2.9919000000000002,1,6,66.83000000000001,5,3,0.7872334360852137,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL53777,IC50,0.95,nM,9.02,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1)CCO,527.6290000000006,3.511600000000002,2,9,122.63000000000001,12,4,0.3172066843129776,1,c1ccc(Oc2ccc(-c3nn(C4CCCNC4)c4ncncc34)cc2)cc1,CHEMBL3931858,IC50,74.5,nM,7.13,CHEMBL3887533,CHEMBL203,CHEMBL3886356,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN(C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)CCO,456.3439999999997,3.5547000000000017,3,6,90.38000000000001,10,3,0.44951830152643296,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL93783,IC50,14.0,nM,7.85,CHEMBL680018,CHEMBL203,CHEMBL1134561,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(CC(=O)O)c1c(Br)cccc1Nc1ncnc2ccncc12,388.22499999999985,3.051700000000001,2,7,91.24000000000001,6,3,0.6942731985293545,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL271113,IC50,16.22,nM,7.79,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CC(=O)O)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,388.2249999999998,3.051700000000001,2,7,91.24000000000001,6,3,0.6942731985293545,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL351629,IC50,0.44,nM,9.36,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CC(=O)O)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,388.2249999999998,3.051700000000001,2,7,91.24000000000001,6,3,0.6942731985293545,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL126903,IC50,15.85,nM,7.8,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CC(O)CO)c1c(Br)cccc1Nc1ncnc2ccncc12,404.2679999999998,2.3202999999999996,3,7,94.4,9,3,0.5806128910852083,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL410635,IC50,3.236,nM,8.49,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CC(O)CO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,404.26799999999974,2.3202999999999996,3,7,94.4,9,3,0.5806128910852082,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL165547,IC50,0.56,nM,9.25,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CC(O)CO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,404.2679999999997,2.3202999999999996,3,7,94.4,9,3,0.5806128910852083,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL340700,IC50,3.2,nM,8.49,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,417.3109999999997,2.8669000000000002,3,7,86.2,10,3,0.519752965701199,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL166255,IC50,1.7,nM,8.77,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CCO)Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,445.5019999999997,3.434100000000001,2,8,83.50999999999999,10,5,0.38080291110402104,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL391521,IC50,110.0,nM,6.96,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CN(CCO)c1c(Br)cccc1Nc1ncnc2ccncc12,374.2419999999998,2.9594000000000005,2,6,74.17,7,3,0.7154897998540194,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL408397,IC50,2.63,nM,8.58,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CCO)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,425.49599999999975,3.5949000000000018,2,8,91.99000000000001,9,5,0.4116136387845464,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1,CHEMBL3409482,IC50,36.0,nM,7.44,CHEMBL3412565,CHEMBL203,CHEMBL3407467,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
CN(CCO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,374.2419999999998,2.9594000000000005,2,6,74.17,7,3,0.7154897998540194,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL161956,IC50,0.22,nM,9.66,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CCO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,374.24199999999973,2.9594000000000005,2,6,74.17,7,3,0.7154897998540194,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL341319,IC50,2.57,nM,8.59,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(CCO)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,373.2539999999997,3.564400000000002,2,5,61.28,7,3,0.7162296304589271,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL4646415,IC50,145.0,nM,6.84,CHEMBL4606713,CHEMBL203,CHEMBL4602739,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,495.56099999999986,2.1525999999999987,1,8,115.65,8,4,0.4357716303065281,0,O=c1c2cc(NS(=O)(=O)NCC3COCCO3)ccc2ccc2ncc(-c3cn[nH]c3)cc12,CHEMBL1822792,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(Cc1ccccc1)c1ncnc2[nH]c(-c3ccc(CO)cc3)nc12,345.4059999999997,3.148600000000001,2,5,77.93,7,4,0.5808921038582984,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)nc23)cc1,CHEMBL5413223,IC50,109.0,nM,6.96,CHEMBL5323119,CHEMBL203,CHEMBL5321237,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(Cc1ccccn1)c1ncnc2[nH]c(-c3ccc(CO)cc3)cc12,345.4059999999997,3.148600000000001,2,5,77.93,7,4,0.5808921038582984,0,c1ccc(-c2cc3c(NCc4ccccn4)ncnc3[nH]2)cc1,CHEMBL5403478,IC50,133.0,nM,6.88,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(Cc1cccnc1)c1ncnc2[nH]c(-c3ccc(CO)cc3)cc12,345.4059999999997,3.148600000000001,2,5,77.93,7,4,0.5808921038582984,0,c1ccc(-c2cc3c(NCc4cccnc4)ncnc3[nH]2)cc1,CHEMBL5426924,IC50,500.0,nM,,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(Cc1ccncc1)c1ncnc2[nH]c(-c3ccc(CO)cc3)cc12,345.4059999999997,3.148600000000001,2,5,77.93,7,4,0.5808921038582984,0,c1ccc(-c2cc3c(NCc4ccncc4)ncnc3[nH]2)cc1,CHEMBL5424694,IC50,236.0,nM,6.63,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(N)C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ccnc2cn1,427.3059999999997,3.4361000000000015,3,6,96.17,8,3,0.3169957225806823,0,c1ccc(Nc2ccnc3cnccc23)cc1,CHEMBL460736,IC50,8.6,nM,8.07,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(c1ccccc1)c1[nH]cnc2nncc1-2.Cl,261.71599999999995,2.4942000000000006,1,4,57.7,3,1,0.770032065953689,0,c1ccc(Nc2[nH]cnc3nncc2-3)cc1,CHEMBL541334,IC50,50000.0,nM,,CHEMBL873587,CHEMBL203,CHEMBL1129840,0.4,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
CN(c1ccccc1)c1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12,419.48499999999973,3.0279000000000016,0,8,76.63,7,4,0.47541092811661106,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064397,IC50,7200.0,nM,5.14,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN(c1ccccc1)c1ncnc2ccc(N)cc12,250.3050000000001,2.9799000000000007,1,4,55.040000000000006,4,3,0.7103069408166413,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL136492,IC50,8400.0,nM,5.08,CHEMBL677833,CHEMBL203,CHEMBL1145114,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(c1nc(-c2cn[nH]c2)nc2c1COC2(C)C)c1n[nH]c2ccccc12,361.40899999999976,3.276200000000001,2,6,95.61000000000001,6,4,0.581343798313336,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3758981,Ki,519.0,nM,6.29,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,507.49799999999976,3.1365000000000007,3,8,129.21,9,3,0.4449652129709726,1,O=C1Cc2cc(Nc3nccc(NCc4cccnc4)n3)ccc2N1,CHEMBL1084546,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN(c1ncnc2[nH]c(-c3ccc(CO)cc3)cc12)[C@@H](CO)c1ccccc1,374.44399999999973,3.2870000000000017,3,5,85.27000000000001,9,4,0.4822093248099072,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL5419520,IC50,65.0,nM,7.19,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN(c1ncnc2[nH]c(-c3ccc(CO)cc3)cc12)[C@H](CO)c1ccccc1,374.44399999999973,3.2870000000000017,3,5,85.27000000000001,9,4,0.4822093248099072,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL5406951,IC50,3.7,nM,8.43,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN/C(=N\C#N)N1CCOC(COc2cc3ncnc(Nc4ccc(Cl)c(C)c4)c3cc2OC)C1,495.9709999999998,3.4799000000000015,2,8,116.92000000000002,9,3,0.30081052750124965,0,c1ccc(Nc2ncnc3cc(OCC4CNCCO4)ccc23)cc1,CHEMBL3904460,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,390.4259999999998,2.8928000000000003,3,8,106.03999999999999,8,4,0.34527717621024584,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL497697,IC50,12.0,nM,7.92,CHEMBL1007322,CHEMBL203,CHEMBL1155952,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21,481.34999999999985,3.116200000000001,0,5,67.67,4,3,0.5769432783627203,0,O=C1Nc2ccccc2OCC1N1CCc2cn(Cc3ccccc3)nc2C1=O,CHEMBL4549667,IC50,1000.0,nM,6.0,CHEMBL4884981,CHEMBL203,CHEMBL4507326,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21,458.5399999999998,1.1301999999999994,0,7,101.81000000000002,4,2,0.683445922436075,0,O=C1Nc2ccccc2OCC1N1CCc2cn(CC3CCS(=O)(=O)CC3)nc2C1=O,CHEMBL4097778,IC50,1000.0,nM,6.0,CHEMBL4885272,CHEMBL203,CHEMBL4507327,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21,402.4539999999998,2.353699999999999,0,5,67.67,4,3,0.6745825305125924,0,O=C1Nc2ccccc2OCC1N1CCc2cn(Cc3ccccc3)nc2C1=O,CHEMBL4088216,IC50,1000.0,nM,6.0,CHEMBL4884690,CHEMBL203,CHEMBL4507327,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1C(=S)C(C(=O)Nc2ccccc2)c2ccccc21,282.3679999999997,3.1861000000000015,1,2,32.34,3,2,0.8586192928395768,0,O=C(Nc1ccccc1)C1C(=S)Nc2ccccc21,CHEMBL62176,IC50,1000.0,nM,6.0,CHEMBL677391,CHEMBL203,CHEMBL1127560,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1,415.5009999999997,2.907300000000001,1,8,94.86000000000001,6,4,0.5507029390261982,0,O=C(C1CCNCC1)n1ncc2cc(-c3cn(Cc4ccccc4)nn3)ccc21,CHEMBL1978014,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1,452.5109999999997,3.435100000000002,3,8,111.30000000000001,11,3,0.5216587745840847,0,O=C(NC1CCNCC1)c1cc(-c2ccccc2Oc2ccccc2)on1,CHEMBL2443138,IC50,10.0,nM,,CHEMBL2444011,CHEMBL203,CHEMBL2439976,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1,454.4389999999998,3.277300000000001,3,9,151.2,9,3,0.37629018000017667,0,O=C(NC1CCNCC1)c1cc(-c2ccccc2Oc2ccccc2)on1,CHEMBL2443044,IC50,10.0,nM,,CHEMBL2444011,CHEMBL203,CHEMBL2439976,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1,340.45199999999966,3.115400000000001,2,4,61.02,4,3,0.7700159190682176,0,O=C(NC1CCNCC1)c1cc2c(-c3ccccc3)n[nH]c2s1,CHEMBL1987007,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1,481.3839999999998,2.5226000000000006,4,8,111.64000000000001,8,2,0.4983892101563809,0,O=C(NC1CCNCC1)c1cnc(Nc2ccccc2)nc1NC1CCOC1,CHEMBL2312652,IC50,30000.0,nM,4.52,CHEMBL2317775,CHEMBL203,CHEMBL2311250,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,387.8499999999998,3.4620000000000015,2,7,78.86,5,3,0.7091922744684136,0,c1ccc(Nc2ncnc3cnc(NC4CCNCC4)nc23)cc1,CHEMBL258940,IC50,3.0,nM,8.52,CHEMBL937172,CHEMBL203,CHEMBL1145498,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCC(O)(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)o2)CC1,353.39699999999965,3.4559000000000024,1,5,62.39,5,3,0.7812982780426704,0,c1ccc(-c2nc(C3CCNCC3)oc2-c2ccncc2)cc1,CHEMBL22978,IC50,797.0,nM,6.1,CHEMBL674025,CHEMBL203,CHEMBL1132910,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1,401.8459999999997,3.3046000000000015,3,6,94.14,6,3,0.6095989367593201,0,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12,CHEMBL422897,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1,401.8459999999997,3.3046000000000015,3,6,94.14,6,3,0.6095989367593201,0,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12,CHEMBL418203,IC50,4600.0,nM,5.34,CHEMBL674692,CHEMBL203,CHEMBL1135924,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCC(n2cc(-c3cnc(N)c(-c4nc5ccccc5[nH]4)n3)cn2)CC1,374.45199999999966,2.7323000000000004,2,7,101.53999999999999,5,4,0.5716741767699911,0,c1ccc2[nH]c(-c3cncc(-c4cnn(C5CCNCC5)c4)n3)nc2c1,CHEMBL3813979,IC50,290.0,nM,6.54,CHEMBL3817134,CHEMBL203,CHEMBL3813644,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1,338.4109999999996,2.3833,1,6,69.56,5,2,0.8634138767670326,0,c1ccc(-c2cncc(N3CCCNCC3)n2)cc1,CHEMBL493937,Ki,10000.0,nM,,CHEMBL960112,CHEMBL203,CHEMBL1153342,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(/N=C/c2c(N)ncnc2Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)CC1,459.53299999999973,2.9208000000000007,2,9,100.49000000000001,8,4,0.42773761334531024,0,C(=N/N1CCNCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1,CHEMBL498134,IC50,16.0,nM,7.8,CHEMBL1007322,CHEMBL203,CHEMBL1155952,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(C(=O)Cn2c(-c3ccc(Cl)cc3)csc2=N)CC1,350.87499999999966,2.12347,1,5,52.33,4,2,0.9215008613329946,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437298,Ki,15650.0,nM,4.8,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(C(=O)Cn2c(-c3ccccc3)csc2=N)CC1,316.42999999999967,1.47007,1,5,52.33,4,2,0.932159986078013,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437300,Ki,41580.0,nM,4.38,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(C(=O)c2cccc(Cn3nnc4c3C(=O)c3ccccc3C4=O)c2)CC1,415.45299999999986,1.4894,0,7,88.4,4,3,0.5038128442829902,0,O=C1c2ccccc2C(=O)c2c1nnn2Cc1cccc(C(=O)N2CCNCC2)c1,CHEMBL3628599,IC50,10000.0,nM,,CHEMBL3631092,CHEMBL203,CHEMBL3627649,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(C/C=C/C(=O)N2CCc3c(sc4ncnc(N[C@H](CO)c5ccccc5)c34)C2)CC1,492.6489999999997,2.5251,2,8,84.83,9,3,0.4904931675063274,0,O=C(/C=C/CN1CCNCC1)N1CCc2c(sc3ncnc(NCc4ccccc4)c23)C1,CHEMBL1271507,IC50,89.0,nM,7.05,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(Cc5ccccn5)cc4)ncnc3cn2)CC1,494.6029999999997,3.4963000000000015,2,8,99.17,9,4,0.35931201604119645,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1,CHEMBL3921446,IC50,100.0,nM,7.0,CHEMBL3854867,CHEMBL203,CHEMBL3853319,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,455.9249999999997,3.303000000000001,2,7,86.28,7,3,0.5513115587176053,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL3921555,IC50,9.0,nM,8.05,CHEMBL3854867,CHEMBL203,CHEMBL3853319,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CC(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,434.9279999999997,3.4133000000000013,2,7,73.39,6,3,0.640719650836209,0,O=C(CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1,CHEMBL3233765,IC50,3399.0,nM,5.47,CHEMBL3238947,CHEMBL203,CHEMBL3233010,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CC(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)CC1,455.35999999999973,3.3218000000000014,2,6,73.39,6,3,0.6152803409194524,0,O=C(CN1CCNCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL4169489,IC50,32.0,nM,7.5,CHEMBL4156805,CHEMBL203,CHEMBL4152342,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Br)c4)ncnc3cn2)CC1,512.3869999999997,3.2494000000000014,2,7,86.28,6,3,0.5080691835899174,1,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL437890,IC50,1.1,nM,8.96,CHEMBL862512,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,467.9359999999997,3.1403000000000016,2,7,86.28,6,3,0.5573199953981703,0,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL203599,IC50,0.5,nM,9.3,CHEMBL862512,CHEMBL203,CHEMBL1138126,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCC(=O)N2CCOc3c2ccc2ncnc(Nc4ccc(F)c(Cl)c4)c32)CC1,484.96299999999974,3.5288000000000013,1,7,73.83,6,3,0.5935100477043886,0,O=C(CCN1CCNCC1)N1CCOc2c1ccc1ncnc(Nc3ccccc3)c21,CHEMBL5286368,IC50,25.69,nM,7.59,CHEMBL5240016,CHEMBL203,CHEMBL5236631,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(CCC(=O)N2CCOc3c2ccc2ncnc(Nc4cccc(Br)c4)c32)CC1,511.4239999999997,3.498800000000001,1,7,73.83,6,3,0.5623964287093288,1,O=C(CCN1CCNCC1)N1CCOc2c1ccc1ncnc(Nc3ccccc3)c21,CHEMBL5276304,IC50,40.7,nM,7.39,CHEMBL5240016,CHEMBL203,CHEMBL5236631,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCCNc2c(Br)cccc2Nc2ncnc3ccncc23)CC1,456.3919999999997,3.580300000000001,2,7,69.21000000000001,8,3,0.5270673086953137,0,c1ccc(Nc2ncnc3ccncc23)c(NCCCN2CCNCC2)c1,CHEMBL271532,IC50,5.012,nM,8.3,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(CCCNc2cc3ncnc(Nc4cccc(Br)c4)c3cn2)CC1,456.39199999999965,3.580300000000001,2,7,69.21000000000001,8,3,0.5270673086953137,0,c1ccc(Nc2ncnc3cc(NCCCN4CCNCC4)ncc23)cc1,CHEMBL340484,IC50,4.898,nM,8.31,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1,393.4949999999996,1.773199999999999,3,6,103.17,8,3,0.5288372439758109,0,c1cc(NCCCN2CCNCC2)nc(-c2nc3ccccc3[nH]2)c1,CHEMBL2006237,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1,461.39699999999976,3.351700000000001,1,7,66.28999999999999,8,3,0.568439967544195,0,O=c1[nH]c2nc(NCCCN3CCNCC3)ncc2cc1-c1ccccc1,CHEMBL299194,IC50,8700.0,nM,5.06,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,494.9869999999998,3.350100000000001,2,9,104.32000000000001,10,4,0.3621282861742475,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1,CHEMBL258282,IC50,5.0,nM,8.3,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1,350.49099999999964,3.456800000000002,1,4,35.16,4,3,0.6145345775474615,0,c1cc(-c2n[nH]c3c2Cc2ccc(CN4CCNCC4)cc2-3)cs1,CHEMBL213743,IC50,50000.0,nM,,CHEMBL863746,CHEMBL203,CHEMBL1145317,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(NCCCNc2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,471.4069999999996,3.084900000000001,3,8,81.24,9,3,0.43290165886127435,0,c1ccc(Nc2ncnc3cnc(NCCCNN4CCNCC4)cc23)cc1,CHEMBL166307,IC50,3.9,nM,8.41,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(c2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,399.29599999999976,3.282700000000002,1,6,57.18,4,3,0.7297616764399676,0,c1ccc(Nc2ncnc3cnc(N4CCNCC4)cc23)cc1,CHEMBL162719,IC50,6.4,nM,8.19,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(NC(=O)c3c(N)cc[nH]c3=O)cc2)CC1,327.3879999999997,0.9611999999999996,3,5,94.45999999999998,5,2,0.7805216571117369,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1ccc[nH]c1=O,CHEMBL3780635,Ki,346.0,nM,6.46,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(c2ccc(NC(=O)c3c(NCCc4ccccc4)cc[nH]c3=O)cc2)CC1,431.5399999999997,3.0336000000000007,3,5,80.47,8,3,0.535889763060689,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(NCCc2ccccc2)cc[nH]c1=O,CHEMBL3780109,Ki,49.0,nM,7.31,CHEMBL3784892,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(NC(=O)c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)cc2)CC1,481.98399999999975,3.177900000000001,4,6,100.69999999999999,9,3,0.41333458801758655,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(NCCc2ccccc2)cc[nH]c1=O,CHEMBL3781433,Ki,18.0,nM,7.75,CHEMBL3784892,CHEMBL203,CHEMBL3779874,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(NC(=O)c3c(NCc4ccccc4)cc[nH]c3=O)cc2)CC1,417.5129999999997,2.991100000000001,3,5,80.47,7,3,0.5746120825629053,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(NCc2ccccc2)cc[nH]c1=O,CHEMBL3780709,Ki,349.0,nM,6.46,CHEMBL3784892,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(NC(=O)c3c(Nc4ccccc4)cc[nH]c3=O)cc2)CC1,403.4859999999997,3.122600000000001,3,5,80.47,6,3,0.6099652730138052,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780484,Ki,144.0,nM,6.84,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(NC(=O)c3c(Nc4ccccn4)cc[nH]c3=O)cc2)CC1,404.4739999999997,2.5176000000000007,3,6,93.35999999999999,6,3,0.6051325090091374,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccn2)cc[nH]c1=O,CHEMBL3781988,Ki,108.0,nM,6.97,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(NC(=O)c3c(Nc4ccnc(N)n4)cc[nH]c3=O)cc2)CC1,420.4769999999997,1.4948,4,8,132.26999999999998,7,3,0.48813751263353883,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccncn2)cc[nH]c1=O,CHEMBL3781993,Ki,4.0,nM,8.4,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(NC(=O)c3c(Nc4ccncc4N)cc[nH]c3=O)cc2)CC1,419.4889999999997,2.0997999999999997,4,7,119.38,7,3,0.49992426528570266,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccncc2)cc[nH]c1=O,CHEMBL3781676,Ki,145.0,nM,6.84,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(NC(=O)c3c(Nc4ccncn4)cc[nH]c3=O)cc2)CC1,405.4619999999997,1.9125999999999999,3,7,106.25,6,3,0.5953216472909942,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccncn2)cc[nH]c1=O,CHEMBL3781344,Ki,95.0,nM,7.02,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2ccc(Nc3cc4c(N5CCOCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,497.6069999999997,3.495400000000002,2,10,94.57000000000001,7,4,0.41217490420614955,0,c1ccc(Nc2nc(N3CCOCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1,CHEMBL4206288,IC50,2.1,nM,8.68,CHEMBL4197223,CHEMBL203,CHEMBL4196024,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NO)n3)cc2)CC1,453.9339999999998,3.4880000000000013,4,8,105.65,8,3,0.3318289994314003,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL4861707,IC50,6.564,nM,8.18,CHEMBL4832126,CHEMBL203,CHEMBL4831496,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccc(F)cc5)n(C5CCN(C(=O)CO)CC5)c4n3)cc2)CC1,559.6500000000016,3.3602000000000016,3,10,114.68,9,4,0.31361507387836707,1,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCNCC2)cc1,CHEMBL5183865,IC50,41.0,nM,7.39,CHEMBL5143769,CHEMBL203,CHEMBL5143505,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccc(F)cc5)n([C@H]5CCCN(C(=O)CO)C5)c4n3)cc2)CC1,559.6500000000016,3.3602000000000016,3,10,114.68,9,4,0.31361507387836707,1,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCCNC2)cc1,CHEMBL4797395,IC50,41.0,nM,7.39,CHEMBL4722830,CHEMBL203,CHEMBL4715846,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)[nH]c4n3)cc2)CC1,400.4899999999997,3.5919000000000016,3,7,85.0,6,4,0.4719814298790411,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3[nH]2)cc1,CHEMBL2178368,IC50,5.0,nM,8.3,CHEMBL3887185,CHEMBL203,CHEMBL3638579,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,392.4379999999997,2.5445,3,5,94.03999999999999,4,4,0.4874373998840835,0,O=c1[nH]c2ccccc2cc1-c1nc2ccc(N3CCNCC3)cc2[nH]1,CHEMBL522892,Kd,940.0,nM,6.03,CHEMBL1908701,CHEMBL203,CHEMBL1908390,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1,428.4999999999997,2.3856,2,8,104.68,6,4,0.5028357907919779,0,c1cc(Nc2nccc(-c3cnc4ccccn34)n2)cc(N2CCNCC2)c1,CHEMBL1971245,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,438.4909999999998,2.4301000000000004,2,6,94.21999999999998,4,4,0.4774001293705332,0,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12,CHEMBL565612,Ki,1258.93,nM,5.9,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CCN(c2nc(Oc3ccc4ccc(=O)[nH]c4c3)c3sccc3n2)CC1,393.47199999999975,3.076900000000001,1,7,74.35,4,4,0.5766224517720624,0,O=c1ccc2ccc(Oc3nc(N4CCNCC4)nc4ccsc34)cc2[nH]1,CHEMBL4793630,IC50,1000.0,nM,,CHEMBL4770070,CHEMBL203,CHEMBL4765321,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,401.8459999999997,3.3046000000000015,3,6,94.14,6,3,0.6095989367593201,0,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12,CHEMBL428690,Kd,520.0,nM,6.28,CHEMBL1908695,CHEMBL203,CHEMBL1908390,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)[C@H](O)C1,417.84499999999974,3.4299000000000017,3,7,103.37,7,3,0.599384840739625,0,O=c1cc(Oc2ccccc2)oc2c(C3CCNCC3)cccc12,CHEMBL133498,IC50,50000.0,nM,,CHEMBL873605,CHEMBL203,CHEMBL1133502,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)C1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,508.60199999999963,2.7682,3,9,119.4,11,3,0.46169423943959736,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5187021,IC50,1.0,nM,9.0,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12,353.4029999999998,3.033400000000001,2,6,86.47000000000001,5,3,0.7069645131829917,0,c1cc2scc(-c3ccc4c(c3)OCO4)c2cn1,CHEMBL1993243,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)CN1CC[C@H](n2c(Nc3ccc(F)cc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)C1,558.6660000000016,3.1972000000000005,3,10,106.48,10,4,0.3006546759970549,1,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCNC2)cc1,CHEMBL4758107,IC50,561.0,nM,6.25,CHEMBL4722830,CHEMBL203,CHEMBL4715846,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1,460.4909999999998,2.183519999999999,4,8,148.32999999999998,11,3,0.3997332369870189,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1978099,Ki,630.96,nM,6.2,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)COc1cccc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(F)(F)O4)n2)c1,474.3989999999999,3.1514000000000006,4,8,126.5,8,3,0.41154232640083593,0,O=C1COc2ccc(Nc3ccnc(Nc4ccccc4)n3)cc2N1,CHEMBL2170582,Ki,35.0,nM,7.46,CHEMBL2173384,CHEMBL203,CHEMBL2169784,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1,457.5379999999997,2.640480000000001,2,6,110.17,7,3,0.43089835694622125,0,c1cncc(-c2n[nH]c3c2Cc2ccc(OCCCN4CCNCC4)cc2-3)c1,CHEMBL2001998,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1c([Se][Se]c2c(C(=O)NC)c3ccccc3n2C)n(C)c2ccccc12,532.3640000000012,0.6634000000000013,2,4,68.06,9,4,0.37146527316273087,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1,CHEMBL137422,Ki,3100.0,nM,5.51,CHEMBL674574,CHEMBL203,CHEMBL1129933,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
CNC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,288.3029999999997,1.7750999999999997,5,5,101.82000000000001,8,2,0.5519100986650174,0,c1ccc(CNc2ccccc2)cc1,CHEMBL122260,IC50,9700.0,nM,5.01,CHEMBL677211,CHEMBL203,CHEMBL1159167,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1,275.30799999999977,2.7901000000000007,2,3,57.78,3,3,0.7552381752394268,0,c1ccc(-c2n[nH]c3sccc23)cc1,CHEMBL1977681,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,412.42799999999977,3.429000000000002,1,6,85.07000000000001,5,5,0.48889130178176626,0,c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1,CHEMBL3188267,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,510.50199999999984,2.3965000000000005,3,9,142.09999999999997,11,3,0.4163412604272263,1,c1ccc(Nc2nccc(NCc3cnccn3)n2)cc1,CHEMBL3137331,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1F,368.4159999999997,3.471720000000002,2,6,84.73,9,3,0.7202690042286471,0,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1,CHEMBL455428,IC50,10000.0,nM,,CHEMBL1009270,CHEMBL203,CHEMBL1152177,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C(\C)[N+](=O)[O-])cc2OC)cc1,406.4159999999998,2.460000000000001,1,7,124.84000000000002,10,2,0.4252444204287916,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL78280,IC50,4000.0,nM,5.4,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,362.36299999999983,2.0613,1,6,115.61000000000001,7,2,0.4776384259184007,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL74432,IC50,400.0,nM,6.4,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,462.55399999999963,2.5016,1,8,92.71000000000001,7,3,0.6323731943230402,0,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1,CHEMBL2336325,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NC(=O)CN3CCOCC3)c(C)c2)ncc1Cl,509.9979999999997,3.555920000000002,4,8,120.51,10,3,0.36362232482686113,1,O=C(CN1CCOCC1)Nc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,CHEMBL4862976,IC50,3.89,nM,8.41,CHEMBL4832125,CHEMBL203,CHEMBL4831496,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1cnc(Nc2ccnc(N3CCC(O)CC3)n2)cc1NC(C)C,385.47199999999964,1.7561999999999995,4,8,115.3,10,2,0.5945278271445724,0,c1ccc(Nc2ccnc(N3CCCCC3)n2)nc1,CHEMBL5209276,IC50,290.0,nM,6.54,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1cnc(Nc2ccnc(N3CC[C@@H](O)[C@@H](F)C3)n2)cc1NC(C)C,403.46199999999965,1.7042,4,8,115.3,10,2,0.576190096922985,0,c1ccc(Nc2ccnc(N3CCCCC3)n2)nc1,CHEMBL5177090,IC50,99.0,nM,7.0,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,449.8949999999999,2.98712,3,6,127.07,8,3,0.5491221083448344,0,O=S(=O)(Nc1ccccc1)c1cccc(-c2cnccn2)c1,CHEMBL2152253,IC50,410.0,nM,6.39,CHEMBL2156898,CHEMBL203,CHEMBL2150966,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,453.85799999999995,2.8178,3,6,127.07,7,3,0.5448075241657987,0,O=S(=O)(Nc1ccccc1)c1cccc(-c2cnccn2)c1,CHEMBL2152252,IC50,739.0,nM,6.13,CHEMBL2156898,CHEMBL203,CHEMBL2150966,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNC(=O)c1ncc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(CCO)CC4)c(C(F)(F)F)c3)ccc2C)n1C,582.6270000000014,2.868920000000001,3,7,102.72999999999999,11,3,0.37067279448638013,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc[nH]2)c1,CHEMBL1784637,IC50,231.0,nM,6.64,CHEMBL1785574,CHEMBL203,CHEMBL1781971,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,460.5859999999997,2.5658000000000003,2,8,91.21,9,3,0.6183384741740714,0,c1cc(N2CCNCC2)ccc1Nc1ncc2c(n1)-c1[nH]ncc1CC2,CHEMBL564829,IC50,3069.0,nM,5.51,CHEMBL1058612,CHEMBL203,CHEMBL1151962,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2,530.6550000000008,0.4098000000000024,2,9,142.42000000000002,8,2,0.5660853190229569,1,O=C(C1CCNCC1)N1CCC(Nc2ncc3c(n2)-c2[nH]ncc2CC3)CC1,CHEMBL597754,IC50,10000.0,nM,,CHEMBL1072198,CHEMBL203,CHEMBL1157561,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
CNC1=CC2N=CN(C)/C(=N\c3cccc(Br)c3)C2C=N1,346.23199999999974,2.5828000000000007,1,4,52.35,4,1,0.8949890792867415,0,C1=CC2N=CN/C(=N\c3ccccc3)C2C=N1,CHEMBL52882,IC50,3.1,nM,8.51,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
CNCC(O)COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,406.84499999999974,3.1336000000000013,3,7,88.53,11,3,0.5292514638901695,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL56266,IC50,5.0,nM,8.3,CHEMBL677210,CHEMBL203,CHEMBL1134804,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNCCOc1n[nH]c2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,425.87999999999977,3.3221000000000016,3,8,109.87,10,4,0.3501818129643629,0,c1ccc(COc2ccc(Nc3ncnc4[nH]ncc34)cc2)nc1,CHEMBL255135,IC50,17.0,nM,7.77,CHEMBL947896,CHEMBL203,CHEMBL1143160,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNS(=O)(=O)Nc1cccc(Cc2c(C)c3cc(Cl)c(OC(=O)N(C)C)cc3oc2=O)c1,479.94199999999984,3.2821200000000017,2,6,117.94999999999999,10,3,0.5236637958619083,0,O=c1oc2ccccc2cc1Cc1ccccc1,CHEMBL3086065,IC50,50000.0,nM,,CHEMBL3090914,CHEMBL203,CHEMBL3085763,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,471.4699999999999,2.6847200000000004,2,8,136.31,9,4,0.3927578678332285,0,O=c1oc2cc(Oc3ncccn3)ccc2cc1Cc1ccncc1,CHEMBL3264002,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNS(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc(OC)c(OC)cc23)cc1,408.8669999999999,2.9521000000000015,2,7,102.44000000000001,9,3,0.6042023402364093,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098321,IC50,1630.0,nM,5.79,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)c1cccc(N(C)c2cc(Nc3cccc(C)c3)ncn2)c1,383.47699999999975,3.204620000000002,2,6,87.22000000000001,9,3,0.6796625129823686,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4074045,IC50,2000.0,nM,5.7,CHEMBL4024628,CHEMBL203,CHEMBL4020849,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)c1cccc(Nc2cc(N(C)c3cccc(C)c3)ncn2)c1,383.47699999999975,3.204620000000001,2,6,87.22000000000001,9,3,0.6796625129823686,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4086869,IC50,20.0,nM,7.7,CHEMBL4024628,CHEMBL203,CHEMBL4020849,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)c1cccc(Nc2cc(Nc3ccc(Cl)cc3)ncn2)c1,389.8679999999998,3.5253000000000005,3,6,96.01,7,3,0.5965054103457873,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL3915155,IC50,13.0,nM,7.89,CHEMBL4024628,CHEMBL203,CHEMBL4020849,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNS(=O)(=O)c1cccc(Nc2cc(Nc3ccc(Cl)cn3)ncn2)c1,390.8559999999998,2.9203,3,7,108.9,7,3,0.5932309283808828,0,c1ccc(Nc2cc(Nc3ccccn3)ncn2)cc1,CHEMBL4061645,IC50,630.0,nM,6.2,CHEMBL4024628,CHEMBL203,CHEMBL4020849,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(C)c3)ncn2)c1,369.44999999999976,3.180320000000002,3,6,96.01,8,3,0.617536499818192,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4097027,IC50,3.0,nM,8.52,CHEMBL4024628,CHEMBL203,CHEMBL4020849,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(S(=O)(=O)NC)c3)ncn2)c1,448.5299999999998,1.7799999999999998,4,8,142.18,10,3,0.40845728005642545,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4105656,IC50,1600.0,nM,5.8,CHEMBL4024628,CHEMBL203,CHEMBL4020849,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc([N+](=O)[O-])c3)ncn2)c1,400.41999999999985,2.780100000000001,3,8,139.15,8,3,0.4062831661025963,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4065426,IC50,4.0,nM,8.4,CHEMBL4024628,CHEMBL203,CHEMBL4020849,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br,590.5040000000014,3.3115000000000014,3,9,128.79,11,3,0.3620830965527265,1,c1ccc(Nc2ccnc(Nc3cccc(N4CCNCC4)c3)n2)cc1,CHEMBL1971029,Ki,100.0,nM,7.0,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl,479.9459999999998,3.5511000000000017,3,9,123.70000000000002,13,3,0.4222192846746287,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1993661,Ki,79.43,nM,7.1,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,330.1889999999998,3.572600000000002,2,5,62.730000000000004,4,3,0.7686164717854101,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL53753,IC50,0.008,nM,7.89,CHEMBL676074,CHEMBL203,CHEMBL1131301,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Extremely potent (less typical for Type 1)
CNc1cc2c(Nc3cccc(C)c3)ncnc2cn1,265.3199999999998,3.118520000000001,2,5,62.730000000000004,5,3,0.761492325423499,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL162821,IC50,0.45,nM,9.35,CHEMBL676233,CHEMBL203,CHEMBL1131301,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1cc2c(Nc3cccc(Cl)c3)ncnc2cn1,285.7379999999998,3.4635000000000007,2,5,62.730000000000004,4,3,0.7714383625489651,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL166154,IC50,0.19,nM,9.72,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1cc2c(Nc3ccccc3)ncnc2cn1,251.2930000000001,2.8101000000000003,2,5,62.730000000000004,4,3,0.7490899634447524,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL53940,IC50,9.0,nM,8.05,CHEMBL680021,CHEMBL203,CHEMBL1129564,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,330.18899999999985,3.5726000000000013,2,5,62.730000000000004,4,3,0.7686164717854101,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL54400,IC50,0.1288,nM,9.89,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1cc2ncnc(Nc3cccc(C)c3)c2cn1,265.3199999999998,3.118520000000001,2,5,62.730000000000004,5,3,0.761492325423499,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL127082,IC50,1.4,nM,8.85,CHEMBL677387,CHEMBL203,CHEMBL1130246,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ccc(N(C)c2ncnc3occ(C)c23)cc1,268.31999999999977,3.3408200000000017,1,5,54.19,6,3,0.7891703909476363,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4250210,IC50,6.4,nM,8.19,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ccc(Nc2ncnc3occ(C)c23)cc1,254.2930000000001,3.3165200000000006,2,5,62.980000000000004,5,3,0.7503456147003248,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4247926,IC50,200.0,nM,,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,330.1889999999998,3.5726000000000013,2,5,62.730000000000004,4,3,0.7686164717854101,0,c1ccc(Nc2ncnc3ncccc23)cc1,CHEMBL298637,IC50,52.0,nM,7.28,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,330.1889999999998,3.5726000000000013,2,5,62.730000000000004,4,3,0.7686164717854101,0,c1ccc(Nc2ncnc3cccnc23)cc1,CHEMBL53156,IC50,3.1,nM,8.51,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1,473.5809999999997,3.190500000000002,3,7,106.24999999999999,8,3,0.4838590829967678,0,O=C(Nc1cc(-c2cnccn2)c[nH]c1=O)c1ccc(N2CCCC2CN2CCCC2)cc1,CHEMBL1765781,Ki,1000.0,nM,,CHEMBL1768901,CHEMBL203,CHEMBL1765075,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(OC4CCOCC4)c23)n1,543.6320000000015,3.4265000000000025,3,10,133.42,9,4,0.31833746000133184,1,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC4CCOCC4)c23)cn1,CHEMBL4562744,IC50,937.0,nM,6.03,CHEMBL4349142,CHEMBL203,CHEMBL4346710,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNc1nc(C)c(C(=O)/C=C/c2ccc(O)cc2)s1,274.3449999999997,3.094920000000001,2,5,62.22,7,2,0.6640516896241225,0,O=C(/C=C/c1ccccc1)c1cncs1,CHEMBL4750368,IC50,33.66,nM,7.47,CHEMBL4732644,CHEMBL203,CHEMBL4732032,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1nc(C)c(C(=O)/C=C/c2ccsc2)s1,264.37499999999983,3.450820000000002,1,5,41.99,6,2,0.6790540099653213,0,O=C(/C=C/c1ccsc1)c1cncs1,CHEMBL4797515,IC50,143.63,nM,6.84,CHEMBL4732644,CHEMBL203,CHEMBL4732032,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1nc(C)c(C(=O)/C=C/c2nccs2)s1,265.36299999999983,2.8458200000000007,1,6,54.88,6,2,0.6819572829307526,0,O=C(/C=C/c1nccs1)c1cncs1,CHEMBL4798434,IC50,255.6,nM,6.59,CHEMBL4732644,CHEMBL203,CHEMBL4732032,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1nc(N/N=C/c2ccc(O)cc2)nc(Nc2ccccc2)n1,335.37099999999975,2.8085000000000004,4,8,107.35000000000001,8,3,0.4051173467909558,0,C(=N/Nc1ncnc(Nc2ccccc2)n1)\c1ccccc1,CHEMBL1946847,IC50,30700.0,nM,4.51,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CNc1nc(N/N=C\c2ccc(OC)cc2)nc(Nc2ccccc2)n1,349.39799999999974,3.1115000000000013,3,8,96.35000000000001,9,3,0.445326449189459,0,C(=N\Nc1ncnc(Nc2ccccc2)n1)\c1ccccc1,CHEMBL1946845,IC50,31000.0,nM,4.51,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ncc(C(C)C)c2cc(Nc3ccnc(N4CC[C@@H](O)[C@@H](F)C4)n3)ncc12,411.4849999999996,3.2376000000000014,3,8,99.09,9,3,0.5885406932031322,0,c1cc2cc(Nc3ccnc(N4CCCCC4)n3)ncc2cn1,CHEMBL5188960,IC50,50.0,nM,7.3,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ncc2c(-c3ccc(N4CCN(C)CC4)cc3)nn(CC3CCCC3)c2n1,405.54999999999956,3.477000000000002,1,7,62.11000000000001,7,3,0.701272832006714,0,c1ncc2c(-c3ccc(N4CCNCC4)cc3)nn(CC3CCCC3)c2n1,CHEMBL4218175,IC50,10000.0,nM,,CHEMBL4188985,CHEMBL203,CHEMBL4184298,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNc1ncc2c(-c3ccc(N4CCN(C)CC4)nc3)nn(CC3CCCC3)c2n1,406.53799999999956,2.8720000000000008,1,8,75.0,7,3,0.6981978071627423,0,c1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(CC3CCCC3)c2n1,CHEMBL4208852,IC50,10000.0,nM,,CHEMBL4188985,CHEMBL203,CHEMBL4184298,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,335.1939999999998,3.344000000000001,1,5,59.81,4,3,0.7802615156973671,0,O=c1[nH]c2ncncc2cc1-c1ccccc1,CHEMBL107472,IC50,7500.0,nM,5.12,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,331.1769999999998,2.967600000000001,2,6,75.62,4,3,0.7684706048512752,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL299622,IC50,0.76,nM,9.12,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CNc1ncc2ncnc(Nc3cccc(C)c3)c2n1,266.3079999999998,2.5135200000000006,2,6,75.62,5,3,0.7583117224232307,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL52591,IC50,4.3,nM,8.37,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CNc1ncc2ncnc(Nc3ccccc3)c2n1,252.2810000000001,2.2051,2,6,75.62,4,3,0.7439378482757566,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL53310,IC50,13.0,nM,7.89,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1NCc1ccc(F)c(Cl)c1,309.73199999999974,2.4437000000000006,2,6,85.42,7,2,0.6542747458447582,0,c1ccc(CNc2ccncn2)cc1,CHEMBL255291,IC50,1123.0,nM,5.95,CHEMBL934832,CHEMBL203,CHEMBL1145585,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CO/N=C/c1c(N)ncnc1Nc1ccc(F)c(Cl)c1,295.7049999999998,2.5752000000000006,2,6,85.42,6,2,0.6686493258688306,0,c1ccc(Nc2ccncn2)cc1,CHEMBL255490,IC50,70.0,nM,7.16,CHEMBL934832,CHEMBL203,CHEMBL1145585,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2[nH]c(Cc3cccc(F)c3)nc2c1,391.4099999999998,3.3889000000000022,3,7,114.10000000000001,8,4,0.34287483688264747,0,c1ccc(Cc2nc3cc(Nc4ccncn4)ccc3[nH]2)cc1,CHEMBL402316,IC50,48.0,nM,7.32,CHEMBL934832,CHEMBL203,CHEMBL1145585,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CO/N=C/c1c(N)ncnc1Nc1ccc2[nH]ncc2c1,283.2949999999998,1.659,3,7,114.10000000000001,6,3,0.49531051607739857,0,c1cc(Nc2ccc3[nH]ncc3c2)ncn1,CHEMBL255866,IC50,306.0,nM,6.51,CHEMBL934832,CHEMBL203,CHEMBL1145585,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2c(c1)CCN2Cc1cccc(F)c1,392.4379999999997,3.4845000000000024,2,7,88.66,8,3,0.49317596107130274,0,c1ccc(CN2CCc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL257814,IC50,57.0,nM,7.24,CHEMBL934832,CHEMBL203,CHEMBL1145585,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2ccc(F)cc2)c1,391.4099999999998,3.3198000000000025,2,8,103.24000000000001,8,4,0.38603335373577724,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL256527,IC50,104.0,nM,6.98,CHEMBL934832,CHEMBL203,CHEMBL1145585,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(C#N)c2)c1,398.42999999999984,3.052380000000002,2,9,127.03,8,4,0.37732059776516264,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL255865,IC50,20.0,nM,7.7,CHEMBL934832,CHEMBL203,CHEMBL1145585,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,391.4099999999998,3.3198000000000025,2,8,103.24000000000001,8,4,0.38603335373577724,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL255871,IC50,8.0,nM,8.1,CHEMBL1007322,CHEMBL203,CHEMBL1155952,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(OC)c2)c1,403.4459999999998,3.189300000000002,2,9,112.47000000000001,10,4,0.35985192452726406,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL403357,IC50,267.0,nM,6.57,CHEMBL934832,CHEMBL203,CHEMBL1145585,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1,373.4199999999998,3.1807000000000016,2,8,103.24000000000001,8,4,0.3973755453580509,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1,CHEMBL402113,IC50,44.0,nM,7.36,CHEMBL934832,CHEMBL203,CHEMBL1145585,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO/N=C/c1c(N)ncnc1Nc1cccc(Br)c1,322.16599999999977,2.5452000000000012,2,6,85.42,6,2,0.6672953822476282,0,c1ccc(Nc2ccncn2)cc1,CHEMBL402149,IC50,24.0,nM,7.62,CHEMBL934832,CHEMBL203,CHEMBL1145585,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(C)ccc2n2nnnc12,481.51599999999985,2.9351200000000013,1,10,128.60000000000002,6,4,0.4391494062281252,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325474,IC50,4300.0,nM,5.37,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(Cl)ccc2n2nnnc12,501.93399999999986,3.280100000000002,1,10,128.60000000000002,5,4,0.4201975063557303,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325476,IC50,8100.0,nM,5.09,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(OC)ccc2n2nnnc12,497.5149999999999,2.635300000000001,1,11,137.83,7,4,0.41879120851432416,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325475,IC50,1300.0,nM,5.89,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,467.48899999999986,2.6267000000000005,1,10,128.60000000000002,5,4,0.45209886196150656,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325473,IC50,1100.0,nM,5.96,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)CCC1(CCC(=O)OC)C(S)=Nc2ccccc21,321.3979999999997,2.8042000000000007,1,6,64.96000000000001,8,1,0.6462000417326148,0,C1=Nc2ccccc2C1,CHEMBL312247,IC50,100000.0,nM,,CHEMBL674029,CHEMBL203,CHEMBL1127050,0.35000000000000003,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties; Very weak activity (penalty)
COC(=O)CCc1c[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C,310.3529999999997,2.9214200000000012,2,3,71.19,6,2,0.6735413963993901,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL316009,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
COC(=O)CCc1nc2ccc(Br)cc2[nH]c1=O,311.1349999999998,1.7911999999999995,1,4,72.05,4,2,0.8773260687121589,0,O=c1cnc2ccccc2[nH]1,CHEMBL5208825,IC50,75.42,nM,7.12,CHEMBL5114136,CHEMBL203,CHEMBL5113380,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains quinazoline core; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC(=O)CCc1nc2ccc(Cl)cc2[nH]c1=O,266.6839999999998,1.6821,1,4,72.05,4,2,0.8582232676817638,0,O=c1cnc2ccccc2[nH]1,CHEMBL5206400,IC50,82.76,nM,7.08,CHEMBL5114136,CHEMBL203,CHEMBL5113380,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains quinazoline core; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,367.4089999999997,1.8058999999999992,2,8,106.5,7,3,0.6773169999612424,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL355019,IC50,740.0,nM,6.13,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,381.4359999999997,2.1959999999999997,2,8,106.5,7,3,0.6672915324998311,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL262276,IC50,800.0,nM,6.1,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)CN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)C1,381.4359999999997,2.1088999999999993,1,8,95.5,8,3,0.6763416773244504,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL355891,IC50,830.0,nM,6.08,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)CN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,395.4629999999997,2.4990000000000006,1,8,95.5,8,3,0.6632370567752006,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL169065,IC50,1470.0,nM,5.83,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)CNC(=O)c1ccc(Nc2ncnc3cc(OCCN4CCCCC4)c(OC)cc23)cc1,493.5639999999998,3.1495000000000006,2,9,114.91,12,3,0.4110751828465018,0,c1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1,CHEMBL3917723,IC50,9941.0,nM,5.0,CHEMBL3877875,CHEMBL203,CHEMBL3877259,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,301.2979999999997,2.2695000000000003,3,6,99.35000000000001,8,2,0.4568364574492507,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL169081,IC50,20000.0,nM,4.7,CHEMBL674005,CHEMBL203,CHEMBL1127676,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,303.3139999999997,2.131,4,6,99.02000000000001,9,2,0.4987165446563188,0,c1ccc(CNc2ccccc2)cc1,CHEMBL355461,IC50,3000.0,nM,5.52,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)Cn1cc(-c2cccc(Cl)c2)c(=O)c2c(O)cc(OC)cc21,373.79199999999986,3.209100000000002,1,6,77.76,7,3,0.710392018231355,0,O=c1c(-c2ccccc2)c[nH]c2ccccc12,CHEMBL7866,IC50,64.0,nM,7.19,CHEMBL677887,CHEMBL203,CHEMBL1132606,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1,354.36599999999976,3.568900000000002,2,7,94.60000000000001,8,3,0.7230647244781249,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL1761929,IC50,6900.0,nM,5.16,CHEMBL3226103,CHEMBL203,CHEMBL3217416,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1OC,301.2979999999997,2.6436,2,6,88.35000000000001,8,2,0.514669207722048,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL129989,IC50,100000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COC(=O)c1cc(/N=C/c2ccc(O)cc2)ccc1O,271.2719999999997,2.635000000000001,2,5,79.12,6,2,0.6640464018622073,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL130117,IC50,10000.0,nM,,CHEMBL676147,CHEMBL203,CHEMBL1127084,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1cc(/N=C/c2ccccc2O)ccc1O,271.2719999999997,2.635000000000001,2,5,79.12,6,2,0.6640464018622073,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL335074,IC50,10000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,289.2869999999997,2.2021,4,6,99.02000000000001,8,2,0.5085211538935756,0,c1ccc(CNc2ccccc2)cc1,CHEMBL131653,IC50,600.0,nM,6.22,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1OC,303.3139999999997,2.5051000000000005,3,6,88.02000000000001,9,2,0.5808404311335038,0,c1ccc(CNc2ccccc2)cc1,CHEMBL129930,IC50,9500.0,nM,5.02,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC(=O)c1cc(NCc2ccc(O)cc2)ccc1O,273.28799999999967,2.4965000000000006,3,5,78.79,7,2,0.5889434026503026,0,c1ccc(CNc2ccccc2)cc1,CHEMBL130337,IC50,10000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1cc(NCc2cccc(O)c2)ccc1O,273.28799999999967,2.4965000000000006,3,5,78.79,7,2,0.5889434026503026,0,c1ccc(CNc2ccccc2)cc1,CHEMBL423159,IC50,21000.0,nM,4.68,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1cc(NCc2ccccc2O)ccc1O,273.28799999999967,2.4965000000000006,3,5,78.79,7,2,0.5889434026503026,0,c1ccc(CNc2ccccc2)cc1,CHEMBL132907,IC50,20000.0,nM,4.7,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1ccc(/N=C/c2cc(O)ccc2O)cc1O,287.27099999999973,2.3406000000000007,3,6,99.35000000000001,7,2,0.45689473562096905,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL130893,IC50,10000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1ccc(NCc2cc(O)ccc2O)cc1O,289.2869999999997,2.2021,4,6,99.02000000000001,8,2,0.5085211538935756,0,c1ccc(CNc2ccccc2)cc1,CHEMBL133283,IC50,10000.0,nM,5.0,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,363.34699999999987,2.4883000000000006,0,7,112.81,7,2,0.3351970792885412,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL77401,IC50,1500.0,nM,5.82,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,379.3459999999999,2.1939000000000006,1,8,133.04,8,2,0.3493956784108064,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL76929,IC50,1800.0,nM,5.75,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(=O)c1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,400.2749999999999,3.1579000000000015,0,4,72.80000000000001,3,2,0.7264409496596241,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL1917092,IC50,1000.0,nM,6.0,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC(=O)c1cccc(NCc2cc(O)ccc2O)c1,273.28799999999967,2.4965,3,5,78.79,7,2,0.5889434026503025,0,c1ccc(CNc2ccccc2)cc1,CHEMBL334334,IC50,9000.0,nM,5.05,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,474.56499999999977,2.643700000000001,2,6,93.79999999999998,8,3,0.5706345117127313,0,O=C(Nc1n[nH]c2c1CN(C(=O)Cc1ccccc1)C2)c1ccc(N2CCNCC2)cc1,CHEMBL1981047,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC1(CCN)CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,424.55299999999954,3.1884200000000016,2,9,107.01,12,3,0.5954440188669036,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736430,Ki,28.0,nM,7.55,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1(CCO)CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,425.5369999999996,3.2220200000000014,2,9,101.22000000000001,12,3,0.5950068505919427,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736191,Ki,50.0,nM,7.3,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1(CN(C)C)CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,438.57999999999953,3.401220000000002,1,9,84.23,13,3,0.6008677755537866,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735927,Ki,492.0,nM,6.31,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1(CO)CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,411.5099999999996,2.831920000000001,2,9,101.22000000000001,11,3,0.6385330202571642,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736395,Ki,24.0,nM,7.62,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)cc4cn3)n2)CC1,390.45099999999974,3.101800000000001,3,7,107.63999999999999,6,4,0.48046552074209614,0,c1cc(Nc2cc3[nH]c(-c4cn[nH]c4)cc3cn2)nc(N2CCCCC2)n1,CHEMBL3354186,Ki,66.0,nM,7.18,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)nc4cn3)n2)CC1,391.43899999999974,2.4968000000000004,3,8,120.52999999999999,6,4,0.47449800153471455,0,c1cc(Nc2cc3[nH]c(-c4cn[nH]c4)nc3cn2)nc(N2CCCCC2)n1,CHEMBL3354185,Ki,51.0,nM,7.29,CHEMBL3375800,CHEMBL203,CHEMBL3351701,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4[nH]cnc4cn3)n2)CC1,325.3759999999997,2.1067,2,7,91.85,5,3,0.7586809757842543,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735952,Ki,329.0,nM,6.48,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC1CCN(c2nccc(Nc3cc4c(C(C)C)n[nH]c4cn3)n2)CC1,367.4569999999996,3.230100000000001,2,7,91.85,8,3,0.7150758077269257,0,c1cc(Nc2cc3cn[nH]c3cn2)nc(N2CCCCC2)n1,CHEMBL3354192,Ki,18.0,nM,7.75,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC1CCN(c2nccc(Nc3cc4c(ccc(=O)n4C(C)C)cn3)n2)CC1,394.47899999999964,3.1262000000000016,1,8,85.17,8,3,0.7114819500566487,0,O=c1ccc2cnc(Nc3ccnc(N4CCCCC4)n3)cc2[nH]1,CHEMBL3354195,Ki,82.0,nM,7.09,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)CCN4C(C)C)n2)CC1,368.48499999999956,3.0013000000000014,1,7,66.41,8,2,0.8700391488467951,0,c1cc(Nc2cc3c(cn2)CCN3)nc(N2CCCCC2)n1,CHEMBL3354194,Ki,423.0,nM,6.37,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC1CCN(c2nccc(Nc3cc4c(cn3)[nH]c(=O)n4C(C)C)n2)CC1,383.4559999999997,2.4543,2,8,100.96,8,3,0.6977477464366867,0,O=c1[nH]c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2[nH]1,CHEMBL3354193,Ki,114.0,nM,6.94,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)c(C(N)=O)cn4C(C)C)n2)CC1,409.49399999999963,2.8649000000000013,2,8,111.19000000000001,9,3,0.6437742807523027,0,c1cc(Nc2cc3[nH]ccc3cn2)nc(N2CCCCC2)n1,CHEMBL5282852,Ki,5.3,nM,8.28,CHEMBL5253712,CHEMBL203,CHEMBL5252534,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)c(C(N)=O)nn4C(C)C)n2)CC1,410.48199999999963,2.2599,2,9,124.08,9,3,0.6340478502582384,0,c1cc(Nc2cc3[nH]ncc3cn2)nc(N2CCCCC2)n1,CHEMBL5268573,Ki,29.0,nM,7.54,CHEMBL5253712,CHEMBL203,CHEMBL5252534,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)c(N)nn4C(C)C)n2)CC1,382.47199999999964,2.7432000000000007,2,9,107.01,9,3,0.6935631143570913,0,c1cc(Nc2cc3[nH]ncc3cn2)nc(N2CCCCC2)n1,CHEMBL3354191,Ki,12.0,nM,7.92,CHEMBL3375799,CHEMBL203,CHEMBL3351701,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,381.48399999999964,3.469420000000002,1,8,80.99,9,3,0.7245624081328449,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736508,Ki,19.0,nM,7.72,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)CC1,397.48299999999966,2.6533000000000007,2,9,101.22000000000001,10,3,0.6546231273158212,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3734877,Ki,19.0,nM,7.72,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C(C)C)n2)CC1,367.45699999999965,3.1610000000000014,1,8,80.99,8,3,0.7416395340252077,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3354190,Ki,40.0,nM,7.4,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C3CC3)n2)CC1,365.4409999999997,2.915000000000001,1,8,80.99,6,3,0.7443490744106771,0,c1cc(Nc2cc3c(cn2)ncn3C2CC2)nc(N2CCCCC2)n1,CHEMBL3736178,Ki,87.0,nM,7.06,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C3CCC3)n2)CC1,379.4679999999997,3.305100000000002,1,8,80.99,6,3,0.7282406239525935,0,c1cc(Nc2cc3c(cn2)ncn3C2CCC2)nc(N2CCCCC2)n1,CHEMBL3736409,Ki,48.0,nM,7.32,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C3CCOC3)n2)CC1,395.4669999999997,2.541500000000001,1,9,90.22,6,3,0.704885897866207,0,c1cc(Nc2cc3c(cn2)ncn3C2CCOC2)nc(N2CCCCC2)n1,CHEMBL3734928,Ki,149.0,nM,6.83,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C3CCOCC3)n2)CC1,409.4939999999997,2.9316000000000013,1,9,90.22,6,3,0.6879277610892389,0,c1cc(Nc2cc3c(cn2)ncn3C2CCOCC2)nc(N2CCCCC2)n1,CHEMBL3735725,Ki,76.0,nM,7.12,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4CC(F)(F)F)n2)CC1,407.3999999999997,3.142400000000001,1,8,80.99,6,3,0.695903653907548,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736254,Ki,71.0,nM,7.15,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COC1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,481.5759999999996,3.421000000000002,2,9,99.53,11,3,0.5485272832913666,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1,CHEMBL5205583,IC50,3.4,nM,8.47,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,500.5819999999998,3.430200000000001,2,9,84.53999999999999,8,5,0.35425545064556996,1,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1,CHEMBL392774,IC50,190.0,nM,6.72,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
COCC(=O)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,434.2369999999998,3.5629000000000017,2,5,76.14,6,3,0.6011326524469336,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL190567,IC50,150.0,nM,6.82,CHEMBL832761,CHEMBL203,CHEMBL1141151,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1,348.3579999999998,3.4320000000000013,2,4,84.18,6,4,0.32870728990337494,0,O=C(c1cc2ccccc2[nH]1)c1cc2ccccc2[nH]1,CHEMBL7600,IC50,30000.0,nM,,CHEMBL678295,CHEMBL203,CHEMBL1135728,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCC1(OC)CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,425.5369999999996,3.4860200000000017,1,9,90.22000000000001,12,3,0.6152525437085266,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735848,Ki,77.0,nM,7.11,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,390.4469999999997,2.5881000000000007,1,6,88.93,9,4,0.5239258705255828,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1986970,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCN(C)CCN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,438.57599999999957,2.9042000000000012,1,8,81.67,13,3,0.5500459044125651,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL274732,IC50,930.0,nM,6.03,CHEMBL677879,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCN(Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)[C@@H](C)C(N)=O,461.9249999999997,3.4967000000000006,2,7,102.6,13,3,0.47598834671345036,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL382823,IC50,10.0,nM,8.0,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCN1CC(C(N)=O)(N(C)Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1,502.9779999999997,2.7924000000000007,2,8,105.84,13,3,0.435764230568712,1,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1,CHEMBL207815,IC50,6.0,nM,8.22,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,545.6440000000017,2.4208000000000007,3,8,115.06,9,3,0.3093922698692974,1,O=C(Nc1cccc2c1C(=O)c1c(-c3ccc(CN4CCNCC4)cc3)n[nH]c1-2)NN1CCOCC1,CHEMBL3545083,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCNCCN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,424.5489999999996,2.5619999999999994,2,8,90.46,12,3,0.5103024227972388,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL172514,IC50,310.0,nM,6.51,CHEMBL677879,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1,476.60199999999975,3.1115000000000013,1,7,70.69,9,3,0.3265512247011574,0,O=C1c2cc(CN3CCNCC3)ccc2-c2[nH]nc(-c3ccsc3)c21,CHEMBL387971,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(F)c4)=CC3=O)c2cc1OC,479.4639999999999,3.3510000000000018,1,9,108.87000000000002,12,3,0.34583247917269766,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12,CHEMBL396472,IC50,10000.0,nM,,CHEMBL892951,CHEMBL203,CHEMBL1147965,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(OC)c4)=CC3=O)c2cc1OC,491.4999999999999,3.220500000000002,1,10,118.10000000000001,14,3,0.3163415671474866,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12,CHEMBL242349,IC50,7710.0,nM,5.11,CHEMBL892951,CHEMBL203,CHEMBL1147965,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccccc4)=CC3=O)c2cc1OC,461.4739999999999,3.2119000000000018,1,9,108.87000000000002,12,3,0.35949769710179363,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12,CHEMBL242555,IC50,10000.0,nM,,CHEMBL892951,CHEMBL203,CHEMBL1147965,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3c(Cl)ccc4c3OCO4)c2cc1NC(=O)[C@@H]1CCCN1,485.9279999999999,3.4712000000000005,3,9,115.86000000000001,9,3,0.4121912474582424,0,O=C(Nc1ccc2ncnc(Nc3cccc4c3OCO4)c2c1)C1CCCN1,CHEMBL523122,IC50,7130.0,nM,5.15,CHEMBL1022371,CHEMBL203,CHEMBL1153429,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OCCOC,459.49899999999974,3.449600000000002,1,10,102.42000000000002,18,3,0.3823896890672834,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL4468521,Kd,53.0,nM,7.28,CHEMBL4394506,CHEMBL203,CHEMBL4393671,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(B(O)O)cc3)c2cc1OC,369.1859999999998,1.0869999999999997,3,8,105.96000000000001,12,3,0.4003156775161957,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219513,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(B(O)O)cc3)c2cc1OCCOC,413.2389999999998,1.1036,3,9,115.19000000000001,15,3,0.3140551907173026,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219512,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(C)c([N+](=O)[O-])c3)c2c2c1OCCO2,412.4019999999998,3.386420000000002,1,9,117.87,9,3,0.3537717907169949,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805299,IC50,74.6,nM,7.13,CHEMBL3807186,CHEMBL203,CHEMBL3804755,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(F)c(C#N)c3)c2c2c1OCCO2,396.3779999999999,3.180580000000001,1,8,98.52000000000001,7,3,0.6345937723276941,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805280,IC50,387.8,nM,6.41,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(F)c(C#N)c3)c2cc1NC(=O)/C=C/CN(C)C,464.5009999999998,3.4656800000000016,2,8,112.39999999999999,13,3,0.3465326891696408,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3622635,IC50,1000.0,nM,,CHEMBL3625155,CHEMBL203,CHEMBL3621102,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(F)c([N+](=O)[O-])c3)c2c2c1OCCO2,416.3649999999999,3.217100000000001,1,9,117.87,8,3,0.3517455275570591,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805333,IC50,43.8,nM,7.36,CHEMBL3807186,CHEMBL203,CHEMBL3804755,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3ccc(F)cc3)c2c2c1OCCO2,371.3679999999998,3.3089000000000013,1,7,74.73,7,3,0.6664480158120679,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3806005,IC50,200.3,nM,6.7,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCOc1cc2ncnc(Nc3ccc(OC)c([N+](=O)[O-])c3)c2c2c1OCCO2,428.40099999999984,3.0866000000000016,1,10,127.10000000000002,10,3,0.32468986089173585,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3805491,IC50,1000.0,nM,,CHEMBL3807187,CHEMBL203,CHEMBL3804755,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3cccc(B(O)O)c3)c2cc1OC,369.1859999999998,1.0869999999999995,3,8,105.96000000000001,12,3,0.4003156775161957,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219510,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3cccc(B(O)O)c3)c2cc1OCCOC,413.2389999999998,1.1035999999999997,3,9,115.19000000000001,15,3,0.3140551907173026,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3217774,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCOc1cc2ncnc(Nc3cccc(OC)c3)c2c2c1OCCO2,383.40399999999977,3.1784000000000017,1,8,83.96000000000001,9,3,0.6230309292396419,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1,CHEMBL3806066,IC50,109.1,nM,6.96,CHEMBL3807187,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCOc1cc2ncnc(Sc3nc[nH]n3)c2cc1OCCOC,377.4259999999998,1.9495,1,9,104.27000000000001,12,3,0.4191016766621076,0,c1ccc2c(Sc3nc[nH]n3)ncnc2c1,CHEMBL4868123,IC50,5210.0,nM,5.28,CHEMBL4832760,CHEMBL203,CHEMBL4831513,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,461.9249999999997,3.4967000000000015,2,7,102.60000000000001,13,3,0.4759883467134506,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL207445,IC50,10.0,nM,8.0,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCn1c(=O)oc2cc3ncnc(Nc4ccc(Cl)cc4)c3cc21,370.7959999999998,3.581100000000002,1,7,82.18,6,4,0.5778607613056025,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612566,IC50,10000.0,nM,,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,372.33099999999985,3.2059000000000015,1,7,82.18,6,4,0.5793369386473354,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612563,IC50,26.0,nM,7.58,CHEMBL3614855,CHEMBL203,CHEMBL3611993,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC)c(OC)c4)c3cc21,396.40299999999985,2.9449000000000014,1,9,100.64000000000001,10,4,0.5088734793200087,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612572,IC50,5500.0,nM,5.26,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC)cc4)c3cc21,366.37699999999984,2.936300000000001,1,8,91.41000000000001,8,4,0.5608139188934559,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612564,IC50,5100.0,nM,5.29,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCn1c(=O)oc2cc3ncnc(Nc4ccc(S(N)(=O)=O)cc4)c3cc21,415.43099999999987,1.5751000000000002,2,9,142.34,8,4,0.48313948767769377,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612569,IC50,10000.0,nM,,CHEMBL3614855,CHEMBL203,CHEMBL3611993,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCn1c(=O)oc2cc3ncnc(Nc4cccc(C(C)=O)c4)c3cc21,378.38799999999986,3.130300000000002,1,8,99.25,8,4,0.5146163010185203,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3612570,IC50,560.0,nM,6.25,CHEMBL3614855,CHEMBL203,CHEMBL3611993,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1,314.7759999999997,3.3069000000000015,0,5,52.83,6,3,0.7247634606475188,0,c1ccc(-c2n[nH]cc2-c2ccncn2)cc1,CHEMBL1982866,Ki,25.12,nM,7.6,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1,361.43099999999976,2.0777,1,9,99.75,10,3,0.6914761827097196,0,O=C(Nc1cn[nH]c1)c1csc(-c2nnc[nH]2)n1,CHEMBL4073198,IC50,19952.62,nM,,CHEMBL4011136,CHEMBL203,CHEMBL4007491,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1Br,392.2569999999997,3.401600000000001,1,7,88.08,9,3,0.6699567614592662,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242286,IC50,4320.0,nM,5.37,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,447.8979999999997,3.106600000000002,2,7,102.60000000000001,12,3,0.5191485235923676,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL379905,IC50,30.0,nM,7.52,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COC[C@@H](C)Nc1cc(NC(=O)N2CCCc3cc(CN4CCCCOC4=O)c(C=O)nc32)ncc1C#N,521.5780000000002,3.3246800000000025,2,9,149.78,10,2,0.4986970775913168,1,O=C1OCCCCN1Cc1cnc2c(c1)CCCN2C(=O)Nc1ccccn1,CHEMBL4475216,IC50,10000.0,nM,,CHEMBL4339989,CHEMBL203,CHEMBL4339212,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C,546.6610000000015,2.1359000000000012,2,10,125.84000000000002,17,0,0.34543452413266984,1,C=C1C(=O)OCC2C1=CC(=O)C1=C2CCC2CCCC12,CHEMBL410643,IC50,10000.0,nM,,CHEMBL950973,CHEMBL203,CHEMBL1143164,0.5,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range
COC[C@H]1OC(=O)/C(=C/N(CCO)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C,547.6450000000017,2.3452,3,10,142.83,13,0,0.33492189979210124,1,C=C1C(=O)OCC2C1=CC(=O)C1=C2CCC2CCCC12,CHEMBL271190,IC50,10000.0,nM,,CHEMBL950973,CHEMBL203,CHEMBL1143164,0.5,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range
COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O,388.34399999999994,-0.05589999999999984,4,12,186.79999999999995,11,3,0.32898498304181434,1,O=C(NN=Cc1ccccc1)c1cnnn1-c1cnon1,CHEMBL1991180,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
CONC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,302.2859999999997,1.8451999999999997,4,6,111.38000000000001,8,2,0.391064864716785,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL354300,IC50,27000.0,nM,4.57,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CONC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,304.3019999999997,1.7066999999999997,5,6,111.05000000000001,9,2,0.42460905103623064,0,c1ccc(CNc2ccccc2)cc1,CHEMBL169657,IC50,300.0,nM,6.52,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C)o4)c(C(C)C)c23)c(F)cc1F,443.4139999999999,3.5241200000000026,2,9,119.47,10,4,0.434575161773436,0,c1ccc(Nc2ncnn3cc(-c4nnco4)cc23)cc1,CHEMBL365318,IC50,10000.0,nM,,CHEMBL830273,CHEMBL203,CHEMBL1144449,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,474.56499999999977,2.643700000000001,2,6,93.79999999999998,8,3,0.5706345117127313,0,O=C(Nc1n[nH]c2c1CN(C(=O)Cc1ccccc1)C2)c1ccc(N2CCNCC2)cc1,CHEMBL402548,IC50,10000.0,nM,,CHEMBL913518,CHEMBL203,CHEMBL1137365,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CO[C@@H]1[C@H](O)CN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)CC1(F)F,590.6970000000018,3.5923000000000025,2,10,120.78,14,3,0.40271879015039314,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1,CHEMBL5193016,IC50,0.7,nM,9.15,CHEMBL5141214,CHEMBL203,CHEMBL5137066,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H](C)c1c(O)cc2c(c1O)C(=O)c1c(O)cc(O)cc1C2=O,330.2919999999998,1.9918000000000007,4,7,124.28999999999999,8,2,0.5661339812937334,0,O=C1c2ccccc2C(=O)c2ccccc21,CHEMBL498248,IC50,27500.0,nM,4.56,CHEMBL974188,CHEMBL203,CHEMBL1142620,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H](C)c1c(O)cc2c(c1O)C(=O)c1c(cc(O)c(O)c1O)C2=O,346.2909999999998,1.6974000000000014,5,8,144.52,9,2,0.44091781931045104,0,O=C1c2ccccc2C(=O)c2ccccc21,CHEMBL498249,IC50,41000.0,nM,4.39,CHEMBL974188,CHEMBL203,CHEMBL1142620,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)C[C@@H]1F,399.47399999999965,3.4174200000000017,1,8,80.99,9,3,0.7039671559011416,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735740,Ki,44.0,nM,7.36,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)C[C@H]1F,399.47399999999965,3.4174200000000017,1,8,80.99,9,3,0.7039671559011416,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736183,Ki,2.7,nM,8.57,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)CC1(F)F,433.4629999999997,2.898500000000001,2,9,101.22000000000001,10,3,0.6120621091542781,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735474,Ki,7.4,nM,8.13,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)C[C@@H]1F,415.4729999999997,2.6013,2,9,101.22000000000001,10,3,0.6335995185220181,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3736181,Ki,57.0,nM,7.24,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)C[C@H]1F,415.4729999999997,2.6013,2,9,101.22000000000001,10,3,0.6335995185220181,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3734933,Ki,4.3,nM,8.37,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CO[C@H]1[C@@H](N(C)C(=O)CN)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,523.5930000000005,3.551700000000003,2,7,103.75,7,5,0.37653664093369865,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCCC3O1,CHEMBL338935,IC50,220.0,nM,6.66,CHEMBL677890,CHEMBL203,CHEMBL1127758,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
COc1c(Br)cccc1Nc1ncnc2ccncc12,331.1729999999999,3.5395000000000003,1,5,59.93,4,3,0.795411943732026,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL441333,IC50,39.81,nM,7.4,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1c(O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O,300.2659999999998,2.5854000000000004,3,6,100.13000000000001,6,3,0.6723108130019759,0,O=c1c(-c2ccccc2)coc2ccccc12,CHEMBL242740,IC50,3300.0,nM,5.48,CHEMBL970971,CHEMBL203,CHEMBL1157216,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,480.5289999999997,0.661800000000002,2,11,139.79000000000002,9,2,0.5470559666602671,1,O=C(NC1=Nc2cc(OCCCN3CCOCC3)ccc2C2=NCCN12)c1cncnc1,CHEMBL3218576,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,Contains aniline substituent; MW in Type 1 range; Aromatic ring count typical
COc1cc(-c2ccc3c(c2)NC(=O)/C3=C\c2ncc[nH]2)ccc1O,333.34699999999975,3.283600000000001,3,4,87.24,5,3,0.641977162081218,0,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ncc[nH]1,CHEMBL199299,IC50,50000.0,nM,,CHEMBL865812,CHEMBL203,CHEMBL1148568,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O,460.4899999999998,3.2430000000000008,5,6,128.79,9,3,0.3593662605509649,0,O=C1Nc2ccccc2Nc2cc(-c3ccccc3)ccc21,CHEMBL1975500,Ki,794.33,nM,6.1,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(-c2nc(=O)c3c([nH]2)sc2ccc(C)cc23)ccc1OCC(=O)O,396.4239999999999,3.5852200000000014,2,7,101.51,7,4,0.5346038724437879,0,O=c1nc(-c2ccccc2)[nH]c2sc3ccccc3c12,CHEMBL599388,IC50,2400.0,nM,5.62,CHEMBL1069630,CHEMBL203,CHEMBL1156931,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(-c2nc3ccccc3s2)ccc1OCC(=O)NNC(=O)CN1CCC[C@H]1C(=O)O,484.5339999999998,2.0471000000000004,3,9,130.09,9,3,0.41437884872047664,0,O=C(COc1ccc(-c2nc3ccccc3s2)cc1)NNC(=O)CN1CCCC1,CHEMBL5192184,IC50,342.0,nM,6.47,CHEMBL5133605,CHEMBL203,CHEMBL5131433,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)cc(OC)c1OC,343.3869999999997,2.682200000000001,1,8,97.31,11,3,0.7603117255995497,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242660,IC50,5140.0,nM,5.29,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1F,301.3249999999997,2.8041,1,6,78.85,7,3,0.8044166571227604,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241483,IC50,3860.0,nM,5.41,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1N,298.3499999999997,2.2472,2,7,104.86999999999999,8,3,0.7184350915582113,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241485,IC50,3850.0,nM,5.42,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(C)CO,356.42999999999967,2.4577000000000004,3,8,111.11,12,3,0.6218645535605837,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241486,IC50,5320.0,nM,5.27,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1O,299.3339999999997,2.3706,2,7,99.08,8,3,0.7699596666846392,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242112,IC50,908.0,nM,6.04,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(-c2nn(C3CCCC3)c3ncnc(N)c23)ccc1N,324.3879999999997,2.7814000000000005,2,7,104.86999999999999,6,3,0.7177517828961364,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1241581,IC50,84.0,nM,7.08,CHEMBL1243977,CHEMBL203,CHEMBL1240340,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=C(C#N)C#N)cc(O)c1O,282.2589999999998,1.27334,3,7,147.07999999999998,7,1,0.4292326375772375,0,c1ccccc1,CHEMBL80745,IC50,1000.0,nM,6.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
COc1cc(/C=C(\C#N)C(N)=O)cc(CSC2=NCCS2)c1O,349.4369999999998,2.1290800000000005,2,7,108.69999999999999,7,1,0.6224878338878178,0,c1ccc(CSC2=NCCS2)cc1,CHEMBL324030,IC50,8709.64,nM,5.06,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCC(=O)O)c1O,336.36899999999974,1.5009800000000002,3,7,133.64,10,1,0.3718801034797278,0,c1ccccc1,CHEMBL424625,IC50,50000.0,nM,,CHEMBL677393,CHEMBL203,CHEMBL1126897,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCCC(=O)O)c1O,350.39599999999973,1.89108,3,7,133.64,11,1,0.3515762172747175,0,c1ccccc1,CHEMBL326044,IC50,6500.0,nM,5.19,CHEMBL689290,CHEMBL203,CHEMBL1126897,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2)c1O,354.43099999999976,3.2264800000000027,2,5,96.33999999999999,9,2,0.5876900704178231,0,c1ccc(CSCc2ccccc2)cc1,CHEMBL326318,IC50,891.25,nM,6.05,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(C)cc2)c1O,354.43099999999976,3.393800000000003,2,5,96.33999999999999,9,2,0.4707562386753929,0,c1ccc(CSc2ccccc2)cc1,CHEMBL333454,IC50,1737.8,nM,5.76,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(O)cc2)c1O,356.4029999999998,2.7909800000000007,3,6,116.57,9,2,0.41619473564798,0,c1ccc(CSc2ccccc2)cc1,CHEMBL419047,IC50,2000.0,nM,5.7,CHEMBL689290,CHEMBL203,CHEMBL1126897,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,340.40399999999977,3.085380000000002,2,5,96.33999999999999,8,2,0.4784177827285905,0,c1ccc(CSc2ccccc2)cc1,CHEMBL116595,IC50,398.11,nM,6.4,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2C(=O)O)c1O,384.41299999999984,2.783580000000001,3,7,133.64,9,2,0.3795089862181673,0,c1ccc(CSc2ccccc2)cc1,CHEMBL119987,IC50,707.95,nM,6.15,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2NC(C)=O)c1O,397.4559999999998,3.043780000000002,3,6,125.43999999999998,10,2,0.37451396081752814,0,c1ccc(CSc2ccccc2)cc1,CHEMBL115895,IC50,5600.0,nM,5.25,CHEMBL677392,CHEMBL203,CHEMBL1126897,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccn2)c1O,341.39199999999977,2.4803800000000016,2,6,109.22999999999999,8,2,0.47445521327039913,0,c1ccc(CSc2ccccn2)cc1,CHEMBL119156,IC50,3388.44,nM,5.47,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3[nH]2)c1O,380.42899999999986,2.9616800000000016,3,6,125.02,8,3,0.34291517282073425,0,c1ccc(CSc2nc3ccccc3[nH]2)cc1,CHEMBL331026,IC50,14454.4,nM,4.84,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3o2)c1O,381.4129999999999,3.2265800000000016,2,7,122.36999999999999,8,3,0.3816580809807542,0,c1ccc(CSc2nc3ccccc3o2)cc1,CHEMBL118205,IC50,5248.07,nM,5.28,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C(\C#N)C(N)=O)cc(Sc2nc3ccccc3s2)c1O,383.4539999999999,3.5539800000000024,2,7,109.22999999999999,7,3,0.5149704138774894,0,c1ccc(Sc2nc3ccccc3s2)cc1,CHEMBL290389,IC50,350.0,nM,6.46,CHEMBL821544,CHEMBL203,CHEMBL1133720,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(/C=C(\C#N)S(=O)(=O)/C(C#N)=C/c2cc(O)c(O)c(OC)c2)cc(O)c1O,444.42099999999994,2.370160000000002,4,10,181.09999999999997,12,2,0.3811732306896972,0,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1,CHEMBL342792,IC50,940.0,nM,6.03,CHEMBL677831,CHEMBL203,CHEMBL1129590,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(/C=C(\C#N)c2ccccn2)ccc1O,252.27300000000008,2.8599800000000015,1,4,66.14,5,2,0.8528311929788023,0,C(=Cc1ccccn1)c1ccccc1,CHEMBL39295,IC50,2100.0,nM,5.68,CHEMBL709833,CHEMBL203,CHEMBL1133720,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(/C=C(\C)[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,393.37299999999993,2.7986000000000013,1,8,133.04,9,2,0.4311727301261984,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL77397,IC50,2500.0,nM,5.6,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,368.38499999999976,3.3699000000000026,2,6,93.06000000000002,12,2,0.5481228320623274,0,O=C(/C=C/c1ccccc1)CC(=O)/C=C/c1ccccc1,CHEMBL140,IC50,8650.0,nM,5.06,CHEMBL3888815,CHEMBL203,CHEMBL3886845,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(/C=C/S(=O)(=O)c2ccccc2)cc(OC)c1OC,334.3929999999997,3.157000000000002,0,5,61.83000000000001,9,2,0.811905258332886,0,O=S(=O)(/C=C/c1ccccc1)c1ccccc1,CHEMBL5201532,IC50,7.85,nM,8.11,CHEMBL5128251,CHEMBL203,CHEMBL5126541,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(/C=C/[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,379.34599999999995,2.4085,1,8,133.04,8,2,0.4403469997385978,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL418907,IC50,2800.0,nM,5.55,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(/C=N/NC(=O)COC2=NC(C)=NC3C2C(C)=NN3c2ccccc2)cc(OC)c1OC,492.53599999999983,2.8480000000000008,1,10,118.7,13,2,0.44718683285233884,0,O=C(COC1=NC=NC2C1C=NN2c1ccccc1)N/N=C/c1ccccc1,CHEMBL5281486,IC50,4180.0,nM,5.38,CHEMBL5228534,CHEMBL203,CHEMBL5226337,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Br)cc(-c2nn(C(C)C)c3ncnc(N)c23)c1,362.2309999999998,3.427500000000001,1,6,78.85,7,3,0.7723633958839187,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242200,IC50,11000.0,nM,4.96,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,347.71799999999985,2.35248,3,7,137.23000000000002,5,2,0.7712464515565093,0,O=C(Nc1ccccc1)Nc1cnccn1,CHEMBL1983006,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,403.4419999999998,2.8779000000000003,4,6,126.15,9,4,0.3758612351097897,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4776751,IC50,0.5,nM,9.3,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,317.7359999999998,2.9627,2,5,99.92999999999999,5,2,0.9060859759644715,0,O=C(Nc1ccccc1)Nc1cnccn1,CHEMBL1975233,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C2=C(c3c[nH]c4ccc(Br)cc34)C(=O)NC2=O)cc(OC)c1OC,457.28,3.5234000000000014,2,5,89.65,8,3,0.5727790589176563,0,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1,CHEMBL605957,IC50,5797.0,nM,5.24,CHEMBL1070746,CHEMBL203,CHEMBL1158526,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(C2=C(c3c[nH]c4ccc(F)cc34)C(=O)NC2=O)cc(OC)c1OC,396.37399999999985,2.9000000000000004,2,5,89.65,8,3,0.6476051236833441,0,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1,CHEMBL606168,IC50,8480.0,nM,,CHEMBL1070746,CHEMBL203,CHEMBL1158526,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C2=C(c3c[nH]c4ccc(I)cc34)C(=O)NC2=O)cc(OC)c1OC,504.28,3.3655000000000017,2,5,89.65,8,3,0.4111990928520628,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1,CHEMBL597492,IC50,1688.0,nM,5.77,CHEMBL1070746,CHEMBL203,CHEMBL1158526,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,378.3839999999998,2.7609000000000004,2,5,89.65,8,3,0.6666129759294205,0,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1,CHEMBL201511,IC50,10133.0,nM,4.99,CHEMBL1070746,CHEMBL203,CHEMBL1158526,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C2=C(c3c[nH]c4ccccc34)CNC2=O)cc(OC)c1OC,364.4009999999997,3.234300000000001,2,4,72.58,8,3,0.7290461645085053,0,O=C1NCC(c2c[nH]c3ccccc23)=C1c1ccccc1,CHEMBL529663,IC50,23000.0,nM,4.64,CHEMBL957972,CHEMBL203,CHEMBL1157465,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C=C(C#N)C#N)cc(CS(=O)(=O)c2ccc(C)cc2)c1O,368.4139999999998,3.1136800000000027,1,6,111.17999999999999,8,2,0.8117815535840848,0,O=S(=O)(Cc1ccccc1)c1ccccc1,CHEMBL334032,IC50,15000.0,nM,4.82,CHEMBL689291,CHEMBL203,CHEMBL1126897,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C=C(C#N)C#N)cc(CSCC(=O)O)c1O,304.32699999999977,2.1491599999999997,2,7,114.34,8,1,0.7736098888167434,0,c1ccccc1,CHEMBL120719,IC50,50000.0,nM,,CHEMBL689290,CHEMBL203,CHEMBL1126897,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O,281.27499999999975,1.6419599999999996,3,6,131.73999999999998,6,2,0.7325285102958189,0,C(=Cc1cc[nH]n1)c1ccccc1,CHEMBL2002407,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O,326.3769999999998,3.292400000000002,2,5,70.92,5,2,0.8491871718766268,0,O=C1NC(=Nc2ccccc2)SC1=Cc1ccccc1,CHEMBL1970522,Ki,199.53,nM,6.7,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(C=C2SC(=O)NC2=O)ccc1O,251.26300000000003,1.7247,2,5,75.63,4,1,0.7826894962582861,0,O=C1NC(=O)C(=Cc2ccccc2)S1,CHEMBL2003286,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
COc1cc(C=C2SC(=S)NC2=O)ccc1O,267.3309999999998,1.8896000000000002,2,5,58.56,4,1,0.6327756243504743,0,O=C1NC(=S)SC1=Cc1ccccc1,CHEMBL1973098,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,331.7189999999999,2.466779999999999,2,6,116.99999999999999,5,2,0.8309273729979308,0,O=C(Nc1ccccc1)Nc1cnccn1,CHEMBL207995,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,390.4429999999997,3.2713,4,6,103.28999999999999,10,4,0.3861837707859719,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4164805,IC50,0.2,nM,9.7,CHEMBL4718840,CHEMBL203,CHEMBL4715760,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(F)c(-c2nn(C(C)C)c3ncnc(N)c23)cc1F,319.31499999999977,2.9432,1,6,78.85,7,3,0.802729355420685,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242027,IC50,10200.0,nM,4.99,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,572.3430000000009,3.478300000000001,4,6,107.89000000000001,12,2,0.3432308565058528,1,O=S(=O)(Nc1ccccc1Nc1ccccc1)C1CC1,CHEMBL1236682,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(N)c2oc(-c3ccc(N)cc3)cc(=O)c2c1,282.29899999999975,2.633000000000001,2,5,91.47999999999999,5,3,0.70487734049539,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL116353,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc(N)c2oc(-c3cccc(N)c3)cc(=O)c2c1,282.29899999999975,2.633000000000001,2,5,91.47999999999999,5,3,0.70487734049539,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL114550,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)CO)cc2)n1,498.9709999999998,3.357100000000001,3,9,112.08000000000001,11,3,0.43001503805366487,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL4214040,IC50,860.0,nM,6.07,CHEMBL4179475,CHEMBL203,CHEMBL4177590,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CO)c2)n1,498.9709999999998,3.357100000000001,3,9,112.08000000000001,11,3,0.43001503805366487,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL4207305,IC50,1230.0,nM,5.91,CHEMBL4179475,CHEMBL203,CHEMBL4177590,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)CO)n1,498.9709999999998,3.3571000000000004,3,9,112.08000000000001,11,3,0.43001503805366487,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL4212450,IC50,100.0,nM,7.0,CHEMBL4179475,CHEMBL203,CHEMBL4177590,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(c1cccc(N)c1)C(=O)N(C)C2,474.5689999999997,3.266300000000001,2,8,103.08999999999999,9,3,0.5434235662512146,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1,CHEMBL2029442,IC50,478.0,nM,6.32,CHEMBL2033653,CHEMBL203,CHEMBL2029259,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(N2CCN(CC(N)=O)C2=O)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,574.0630000000014,3.5352000000000015,3,9,159.85000000000002,13,3,0.32937486156684803,1,O=C1NCCN1c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,CHEMBL4573193,IC50,1000.0,nM,,CHEMBL4348480,CHEMBL203,CHEMBL4346688,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(NC(=O)Nc2ccccn2)cc(-c2c[nH]cn2)c1OC,339.35499999999973,3.1329000000000002,3,5,101.16,7,3,0.6627788908367291,0,O=C(Nc1cccc(-c2c[nH]cn2)c1)Nc1ccccn1,CHEMBL3753532,IC50,24.81,nM,7.61,CHEMBL3756968,CHEMBL203,CHEMBL3751776,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(NC(=O)Nc2ccncc2)cc(-c2cncnc2)c1OC,351.36599999999976,3.1998000000000015,2,6,98.26,7,3,0.7323650294052158,0,O=C(Nc1ccncc1)Nc1cccc(-c2cncnc2)c1,CHEMBL3754722,IC50,290.46,nM,6.54,CHEMBL3756968,CHEMBL203,CHEMBL3751776,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(NC(=O)Nc2nccs2)cc(-c2cn(C)cn2)c1OC,359.4109999999998,3.2048000000000014,2,7,90.30000000000001,8,3,0.729967257857499,0,O=C(Nc1cccc(-c2c[nH]cn2)c1)Nc1nccs1,CHEMBL3752129,IC50,362.0,nM,6.44,CHEMBL3756968,CHEMBL203,CHEMBL3751776,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(NS(C)(=O)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,453.5239999999998,3.150500000000001,4,7,129.23,11,4,0.3224598387945573,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4740573,IC50,0.3,nM,9.52,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2c(C#N)cnc3cc4[nH]c(CN5CCOCC5)nc4cc23)cc(OC)c1OC,474.5209999999998,3.584380000000002,2,9,117.55,10,4,0.41426875316540396,0,c1ccc(Nc2ccnc3cc4[nH]c(CN5CCOCC5)nc4cc23)cc1,CHEMBL330657,IC50,1000.0,nM,,CHEMBL677886,CHEMBL203,CHEMBL1135352,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2c(C#N)cnc3cc4[nH]c(NCCN5CCOCC5)nc4cc23)cc(OC)c1OC,503.56299999999976,3.4962800000000023,3,10,129.57999999999998,12,4,0.31199846766755013,1,c1ccc(Nc2ccnc3cc4[nH]c(NCCN5CCOCC5)nc4cc23)cc1,CHEMBL93262,IC50,1000.0,nM,,CHEMBL677886,CHEMBL203,CHEMBL1135352,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2c(C#N)cnc3cc4c(cc23)ncn4CCN2CCOCC2)cc(OC)c1OC,488.5479999999998,3.557780000000002,1,10,106.69,11,4,0.39834124488016887,0,c1ccc(Nc2ccnc3cc4c(cc23)ncn4CCN2CCOCC2)cc1,CHEMBL96633,IC50,1000.0,nM,,CHEMBL677886,CHEMBL203,CHEMBL1135352,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC,440.4159999999999,2.9967000000000006,3,10,163.76,12,3,0.3326440116518101,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1241473,Ki,1000.0,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2nccc(-c3ccc(N4CCNCC4)nc3)n2)cc(OC)c1OC,422.4889999999997,2.717600000000001,2,9,93.66000000000001,10,3,0.5959378591775808,0,c1ccc(Nc2nccc(-c3ccc(N4CCNCC4)nc3)n2)cc1,CHEMBL322066,IC50,1704.0,nM,5.77,CHEMBL674700,CHEMBL203,CHEMBL1131898,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2nccc(-c3ccc(NCCN)nc3)n2)cc(OC)c1OC,396.45099999999974,2.6786000000000003,3,9,116.44000000000001,13,3,0.5016948719689899,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL113185,IC50,5100.0,nM,5.29,CHEMBL674700,CHEMBL203,CHEMBL1131898,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(Nc2nccc(-c3cccnc3)n2)cc(OC)c1OC,338.36699999999973,3.3080000000000016,1,7,78.39,9,3,0.7384647589954522,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL112263,IC50,10000.0,nM,,CHEMBL674700,CHEMBL203,CHEMBL1131898,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(Nc2ncnc3[nH]nc(OCCN4CCC(O)CC4)c23)ccc1OCc1ccccn1,491.5519999999998,2.914600000000001,3,10,130.54000000000002,12,4,0.3042959191078176,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1,CHEMBL401713,IC50,104.0,nM,6.98,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)cn(C)c2c1,315.75599999999974,3.573100000000002,1,4,51.46,5,3,0.7862128834554566,0,O=c1c(-c2ccccc2)c[nH]c2ccccc12,CHEMBL7819,IC50,170.0,nM,6.77,CHEMBL677887,CHEMBL203,CHEMBL1132606,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc(O)c2c(=O)n(-c3cccc(C(=O)N4CCCCC4)c3)ccc2c1,378.4279999999997,3.331000000000002,1,5,71.77,5,3,0.7588416445826474,0,O=C(c1cccc(-n2ccc3ccccc3c2=O)c1)N1CCCCC1,CHEMBL2442329,IC50,1380.0,nM,5.86,CHEMBL2446217,CHEMBL203,CHEMBL2440093,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(O)c2c(c1)CCN(c1cccc(C(=O)N3CCCCC3)c1)C2=O,380.4439999999997,3.229800000000002,1,4,70.08000000000001,5,2,0.8875828083056875,0,O=C(c1cccc(N2CCc3ccccc3C2=O)c1)N1CCCCC1,CHEMBL2442333,IC50,1180.0,nM,5.93,CHEMBL2446217,CHEMBL203,CHEMBL2440093,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,451.4969999999998,2.8032000000000004,2,9,120.39000000000001,15,2,0.5311391582358496,0,O=S(=O)(/C=C/c1ccccc1)Cc1ccccc1,CHEMBL1241855,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(OC)c2cc(-c3ccncc3)cnc2c1,266.2999999999998,3.314000000000002,0,4,44.24,5,3,0.7291625080611583,0,c1ccc2ncc(-c3ccncc3)cc2c1,CHEMBL68423,IC50,10000.0,nM,,CHEMBL676154,CHEMBL203,CHEMBL1127615,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc(OC)cc(-c2cc3cnc(N)nc3nc2NC(=O)NC(C)(C)C)c1,396.45099999999974,3.2112000000000016,3,7,124.28,7,3,0.6182957082110595,0,c1ccc(-c2cnc3ncncc3c2)cc1,CHEMBL299763,IC50,50000.0,nM,4.3,CHEMBL675521,CHEMBL203,CHEMBL1130094,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1,448.50099999999975,1.9245799999999997,2,9,153.63,14,2,0.6161780265142203,0,O=C(Cc1ccccc1)Nc1ccccn1,CHEMBL378627,Ki,1800.0,nM,,CHEMBL860206,CHEMBL203,CHEMBL1148638,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC,414.4099999999998,2.4092000000000002,1,8,92.68,8,2,0.7629173210900769,0,O=C1OCC2Cc3cc4c(cc3C(c3ccccc3)C12)OCO4,CHEMBL283120,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2[nH]c3nc(N)nc(NCc4ccccc4)c3c2cc1O,335.36699999999973,3.019600000000002,4,6,109.08,7,4,0.45633022602131984,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4073523,Ki,610.0,nM,6.21,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(NCc3ccccc3)ncnc2cc1O,281.3149999999997,2.9561000000000015,2,5,67.27,6,3,0.7692660944252158,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL333851,IC50,588.0,nM,6.23,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2c(N[C@H]3COC[C@@H]3OC)ncnc2cc1O[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,419.43399999999974,0.3699999999999997,2,10,113.42000000000002,9,2,0.6807426264524993,0,c1nc(NC2CCOC2)c2ccc(OC3COC4CCOC43)cc2n1,CHEMBL3916828,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,0.7,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; Aromatic ring count typical
COc1cc2c(Nc3ccc(Br)c(Cl)c3)ncnc2cc1O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2NS(C)(=O)=O,585.8640000000012,3.2607000000000017,2,9,120.9,9,3,0.4303621025751743,1,c1ccc(Nc2ncnc3cc(OC4COC5CCOC54)ccc23)cc1,CHEMBL3943734,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCC1CN(CC(N)=O)CCO1,492.3629999999999,3.253700000000001,2,8,111.83,9,3,0.4931719768497395,0,c1ccc(Nc2ncnc3cc(OCC4CNCCO4)ccc23)cc1,CHEMBL3916567,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OC[C@@H]1O[C@@H](OC)[C@@H](O)[C@H](O)[C@H]1O,512.346,2.5216000000000016,4,10,135.42000000000002,12,3,0.3740925222253897,1,c1ccc(Nc2ncnc3cc(OCC4CCCCO4)ccc23)cc1,CHEMBL3949434,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(Nc3ccc(N4CCN(C)C(F)C4)cc3)ncnc2cc1O[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2F,513.5449999999998,3.3125000000000018,1,9,81.21000000000001,8,3,0.49953709460300083,1,c1nc(Nc2ccc(N3CCNCC3)cc2)c2ccc(OC3COC4CCOC43)cc2n1,CHEMBL3890300,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(Nc3ccc(N4CCN(C)CC4)cc3)ncnc2cc1O[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2F,495.5549999999997,3.0169000000000015,1,9,81.21000000000001,8,3,0.5550443190005719,0,c1nc(Nc2ccc(N3CCNCC3)cc2)c2ccc(OC3COC4CCOC43)cc2n1,CHEMBL3924442,IC50,50.0,nM,,CHEMBL3883067,CHEMBL203,CHEMBL3882729,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,331.17299999999983,3.539500000000002,1,5,59.93,4,3,0.795411943732026,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL53062,IC50,2.6,nM,8.59,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2c(c(OC)c1)C(=O)N(c1cccc(C(=O)N3CCCCC3)c1)CC2,394.47099999999966,3.5328000000000026,0,4,59.080000000000005,6,2,0.7960242627633343,0,O=C(c1cccc(N2CCc3ccccc3C2=O)c1)N1CCCCC1,CHEMBL2442332,IC50,1230.0,nM,5.91,CHEMBL2446217,CHEMBL203,CHEMBL2440093,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2c(cc1OC)Nc1ncn(C)c(=O)c1C2,273.2919999999997,1.4452999999999996,1,6,65.38,5,2,0.7651610060989824,0,O=c1[nH]cnc2c1Cc1ccccc1N2,CHEMBL6976,IC50,160000.0,nM,,CHEMBL843057,CHEMBL203,CHEMBL1128884,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc2c(cc1OC)Nc1ncnc(O)c1C2,259.265,1.8471999999999997,2,6,76.5,5,2,0.7310426247897885,0,c1ccc2c(c1)Cc1cncnc1N2,CHEMBL414013,IC50,75000.0,nM,4.12,CHEMBL843057,CHEMBL203,CHEMBL1128884,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc2cc(-c3ccc(O)nc3)cnc2cc1OC,282.29899999999975,3.0196000000000014,1,5,64.47,6,3,0.799601091075232,0,c1cncc(-c2cnc3ccccc3c2)c1,CHEMBL66981,IC50,20000.0,nM,,CHEMBL679946,CHEMBL203,CHEMBL1127568,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2cc(-c3ccncc3)cnc2cc1OC,266.2999999999998,3.314000000000002,0,4,44.24000000000001,5,3,0.7291625080611583,0,c1ccc2ncc(-c3ccncc3)cc2c1,CHEMBL280069,IC50,10000.0,nM,,CHEMBL676154,CHEMBL203,CHEMBL1127615,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12,351.34099999999984,2.6068999999999996,3,5,119.90999999999998,5,4,0.5239072895186824,0,c1cnc2c(-c3ccc4cn[nH]c4c3)cccc2c1,CHEMBL4475004,IC50,2000.0,nM,,CHEMBL4335772,CHEMBL203,CHEMBL4334447,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O,258.233,1.1356,1,5,77.52000000000001,4,2,0.8170410383637126,0,O=C1NC(=O)c2c1ncc1ccccc21,CHEMBL1982506,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2nc(C)nc(N[C@H](C)c3cccc(S(N)(=O)=O)c3)c2cc1OC,402.4759999999998,2.775920000000001,2,7,116.42999999999999,11,3,0.6509882838130322,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL5085531,IC50,20000.0,nM,,CHEMBL5036476,CHEMBL203,CHEMBL5036304,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2nc(Cl)nc(Nc3ccc(C(N)=O)cc3)c2cc1OC,358.78499999999985,3.142900000000001,2,6,99.36,7,3,0.6795576545818174,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098325,IC50,900.0,nM,6.05,CHEMBL3101602,CHEMBL203,CHEMBL3098085,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2nc(Cl)nc(Nc3ccc(S(=O)(=O)N(C)C)cc3)c2cc1OC,422.8939999999999,3.2943000000000016,1,7,93.65,10,3,0.6088518757398164,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098312,IC50,67200.0,nM,4.17,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1cc2nc(Cl)nc(Nc3ccc(S(=O)(=O)O)cc3)c2cc1OC,395.82399999999996,3.290700000000002,2,8,110.64000000000001,8,3,0.49975760804300723,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098323,IC50,100000.0,nM,,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc2nc(Cl)nc(Nc3ccc(S(C)(=O)=O)cc3)c2cc1OC,393.8519999999999,3.4475000000000025,1,7,90.41000000000001,8,3,0.6636074961738161,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098315,IC50,61500.0,nM,4.21,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1cc2nc(Cl)nc(Nc3ccc(S(N)(=O)=O)cc3)c2cc1OC,394.8399999999999,2.6914000000000007,2,7,116.42999999999999,8,3,0.6386572240096022,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3098317,IC50,2370.0,nM,5.62,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncc(C#N)c(Nc3cccc(C(N)=O)c3)c2cc1OC,348.3619999999998,2.9661800000000005,2,6,110.26,7,3,0.7332684043543012,0,c1ccc(Nc2ccnc3ccccc23)cc1,CHEMBL323970,IC50,7762.47,nM,5.11,CHEMBL1798351,CHEMBL203,CHEMBL1795334,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncc(C#N)c(Nc3cccc(N)c3)c2cc1OC,320.35199999999975,3.449480000000001,2,6,93.19,7,3,0.7151778753142859,0,c1ccc(Nc2ccnc3ccccc23)cc1,CHEMBL110036,IC50,812.83,nM,6.09,CHEMBL1798351,CHEMBL203,CHEMBL1795334,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncc(C#N)c(Nc3cccc(O)c3)c2cc1OC,321.33599999999973,3.5728800000000014,2,6,87.4,7,3,0.7635629317836543,0,c1ccc(Nc2ccnc3ccccc23)cc1,CHEMBL110577,IC50,6309.57,nM,5.2,CHEMBL1798351,CHEMBL203,CHEMBL1795334,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncc(N[C@H]3CC[C@H](O)CC3)nc2cc1OC,303.3619999999996,2.3624,2,6,76.5,7,2,0.902753334962448,0,c1ccc2nc(NC3CCCCC3)cnc2c1,CHEMBL104466,IC50,3700.0,nM,5.43,CHEMBL674697,CHEMBL203,CHEMBL1136216,1.0,Activity in Type 1 range; Contains quinazoline core; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12,336.37599999999986,3.5004000000000017,1,6,77.0,4,4,0.6194395227458619,0,O=C(Nc1ccc2ncccc2c1)c1csc2cncnc12,CHEMBL3822972,IC50,50000.0,nM,,CHEMBL4004202,CHEMBL203,CHEMBL4002626,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(C#CCOc3ccccc3)c2cc1OC,320.34799999999973,3.0775000000000015,0,5,53.47000000000001,6,3,0.6915610730912566,0,C(#Cc1ncnc2ccccc12)COc1ccccc1,CHEMBL250523,IC50,15.0,nM,7.82,CHEMBL925198,CHEMBL203,CHEMBL1140492,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(C#C[C@](C)(O)Cc3ccccc3)c2cc1OC,348.4019999999997,2.9922000000000013,1,5,64.47000000000001,8,3,0.7345035169408588,0,C(#Cc1ncnc2ccccc12)CCc1ccccc1,CHEMBL3085374,IC50,9.0,nM,8.05,CHEMBL925198,CHEMBL203,CHEMBL1140492,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(C#Cc3ccccc3)c2cc1OC,290.3219999999997,3.046800000000002,0,4,44.24000000000001,4,3,0.6804442563492695,0,C(#Cc1ncnc2ccccc12)c1ccccc1,CHEMBL250315,IC50,5600.0,nM,5.25,CHEMBL925198,CHEMBL203,CHEMBL1140492,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(C#N)cc4)CC3)c2cc1OC,418.4569999999998,2.8727800000000014,1,7,103.61,6,3,0.6947180886473493,0,O=C(Nc1ccccc1)N1CCN(c2ncnc3ccccc23)CC1,CHEMBL106966,IC50,100000.0,nM,,CHEMBL678297,CHEMBL203,CHEMBL1135502,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1cc2ncnc(N3CCN(C(=O)Nc4ccc([N+](=O)[O-])cc4)CC3)c2cc1OC,438.44399999999985,2.9093000000000018,1,8,122.96000000000002,7,3,0.47646934753521347,0,O=C(Nc1ccccc1)N1CCN(c2ncnc3ccccc23)CC1,CHEMBL99743,IC50,100000.0,nM,,CHEMBL678297,CHEMBL203,CHEMBL1135502,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1cc2ncnc(N3CCc4ccccc43)c2cc1NC(=O)/C=C/CN1CCC(CO)CC1,473.57699999999966,3.531600000000002,2,7,90.82000000000001,9,3,0.5074714826864418,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(N3CCc4ccccc43)c2c1,CHEMBL4172718,IC50,4.0,nM,8.4,CHEMBL4155049,CHEMBL203,CHEMBL4152264,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(N3CCc4ccccc43)c2cc1OC,307.35299999999967,3.3412000000000015,0,5,47.480000000000004,5,3,0.7424647737387756,0,c1ccc2c(c1)CCN2c1ncnc2ccccc12,CHEMBL328277,IC50,820.0,nM,6.09,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1O,307.35299999999967,3.3120000000000016,2,5,67.27000000000001,6,3,0.773773154589807,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1,CHEMBL93423,IC50,390.0,nM,6.41,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OC(C)=O,349.3899999999997,3.5317000000000016,1,6,73.34,7,3,0.5610340680218242,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1,CHEMBL90540,IC50,84.0,nM,7.08,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OCCN1CCOCC1,420.51299999999964,3.317400000000002,1,7,68.74000000000001,9,3,0.5995269083002686,0,c1ccc(C2CC2Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1,CHEMBL420059,IC50,300.0,nM,6.52,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(NCCOc3ccccc3F)c2cc1OC,343.3579999999997,3.277000000000002,1,6,65.50000000000001,9,3,0.6643293983768331,0,c1ccc(OCCNc2ncnc3ccccc23)cc1,CHEMBL5270270,IC50,44.0,nM,7.36,CHEMBL5253687,CHEMBL203,CHEMBL5252533,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(NCc3cccc(C)c3)c2cc1OC,309.36899999999963,3.5675200000000027,1,5,56.27000000000001,8,3,0.7806092569588597,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL93173,IC50,170.0,nM,6.77,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(NCc3ccccc3)c2cc1O,281.31499999999966,2.9561000000000015,2,5,67.27000000000001,6,3,0.7692660944252158,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL115745,IC50,56.0,nM,7.25,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(NCc3ccccc3)c2cc1OC,295.34199999999964,3.259100000000002,1,5,56.27000000000001,7,3,0.7826830931516778,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL325245,IC50,10.0,nM,8.0,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cc(Cl)c(F)cc3O)c2cc1O,335.72199999999987,3.5857000000000014,3,6,87.50000000000001,6,3,0.6340037724102157,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL5206697,IC50,11.5,nM,7.94,CHEMBL5153035,CHEMBL203,CHEMBL5150044,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(CC(N)=O)CC1,459.9089999999998,3.503000000000002,2,7,102.60000000000002,8,3,0.5569767590087459,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1,CHEMBL214478,IC50,9.0,nM,8.05,CHEMBL856356,CHEMBL203,CHEMBL1149481,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC,371.39299999999974,3.416400000000002,1,8,83.96000000000002,12,3,0.6763459526350728,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL309682,Kd,22.0,nM,7.66,CHEMBL4394506,CHEMBL203,CHEMBL4393671,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(B(O)O)cc3)c2cc1OC,325.13299999999975,1.0703999999999998,3,7,96.73000000000002,9,3,0.6038442565134078,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219511,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1OCCCN1CCNCCNCC1,533.446000000001,3.5473000000000017,3,8,83.57000000000001,9,3,0.3796902549137243,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1,CHEMBL4435885,IC50,28.2,nM,7.55,CHEMBL4329616,CHEMBL203,CHEMBL4325914,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Br)c3)c2cc1OCCCN1CCNCCNCC1,533.4460000000009,3.5473000000000017,3,8,83.57000000000001,9,3,0.3796902549137243,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1,CHEMBL4563873,IC50,5.6,nM,8.25,CHEMBL4329616,CHEMBL203,CHEMBL4325914,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1B(O)O,347.54199999999986,1.8543000000000003,3,6,87.50000000000001,7,3,0.6244827643858579,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219508,IC50,510.0,nM,6.29,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN(C)[C@@H](C)C(N)=O,417.8719999999998,3.480100000000002,2,6,93.37,10,3,0.6109318063179581,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL461968,IC50,8.0,nM,8.1,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN(C)[C@H](C)C(N)=O,417.8719999999998,3.480100000000002,2,6,93.37,10,3,0.6109318063179581,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL517130,IC50,9.0,nM,8.05,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CC[C@@H](C(N)=O)C1,429.8829999999998,3.481700000000002,2,6,93.37,7,3,0.6227210657884537,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1,CHEMBL461795,IC50,6.0,nM,8.22,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/n1cc(F)c(=O)[nH]c1=O,500.849,3.2730000000000006,3,8,131.0,7,4,0.3461810787339187,1,O=C(/C=C/n1ccc(=O)[nH]c1=O)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL5429059,IC50,2511.89,nM,5.6,CHEMBL5325035,CHEMBL203,CHEMBL5321292,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,431.8109999999999,3.221400000000001,3,7,114.47000000000003,6,3,0.5678078538827835,0,O=C1NC(C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)CO1,CHEMBL3818547,IC50,0.31,nM,9.51,CHEMBL3820193,CHEMBL203,CHEMBL3817746,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(=O)NO,392.7739999999999,3.058700000000001,3,7,105.60000000000001,8,3,0.4369942863092165,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3949197,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(O)CN,392.8179999999998,2.8729000000000005,3,7,102.52000000000001,10,3,0.5677147997463499,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL56502,IC50,6.0,nM,8.22,CHEMBL677210,CHEMBL203,CHEMBL1134804,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(O)CN(CCO)CCO,480.9239999999998,2.2008000000000005,4,9,120.20000000000002,16,3,0.30894501436786914,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL299893,IC50,5.0,nM,8.3,CHEMBL677210,CHEMBL203,CHEMBL1134804,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCC(=O)NO,406.8009999999999,3.448800000000001,3,7,105.60000000000001,9,3,0.40732305863036944,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL597551,IC50,7.1,nM,8.15,CHEMBL1064921,CHEMBL203,CHEMBL1157563,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCNCCNCC1,488.9949999999997,3.438200000000001,3,8,83.57000000000001,9,3,0.4158724209450245,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1,CHEMBL4586581,IC50,8.3,nM,8.08,CHEMBL4329616,CHEMBL203,CHEMBL4325914,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCNCCNCCNCC1,532.0640000000008,3.027800000000001,4,9,95.60000000000001,9,3,0.3270697449439508,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCCNCC4)cc23)cc1,CHEMBL4534611,IC50,6.6,nM,8.18,CHEMBL4329616,CHEMBL203,CHEMBL4325914,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCNCCN,419.88799999999975,3.4917000000000007,3,7,94.32000000000001,12,3,0.43281894595300474,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2334003,IC50,13.6,nM,7.87,CHEMBL2341281,CHEMBL203,CHEMBL2331141,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN(CCO)CCO,450.8979999999998,2.8399000000000014,3,8,99.97000000000001,14,3,0.40985197719241523,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL56505,IC50,35.0,nM,7.46,CHEMBL677210,CHEMBL203,CHEMBL1134804,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC(O)C1,418.8559999999998,3.229800000000002,2,7,79.74000000000001,9,3,0.6093679753626773,0,c1ccc(Nc2ncnc3ccc(OCCN4CCC4)cc23)cc1,CHEMBL2425090,IC50,26.0,nM,7.58,CHEMBL2429426,CHEMBL203,CHEMBL2424588,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(C1)CS(=O)(=O)C2,492.95999999999987,3.2837000000000014,1,8,93.65,8,3,0.5367849398453762,0,O=S1(=O)CC2(CN(CCOc3ccc4ncnc(Nc5ccccc5)c4c3)C2)C1,CHEMBL2424664,IC50,158.0,nM,6.8,CHEMBL2429426,CHEMBL203,CHEMBL2424588,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNC(C)(CO)CO,450.8979999999998,2.886200000000001,4,8,108.76000000000002,14,3,0.34908252551940466,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL56027,IC50,69.0,nM,7.16,CHEMBL677210,CHEMBL203,CHEMBL1134804,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNCCN,405.86099999999976,3.1016000000000004,3,7,94.32000000000001,11,3,0.4707016105713961,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2334002,IC50,12.1,nM,7.92,CHEMBL2341281,CHEMBL203,CHEMBL2331141,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCO,363.77599999999984,3.5456000000000025,2,6,76.50000000000001,8,3,0.6972041861418209,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2334001,IC50,63.4,nM,7.2,CHEMBL2341281,CHEMBL203,CHEMBL2331141,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC[C@@H](O)CN1CCOCC1,462.9089999999998,3.246400000000002,2,8,88.97000000000001,10,3,0.5271294030085238,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1,CHEMBL1744086,IC50,95.0,nM,7.02,CHEMBL677210,CHEMBL203,CHEMBL1134804,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC[C@H](O)CN1CCOCC1,462.9089999999998,3.246400000000002,2,8,88.97000000000001,10,3,0.5271294030085238,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1,CHEMBL1788321,IC50,67.0,nM,7.17,CHEMBL677210,CHEMBL203,CHEMBL1134804,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(NC(C)=O)cc3)c2cc1OC,338.36699999999973,3.349000000000001,2,6,85.37000000000002,8,3,0.7419300978239387,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL1761927,IC50,10000.0,nM,,CHEMBL1763554,CHEMBL203,CHEMBL1759979,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC,297.3139999999997,3.0962000000000014,2,6,76.50000000000001,7,3,0.7206212294021629,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL405130,Kd,1163.0,nM,5.93,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC.Cl,333.77499999999964,3.518000000000002,2,6,76.50000000000001,7,3,0.7113729632098628,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL555201,IC50,100.0,nM,7.0,CHEMBL676160,CHEMBL203,CHEMBL1129839,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccc(O[C@H]4CO[C@H]5[C@@H]4OC[C@@H]5O)c(Cl)c3)c2cc1OC,459.8859999999998,2.9499000000000013,2,9,104.19000000000003,9,3,0.5751991702061804,0,c1ccc2c(Nc3ccc(OC4COC5CCOC54)cc3)ncnc2c1,CHEMBL5272200,IC50,5.3,nM,8.28,CHEMBL5226148,CHEMBL203,CHEMBL5223181,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(B(O)O)c3)c2cc1OC,325.13299999999975,1.0703999999999998,3,7,96.73000000000002,9,3,0.6038442565134078,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219509,IC50,1000.0,nM,,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,458.27199999999993,3.1914000000000007,3,7,114.47000000000003,6,3,0.5381913632489057,0,O=C1NC(C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)CO1,CHEMBL3818015,IC50,0.38,nM,9.42,CHEMBL3820193,CHEMBL203,CHEMBL3817746,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,331.17299999999983,3.539500000000002,1,5,59.93000000000001,4,3,0.795411943732026,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL53375,IC50,39.0,nM,7.41,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(C#CC(C)(C)O)c3)c2cc1OC,363.4169999999997,3.5130000000000026,2,6,76.50000000000001,9,3,0.6909979430984114,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL248864,IC50,205.8,nM,6.69,CHEMBL924351,CHEMBL203,CHEMBL1140520,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(C#CCCCO)c3)c2cc1OC,363.4169999999997,3.5146000000000024,2,6,76.50000000000001,9,3,0.5154968864344117,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL437197,IC50,1362.6,nM,5.87,CHEMBL924351,CHEMBL203,CHEMBL1140520,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(C#CCCO)c3)c2cc1OC,349.3899999999997,3.124500000000002,2,6,76.50000000000001,8,3,0.6894091866137548,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL248674,IC50,402.1,nM,6.4,CHEMBL924351,CHEMBL203,CHEMBL1140520,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(C#CCO)c3)c2cc1OC,335.3629999999997,2.734400000000001,2,6,76.50000000000001,7,3,0.7141264441098916,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL399736,IC50,1643.6,nM,5.78,CHEMBL924351,CHEMBL203,CHEMBL1140520,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(C#N)c3)c2cc1OC,306.32499999999976,3.2622800000000014,1,6,80.06000000000002,6,3,0.7965862320279273,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2333998,IC50,412.8,nM,6.38,CHEMBL2341281,CHEMBL203,CHEMBL2331141,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1B(O)O,329.5519999999998,1.7152000000000003,3,6,87.50000000000001,7,3,0.6317616453475071,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219507,IC50,460.0,nM,6.34,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C)CC1,486.97899999999976,3.5560000000000027,2,7,96.61,10,3,0.5267313862822908,0,c1ccc(Nc2ncnc3ccc(CNC4CCNCC4)cc23)cc1,CHEMBL207130,IC50,9.0,nM,8.05,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C(C)C)C1,486.97899999999976,3.554400000000003,2,7,96.61,12,3,0.5022016590299158,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1,CHEMBL425601,IC50,9.0,nM,8.05,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C)C1,458.9249999999998,2.775800000000001,2,7,96.61,10,3,0.5615443097632323,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1,CHEMBL207718,IC50,10.0,nM,8.0,CHEMBL853150,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1CCNC1=O,429.8829999999998,3.4948000000000023,2,6,79.38000000000001,8,3,0.6240608668605482,0,O=C1NCCC1NCc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL378370,IC50,20.0,nM,7.7,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)CC(N)=O,403.8449999999998,3.0916000000000015,2,6,93.37,9,3,0.6292912775222083,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL379601,IC50,20.0,nM,7.7,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](C)C(N)=O,417.8719999999998,3.480100000000002,2,6,93.37,10,3,0.6109318063179581,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL207687,IC50,8.0,nM,8.1,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CN(C)C)C(N)=O,460.94099999999975,3.0218000000000007,2,7,96.61000000000001,13,3,0.5062586559946664,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL380889,IC50,50.0,nM,7.3,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CO)C(N)=O,433.8709999999998,2.4525,3,7,113.6,11,3,0.4996198529105883,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL208286,IC50,20.0,nM,7.7,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(N)=O,417.8719999999998,3.480100000000002,2,6,93.37,10,3,0.6109318063179581,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL208118,IC50,9.0,nM,8.05,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(CCN(C)C)[C@@H](C)C(N)=O,474.96799999999973,3.411900000000002,2,7,96.61000000000001,14,3,0.4644259004529301,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL376967,IC50,90.0,nM,7.05,CHEMBL853150,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC(C(N)=O)C1,415.8559999999998,3.0916000000000015,2,6,93.37,7,3,0.6422273242684073,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1,CHEMBL207037,IC50,50.0,nM,7.3,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC1C(N)=O,415.8559999999998,3.2341000000000015,2,6,93.37,7,3,0.6416210070738549,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1,CHEMBL207246,IC50,70.0,nM,7.16,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCN(C)CC1C(N)=O,458.9249999999998,2.7758000000000003,2,7,96.61000000000001,8,3,0.5858651475751573,0,c1ccc(Nc2ncnc3ccc(CN4CCNCC4)cc23)cc1,CHEMBL204420,IC50,30.0,nM,7.52,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1C(N)=O,445.88199999999983,2.8606000000000007,2,7,102.6,7,3,0.6009733301700416,0,c1ccc(Nc2ncnc3ccc(CN4CCOCC4)cc23)cc1,CHEMBL207674,IC50,50.0,nM,7.3,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC[C@H](C(N)=O)C1,429.8829999999998,3.481700000000002,2,6,93.37,7,3,0.6227210657884537,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1,CHEMBL380454,IC50,80.0,nM,7.1,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1C[C@H](OC)C[C@@H]1C(N)=O,459.9089999999998,3.249100000000001,2,7,102.6,9,3,0.5586634053141548,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1,CHEMBL207235,IC50,10.0,nM,8.0,CHEMBL853149,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN[C@H](C)C(N)=O,403.8449999999998,3.137900000000001,3,6,102.16,9,3,0.5597791164628212,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL380386,IC50,120.0,nM,6.92,CHEMBL853150,CHEMBL203,CHEMBL1147701,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(C(=O)CO)CC1,460.89299999999986,3.5366000000000017,2,7,96.81000000000002,8,3,0.5803654562252648,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1,CHEMBL3900054,IC50,204.0,nM,6.69,CHEMBL3882125,CHEMBL203,CHEMBL3881529,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(CC(N)=O)CC1,459.9089999999998,3.503000000000002,2,7,102.60000000000002,8,3,0.5569767590087459,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1,CHEMBL218677,IC50,2.0,nM,8.7,CHEMBL856356,CHEMBL203,CHEMBL1149481,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC,299.3049999999997,3.529700000000002,1,5,56.27000000000001,6,3,0.7983836473287707,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL94431,IC50,3.8,nM,8.42,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccccc3)c2cc1OC,281.31499999999966,3.390600000000002,1,5,56.27000000000001,6,3,0.7940400286227499,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL94191,IC50,29.0,nM,7.54,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3ccccc3N)c2cn1,267.29199999999975,2.3591999999999995,2,6,85.95,5,3,0.7083825929972489,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL408105,IC50,3715.35,nM,5.43,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Nc3cnc4ccccc4n3)c2cc1OC,333.3509999999998,3.333800000000002,1,7,82.05000000000001,6,4,0.6131125221219932,0,c1ccc2nc(Nc3ncnc4ccccc34)cnc2c1,CHEMBL330668,IC50,780.0,nM,6.11,CHEMBL680029,CHEMBL203,CHEMBL1129210,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains quinazoline core; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Nc3nnc4ccccc4n3)c2cc1OC,334.3389999999998,2.7288000000000006,1,8,94.94000000000001,6,4,0.6085421562625346,0,c1ccc2nc(Nc3ncnc4ccccc34)nnc2c1,CHEMBL90541,IC50,820.0,nM,6.09,CHEMBL680029,CHEMBL203,CHEMBL1129210,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc(Oc3ccc(NC(C)=O)cc3)c2cc1OC,339.3509999999998,3.3977000000000013,1,6,82.57000000000001,8,3,0.7670026283138522,0,c1ccc(Oc2ncnc3ccccc23)cc1,CHEMBL1761928,IC50,10000.0,nM,,CHEMBL1763554,CHEMBL203,CHEMBL1759979,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc(Oc3cccc(NC(C)=O)c3)c2cc1OC,339.3509999999998,3.3977000000000013,1,6,82.57000000000001,8,3,0.7670026283138522,0,c1ccc(Oc2ncnc3ccccc23)cc1,CHEMBL2018880,IC50,10000.0,nM,,CHEMBL2020642,CHEMBL203,CHEMBL2016491,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc3c2cc1OCCOCCOCCOc1ccccc1N3,397.43099999999976,3.186400000000001,1,8,83.96000000000002,2,3,0.6703115264202348,0,c1ccc2c(c1)Nc1ncnc3ccc(cc13)OCCOCCOCCO2,CHEMBL5204446,IC50,87.6,nM,7.06,CHEMBL5153036,CHEMBL203,CHEMBL5150044,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cc2ncnc3c2cc1OCCOCCOc1cccc(c1)N3,353.37799999999976,3.1698000000000013,1,7,74.73000000000002,2,3,0.7200357411671081,0,c1cc2cc(c1)OCCOCCOc1ccc3ncnc(c3c1)N2,CHEMBL5183329,IC50,33860.0,nM,4.47,CHEMBL5153035,CHEMBL203,CHEMBL5150044,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cc2ncnc3c2cc1OCCOCCOc1ccccc1N3,353.37799999999976,3.1698000000000013,1,7,74.73000000000002,2,3,0.7200357411671081,0,c1ccc2c(c1)Nc1ncnc3ccc(cc13)OCCOCCO2,CHEMBL5185330,IC50,154.6,nM,6.81,CHEMBL5153035,CHEMBL203,CHEMBL5150044,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2c(CN3CCOCC3)nc3scc(C(=O)NN)n23)cc1,387.46499999999975,1.5070999999999997,2,8,94.12,7,3,0.39153098209315257,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1,CHEMBL5173449,IC50,122.0,nM,6.91,CHEMBL5110647,CHEMBL203,CHEMBL5108025,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2cc(=O)oc3c(O)c(O)ccc23)cc1O,300.2659999999998,2.5854000000000013,3,6,100.13000000000001,6,3,0.4966124999954428,0,O=c1cc(-c2ccccc2)c2ccccc2o1,CHEMBL5282499,IC50,4900.0,nM,5.31,CHEMBL5227743,CHEMBL203,CHEMBL5226311,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,425.4889999999997,2.2453200000000004,2,9,125.38000000000001,10,3,0.6158991705318287,0,O=c1c(-c2cccnc2)cc2cncnc2n1C1CCCCC1,CHEMBL1234354,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(-c2cc3c(N[C@@H](C)CO)ncnc3o2)cc1,299.3299999999997,2.6911000000000005,2,6,80.41,8,3,0.7536921947321769,0,c1ccc(-c2cc3cncnc3o2)cc1,CHEMBL3962640,IC50,100.0,nM,,CHEMBL3857034,CHEMBL203,CHEMBL3856204,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC,389.4149999999998,3.2560000000000002,2,7,103.77000000000001,8,4,0.5245774709653223,0,c1ccc(Nc2nc(-c3ccccc3)cc3nccn23)cc1,CHEMBL1998112,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC,390.4029999999998,2.651,2,8,116.66,8,4,0.5196773557177122,0,c1ccc(-c2cc3nccn3c(Nc3ccccn3)n2)cc1,CHEMBL1190711,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,465.55399999999963,2.6429000000000014,1,9,93.07000000000001,9,3,0.6103026509720985,0,c1ccc(-c2ccc3c(N4CCOCC4)nc(N4CCOCC4)nc3n2)cc1,CHEMBL1801204,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(-c2cnc3c(Br)cnn3c2)cc1,304.1469999999999,3.1674000000000015,0,4,39.42,3,3,0.7298139482883765,0,c1ccc(-c2cnc3ccnn3c2)cc1,CHEMBL443962,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1OC,327.3879999999997,2.8477000000000006,1,7,88.08,6,3,0.7955814215619741,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242379,IC50,6340.0,nM,5.2,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,283.3349999999997,2.665,1,6,78.85,7,3,0.7990760329270634,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242847,IC50,4300.0,nM,5.37,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,299.3339999999997,2.3706,2,7,99.08,8,3,0.7699596666846391,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242114,IC50,2190.0,nM,5.66,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,313.3609999999997,2.6736000000000004,1,7,88.08,9,3,0.7963965169809273,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242290,IC50,3020.0,nM,5.52,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C3CCC(C)C3)c3ncnc(N)c23)cc1O,339.39899999999966,3.1508000000000016,2,7,99.08,7,3,0.7602924695768061,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242202,IC50,270.0,nM,6.57,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,325.37199999999973,2.8177000000000003,1,7,88.08,7,3,0.7933125882498722,0,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1,CHEMBL1233881,IC50,2300.0,nM,5.64,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,325.37199999999973,2.904800000000001,2,7,99.08,6,3,0.7679244122217609,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242201,IC50,437.0,nM,6.36,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,339.3989999999997,3.2078000000000007,1,7,88.08,7,3,0.7850604103607054,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1240553,IC50,3300.0,nM,5.48,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2nn(C3CNC3)c3ncnc(N)c23)cc1O,312.3329999999998,0.9339999999999995,3,8,111.11,6,3,0.6594893690978505,0,c1ccc(-c2nn(C3CNC3)c3ncncc23)cc1,CHEMBL1242203,IC50,17000.0,nM,4.77,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nn(C[C@@H](C)CO)c3ncnc(N)c23)cc1OC,343.3869999999997,1.7210999999999999,2,8,108.31,11,3,0.7012485826599023,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242381,IC50,18000.0,nM,4.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nn(C[C@H](C)CO)c3ncnc(N)c23)cc1OC,343.3869999999997,1.7210999999999999,2,8,108.31,11,3,0.7012485826599023,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242380,IC50,12000.0,nM,4.92,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nn([C@@H]3CCNC3)c3ncnc(N)c23)cc1O,326.35999999999973,1.3240999999999998,3,8,111.11,6,3,0.6654097396802153,0,c1ccc(-c2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL1242288,IC50,12600.0,nM,4.9,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,306.32499999999976,3.212300000000001,1,5,76.83000000000001,5,4,0.626202072101551,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4084249,IC50,97.95,nM,7.01,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,309.32499999999976,2.675200000000001,1,5,77.25,6,3,0.7837716418246529,0,O=C(NCc1ccncc1)c1ncoc1-c1ccccc1,CHEMBL1957085,IC50,10000.0,nM,,CHEMBL1960381,CHEMBL203,CHEMBL1955730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N)cc4)nc32)cc1,360.37699999999984,2.5101000000000004,2,8,107.95,6,4,0.5383484665954891,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437475,IC50,6754.0,nM,5.17,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(-n2c(=O)cnc3cnc(Nc4cccc(N)c4)nc32)cc1,360.37699999999984,2.5100999999999996,2,8,107.95,6,4,0.5383484665954891,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437474,IC50,3836.0,nM,5.42,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(/C=C(\C#N)c2cccnc2)cc1OC,266.2999999999998,3.162980000000001,0,4,55.14,6,2,0.7975213498295343,0,C(=Cc1cccnc1)c1ccccc1,CHEMBL67027,IC50,700.0,nM,6.16,CHEMBL679946,CHEMBL203,CHEMBL1127568,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(/C=C/C(=N/NC(N)=S)c2ccccc2)cc1,311.40999999999974,2.9459000000000017,2,3,59.64,6,2,0.5062295847973228,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830268,IC50,14830.0,nM,4.83,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,331.32799999999975,2.3649200000000006,0,7,96.49,9,2,0.3343231309202153,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173713,IC50,10850.0,nM,4.96,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1O,316.35299999999967,3.5970000000000035,1,5,57.150000000000006,11,2,0.8252975349299134,0,C(=C\c1ccccc1)\c1ccccc1,CHEMBL67,IC50,10000.0,nM,,CHEMBL3300694,CHEMBL203,CHEMBL3297684,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(C(/C=C/c2ccccc2)=N\NC(N)=S)cc1,311.4099999999997,2.9459,2,3,59.64,6,2,0.5062295847973228,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830275,IC50,8660.0,nM,5.06,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C(/C=C/c2ccccc2Cl)=N\NC(N)=S)cc1,345.85499999999973,3.5993000000000013,2,3,59.64,6,2,0.4935929036302681,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830279,IC50,7830.0,nM,5.11,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C(=O)NC[C@@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,361.8249999999997,2.6020000000000003,3,4,78.79,10,2,0.6622657251969847,0,C(=C/c1ccccc1)\c1ccccc1,CHEMBL1949788,IC50,50000.0,nM,,CHEMBL1953267,CHEMBL203,CHEMBL1949587,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(C(=O)NC[C@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,361.8249999999997,2.6020000000000003,3,4,78.79,10,2,0.6622657251969847,0,C(=C/c1ccccc1)\c1ccccc1,CHEMBL1949789,IC50,50000.0,nM,,CHEMBL1953267,CHEMBL203,CHEMBL1949587,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(C(=O)n2nc(-c3cccnc3)nc2N)cc1,295.30199999999974,1.6193999999999997,1,7,95.92,5,3,0.7884221372927879,0,O=C(c1ccccc1)n1cnc(-c2cccnc2)n1,CHEMBL4216765,IC50,3600.0,nM,5.44,CHEMBL5246174,CHEMBL203,CHEMBL5244255,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(C(=O)n2nc(-c3ccncc3)nc2N)cc1,295.30199999999974,1.6193999999999997,1,7,95.92,5,3,0.7884221372927879,0,O=C(c1ccccc1)n1cnc(-c2ccncc2)n1,CHEMBL5287053,IC50,4600.0,nM,5.34,CHEMBL5246174,CHEMBL203,CHEMBL5244255,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(C2=C(C#N)C3=NC4=Nc5ccc(S(=O)(=O)N6CCOCC6)cc5C4=NC3C(O)=C2C#N)cc1,540.5610000000012,2.6986600000000003,1,10,160.73,6,2,0.6235718532549684,1,O=S(=O)(c1ccc2c(c1)C1=NC3C=CC(c4ccccc4)=CC3=NC1=N2)N1CCOCC1,CHEMBL4284841,IC50,108.0,nM,6.97,CHEMBL4274200,CHEMBL203,CHEMBL4270595,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(OC)cc3)C2)cc1,381.4569999999998,3.484300000000003,0,6,63.489999999999995,6,2,0.8112866985263665,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,CHEMBL1958223,IC50,8890.0,nM,5.05,CHEMBL1958796,CHEMBL203,CHEMBL1955848,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccccc3)C2)cc1,351.4309999999998,3.4757000000000025,0,5,54.26,4,2,0.849533025486923,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,CHEMBL1958218,IC50,2370.0,nM,5.62,CHEMBL1958796,CHEMBL203,CHEMBL1955848,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C2CC(c3ccccc3)=NN2C2=NC(=O)CS2)cc1,351.43099999999976,3.4757000000000016,0,5,54.26,4,2,0.8495330254869229,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,CHEMBL1958024,IC50,4270.0,nM,5.37,CHEMBL1958796,CHEMBL203,CHEMBL1955848,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(C2N=C(C(N)=O)c3ncn(-c4ccc(F)cc4)c3N2)cc1OC,395.3939999999998,2.4273,2,7,103.76,7,3,0.6905733701991108,0,C1=NC(c2ccccc2)Nc2c1ncn2-c1ccccc1,CHEMBL4793639,IC50,617.33,nM,6.21,CHEMBL4700377,CHEMBL203,CHEMBL4699428,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O,326.3769999999998,3.292400000000002,2,5,70.92,5,2,0.8491871718766268,0,O=C1NC(=Nc2ccccc2)SC1=Cc1ccccc1,CHEMBL2000354,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC,347.3779999999998,3.574300000000002,2,6,84.42,7,4,0.42576415317904215,0,C(=NNc1ncnc2c1[nH]c1ccccc12)c1ccccc1,CHEMBL1974664,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Br)cc2)cc1,384.25099999999975,2.505300000000001,1,4,72.47,6,2,0.8600623864542875,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828884,IC50,24150.0,nM,4.62,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,319.3819999999997,2.0512200000000003,1,4,72.47,7,2,0.9152985027402827,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828881,IC50,38520.0,nM,4.41,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Cl)cc2)cc1,339.7999999999998,2.3962000000000003,1,4,72.47,6,2,0.9074826415887477,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828883,IC50,32850.0,nM,4.48,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(=O)NS(=O)(=O)c2ccc(F)cc2)cc1,323.3449999999998,1.8819000000000001,1,4,72.47,6,2,0.9117535208437444,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828882,IC50,21840.0,nM,4.66,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1,305.35499999999973,1.7428000000000001,1,4,72.47,6,2,0.9130638652404699,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828880,IC50,26200.0,nM,4.58,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(CO)n2cc(-c3cccc(O)c3)c3c(N)ncnc32)cc1,390.4429999999997,3.1708000000000007,3,7,106.42,10,4,0.4668601915756109,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1,CHEMBL169467,IC50,3400.0,nM,5.47,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(CO)n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)cc1,404.4699999999997,3.4738000000000016,2,7,95.42,11,4,0.4896802318029536,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1,CHEMBL168555,IC50,9700.0,nM,5.01,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CC(CO)n2cc(-c3ccccc3)c3c(N)ncnc32)cc1,374.4439999999997,3.465200000000001,2,6,86.19,9,4,0.5396836597980335,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1,CHEMBL171256,IC50,14400.0,nM,4.84,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CCNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1OC,368.3889999999998,2.3808800000000003,3,6,111.81,11,2,0.3929804818838246,0,O=C(/C=C/c1ccccc1)NCCc1ccccc1,CHEMBL56455,IC50,1700.0,nM,5.77,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CCNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)cc1OC,510.6389999999996,3.2452000000000014,3,8,117.71000000000001,15,2,0.35170616627822093,1,O=C(NCCCN1CCCC1=O)c1cnc(NCCc2ccccc2)nc1NC1CCCC1,CHEMBL2312290,IC50,30000.0,nM,,CHEMBL2319132,CHEMBL203,CHEMBL2311468,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,308.3189999999998,2.3815999999999997,2,6,106.39000000000001,6,2,0.6512093777839975,0,O=C(NCc1ccccc1)Nc1nccs1,CHEMBL259850,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1,348.3619999999998,2.5232,3,6,96.10999999999999,7,4,0.46348214647596897,0,O=c1c(NCc2ccccc2)c(Nc2ccc3[nH]ncc3c2)c1=O,CHEMBL1992536,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(CNc2nc(N)nc3[nH]c4cc(C)c(O)cc4c23)cc1,349.3939999999997,3.3280200000000004,4,6,109.08,8,4,0.44988172969340073,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4072687,Ki,5950.0,nM,5.22,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(CNc2nc(N)nc3[nH]c4ccc(O)cc4c23)cc1,335.3669999999998,3.0196000000000005,4,6,109.08,7,4,0.45633022602131984,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4099589,Ki,120.0,nM,6.92,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(CNc2nc(N)nc3[nH]c4ccc(O)cc4c23)cc1OC,365.3929999999998,3.028200000000001,4,7,118.31,9,4,0.42914791849423156,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4061797,Ki,3680.0,nM,5.43,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(CNc2ncnc3ccccc23)cc1,265.3159999999998,3.2505000000000015,1,4,47.04,5,3,0.7862702231990562,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL116919,IC50,10000.0,nM,5.0,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,366.4209999999997,2.828000000000001,2,7,105.51,11,3,0.6621176234986874,0,c1ccc(COc2ccc(Cc3cncnc3)cc2)cc1,CHEMBL261849,Kd,10000.0,nM,,CHEMBL1908697,CHEMBL203,CHEMBL1908390,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,441.45999999999975,1.4125,2,8,127.50999999999999,9,2,0.6444372200934387,0,O=C(c1ccccc1)c1cnc(NC2CCNCC2)nc1,CHEMBL384304,Kd,4600.0,nM,5.34,CHEMBL1908698,CHEMBL203,CHEMBL1908390,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(N(C)c2ncnc3occ(C)c23)cc1,269.3039999999997,3.3077200000000015,0,5,51.39,6,3,0.7297806613257029,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4250191,IC50,15.5,nM,7.81,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COc1ccc(N)c2oc(-c3ccc(N)cc3)cc(=O)c12,282.29899999999975,2.633000000000001,2,5,91.47999999999999,5,3,0.70487734049539,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL115397,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
COc1ccc(N2C(=O)CS/C2=N/Nc2nncc3ccccc23)cc1,365.4179999999999,3.101300000000001,1,7,79.71,5,3,0.7158721310462665,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1,CHEMBL3974626,IC50,36.0,nM,7.44,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2,448.53099999999966,1.5786,2,9,114.43,8,3,0.6047142968160637,0,c1cc(Nc2ncc3c(n2)-c2[nH]ncc2CC3)cc(N2CCNCC2)c1,CHEMBL1094408,IC50,10000.0,nM,,CHEMBL1111951,CHEMBL203,CHEMBL1157785,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(NC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c(OC)c1,340.3349999999998,2.660680000000001,3,6,111.81,9,2,0.43817895186950906,0,O=C(/C=C/c1ccccc1)Nc1ccccc1,CHEMBL57251,IC50,1700.0,nM,5.77,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1nccc(-c2cnn3ccccc23)n1,443.51099999999974,3.599800000000002,2,8,96.68,11,4,0.40174264173596325,0,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1,CHEMBL2426289,IC50,250.0,nM,6.6,CHEMBL2427158,CHEMBL203,CHEMBL2424560,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(NC(=O)/C=C/c2ccccc2)cc1,253.3010000000001,3.347100000000001,1,2,38.33,5,2,0.8485069661547031,0,O=C(/C=C/c1ccccc1)Nc1ccccc1,CHEMBL2336357,IC50,9050.0,nM,5.04,CHEMBL3077166,CHEMBL203,CHEMBL3046969,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COc1ccc(NC(=S)NNc2nncc3ccccc23)cc1,325.3969999999998,2.951900000000001,3,5,71.1,5,3,0.5030217551183264,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1,CHEMBL3927914,IC50,53.0,nM,7.28,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(Nc2cc(NC(=O)c3ccccc3)ncn2)cc1,320.3519999999997,3.4811000000000005,2,5,76.14,6,3,0.7524639084933398,0,O=C(Nc1cc(Nc2ccccc2)ncn1)c1ccccc1,CHEMBL4283823,IC50,26.0,nM,7.58,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(Nc2nc(C)nc3oc(C)cc23)cc1,269.30399999999975,3.591840000000002,1,5,60.18,6,3,0.7869186996196841,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL3297897,IC50,42.2,nM,7.38,CHEMBL3299340,CHEMBL203,CHEMBL3297731,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(Nc2nc(Cl)nc(NCc3ccco3)n2)cc1,331.7629999999998,3.4823000000000004,2,7,85.10000000000001,7,3,0.7147532889697801,0,c1ccc(Nc2ncnc(NCc3ccco3)n2)cc1,CHEMBL1348499,IC50,20900.0,nM,4.68,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(Nc2ncc3ncc(=O)n(-c4ccc(NC(=O)/C=C/CN(C)C)cc4)c3n2)cc1,471.52099999999984,2.9842000000000013,2,9,114.26999999999998,11,4,0.3771577495076628,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437483,IC50,31.3,nM,7.5,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Nc2ncc3ncc(=O)n(-c4cccc(N)c4)c3n2)cc1,360.37699999999984,2.5101000000000004,2,8,107.94999999999999,6,4,0.5383484665954891,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437473,IC50,21280.0,nM,4.67,CHEMBL2439334,CHEMBL203,CHEMBL2434822,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(Nc2ncc3ncc(=O)n(-c4cccc(NC(=O)/C=C/CN(C)C)c4)c3n2)cc1,471.52099999999984,2.9842000000000013,2,9,114.26999999999998,11,4,0.3771577495076628,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1,CHEMBL2437484,IC50,26283.0,nM,4.58,CHEMBL2439336,CHEMBL203,CHEMBL2434822,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC,425.4889999999997,3.4235000000000015,3,9,114.47,11,3,0.466991093089682,0,O=c1cc(Nc2ccnc(Nc3ccccc3)n2)c1=O,CHEMBL1964399,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Nc2ncnc3cc(N)ncc23)cc1,267.2919999999998,2.3591999999999995,2,6,85.95,5,3,0.7572555963196137,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL128001,IC50,670.0,nM,6.17,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1OC,341.36699999999973,3.4078000000000017,1,7,74.73,10,3,0.7361746107603587,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL100714,IC50,2800.0,nM,5.55,CHEMBL621024,CHEMBL203,CHEMBL1152084,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)cc1OC,479.53699999999975,2.838300000000001,1,9,98.28,10,3,0.5229008535566778,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3775372,IC50,1000.0,nM,,CHEMBL3776094,CHEMBL203,CHEMBL3774304,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,435.4839999999998,3.0122000000000018,1,9,94.65,8,4,0.47345266253393564,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064376,IC50,380.0,nM,6.42,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Nc2ncnc3ccncc23)c(N)c1,267.2919999999998,2.3591999999999995,2,6,85.95,5,3,0.7083825929972489,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL407591,IC50,676.08,nM,6.17,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(Nc2ncnc3occ(C)c23)cc1,255.2770000000001,3.2834200000000013,1,5,60.18,5,3,0.7777835705799989,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4245874,IC50,283.1,nM,6.55,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)cc1Cl,386.88699999999966,3.0580000000000007,2,7,80.71000000000001,7,3,0.70104090144772,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645477,IC50,210.0,nM,6.68,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(OC)c(CNc2ccc(O)c(C(=O)O)c2)c1,303.3139999999997,2.7197000000000005,3,6,88.02,9,2,0.7111593036263383,0,c1ccc(CNc2ccccc2)cc1,CHEMBL341459,IC50,100000.0,nM,,CHEMBL674642,CHEMBL203,CHEMBL1127418,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1ccc(OC)c(Nc2cc(NC(=O)CCCC(=O)O)ncn2)c1,360.36999999999966,2.4307999999999996,3,8,122.67,11,2,0.622982689413068,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4282879,IC50,68.0,nM,7.17,CHEMBL4267255,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(OC)c(Nc2cc(Nc3ccc(S(N)(=O)=O)cc3)ncn2)c1,401.44799999999975,2.6284,3,8,128.46,10,3,0.5510383437498766,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4276965,IC50,467.0,nM,6.33,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc(OC)c(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)c1,367.43399999999974,3.4439,3,7,112.07,8,4,0.5062806587257961,0,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1,CHEMBL4069070,IC50,4300.0,nM,5.37,CHEMBL4007193,CHEMBL203,CHEMBL4004880,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,424.47799999999984,3.240800000000002,0,5,90.62,8,3,0.44756418880689397,0,O=S(=O)(Nc1ccccc1/C=C/c1cc[nH+]cc1)c1ccccc1,CHEMBL3991927,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)cc1,337.4079999999998,3.4353,3,6,102.83999999999999,6,4,0.5290477702799782,0,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1,CHEMBL4096329,IC50,20800.0,nM,4.68,CHEMBL4007193,CHEMBL203,CHEMBL4004880,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc2c(NCc3ccccc3)ncnc2c1,265.31599999999986,3.2505000000000015,1,4,47.04,5,3,0.7862702231990562,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL326596,IC50,58.0,nM,7.24,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,331.17299999999983,3.539500000000002,1,5,59.93,4,3,0.795411943732026,0,c1ccc(Nc2ncnc3ncccc23)cc1,CHEMBL301549,IC50,263.0,nM,6.58,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc2c(Nc3ccccc3)ncnc2c1,251.2890000000001,3.3820000000000006,1,4,47.04,4,3,0.774783826983707,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL92398,IC50,120.0,nM,6.92,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc2c(c1)CCN2c1nc(C)nc2oc(C)cc12,295.34199999999964,3.5424400000000027,0,5,51.39,5,3,0.7234615993940438,0,c1ccc2c(c1)CCN2c1ncnc2occc12,CHEMBL3403515,IC50,103.2,nM,6.99,CHEMBL3404061,CHEMBL203,CHEMBL3400114,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COc1ccc2c(c1)NC(=O)/C2=C\c1[nH]c(C)c(CCC(=O)O)c1C,340.3789999999997,3.1500400000000015,3,4,91.42,8,2,0.7292584828416813,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL356245,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc2c(c1)NC(=O)/C2=C\c1[nH]c2c(c1CCC(=O)O)CCCC2,366.4169999999997,3.4120000000000017,3,4,91.42,6,2,0.7073389243374448,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL420609,IC50,100000.0,nM,,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1ccc2c(c1)NC(=O)/C2=C\c1[nH]cc(CCC(=O)O)c1C,326.3519999999997,2.8416200000000007,3,4,91.42,7,2,0.7368515238840097,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL149243,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccc2c(c1)cc(C1C(C#N)=C(N)N(c3cccnc3)C3=C1C(=O)CCC3)c1nnnn12,464.48899999999986,2.9858800000000008,1,10,135.31999999999996,5,4,0.4851502900596401,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325471,IC50,5400.0,nM,5.27,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccc2ncnc(NCc3ccccc3)c2c1,265.31599999999986,3.2505000000000015,1,4,47.040000000000006,5,3,0.7862702231990562,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL332938,IC50,200.0,nM,6.7,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,331.17299999999983,3.539500000000002,1,5,59.93000000000001,4,3,0.795411943732026,0,c1ccc(Nc2ncnc3cccnc23)cc1,CHEMBL50519,IC50,4.3,nM,8.37,CHEMBL680030,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccc2ncnc(Nc3ccccc3)c2c1,251.2890000000001,3.3820000000000014,1,4,47.040000000000006,4,3,0.774783826983707,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL328879,IC50,55.0,nM,7.26,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1,290.3219999999997,3.4564000000000012,1,3,46.5,3,4,0.6143160211751838,0,O=c1[nH]c2ccccc2n2cc(-c3ccccc3)cc12,CHEMBL1991356,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains quinazoline core; LogP in drug-like range; Aromatic ring count typical
COc1cccc(-c2cn(-c3ccc(CC(=O)NCCO)cc3)c3ncnc(N)c23)c1,417.4689999999997,2.3293,3,7,115.28999999999999,10,4,0.425109652873353,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL175409,IC50,800.0,nM,6.1,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(-c3ccc(CCN(C)CCO)cc3)c3ncnc(N)c23)c1,417.51299999999964,3.1449000000000007,2,7,89.42999999999999,12,4,0.4578252695554586,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL105436,IC50,300.0,nM,6.52,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(-c3ccc(CNCCO)cc3)c3ncnc(N)c23)c1,389.45899999999966,2.7602,3,7,98.22,10,4,0.420574866746385,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL424375,IC50,300.0,nM,6.52,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(-c3cccc(CO)c3)c3ncnc(N)c23)c1,346.3899999999997,3.1706000000000003,2,6,86.19,7,4,0.5926421919529639,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL176815,IC50,800.0,nM,6.1,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CC(C(=O)NCCO)C3)c3ncnc(N)c23)c1,381.4359999999997,1.7486999999999997,3,7,115.28999999999999,9,3,0.5991251973750827,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL354310,IC50,330.0,nM,6.48,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CC(CNCCO)C3)c3ncnc(N)c23)c1,367.4529999999996,2.2220999999999993,3,7,98.22,10,3,0.5540600392323989,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL168550,IC50,490.0,nM,6.31,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CC(CO)C3)c3ncnc(N)c23)c1,324.3839999999997,2.6324999999999994,2,6,86.19,7,3,0.7702714772989594,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL352801,IC50,420.0,nM,6.38,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CCC3)c3ncnc(N)c23)c1,294.35799999999966,3.4141000000000012,1,5,65.96,5,3,0.8035353953263906,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL355191,IC50,450.0,nM,6.35,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(-c2cn(C3CCN(CC(=O)N(C)C)CC3)c3ncnc(N)c23)c1,408.50599999999963,2.4141999999999992,1,7,89.51,9,3,0.6973833950292586,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL355269,IC50,750.0,nM,6.12,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CCN(CC(N)=O)C3)c3ncnc(N)c23)c1,366.42499999999967,1.4211999999999994,2,7,112.28999999999999,7,3,0.7061580832139875,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL355322,IC50,440.0,nM,6.36,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(-c2cn(C3CCN(CC(N)=O)CC3)c3ncnc(N)c23)c1,380.45199999999966,1.8112999999999995,2,7,112.28999999999999,7,3,0.6980449395457748,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL169064,IC50,350.0,nM,6.46,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CCN(CCN(C)CCO)CC3)c3ncnc(N)c23)c1,424.5489999999996,2.2500999999999998,2,8,92.67,12,3,0.5728756057834471,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL168661,IC50,295.0,nM,6.53,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(-c2cn(C3CCN(CCO)CC3)c3ncnc(N)c23)c1,367.4529999999996,2.3183,2,7,89.42999999999999,8,3,0.7193286942004943,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL169200,IC50,900.0,nM,6.05,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2cn(C3CCNC3)c3ncnc(N)c23)c1,309.37299999999965,2.2234999999999996,2,6,77.99,5,3,0.7754718713804367,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL169519,IC50,1120.0,nM,5.95,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,283.33499999999964,2.665,1,6,78.85,7,3,0.7990760329270634,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242029,IC50,1400.0,nM,5.85,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1OC,313.36099999999965,2.6736000000000004,1,7,88.08,9,3,0.7963965169809273,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242751,IC50,3660.0,nM,5.44,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(/C=C/C(=N/NC(N)=S)c2ccccc2)c1,311.40999999999974,2.945900000000001,2,3,59.64,6,2,0.5062295847973228,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830262,IC50,10950.0,nM,4.96,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)c1,331.32799999999975,2.3649199999999997,0,7,96.49,9,2,0.3343231309202153,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173014,IC50,13870.0,nM,4.86,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1,347.41799999999967,3.187000000000002,2,4,77.24,8,3,0.7178252265444567,0,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1,CHEMBL1976240,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1,310.37799999999976,3.586800000000003,1,4,50.69,4,2,0.8815202816292518,0,O=C1NC(=Nc2ccccc2)SC1=Cc1ccccc1,CHEMBL1972937,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(CNc2nc(N)nc3[nH]c4ccc(O)cc4c23)c1,335.36699999999973,3.0195999999999996,4,6,109.08,7,4,0.45633022602131984,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4084090,Ki,1260.0,nM,5.9,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cccc(CNc2ncnc3cc(N)ncc23)c1,281.3189999999997,2.2276999999999996,2,6,85.95,6,3,0.7623510732230306,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL332173,IC50,2870.0,nM,5.54,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)c1,330.3439999999997,2.4222,3,7,113.44000000000001,9,2,0.6808223440550079,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4294156,IC50,12.0,nM,7.92,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(Nc2cc(Nc3ccc(S(N)(=O)=O)cc3)ncn2)c1,371.4219999999998,2.6198000000000006,3,7,119.22999999999999,8,3,0.6091186334537767,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL4284911,IC50,1229.0,nM,5.91,CHEMBL4267257,CHEMBL203,CHEMBL4265907,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cccc(Nc2nc(N)nc3c2-c2ccccc2C3)c1,304.3529999999997,3.382200000000001,2,5,73.06,5,3,0.6067761936201319,0,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1,CHEMBL2047251,IC50,200000.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
COc1cccc(Nc2ncnc3[nH]c(C)c(C)c23)c1,268.31999999999977,3.3269400000000013,2,4,62.83,6,3,0.7644985071713899,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL73301,IC50,1200.0,nM,5.92,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,294.35799999999966,3.5889000000000015,2,4,62.83,4,3,0.7746197438327891,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,CHEMBL431191,IC50,860.0,nM,6.07,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnc3cc(N)ncc23)c1,267.29199999999975,2.3591999999999995,2,6,85.95,5,3,0.7572555963196137,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL334173,IC50,130.0,nM,6.89,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)c1,449.51099999999974,2.8297000000000008,1,8,89.05,8,3,0.5891574325760128,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774910,IC50,1000.0,nM,,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnc3ccccc23)c1,251.28900000000007,3.3820000000000014,1,4,47.04,4,3,0.774783826983707,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL117697,Ki,50.12,nM,7.3,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnc3ccncc23)c1N,267.29199999999975,2.3591999999999995,2,6,85.95,5,3,0.7083825929972489,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL441335,IC50,131.83,nM,6.88,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,368.44099999999963,1.3753999999999997,3,8,100.94000000000001,8,3,0.6252632540499532,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL3545396,Kd,220.0,nM,6.66,CHEMBL4394506,CHEMBL203,CHEMBL4393671,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc2c(NCc3ccccc3)ncnc12,265.31599999999986,3.2505000000000006,1,4,47.04,5,3,0.7862702231990562,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL424255,IC50,10000.0,nM,,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc2c1C(=O)C1=C(C2=O)c2c(O)cc(CO)cc2[C@@H](O)[C@@H]1O,368.34099999999984,1.1337999999999997,4,7,124.29000000000002,7,2,0.6263387137236712,0,O=C1C2=C(C(=O)c3ccccc31)c1ccccc1CC2,CHEMBL5181037,IC50,6.54,nM,8.18,CHEMBL5133518,CHEMBL203,CHEMBL5131428,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1cccc2c1C(=O)c1c(O)ccc(O)c1C2=O,270.2399999999998,1.8817999999999997,2,5,83.83000000000001,4,2,0.6594906438658489,0,O=C1c2ccccc2C(=O)c2ccccc21,CHEMBL1944921,IC50,4300.0,nM,5.37,CHEMBL1947770,CHEMBL203,CHEMBL1944545,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,406.44599999999963,3.2218,3,8,131.42,6,4,0.4739744643395481,0,c1ccc2[nH]c(-c3nc(C4CCCCC4)n4ncncc34)cc2c1,CHEMBL3120215,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1cccc2ncnc(NCc3ccccc3)c12,265.3159999999998,3.2505000000000015,1,4,47.040000000000006,5,3,0.7862702231990562,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL330882,IC50,4900.0,nM,5.31,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccccc1/C(C)=C/c1coc2nc(N)nc(N)c12,296.3299999999997,2.9562999999999997,2,6,100.19,7,3,0.770337095558402,0,C(=C/c1coc2ncncc12)\c1ccccc1,CHEMBL610181,IC50,50000.0,nM,,CHEMBL1038898,CHEMBL203,CHEMBL1152608,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccccc1/C=C/C(=N/NC(N)=S)c1ccccc1,311.40999999999974,2.945900000000001,2,3,59.64,6,2,0.5062295847973228,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830260,IC50,33000.0,nM,4.48,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccccc1/C=C/C(=O)OCCn1c([N+](=O)[O-])cnc1C,331.32799999999975,2.3649199999999997,0,7,96.49,9,2,0.3343231309202153,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1171273,IC50,32000.0,nM,4.5,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccccc1C(Cc1coc2nc(N)nc(N)c12)C(C)C,326.39999999999964,3.3781000000000008,2,6,100.19,10,3,0.74525311275982,0,c1ccc(CCc2coc3ncncc23)cc1,CHEMBL595757,IC50,18200.0,nM,4.74,CHEMBL1038898,CHEMBL203,CHEMBL1152608,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1CNc1nc(N)nc2[nH]c3cc(C)c(O)cc3c12,349.3939999999998,3.3280200000000004,4,6,109.08,8,4,0.44988172969340073,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4091355,Ki,4030.0,nM,5.39,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccccc1CNc1nc(N)nc2[nH]c3ccc(O)cc3c12,335.3669999999998,3.0195999999999996,4,6,109.08,7,4,0.45633022602131984,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4102074,Ki,1870.0,nM,5.73,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1,438.57599999999957,3.275800000000001,3,7,91.41,10,2,0.5825594118988934,0,O=C(NC1CCNCC1)c1cnc(NCc2ccccc2)nc1NC1CCCC1,CHEMBL2312645,IC50,30000.0,nM,4.52,CHEMBL2317775,CHEMBL203,CHEMBL2311250,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1CNc1ncc(C(=O)NCCCN2CCCC2=O)c(NC2CCCC2)n1,466.5859999999996,3.1941000000000015,3,7,108.48,12,2,0.4365303837028366,0,O=C(NCCCN1CCCC1=O)c1cnc(NCc2ccccc2)nc1NC1CCCC1,CHEMBL2312301,IC50,30000.0,nM,,CHEMBL2319132,CHEMBL203,CHEMBL2311468,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1,447.5389999999997,3.1555000000000017,2,6,80.90999999999998,9,3,0.6043274735062785,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780887,Ki,2060.0,nM,,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1NC(=O)/C=C/c1ccccc1,253.3010000000001,3.347100000000001,1,2,38.33,5,2,0.848506966154703,0,O=C(/C=C/c1ccccc1)Nc1ccccc1,CHEMBL2336355,IC50,5160.0,nM,5.29,CHEMBL4362038,CHEMBL203,CHEMBL4359862,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(CN2CCN(C)CC2)cc1,447.5389999999997,3.126800000000001,3,6,89.69999999999999,9,3,0.5157330559524822,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780563,Ki,51.0,nM,7.29,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCCN(C)CC2)cc1,447.5389999999997,3.521300000000002,3,6,89.69999999999999,8,3,0.5358189297968386,0,O=C(Nc1ccc(N2CCCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3779957,Ki,12.0,nM,7.92,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)c(C)c1,447.5389999999997,3.4396200000000023,3,6,89.69999999999999,9,3,0.5364702948470762,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780320,Ki,26.0,nM,7.58,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1,433.5119999999997,3.1312000000000015,3,6,89.69999999999999,8,3,0.5535147945597213,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780090,Ki,19.0,nM,7.72,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cn1,434.4999999999997,2.5262000000000002,3,7,102.58999999999999,8,3,0.5478546234350126,0,O=C(Nc1ccc(N2CCNCC2)cn1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780156,Ki,2060.0,nM,,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)nc1,434.4999999999997,2.5262000000000002,3,7,102.58999999999999,8,3,0.5478546234350126,0,O=C(Nc1ccc(N2CCNCC2)nc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3781462,Ki,78.0,nM,7.11,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCS(=O)(=O)CC2)cc1,468.5349999999998,2.6142000000000003,3,7,120.6,7,3,0.5085340894542443,0,O=C(Nc1ccc(N2CCS(=O)(=O)CC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780175,Ki,37.0,nM,7.43,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1cc[nH]c(=O)c1C(N)=O,259.265,1.2259999999999995,3,4,97.21000000000001,5,2,0.7687180768436177,0,O=c1cc(Nc2ccccc2)cc[nH]1,CHEMBL3781934,Ki,688.0,nM,,CHEMBL3784893,CHEMBL203,CHEMBL3779874,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccccc1Nc1nccc(-c2cc3c([nH]2)C2(CCN(C(=O)C#CN(C)C)CC2)CNC3=O)n1,499.5749999999997,2.3499999999999996,3,7,115.48,7,3,0.3728536765737957,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21,CHEMBL5088102,IC50,2.8,nM,8.55,CHEMBL5029924,CHEMBL203,CHEMBL5029169,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1ccccc1Nc1ncnc2cc(N)ncc12,267.29199999999975,2.3591999999999995,2,6,85.95,5,3,0.7572555963196137,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL126101,IC50,3710.0,nM,5.43,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ccncc1-c1cc(C(=O)/N=c2\[nH]c3ccccc3n2CC(C)(C)O)ccn1,417.46899999999977,2.947000000000001,2,6,105.39000000000001,9,4,0.5193977210200514,0,O=C(N=c1[nH]c2ccccc2[nH]1)c1ccnc(-c2cccnc2)c1,CHEMBL4532034,IC50,1.0,nM,9.0,CHEMBL4324122,CHEMBL203,CHEMBL4321840,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1COC[C@@H]1CNCCO1,517.5650000000002,3.523600000000002,2,10,99.76000000000002,10,5,0.3064898439298803,1,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCO6)c45)ccc32)cc1,CHEMBL395883,IC50,430.0,nM,6.37,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
COc1cnccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,361.4049999999997,3.1740000000000004,3,6,95.94999999999999,8,4,0.48811570701116663,0,c1ccc(CNc2ncnc3[nH]c(-c4ccncc4)cc23)cc1,CHEMBL4749862,IC50,0.6,nM,9.22,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1nc(N(C)c2ccccc2)c2cc(OC)c(OC)cc2n1,325.3679999999997,3.4235000000000024,0,6,56.71000000000001,9,3,0.7162368412749659,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL135928,IC50,50000.0,nM,,CHEMBL873587,CHEMBL203,CHEMBL1129840,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1nc(N2CC(O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1,491.96099999999984,2.5732,4,10,141.60000000000002,11,3,0.3710451973760798,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC4)nc3)n2)cc1,CHEMBL4281394,IC50,1000000.0,nM,,CHEMBL4267886,CHEMBL203,CHEMBL4265930,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
COc1nc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1,519.0310000000001,3.144100000000001,3,10,124.61,11,3,0.4092178455940594,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)nc3)n2)cc1,CHEMBL4277936,IC50,1000000.0,nM,,CHEMBL4267886,CHEMBL203,CHEMBL4265930,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
COc1nc(NCCN2CCOCC2)nc(Nc2ccc(Cl)cc2)n1,364.83699999999965,2.021299999999999,2,8,84.43,8,2,0.7715710043560778,0,c1ccc(Nc2ncnc(NCCN3CCOCC3)n2)cc1,CHEMBL1946846,IC50,1500.0,nM,5.82,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ncc(-c2cc3c(c(NC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,462.52799999999974,1.4295999999999993,2,8,119.09,9,2,0.6343716223720903,0,O=C(CN1CCOCC1)Nc1cc(-c2cccnc2)cc2c1COC2,CHEMBL4561692,IC50,10000.0,nM,,CHEMBL4479367,CHEMBL203,CHEMBL4477235,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(C)(=O)=O,455.49999999999983,2.0042999999999997,3,10,144.15,11,4,0.36319018047688034,0,c1cncc(-c2ccc3ncnc(Nc4cn[nH]c4)c3c2)c1,CHEMBL4745877,IC50,2520.0,nM,5.6,CHEMBL4667354,CHEMBL203,CHEMBL4665651,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
COc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,332.1609999999999,2.9345,1,6,72.82000000000001,4,3,0.7949884729056614,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL51854,IC50,3.8,nM,8.42,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,353.4009999999997,3.079300000000001,1,6,64.86000000000001,5,3,0.7808336815511909,0,c1ccc(-c2ncn(C3CCNCC3)c2-c2ccncn2)cc1,CHEMBL95692,IC50,10.0,nM,,CHEMBL674026,CHEMBL203,CHEMBL1134743,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12,422.46399999999977,3.431400000000002,2,8,97.46000000000001,11,4,0.4708566388416263,0,c1ccc(-c2nc3cnccn3c2-c2ccncn2)cc1,CHEMBL2005792,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CS(=O)(=O)CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,523.9740000000005,3.4997000000000016,3,8,131.54,9,3,0.4085887077605551,1,c1ccc(Nc2ncnc3cc(OC4CCOC4)ccc23)cc1,CHEMBL3092324,IC50,41.0,nM,7.39,CHEMBL3095060,CHEMBL203,CHEMBL3091333,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CS(=O)(=O)CCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,483.97799999999984,3.356300000000001,3,8,113.08,10,3,0.3156863038781644,0,c1ccc(Nc2ncnc3sccc23)cc1,CHEMBL3233773,IC50,3.0,nM,8.52,CHEMBL3238947,CHEMBL203,CHEMBL3233010,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1,331.39699999999976,1.7047999999999999,1,4,74.65,5,3,0.7906269395715045,0,O=c1[nH]c2ccc(CNC3CC3)cc2n2cccc12,CHEMBL1978448,Ki,501.19,nM,6.3,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains quinazoline core; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)N1CCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,548.6480000000015,3.4773000000000014,1,9,100.66,8,5,0.33242241888292756,1,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1,CHEMBL400413,IC50,210.0,nM,6.68,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,513.6489999999999,2.1483999999999996,1,9,107.55000000000001,6,4,0.4326446499729263,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cn[nH]c2c1,CHEMBL521851,Kd,10000.0,nM,,CHEMBL1908701,CHEMBL203,CHEMBL1908390,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CS(=O)(=O)N1CCc2cc(Nc3ncc(C(F)(F)F)c(NCCCN)n3)ccc2C1,444.4829999999998,2.3174,3,7,113.24,9,2,0.5618797440392734,0,c1cnc(Nc2ccc3c(c2)CCNC3)nc1,CHEMBL5401267,IC50,10000.0,nM,,CHEMBL5380748,CHEMBL203,CHEMBL5376027,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1,343.4079999999998,2.2248,1,5,81.18,7,3,0.6942281648808475,0,c1cncc(-c2ccc3cnccc3c2)c1,CHEMBL1964804,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl,283.7399999999998,2.1685,1,4,71.95,4,2,0.8764287622366344,0,c1cncc(-c2ccncc2)c1,CHEMBL4474208,IC50,10000.0,nM,,CHEMBL4385130,CHEMBL203,CHEMBL4382269,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2,466.9069999999999,2.958680000000001,3,8,155.32999999999998,3,2,0.6094129899011719,0,O=C1Nc2cncc(n2)OCCCCCOc2ccccc2N1,CHEMBL223460,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
CS(=O)(=O)Nc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,423.4979999999998,3.1419000000000006,4,6,120.0,9,4,0.3624701324732318,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4763315,IC50,0.5,nM,9.3,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,302.3589999999998,2.1835999999999993,3,4,100.86999999999999,5,3,0.6899179362751395,0,c1ccc(-c2ccc3[nH]ncc3c2)cc1,CHEMBL2004892,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,435.34599999999995,2.742800000000001,1,4,92.67,4,2,0.8026684264450817,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL2205027,IC50,40000.0,nM,,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,427.51099999999985,3.2391000000000005,3,6,116.83999999999999,7,4,0.4367048261628516,0,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1,CHEMBL4249925,Ki,10000.0,nM,,CHEMBL4235346,CHEMBL203,CHEMBL4229506,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,408.4829999999998,3.1739000000000015,3,6,107.97,8,4,0.4522426132074675,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4740295,IC50,0.8,nM,9.1,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1,332.4059999999999,2.465700000000001,1,5,90.12,4,3,0.7975049211522061,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL1972362,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
CS(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc4c(cc23)OCO4)cc1,377.80899999999997,3.1590000000000016,1,7,90.41000000000001,4,3,0.700816983923881,0,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1,CHEMBL3098316,IC50,100000.0,nM,,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O,278.7639999999998,2.8960000000000017,1,3,41.99,2,2,0.8158050142734654,0,O=C1NCCc2cc3ccccc3nc21,CHEMBL1985074,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CSc1ccccc1Nc1nc(N2CCN(C3CCNCC3)CC2)nc2c(NCC3CC3)ncnc12,505.69599999999963,3.5812000000000017,3,10,94.13000000000001,9,3,0.3944516439700015,1,c1ccc(Nc2nc(N3CCN(C4CCNCC4)CC3)nc3c(NCC4CC4)ncnc23)cc1,CHEMBL2063926,IC50,10000.0,nM,,CHEMBL2065145,CHEMBL203,CHEMBL2062359,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CSc1ccccc1Nc1nc(N2CCNCC2)nc2c(NCC3CC3)ncnc12,422.56199999999967,3.1168000000000013,3,9,90.89,8,3,0.4968055621660034,0,c1ccc(Nc2nc(N3CCNCC3)nc3c(NCC4CC4)ncnc23)cc1,CHEMBL2017214,IC50,40000.0,nM,,CHEMBL2019670,CHEMBL203,CHEMBL2016462,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1,343.4409999999998,3.3498200000000002,2,8,83.79,6,4,0.5529260205074162,0,c1cc(Nc2nccn3c(-c4cn[nH]c4)cnc23)sn1,CHEMBL1270795,IC50,5048.0,nM,5.3,CHEMBL1805338,CHEMBL203,CHEMBL1799927,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C[C@@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,318.76799999999974,1.9542,3,7,115.87,7,3,0.6794166552161769,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1240544,IC50,9140.0,nM,5.04,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,302.3129999999997,1.4399000000000002,3,7,115.87,7,3,0.6738770514920662,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242468,IC50,26000.0,nM,4.58,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C[C@@H](Nc1nc(N)nc2[nH]c3ccc(O)cc3c12)c1ccccc1,319.3679999999997,3.572000000000001,4,5,99.85000000000001,6,4,0.4624017731151832,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4088941,Ki,910.0,nM,6.04,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C[C@@H](Nc1ncnc2[nH]c(-c3ccc(S(N)(=O)=O)cc3)cc12)c1ccccc1,393.47199999999987,3.445400000000001,3,5,113.75999999999999,7,4,0.4804949634399123,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4751641,IC50,0.7,nM,9.15,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@@H](Nc1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12)c1ccccc1,433.5119999999998,3.4331000000000023,1,8,85.42000000000002,8,4,0.4778520329601107,0,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064398,IC50,4500.0,nM,5.35,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C[C@@H](O)c1c(O)cc2c(c1O)C(=O)c1c(O)cc(O)cc1C2=O,316.2649999999998,1.3376999999999997,5,7,135.29,7,2,0.45682763383480357,0,O=C1c2ccccc2C(=O)c2ccccc21,CHEMBL524820,IC50,37500.0,nM,4.43,CHEMBL974188,CHEMBL203,CHEMBL1142620,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C[C@@H](O)c1nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc2n1[C@H](C)C(F)(F)F,469.4429999999997,3.050600000000001,3,9,112.22,9,3,0.48916801892799583,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3734988,Ki,2.5,nM,8.6,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,312.37699999999967,1.5447799999999996,1,5,88.91,5,2,0.9284511020269033,0,c1nc(NC2CCCNC2)c2cc[nH]c2n1,CHEMBL221959,Kd,10000.0,nM,,CHEMBL1061068,CHEMBL203,CHEMBL1150977,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]cc(C#N)c3c21,346.3939999999997,2.71246,1,5,101.5,3,3,0.7704759100299184,0,c1cc2c(ncc3ccn(C4CCCNC4)c32)[nH]1,CHEMBL5273533,IC50,1000.0,nM,,CHEMBL5244417,CHEMBL203,CHEMBL5244205,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]ccc3c21,321.3839999999997,2.8407800000000005,1,4,77.71000000000001,3,3,0.788114638005919,0,c1cc2c(ncc3ccn(C4CCCNC4)c32)[nH]1,CHEMBL5281283,IC50,1000.0,nM,,CHEMBL5244417,CHEMBL203,CHEMBL5244205,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1,530.5040000000009,2.856200000000001,0,10,114.55,9,3,0.42257159432562075,1,c1ccc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)cc1,CHEMBL3358006,IC50,2100.0,nM,5.68,CHEMBL3384643,CHEMBL203,CHEMBL3351317,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@@H]1CC1(F)F,407.39999999999975,1.6888999999999996,2,7,87.97,7,2,0.7844807259867467,0,O=C(N[C@@]12CC1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1,CHEMBL4635625,IC50,4110.0,nM,5.39,CHEMBL4620454,CHEMBL203,CHEMBL4619733,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,318.76799999999974,1.9542,3,7,115.87,7,3,0.6794166552161769,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241579,IC50,4800.0,nM,5.32,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@H](Nc1nc(N)nc2[nH]c3ccc(O)cc3c12)c1ccccc1,319.3679999999997,3.572000000000001,4,5,99.85000000000001,6,4,0.4624017731151832,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4099089,Ki,520.0,nM,6.28,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
C[C@H](Nc1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12)c1ccccc1,433.5119999999998,3.4331000000000023,1,8,85.42000000000002,8,4,0.4778520329601107,0,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064399,IC50,3700.0,nM,5.43,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,323.3929999999997,1.7463999999999993,1,4,62.300000000000004,3,2,0.9144392062998051,0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL3426621,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,406.4209999999998,2.8006800000000016,1,7,110.06,4,3,0.6146965066530885,0,O=C1NCc2n[nH]cc2-c2cncc(c2)OCc2ccccc21,CHEMBL3286830,Ki,56.0,nM,7.25,CHEMBL5213166,CHEMBL203,CHEMBL5212743,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,439.4709999999998,3.474400000000002,3,6,88.65,4,5,0.3732159623688665,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,CHEMBL603469,Kd,7.8,nM,8.11,CHEMBL1908701,CHEMBL203,CHEMBL1908390,0.85,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)c(C)c1CCC(=O)O,354.36199999999974,2.839640000000001,4,5,119.49,7,2,0.6156034792100374,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL149073,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN(C)C,370.4279999999996,2.5547400000000007,3,3,77.22999999999999,9,2,0.7081579472551803,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL13976,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN1CCCC1,396.4659999999996,3.088940000000002,3,3,77.22999999999999,7,2,0.6799925545825998,0,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCCN2CCCC2)c[nH]1,CHEMBL13608,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN1CCOCC1,412.46499999999963,2.3253400000000006,3,4,86.46,7,2,0.6582225024103777,0,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCCN2CCOCC2)c[nH]1,CHEMBL13354,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCn1cncn1,394.4099999999997,2.28484,3,5,104.69999999999999,7,3,0.5776016440912618,0,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCCn2cncn2)c[nH]1,CHEMBL267293,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,442.49099999999964,1.68624,4,5,106.69,9,2,0.5096580614407035,0,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCCCN2CCOCC2)c[nH]1,CHEMBL1721885,Kd,3300.0,nM,5.48,CHEMBL1908704,CHEMBL203,CHEMBL1908390,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCc1ccncc1,390.4179999999997,3.5883400000000023,3,3,86.88,6,3,0.5952208568297892,0,O=C1Nc2ccccc2/C1=C/c1cc(C(=O)NCc2ccncc2)c[nH]1,CHEMBL268731,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c(C)c1CCC(=O)O,389.4329999999998,1.7888400000000002,4,5,142.34999999999997,8,2,0.5766989135602407,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL150177,IC50,50000.0,nM,4.07,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,310.35299999999967,3.141440000000001,3,3,82.19,6,2,0.7587145009871451,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL274654,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCCN1CCN(C)CC1,378.5199999999995,3.304240000000002,2,3,51.370000000000005,8,2,0.7851556583678196,0,O=C1Nc2ccccc2/C1=C/c1cc(CCCN2CCNCC2)c[nH]1,CHEMBL430155,IC50,20000.0,nM,,CHEMBL677212,CHEMBL203,CHEMBL1136732,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,310.35299999999967,3.141440000000001,3,3,82.19,6,2,0.7587145009871451,0,O=C1Nc2ccccc2C1=Cc1ccc[nH]1,CHEMBL2007064,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c2ncnc(NCc3ccccc3)c2c1C,252.3210000000001,3.186840000000002,2,3,53.6,5,3,0.7523553147555245,0,c1ccc(CNc2ncnc3[nH]ccc23)cc1,CHEMBL421686,IC50,1080.0,nM,5.97,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c2ncnc(Nc3ccc(F)cc3)c2c1C,256.28400000000005,3.457440000000002,2,3,53.6,4,3,0.7379111468744611,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL73710,IC50,560.0,nM,6.25,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c2ncnc(Nc3cccc(C#N)c3)c2c1C,263.30399999999986,3.1900200000000014,2,4,77.39,4,3,0.7439501021084884,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL75208,IC50,200.0,nM,6.7,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1[nH]c2ncnc(Nc3cccc(C(=O)O)c3)c2c1C,282.3029999999997,3.016540000000001,3,5,90.9,5,3,0.6865566263169778,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL431001,IC50,16300.0,nM,4.79,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1[nH]c2ncnc(Nc3cccc(F)c3)c2c1C,256.28400000000005,3.457440000000002,2,3,53.6,4,3,0.7379111468744611,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL308582,IC50,550.0,nM,6.26,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1[nH]c2ncnc(Nc3cccc(O)c3)c2c1C,254.2930000000001,3.0239400000000014,3,4,73.83,5,3,0.6568483820668181,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1,CHEMBL74778,IC50,1250.0,nM,5.9,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1[nH]nc(C(C(=O)Nc2nccs2)N2Cc3ccccc3C2=O)c1C,367.43399999999986,2.8188400000000016,2,5,90.97999999999999,6,3,0.741756417639908,0,O=C(Nc1nccs1)C(c1cc[nH]n1)N1Cc2ccccc2C1=O,CHEMBL5205834,IC50,10000.0,nM,,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1,304.35699999999974,2.760320000000001,2,5,85.41,5,4,0.6091815101530806,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1989646,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1c(C#N)c(Nc2ccc(S(N)(=O)=O)cc2)nc2ncnc(N)c12,355.38299999999987,1.1780999999999997,3,8,160.67,6,3,0.6306676536775115,0,c1ccc(Nc2ccc3cncnc3n2)cc1,CHEMBL1910271,IC50,100000.0,nM,,CHEMBL1912180,CHEMBL203,CHEMBL1909587,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Cc1c(C#N)cccc1[C@@H](C)Nc1nnc(C)c2cnc(N3CCOCC3)cc12,388.47499999999974,3.5230200000000016,1,7,86.96000000000001,7,3,0.7314974154670985,0,c1ccc(CNc2nncc3cnc(N4CCOCC4)cc23)cc1,CHEMBL5192659,IC50,10000.0,nM,,CHEMBL5149513,CHEMBL203,CHEMBL5143739,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1c(C(=O)N2CCN(C)CC2)c[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,495.94599999999974,3.5295200000000007,3,6,106.25,6,3,0.47806153545957225,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1cc(C(=O)N2CCNCC2)c[nH]1,CHEMBL304971,IC50,410.0,nM,6.39,CHEMBL674637,CHEMBL203,CHEMBL1134862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F,455.5109999999998,3.2166200000000025,1,6,102.59,6,3,0.6506391929352348,0,O=C(c1ccccc1)N1CCOc2ccc(-c3cccnc3)cc2C1,CHEMBL2333365,IC50,3500.0,nM,,CHEMBL2341967,CHEMBL203,CHEMBL2331117,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1c(C(=O)NC(CO)Cc2ccccc2)[nH]c2ccc(Cl)cc12,342.8259999999996,3.4631200000000018,3,2,65.12,7,3,0.6644574830786105,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1,CHEMBL4209588,IC50,500.0,nM,6.3,CHEMBL4196285,CHEMBL203,CHEMBL4196002,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N,251.24500000000003,2.1856999999999998,1,5,78.38999999999999,3,3,0.6722038858444789,0,c1ccc2c(c1)nc1ccccn12,CHEMBL1989856,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2ccc(C(=O)O)cc21,340.33499999999975,2.5312200000000002,4,5,119.49,6,2,0.623585029292503,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL435227,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2ccc(S(N)(=O)=O)cc21,375.4059999999997,1.4804199999999996,4,5,142.35,7,2,0.585536709416774,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL146697,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2ccccc21,296.3259999999997,2.833020000000001,3,3,82.19,5,2,0.7586898988528975,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL344319,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,498.6129999999997,0.9005200000000009,2,11,133.82999999999998,9,3,0.5224751743548602,1,c1ncc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)cn1,CHEMBL1922094,Kd,4874.0,nM,5.31,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12,336.77899999999977,1.3681200000000002,3,6,112.31,5,2,0.7799597307854779,0,O=c1cc[nH]c2nc(N3CCCC3)ccc12,CHEMBL1999774,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1c(NC(=S)Nc2ccc3c(c2)OCO3)c(=O)n(-c2ccccc2)n1C,382.44499999999977,3.0220200000000013,2,6,69.44999999999999,5,3,0.6789374442011652,0,O=c1c(NC(=S)Nc2ccc3c(c2)OCO3)c[nH]n1-c1ccccc1,CHEMBL4779958,IC50,358.0,nM,6.45,CHEMBL4769431,CHEMBL203,CHEMBL4765304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1c[nH]c(/C=C2\C(=O)Nc3ccc(Br)cc32)c1CCC(=O)O,375.22199999999987,3.5955200000000014,3,3,82.19,5,2,0.7145944922155958,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL148744,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1c[nH]c(/C=C2\C(=O)Nc3cccc(C)c32)c1CCC(=O)O,310.35299999999967,3.141440000000001,3,3,82.19,6,2,0.7587145009871451,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL147761,IC50,28800.0,nM,4.54,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1c[nH]c(/C=C2\C(=O)Nc3ccccc32)c1CCC(=O)O,296.3259999999997,2.8330200000000003,3,3,82.19,5,2,0.7586898988528975,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL89363,IC50,50000.0,nM,,CHEMBL880174,CHEMBL203,CHEMBL1132535,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1cc(-c2nn(C(C)C)c3ncnc(N)c23)sc1C=O,301.3749999999998,2.83882,1,7,86.69,7,3,0.7516052129892167,0,c1csc(-c2n[nH]c3ncncc23)c1,CHEMBL1241947,IC50,9900.0,nM,5.0,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]c1C(=O)N1CCN(C)CC1,495.94599999999986,3.5295200000000015,3,6,106.24999999999997,6,3,0.47806153545957186,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1,CHEMBL69964,IC50,210.0,nM,6.68,CHEMBL674637,CHEMBL203,CHEMBL1134862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(=O)n2nc(SCc3ccc(C(C)(C)C)cc3)nc2[nH]1,328.44099999999963,3.3158200000000013,1,5,63.050000000000004,4,3,0.7492773418362776,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4567599,IC50,86.0,nM,7.07,CHEMBL4341976,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3ccc(C(C)C)cc3)nc2[nH]1,314.41399999999965,3.141720000000001,1,5,63.050000000000004,7,3,0.7514905076400973,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4456976,IC50,62.0,nM,7.21,CHEMBL4341977,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3ccc(Cl)cc3)nc2[nH]1,306.7779999999998,2.6717200000000005,1,5,63.050000000000004,4,3,0.7556969496618425,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL3818535,IC50,54.0,nM,7.27,CHEMBL4341976,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3ccc(Cl)cc3Cl)nc2[nH]1,341.2229999999998,3.325120000000001,1,5,63.050000000000004,4,3,0.7425387180436094,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4570484,IC50,141.0,nM,6.85,CHEMBL4341976,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3ccc(F)cc3)nc2[nH]1,290.32299999999975,2.1574199999999997,1,5,63.050000000000004,4,3,0.7508099382575725,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4441392,IC50,52.0,nM,7.28,CHEMBL4341976,CHEMBL203,CHEMBL4340550,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(=O)n2nc(SCc3ccc([N+](=O)[O-])cc3)nc2[nH]1,317.3299999999998,1.9265199999999998,1,7,106.19,5,3,0.4474759350792064,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4445265,IC50,76.0,nM,7.12,CHEMBL4341977,CHEMBL203,CHEMBL4340550,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3cccc(C(F)(F)F)c3)nc2[nH]1,340.3299999999998,3.0371200000000007,1,5,63.050000000000004,4,3,0.7446079715503562,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4435632,IC50,81.0,nM,7.09,CHEMBL4341976,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3cccc(Cl)c3)nc2[nH]1,306.7779999999998,2.6717200000000005,1,5,63.050000000000004,4,3,0.7556969496618425,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4550473,IC50,59.0,nM,7.23,CHEMBL4341977,CHEMBL203,CHEMBL4340550,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(=O)n2nc(SCc3cccc([N+](=O)[O-])c3)nc2[nH]1,317.3299999999998,1.9265199999999998,1,7,106.19,5,3,0.4474759350792064,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4565086,IC50,77.0,nM,7.11,CHEMBL4341977,CHEMBL203,CHEMBL4340550,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(C(=O)N2CCN(C)CC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,495.94599999999974,3.5295200000000007,3,6,106.25,6,3,0.47806153545957225,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1,CHEMBL305246,IC50,2.8,nM,8.55,CHEMBL674637,CHEMBL203,CHEMBL1134862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(N3CCCCC3)c21,422.4889999999997,2.0685199999999995,2,6,103.44999999999999,4,2,0.7342966354148115,0,O=C1Nc2ncnc(N3CCCCC3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1,CHEMBL68258,IC50,20000.0,nM,,CHEMBL674637,CHEMBL203,CHEMBL1134862,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(c3)CCC4)c21,470.5329999999998,3.3105200000000012,3,6,112.24,5,3,0.504608090635797,0,O=C1Nc2ncnc(Nc3ccc4c(c3)CCC4)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1,CHEMBL65848,IC50,1410.0,nM,5.85,CHEMBL674637,CHEMBL203,CHEMBL1134862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)N(C)c2ncnc(Nc3ccc(F)c(Cl)c3)c21,539.9990000000013,3.228220000000002,3,7,115.48,9,3,0.3947889424056135,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1,CHEMBL443268,IC50,5310.0,nM,5.28,CHEMBL674637,CHEMBL203,CHEMBL1134862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,525.9720000000004,3.203920000000001,4,7,124.27000000000001,8,3,0.34910951558339387,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1,CHEMBL69629,IC50,6.5,nM,8.19,CHEMBL674637,CHEMBL203,CHEMBL1134862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,461.23099999999977,1.8347199999999997,3,6,92.59,9,2,0.3471173989454883,0,O=c1cccc(Nc2ccccc2)[nH]1,CHEMBL3182621,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,445.4829999999998,3.4727400000000017,2,8,115.43999999999998,9,4,0.46954787611676685,0,O=C(Nc1cccc(Oc2ccc3nc(NC(=O)C4CC4)cn3n2)c1)c1ccn[nH]1,CHEMBL2180604,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)nn4c3)ccc2F)n(C)n1,449.4459999999998,3.303420000000001,2,8,115.43999999999998,8,4,0.4667220805674559,0,O=C(Nc1cccc(Oc2ccc3nc(NC(=O)C4CC4)nn3c2)c1)c1ccn[nH]1,CHEMBL2409778,IC50,10000.0,nM,,CHEMBL2410719,CHEMBL203,CHEMBL2407020,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(C)c(NC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c(C)c1,322.36399999999975,3.5687400000000027,3,4,93.35000000000001,8,2,0.4573355520155127,0,O=C(/C=C/c1ccccc1)Nc1ccccc1,CHEMBL141238,IC50,19054.61,nM,4.72,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(C)nc(NS(=O)(=O)c2ccc(Nc3nncc4ccccc34)cc2)n1,406.47099999999983,3.5810400000000016,2,7,109.76,7,4,0.521123240413847,0,O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3950630,IC50,6.7,nM,8.17,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(NC(=O)CN2CCN(c3ccccc3)CC2)no1,300.3619999999996,1.74372,1,5,61.61000000000001,5,2,0.9317543968221527,0,O=C(CN1CCN(c2ccccc2)CC1)Nc1ccon1,CHEMBL4740108,IC50,64.0,nM,7.19,CHEMBL4672269,CHEMBL203,CHEMBL4665865,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(NS(=O)(=O)c2ccc(Nc3nncc4ccccc34)cc2)no1,381.41699999999986,3.470620000000001,2,7,110.01,6,4,0.544462609690953,0,O=S(=O)(Nc1ccon1)c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3899216,IC50,130.0,nM,6.89,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,375.4799999999996,3.1739200000000016,2,6,72.97,7,3,0.7136005782754015,0,C(=C/c1nc(Nc2cc[nH]n2)cc(N2CCNCC2)n1)\c1ccccc1,CHEMBL482968,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1,375.4799999999996,3.1739200000000016,2,6,72.97,7,3,0.7136005782754015,0,C(=Cc1nc(Nc2cc[nH]n2)cc(N2CCNCC2)n1)c1ccccc1,CHEMBL1983923,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc(N)cc3)n2)n[nH]1,380.4559999999996,2.3780199999999994,3,8,108.22,8,3,0.5791461228181294,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604930,IC50,1400.0,nM,5.85,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc(NC(=O)/C=C/CN(C)C)cc3)n2)n[nH]1,491.5999999999996,2.85212,3,9,114.53999999999999,13,3,0.38878505999498914,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604935,IC50,1700.0,nM,5.77,CHEMBL3606403,CHEMBL203,CHEMBL3603765,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc([N+](=O)[O-])cc3)n2)n[nH]1,410.4379999999997,2.7040200000000008,2,9,125.34,8,3,0.46580401347533235,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604928,IC50,900.0,nM,6.05,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3cccc(N)c3)n2)n[nH]1,380.4559999999996,2.3780199999999994,3,8,108.22,8,3,0.5791461228181294,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604929,IC50,4900.0,nM,5.31,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3cccc([N+](=O)[O-])c3)n2)n[nH]1,410.4379999999997,2.70402,2,9,125.34,8,3,0.46580401347533235,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604927,IC50,600.0,nM,6.22,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccccc3[N+](=O)[O-])n2)n[nH]1,410.4379999999997,2.7040200000000008,2,9,125.34,8,3,0.46580401347533235,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1,CHEMBL3604926,IC50,1600.0,nM,5.8,CHEMBL3606405,CHEMBL203,CHEMBL3603765,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,464.59899999999976,3.5032200000000016,3,8,102.07,9,3,0.4568163085513307,0,O=C(Nc1ccc(Sc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1)C1CC1,CHEMBL572878,Ki,1584.89,nM,5.8,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(Nc2nc(-c3cn[nH]c3)nc3c2COC3(C)C)n[nH]1,311.34899999999965,2.407119999999999,3,6,104.4,6,3,0.6858632269275028,0,c1cc(Nc2nc(-c3cn[nH]c3)nc3c2COC3)n[nH]1,CHEMBL3759002,Ki,844.0,nM,6.07,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)c(C#N)cc2F)n[nH]1,355.35199999999975,3.574700000000001,3,6,102.31,7,3,0.6464819759445511,0,c1ccc(CNc2cccc(Nc3cc[nH]n3)n2)nc1,CHEMBL1774056,IC50,10000.0,nM,,CHEMBL1776852,CHEMBL203,CHEMBL1772962,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,348.7729999999998,3.00732,3,7,104.3,7,3,0.6505657114536998,0,c1cnc(CNc2nccc(Nc3ccn[nH]3)n2)nc1,CHEMBL1231124,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1,451.5499999999996,2.5074200000000006,3,7,99.40999999999998,8,2,0.5805608630318185,0,C1=CC2CC1CC2Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1,CHEMBL1967878,Ki,79.43,nM,7.1,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CO)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,591.1160000000016,3.473620000000002,2,8,108.37999999999998,9,3,0.44931497453118674,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1C1CCNC1,CHEMBL4062178,IC50,7.0,nM,8.15,CHEMBL4038017,CHEMBL203,CHEMBL4033795,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(Nc2nccc(Nc3cccc(S(N)(=O)=O)c3)n2)ccc1N1CCN(C)CC1,453.5719999999997,2.6714200000000003,3,8,116.47999999999998,9,3,0.5216260565320133,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1,CHEMBL3884104,IC50,150000.0,nM,,CHEMBL3875840,CHEMBL203,CHEMBL3875172,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Cc1cc(Nc2ncnc3[nH]nc(OCCN4CCC(O)CC4)c23)ccc1OCc1ccccn1,475.55299999999977,3.2144200000000014,3,9,121.31000000000002,11,4,0.33492132383140716,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1,CHEMBL403435,IC50,18.0,nM,7.75,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc(O)ccc1-c1nn(C(C)C)c2ncnc(N)c12,283.33499999999964,2.67042,2,6,89.85000000000001,7,3,0.7542890826314489,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242024,IC50,954.0,nM,6.02,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21,367.7959999999998,2.76572,3,7,120.05,5,4,0.44477328682830947,0,O=c1c2ccccc2n(-c2ccccc2)c2ncncc12,CHEMBL1995592,Ki,316.23,nM,6.5,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21,371.39599999999984,3.1656200000000014,2,5,98.21,5,4,0.5778249661116075,0,O=c1ccn(-c2ccccc2)c2cc(-c3ccncc3)ccc12,CHEMBL340921,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,408.45799999999974,2.710820000000001,2,8,96.16999999999999,7,3,0.6700364833304304,0,O=c1cc(N2CCOCC2)nc2c(CNc3ccccc3)cccn12,CHEMBL2165191,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc2[nH]c3nc(N)nc(NCc4ccccc4)c3c2cc1O,319.3679999999997,3.3194200000000014,4,5,99.85000000000001,6,4,0.4640283863976687,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4094157,Ki,640.0,nM,6.19,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,370.3839999999998,3.518440000000002,2,6,84.67000000000002,9,4,0.5614878444434998,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1,CHEMBL377300,IC50,1900.0,nM,5.58,CHEMBL859796,CHEMBL203,CHEMBL1146078,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,441.4629999999998,3.4165400000000004,2,8,116.76000000000002,12,4,0.4221549724446724,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1,CHEMBL270995,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc2c(Nc3ccc(C)c(O)c3)ncnn2c1,254.29300000000012,2.7953400000000004,2,5,62.45,5,3,0.7378179030908203,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL184750,IC50,405.0,nM,6.39,CHEMBL5262914,CHEMBL203,CHEMBL5260813,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cc2c(Nc3ccc(F)c(Cl)c3)ncnn2c1,276.7019999999998,3.5738200000000013,1,4,42.22,3,3,0.7778899026215155,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL186080,IC50,150.0,nM,6.82,CHEMBL832893,CHEMBL203,CHEMBL1138664,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(-c2c(CN3CCOCC3)nc3scc(C(=O)NN)n23)cc1,371.4659999999997,1.8069199999999999,2,7,84.89,6,3,0.41504325230949995,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1,CHEMBL5170804,IC50,246.0,nM,6.61,CHEMBL5110647,CHEMBL203,CHEMBL5108025,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(-c2csc(=N)n2CC(=O)N2CCN(C)CC2)cc1,330.45699999999965,1.77849,1,5,52.330000000000005,5,2,0.932552767900351,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCNCC1,CHEMBL2437296,Ki,27400.0,nM,4.56,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(-c2csc(=N)n2CC(=O)N2CCN(c3ccccc3)CC2)cc1,392.52799999999974,3.353290000000002,1,5,52.330000000000005,5,3,0.7402696156979668,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCN(c2ccccc2)CC1,CHEMBL2437291,Ki,2970.0,nM,5.53,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(-c2csc(=N)n2CC(=O)N2CCOCC2)cc1,317.4139999999997,1.8632900000000001,1,5,58.32000000000001,4,2,0.9392505553850138,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCOCC1,CHEMBL2437299,Ki,22940.0,nM,4.64,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1,281.36299999999966,3.1389200000000006,1,5,69.62,3,3,0.7436116253858401,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL306380,Ki,199.53,nM,6.7,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(-c2nn(C(C)(C)CNC(=O)c3ccncc3)c3ncnc(N)c23)cc1,401.4739999999997,2.94402,2,7,111.61,9,4,0.5317479099616789,0,O=C(NCCn1nc(-c2ccccc2)c2cncnc21)c1ccncc1,CHEMBL5206121,IC50,10000.0,nM,,CHEMBL5374198,CHEMBL203,CHEMBL5370637,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,283.3349999999997,2.6704200000000005,2,6,89.85000000000001,7,3,0.7542890826314489,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242026,IC50,663.0,nM,6.18,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,255.2810000000001,1.6265199999999997,2,6,89.85000000000001,5,3,0.6893368473403972,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1241271,IC50,19000.0,nM,4.72,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,315.3289999999997,2.664740000000001,0,6,87.26,8,2,0.3538108394380821,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173653,IC50,8110.0,nM,5.09,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(Br)c2c(C#N)cc(C(=O)C3CC3)n12,303.1589999999998,3.4746000000000024,0,3,45.269999999999996,3,2,0.797378804071217,0,O=C(c1ccc2ccccn12)C1CC1,CHEMBL1171792,IC50,85.0,nM,7.07,CHEMBL1174225,CHEMBL203,CHEMBL1177838,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(C(/C=C/c2ccccc2)=N\NC(N)=S)cc1,295.4109999999997,3.2457200000000004,2,2,50.41,5,2,0.5170232456547669,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830274,IC50,350.0,nM,6.46,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1,279.29499999999973,3.196100000000002,2,4,81.32000000000001,6,2,0.3910604151954711,0,O=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL54471,IC50,880.0,nM,6.06,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(=O)n(CC3CC3)nnc2c1,374.4439999999997,3.0691200000000016,1,5,76.88,6,3,0.7445609346418993,0,O=C(NC1CC1)c1cccc(-c2ccc3c(=O)n(CC4CC4)nnc3c2)c1,CHEMBL521734,IC50,25000.0,nM,,CHEMBL998566,CHEMBL203,CHEMBL1141712,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O,449.84099999999984,2.773620000000001,2,6,93.45000000000002,9,3,0.5782721069466515,0,O=c1cc(OCc2ccccc2)ncn1-c1ccccc1,CHEMBL1738710,IC50,10000.0,nM,,CHEMBL1798632,CHEMBL203,CHEMBL1795201,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)cc2)c(Cl)n1,389.65799999999984,2.924620000000001,1,4,76.13,4,2,0.8189841391989673,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945648,IC50,2640.0,nM,5.58,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(C(=O)NS(=O)(=O)c2ccc(Cl)cc2)c(Cl)n1,345.2069999999998,2.8155200000000002,1,4,76.13,4,2,0.8682248174659184,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945649,IC50,1190.0,nM,5.92,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(C(=O)NS(=O)(=O)c2ccccc2)c(Cl)n1,310.7619999999997,2.16212,1,4,76.13,4,2,0.8814424131972618,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945646,IC50,21560.0,nM,4.67,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(C2=NN(C(N)=S)C(c3ccc(O)cc3)C2)cc1C,325.4369999999997,3.4037400000000018,2,3,61.849999999999994,5,2,0.8308268199834478,0,c1ccc(C2=NNC(c3ccccc3)C2)cc1,CHEMBL1173815,IC50,130.0,nM,6.89,CHEMBL1177399,CHEMBL203,CHEMBL1177661,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1,293.32599999999974,2.3417199999999996,2,5,71.09,6,3,0.7065315574801434,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1994864,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C,307.3529999999997,2.6501400000000004,2,5,71.09,7,3,0.709115039515449,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1983449,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(CNc2nc(N)nc3[nH]c4ccc(O)cc4c23)cc1,319.3679999999997,3.31942,4,5,99.85000000000001,6,4,0.46402838639766875,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4080640,Ki,90.0,nM,7.05,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(CSc2nc3[nH]c(C)cc(=O)n3n2)cc1,286.35999999999973,2.32674,1,5,63.05,5,3,0.7505762858586568,0,O=c1cc[nH]c2nc(SCc3ccccc3)nn12,CHEMBL4539566,IC50,168.0,nM,6.78,CHEMBL4341977,CHEMBL203,CHEMBL4340550,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1,303.36899999999974,3.4865400000000006,1,4,59.39,5,4,0.6300403795072678,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1984432,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(F)c(C(=O)n2nc(Nc3ccc(S(N)(=O)=O)cc3)nc2C)c1F,407.4019999999999,2.2526399999999995,2,7,119.96999999999998,7,3,0.6844962024747844,0,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,CHEMBL363607,IC50,45800.0,nM,4.34,CHEMBL829442,CHEMBL203,CHEMBL1139550,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(N)cc1Nc1nccc(-c2cccnc2)n1,277.3309999999997,3.1728200000000006,2,5,76.72,5,3,0.718971891926913,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL278103,IC50,100000.0,nM,,CHEMBL676151,CHEMBL203,CHEMBL1159186,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Cc1ccc(NC(=O)/C=C/CN(C)C)cc1C(=O)Nc1nccc(-c2cccnc2)n1,416.48499999999973,3.1556200000000008,2,6,100.11000000000001,10,3,0.5741144156094414,0,O=C(Nc1nccc(-c2cccnc2)n1)c1ccccc1,CHEMBL2385992,IC50,5000.0,nM,5.3,CHEMBL2390159,CHEMBL203,CHEMBL2384937,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1,269.2639999999998,2.91812,2,5,96.74,4,3,0.5624971638002357,0,c1ccc(Nc2nc3ccccc3[nH]2)nc1,CHEMBL1992937,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,437.5289999999997,3.1390400000000005,2,8,119.03,10,4,0.4921501033338167,0,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1,CHEMBL477772,Kd,10000.0,nM,,CHEMBL1908702,CHEMBL203,CHEMBL1908390,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)cc1,433.5119999999997,3.129520000000002,1,7,79.82000000000001,7,3,0.639748270159147,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774712,IC50,594.5,nM,6.23,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,419.4849999999998,3.312020000000002,1,8,85.42000000000002,7,4,0.5131166805573406,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064383,IC50,67.0,nM,7.17,CHEMBL2066000,CHEMBL203,CHEMBL2062376,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2ncnn3c(C)ccc23)cc1O,254.2930000000001,2.795340000000001,2,5,62.45,5,3,0.7378179030908203,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL187431,IC50,10000.0,nM,4.53,CHEMBL5262914,CHEMBL203,CHEMBL5260813,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2ncnn3cc(C)c(C)c23)cc1O,268.31999999999977,3.1037600000000016,2,5,62.45,6,3,0.7493378152300972,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL186001,IC50,23.0,nM,7.64,CHEMBL5262914,CHEMBL203,CHEMBL5260813,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2ncnn3ccc(C)c23)cc1O,254.2930000000001,2.7953400000000017,2,5,62.45,5,3,0.7378179030908203,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL188522,IC50,66.0,nM,7.18,CHEMBL5262914,CHEMBL203,CHEMBL5260813,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)cc1,336.44299999999964,2.7044200000000007,2,6,71.48,6,3,0.7663711485884525,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645471,IC50,50.0,nM,7.3,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(O)cc1-n1c(=O)c2c(c3c(N)ncnc31)CCCC2,322.36799999999977,2.25572,2,6,94.03,4,3,0.7164552155791707,0,O=c1c2c(c3cncnc3n1-c1ccccc1)CCCC2,CHEMBL2152704,IC50,1620.0,nM,5.79,CHEMBL2154039,CHEMBL203,CHEMBL2150975,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCC(O)CC5)c34)cc2F)cn1,479.5159999999998,3.5668200000000008,3,9,121.31,10,4,0.3481570875777447,0,c1cncc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)c1,CHEMBL257873,IC50,1430.0,nM,5.84,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(Br)cc2)cc1,368.2519999999998,2.8051200000000014,1,3,63.24,5,2,0.9028554049849292,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828876,IC50,18350.0,nM,4.74,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(Cl)cc2)cc1,323.8009999999998,2.6960200000000007,1,3,63.24,5,2,0.9405718679439578,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828871,IC50,13730.0,nM,4.86,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(F)cc2)cc1,307.3459999999998,2.1817200000000003,1,3,63.24,5,2,0.9414371181109075,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828866,IC50,8280.0,nM,5.08,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)Cc2cccc(Br)c2)cc1,368.2519999999998,2.8051200000000014,1,3,63.24,5,2,0.9028554049849292,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1829272,IC50,26170.0,nM,4.58,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,338.3449999999998,0.9132399999999996,1,7,124.2,7,2,0.6381117525513063,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1,CHEMBL1828861,IC50,3430.0,nM,5.46,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)c2ccc(C)nc2Cl)cc1,324.78899999999976,2.4705400000000006,1,4,76.13,5,2,0.8799139748261889,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945647,IC50,15020.0,nM,4.82,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(S(=O)(=O)NC(=O)c2ccc(Cl)nc2)cc1,310.76199999999983,2.16212,1,4,76.13,4,2,0.8814424131972618,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945642,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(S(=O)(=O)NC(=O)c2cccnc2)cc1,276.3169999999997,1.50872,1,4,76.13,4,2,0.9215413943600829,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1916951,IC50,24830.0,nM,4.61,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc(S(=O)(=O)NC(=O)c2cccnc2Cl)cc1,310.7619999999998,2.16212,1,4,76.13,4,2,0.8814424131972618,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945450,IC50,27050.0,nM,4.57,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc(S(=O)(=O)NC(=O)c2cncc(Br)c2)cc1,355.21299999999985,2.2712200000000005,1,4,76.13,4,2,0.9165486016469009,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945445,IC50,12110.0,nM,4.92,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccc([N+](=O)[O-])cc1Nc1nccc(-c2cccnc2)n1,307.31299999999976,3.498820000000001,1,6,93.84,5,3,0.5853527227931791,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL20426,IC50,100000.0,nM,,CHEMBL676151,CHEMBL203,CHEMBL1159186,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
Cc1ccc2c(Nc3ccc(F)c(Cl)c3)ncnn12,276.70199999999977,3.5738200000000013,1,4,42.22,3,3,0.7778899026215155,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL184311,IC50,2000.0,nM,5.49,CHEMBL5262914,CHEMBL203,CHEMBL5260813,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc2c(c1)cc(C1C(C#N)=C(N)N(c3cccnc3)C3=C1C(=O)CCC3)c1nnnn12,448.48999999999984,3.285700000000001,1,9,126.08999999999999,4,4,0.4950241655888603,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3325470,IC50,10400.0,nM,4.98,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2n1,318.3839999999997,3.513020000000001,1,6,82.51,6,4,0.6112746313024788,0,c1cnc2cc(-c3n[nH]c4ncncc34)ccc2c1,CHEMBL1242209,IC50,18000.0,nM,4.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,255.32500000000013,1.86994,2,5,68.24,6,3,0.7493932675754699,0,c1ccc2c(c1)ncc1nccn12,CHEMBL249697,Kd,10000.0,nM,,CHEMBL1908696,CHEMBL203,CHEMBL1908390,0.9999999999999999,Activity in Type 1 range; Contains quinazoline core; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C,307.35699999999974,2.4366399999999997,3,4,110.68,6,3,0.6896899169481803,0,c1ccc(-c2ccc(-c3ccncn3)[nH]2)cc1,CHEMBL1964290,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,369.42799999999977,3.513820000000001,1,5,86.69000000000001,4,4,0.5985637476273389,0,c1ccc(-c2nn3c(c2-c2ccnc4ccccc24)CCC3)nc1,CHEMBL2364611,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(-n2ncc3c(NCc4ccc5c(c4)OCO5)ncnc32)c1,359.3889999999998,3.4647200000000016,1,7,74.09,5,4,0.601425521804457,0,c1ccc(-n2ncc3c(NCc4ccc5c(c4)OCO5)ncnc32)cc1,CHEMBL206483,IC50,15000.0,nM,4.82,CHEMBL863780,CHEMBL203,CHEMBL1146933,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(C)c1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,308.3369999999997,3.260320000000002,3,4,93.35000000000001,7,2,0.46070298566451706,0,O=C(/C=C/c1ccccc1)Nc1ccccc1,CHEMBL55360,IC50,5000.0,nM,5.29,CHEMBL701406,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(CN(C)c2ncnc3[nH]c(-c4ccc(CO)cc4)cc23)n1,359.4329999999997,3.4570200000000018,2,5,77.93,8,4,0.5705343055240174,0,c1ccc(-c2cc3c(NCc4ccccn4)ncnc3[nH]2)cc1,CHEMBL5428404,IC50,78.0,nM,7.11,CHEMBL5342459,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(CN(C)c2ncnc3[nH]c(-c4ccc(S(N)(=O)=O)cc4)cc23)c1,407.49899999999974,3.2171200000000013,2,5,104.97,8,4,0.52845255912111,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL5411617,IC50,98.0,nM,7.01,CHEMBL5342465,CHEMBL203,CHEMBL5338782,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1,340.4309999999996,2.3093199999999996,4,6,118.94999999999999,7,2,0.6629929982859931,0,c1ccc(Nc2cncc(NC3CCCCC3)n2)cc1,CHEMBL1974328,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cc(N)ncc23)c1,251.2930000000001,2.65902,2,5,76.72,4,3,0.731828279797428,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL331792,IC50,40.0,nM,7.4,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cc(NCCCN4CCN(C)CC4)ncc23)c1,391.52299999999957,3.1262200000000018,2,7,69.21000000000001,9,3,0.5998071847275079,0,c1ccc(Nc2ncnc3cc(NCCCN4CCNCC4)ncc23)cc1,CHEMBL341522,IC50,5.6,nM,8.25,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)c1,378.4799999999996,3.2110200000000013,2,7,75.2,8,3,0.6115385063534294,0,c1ccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)cc1,CHEMBL129509,IC50,9.3,nM,8.03,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)c1,345.4099999999997,3.4545200000000014,3,6,91.41,7,4,0.4956474010099026,0,c1ccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)cc1,CHEMBL340399,IC50,7.2,nM,8.14,CHEMBL677386,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)c1,433.5119999999997,3.129520000000001,1,7,79.82000000000001,7,3,0.639748270159147,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3775459,IC50,186.9,nM,6.73,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3ccc(N)cc23)c1,250.3050000000001,3.2640200000000004,2,4,63.83,4,3,0.6850826391478327,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL336113,IC50,1000.0,nM,6.0,CHEMBL870841,CHEMBL203,CHEMBL1148637,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3ccncc23)c1N,251.2930000000001,2.659019999999999,2,5,76.72,4,3,0.6845963463211064,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL405772,IC50,40.74,nM,7.39,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3ccncc23)c1NCCCN1CCN(C)CC1,391.52299999999957,3.126220000000001,2,7,69.21,9,3,0.5998071847275077,0,c1ccc(Nc2ncnc3ccncc23)c(NCCCN2CCNCC2)c1,CHEMBL410253,IC50,5.623,nM,8.25,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3ccncc23)c1NCCCN1CCOCC1,378.4799999999996,3.2110200000000004,2,7,75.2,8,3,0.6115385063534293,0,c1ccc(Nc2ncnc3ccncc23)c(NCCCN2CCOCC2)c1,CHEMBL271410,IC50,9.333,nM,8.03,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cnc(Cl)nc23)c1,271.7109999999998,3.1252200000000014,1,5,63.59,3,3,0.7256571340036954,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL52823,IC50,380.0,nM,6.42,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(N(C)C)cc23)c1,279.34699999999964,3.1428200000000013,1,5,53.940000000000005,6,3,0.79788980599441,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL163188,IC50,2.8,nM,8.55,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(N(C)C)nc23)c1,280.3349999999997,2.53782,1,6,66.83000000000001,6,3,0.7949409635456116,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL52829,IC50,4.0,nM,8.4,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(N)cc23)c1,251.2930000000001,2.65902,2,5,76.72,4,3,0.731828279797428,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL165495,IC50,3.1,nM,8.51,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(N)nc23)c1,252.2810000000001,2.0540199999999995,2,6,89.61,4,3,0.7251543913095554,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL298931,IC50,17.0,nM,7.77,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)c1,378.4799999999997,3.2110200000000013,2,7,75.2,8,3,0.6115385063534294,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1,CHEMBL162508,IC50,1.8,nM,8.74,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,364.4529999999997,2.820920000000001,2,7,75.2,7,3,0.6964677029812328,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1,CHEMBL165731,IC50,1.5,nM,8.82,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)c1,365.4409999999997,2.2159199999999997,2,8,88.09,7,3,0.6874415906245668,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)cc1,CHEMBL299881,IC50,2.3,nM,8.64,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)c1,345.4099999999997,3.4545200000000014,3,6,91.41000000000001,7,4,0.4956474010099026,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)cc1,CHEMBL161895,IC50,1.3,nM,8.89,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)c1,346.3979999999997,2.84952,3,7,104.30000000000001,7,4,0.4929171939465296,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)cc1,CHEMBL416307,IC50,3.0,nM,8.52,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc(Nc2ncnc3nc(Nc4ccc(S(N)(=O)=O)cc4)sc23)c1,412.49999999999983,3.529320000000001,3,8,122.88999999999999,7,4,0.4580596414391077,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1,CHEMBL513362,IC50,14.0,nM,7.85,CHEMBL987693,CHEMBL203,CHEMBL1153982,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1cccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)c1,336.4429999999996,2.7044200000000007,2,6,71.48,6,3,0.7663711485884523,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645470,IC50,20.0,nM,7.7,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cccc2c1/C(=C/c1ccc(N3CCN(C=O)CC3)cc1)C(=O)N2,347.41799999999967,2.766120000000001,1,3,52.650000000000006,3,2,0.6861143229363537,0,O=C1Nc2ccccc2/C1=C/c1ccc(N2CCNCC2)cc1,CHEMBL89040,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
Cc1cccc2c1/C(=C/c1ccc(N3CCOCC3)cc1)C(=O)N2,320.39199999999965,3.324320000000002,1,3,41.57,3,2,0.8631667853794959,0,O=C1Nc2ccccc2/C1=C/c1ccc(N2CCOCC2)cc1,CHEMBL90277,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
Cc1ccccc1-c1nnc(Cc2nc3ccccc3[nH]2)o1,290.32599999999974,3.5121200000000012,1,4,67.6,4,4,0.626642577081822,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4074782,IC50,39700.0,nM,4.4,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccccc1Cc1nnc(Cc2nc3ccccc3[nH]2)o1,304.35299999999967,3.435920000000002,1,4,67.6,5,4,0.6269136990036992,0,c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4095195,IC50,50000.0,nM,4.3,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccccc1Cn1nnc2c1C(=O)c1ccccc1C2=O,303.32099999999974,2.4102200000000007,0,5,64.85,3,3,0.5702185816351999,0,O=C1c2ccccc2C(=O)c2c1nnn2Cc1ccccc1,CHEMBL1442185,IC50,10000.0,nM,,CHEMBL3631092,CHEMBL203,CHEMBL3627649,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ccccc1Nc1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1,417.5129999999997,3.431020000000002,3,5,80.46999999999998,7,3,0.592703826563209,0,O=C(Nc1ccc(N2CCNCC2)cc1)c1c(Nc2ccccc2)cc[nH]c1=O,CHEMBL3780073,Ki,61.0,nM,7.21,CHEMBL3784893,CHEMBL203,CHEMBL3779874,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccccc1Nc1ncnn2ccc(CN3CCC(N)CC3)c12,336.44299999999964,2.7044200000000007,2,6,71.48,6,3,0.7663711485884523,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645469,IC50,660.0,nM,6.18,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ccn2ncnc(Nc3ccc(F)c(Cl)c3)c12,276.70199999999977,3.5738200000000013,1,4,42.22,3,3,0.7778899026215155,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL188304,IC50,100.0,nM,7.0,CHEMBL832893,CHEMBL203,CHEMBL1138664,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccn2ncnc(Nc3ccc4[nH]ncc4c3)c12,264.29199999999986,2.6576200000000005,2,5,70.9,3,4,0.583613255133396,0,c1cc2c(Nc3ccc4[nH]ncc4c3)ncnn2c1,CHEMBL247100,IC50,210.0,nM,6.68,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4ccccn4)c3)c12,355.4049999999998,3.574320000000002,1,7,72.93,5,5,0.5334218247680513,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)nc1,CHEMBL394462,IC50,200.0,nM,6.7,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccnc4)c3)c12,355.4049999999998,3.574320000000002,1,7,72.93,5,5,0.5334218247680513,0,c1cncc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)c1,CHEMBL394463,IC50,1800.0,nM,5.75,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
Cc1ccsc1C(=O)n1nc(Nc2ccc(S(N)(=O)=O)cc2)nc1N,378.43899999999985,1.3097199999999998,3,9,145.98999999999998,7,3,0.6200312136066328,0,O=C(c1cccs1)n1cnc(Nc2ccccc2)n1,CHEMBL363130,IC50,8400.0,nM,5.08,CHEMBL829442,CHEMBL203,CHEMBL1139550,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21,411.82399999999984,2.83542,1,6,95.8,5,4,0.5581509945267705,0,O=c1[nH]c2cnccc2n1-c1ccnc(-c2ccccc2)c1,CHEMBL4564126,IC50,5000.0,nM,,CHEMBL4427690,CHEMBL203,CHEMBL4425174,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,436.30999999999983,2.86714,3,6,97.4,7,2,0.6672332495312251,0,O=C(Nc1cnccn1)Nc1ccccc1OCC1CNCCO1,CHEMBL3039517,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1,428.4739999999999,1.7837199999999998,4,8,162.32,10,3,0.42180775892894756,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1988838,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCC(N)CC6)c45)ccc32)c1,467.5809999999998,3.497420000000001,2,9,102.19,8,5,0.3940216735966273,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)c1,CHEMBL248114,IC50,19.0,nM,7.72,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12,319.42999999999967,1.9157199999999999,1,4,62.300000000000004,4,2,0.9184135158354065,0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL1082440,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1coc2ncnc(N(C)c3ccc(N(C)C)cc3)c12,282.34699999999964,3.3651200000000028,0,5,45.400000000000006,7,3,0.7367366076336572,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4245415,IC50,3.1,nM,8.51,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1coc2ncnc(N(C)c3ccc([N+](=O)[O-])cc3)c12,284.2749999999998,3.207320000000002,0,6,85.3,5,3,0.5419714242902374,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4243157,IC50,200.0,nM,,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1coc2ncnc(Nc3ccc(N(C)C)cc3)c12,268.31999999999977,3.3408200000000017,1,5,54.190000000000005,6,3,0.7891703909476364,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4237915,IC50,200.0,nM,,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1coc2ncnc(Nc3ccc([N+](=O)[O-])cc3)c12,270.2479999999998,3.183020000000001,1,6,94.09,4,3,0.5798213945744344,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4240844,IC50,200.0,nM,,CHEMBL4235834,CHEMBL203,CHEMBL4229524,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1n[nH]c2c1C(c1ccccc1Br)c1c(ncn(N)c1=N)O2,373.2139999999998,2.1562900000000003,3,6,105.60000000000001,3,3,0.4447566155354473,0,N=c1[nH]cnc2c1C(c1ccccc1)c1cn[nH]c1O2,CHEMBL5196209,IC50,60.0,nM,7.22,CHEMBL5097734,CHEMBL203,CHEMBL5096180,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2,286.72199999999975,2.5897000000000006,2,4,87.72,3,2,0.8432188222292462,0,C1=CC(c2ccccc2)c2cn[nH]c2O1,CHEMBL1970189,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C,392.50699999999955,3.359720000000002,1,7,87.39,10,2,0.6228188249013481,0,N=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1,CHEMBL4078023,IC50,20.0,nM,7.7,CHEMBL4034792,CHEMBL203,CHEMBL4033650,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C,377.49199999999956,3.0986200000000013,0,6,71.87,9,2,0.749101132467032,0,O=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1,CHEMBL4083642,IC50,40.0,nM,7.4,CHEMBL4034792,CHEMBL203,CHEMBL4033650,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc(N(C)c2ccc3c(c2)CCO3)c2cc(C)oc2n1,295.34199999999964,3.542440000000002,0,5,51.39,5,3,0.7234615993940438,0,c1nc(Nc2ccc3c(c2)CCO3)c2ccoc2n1,CHEMBL3403513,IC50,226.4,nM,6.64,CHEMBL3404061,CHEMBL203,CHEMBL3400114,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1nc(N(C)c2ccc3c(c2)OCO3)c2cc(C)oc2n1,297.3139999999997,3.336240000000002,0,6,60.620000000000005,5,3,0.7227326271204235,0,c1nc(Nc2ccc3c(c2)OCO3)c2ccoc2n1,CHEMBL3403512,IC50,298.2,nM,6.53,CHEMBL3404061,CHEMBL203,CHEMBL3400114,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,368.4659999999998,3.070920000000001,2,8,89.19,6,3,0.7313327991439837,0,c1cc(-c2cncs2)nc(Nc2ccc(N3CCOCC3)cc2)n1,CHEMBL482967,Ki,1000.0,nM,6.0,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc(Nc2cccc(Br)c2)c2cc(NCCN3CCOCC3)ncc2n1,443.34899999999976,3.583420000000002,2,7,75.2,7,3,0.6033492810887932,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1,CHEMBL165228,IC50,117.0,nM,6.93,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O,506.0319999999997,2.4888400000000006,3,9,138.01,10,3,0.4448978059190101,1,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1,CHEMBL5416410,IC50,20.0,nM,7.7,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2c(Br)cc(Br)cc2c(=O)n1N,332.98299999999995,1.94372,1,4,60.91,2,2,0.7499278863248309,0,O=c1[nH]cnc2ccccc12,CHEMBL4871569,IC50,72.0,nM,7.14,CHEMBL4824512,CHEMBL203,CHEMBL4823273,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc2c(c(C)c1O)/C(=C/c1ccc3ccccc3n1)C(=O)N2,317.3479999999997,3.4449400000000026,2,4,75.11,4,3,0.6741582925888727,0,O=C1Nc2ncccc2/C1=C/c1ccc2ccccc2n1,CHEMBL5409736,IC50,18800.0,nM,4.73,CHEMBL5361793,CHEMBL203,CHEMBL5360540,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1,308.34499999999974,3.106020000000001,1,7,95.65,6,4,0.6109956689588549,0,c1ncc2c(-c3ccc4ocnc4c3)n[nH]c2n1,CHEMBL3991933,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C,280.35599999999977,3.5534200000000027,0,5,43.6,3,4,0.5352833907635061,0,c1csc(-c2cnc3cc4[nH]cnc4cc3n2)c1,CHEMBL2218927,IC50,30000.0,nM,,CHEMBL4342554,CHEMBL203,CHEMBL4342402,0.6,Contains quinazoline core; LogP in drug-like range; Aromatic ring count typical
Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,356.3889999999997,3.35152,3,5,105.38,5,5,0.4310629299105084,0,O=C(c1cnn(-c2ccc3nc[nH]c3c2)c1)c1cc2ccccc2[nH]1,CHEMBL3907479,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C,328.39699999999976,2.629640000000001,2,5,97.97,6,3,0.720249612340316,0,O=S(=O)(Nc1ccc2nccnc2c1)c1ccccc1,CHEMBL2006263,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Contains quinazoline core; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc2n1C(C)C,438.5169999999998,3.058020000000001,1,10,120.47999999999999,9,4,0.48755413078336995,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]cnc4cn3)n2)cn1,CHEMBL5281373,Ki,1.8,nM,8.74,CHEMBL5253713,CHEMBL203,CHEMBL5252534,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(-c4cnn(S(C)(=O)=O)c4)n3)cc2n1C(C)C,412.4789999999998,2.5254200000000004,1,10,120.47999999999999,9,4,0.5307678933802344,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(-c2cn[nH]c2)n1,CHEMBL5277269,Ki,3.5,nM,8.46,CHEMBL5253713,CHEMBL203,CHEMBL5252534,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(/C=C/C(C)(C)C(N)=O)n3)cc2n1C(C)C,379.4679999999996,3.3789200000000017,2,7,111.60999999999999,11,3,0.6789465818262097,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3735559,Ki,196.0,nM,6.71,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nc2cnc(Nc3ccnc(N4CCC(C)(C(N)=O)C4)n3)cc2n1C(C)C,394.48299999999966,2.5559200000000004,2,8,114.85,9,3,0.6831720972252028,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCC2)n1,CHEMBL3735638,Ki,124.0,nM,6.91,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(N4CCC(O)CC4)n3)cc2n1C(C)C,367.4569999999996,2.8153200000000007,2,8,91.99000000000001,8,3,0.7323655609683999,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735533,Ki,34.0,nM,7.47,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(N4CCC(S(C)(=O)=O)CC4)n3)cc2n1C(C)C,429.5499999999997,2.8676200000000014,1,9,105.9,9,3,0.65989575832939,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735045,Ki,64.0,nM,7.19,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(N4CC[C@H](O)C(F)(F)C4)n3)cc2n1C(C)C,403.43699999999967,3.0605200000000012,2,8,91.99000000000001,8,3,0.6916633500450359,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3734786,Ki,9.5,nM,8.02,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc2n1C(C)C,385.44699999999966,2.763320000000001,2,8,91.99000000000001,8,3,0.713348086864648,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1,CHEMBL3735958,Ki,13.0,nM,7.89,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(NCC(C)(C)C(N)=O)n3)cc2n1C(C)C,382.47199999999964,2.7776200000000006,3,8,123.63999999999999,12,3,0.5737778844373509,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3735689,Ki,22.0,nM,7.66,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(NCC(C)(C)S(C)(=O)=O)n3)cc2n1C(C)C,417.53899999999965,3.0893200000000016,2,9,114.69,13,3,0.6025927120977872,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3735782,Ki,38.0,nM,7.42,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(OCC(C)(C)C(N)=O)n3)cc2n1C(C)C,383.4559999999996,2.7445200000000005,2,8,120.84,12,3,0.643208772141365,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3735892,Ki,196.0,nM,6.71,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(OCC(C)(C)S(C)(=O)=O)n3)cc2n1C(C)C,418.5229999999997,3.0562200000000015,1,9,111.88999999999999,13,3,0.6229588783661252,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3736210,Ki,52.0,nM,7.28,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nc2cnc(Nc3ccnc(SCC(C)(C)C(N)=O)n3)cc2n1C(C)C,399.52399999999966,3.4578200000000017,2,8,111.60999999999999,12,3,0.4620519993116051,0,c1cc(Nc2cc3[nH]cnc3cn2)ncn1,CHEMBL3736480,Ki,658.0,nM,6.18,CHEMBL3737823,CHEMBL203,CHEMBL3734664,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,371.4659999999997,3.376520000000002,1,7,89.77000000000001,9,3,0.7394031145969057,0,c1ccc(Nc2nccc(-c3cnc[nH]3)n2)cc1,CHEMBL488436,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccc(O)cc1)c1ccc(Br)cc1,458.2719999999999,3.402120000000002,2,7,122.64999999999999,8,3,0.3331227429974043,0,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1,CHEMBL3088220,IC50,210.0,nM,6.68,CHEMBL3091175,CHEMBL203,CHEMBL3085672,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccccc1O)c1ccc(Br)cc1,458.2719999999999,3.402120000000002,2,7,122.64999999999999,8,3,0.3331227429974043,0,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1,CHEMBL3088222,IC50,2580.0,nM,5.59,CHEMBL3091175,CHEMBL203,CHEMBL3085672,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccncc1)c1ccc(Br)cc1,443.26099999999985,3.091520000000002,1,7,115.30999999999999,7,3,0.35725048060163767,0,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccncc1,CHEMBL3088218,IC50,8190.0,nM,5.09,CHEMBL3091175,CHEMBL203,CHEMBL3085672,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(Br)cc1,403.2139999999999,1.3673199999999996,1,7,124.19999999999999,6,2,0.5940460031745476,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1,CHEMBL1828864,IC50,2170.0,nM,5.66,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(Cl)cc1,358.76299999999986,1.2582199999999997,1,7,124.19999999999999,6,2,0.6332885371258569,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1,CHEMBL1828863,IC50,1510.0,nM,5.82,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(F)cc1,342.3079999999999,0.7439199999999999,1,7,124.19999999999999,6,2,0.6311852047696808,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1,CHEMBL1828862,IC50,390.0,nM,6.41,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccccc1,324.31799999999987,0.6048199999999997,1,7,124.19999999999999,6,2,0.6342502969640154,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1,CHEMBL1828860,IC50,2940.0,nM,5.53,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(Br)cc1,380.19799999999975,3.1188200000000013,0,6,87.25999999999999,7,2,0.3326492251583642,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173651,IC50,3240.0,nM,5.49,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(C(C)C)cc1,343.3829999999997,3.479720000000002,0,6,87.25999999999999,10,2,0.33232183660784304,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173714,IC50,6820.0,nM,5.17,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(Cl)cc1,335.74699999999973,3.0097200000000015,0,6,87.25999999999999,7,2,0.3502788452043797,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172803,IC50,3620.0,nM,5.44,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(F)cc1,319.29199999999975,2.49542,0,6,87.25999999999999,7,2,0.35318659022632576,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172802,IC50,4120.0,nM,5.38,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1cccc(F)c1,319.29199999999975,2.49542,0,6,87.25999999999999,7,2,0.35318659022632576,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172951,IC50,12420.0,nM,4.91,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1cccc([N+](=O)[O-])c1,346.2989999999998,2.26452,0,8,130.4,8,2,0.32504785703177747,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172950,IC50,14530.0,nM,4.84,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1,301.30199999999974,2.35632,0,6,87.25999999999999,7,2,0.3535728069460156,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173652,IC50,7830.0,nM,5.11,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1Br,380.19799999999975,3.118820000000002,0,6,87.25999999999999,7,2,0.3326492251583642,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172947,IC50,24320.0,nM,4.61,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1Cl,335.74699999999973,3.0097200000000015,0,6,87.25999999999999,7,2,0.3502788452043797,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172878,IC50,20810.0,nM,4.68,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1F,319.29199999999975,2.49542,0,6,87.25999999999999,7,2,0.35318659022632576,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1172877,IC50,26740.0,nM,4.57,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1[N+](=O)[O-],346.2989999999998,2.26452,0,8,130.4,8,2,0.32504785703177747,0,O=C(/C=C/c1ccccc1)OCCn1ccnc1,CHEMBL1173789,IC50,25000.0,nM,4.6,CHEMBL1177207,CHEMBL203,CHEMBL1177684,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12,408.41199999999975,3.3767200000000015,2,7,88.23,7,4,0.5264494238389517,0,c1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1,CHEMBL1965589,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O,325.7549999999998,3.539520000000002,1,5,60.05,3,4,0.5444827748426838,0,O=c1c2ccccc2[nH]c2c1cnn2-c1ccccc1,CHEMBL379835,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cc1nn(-c2ccccc2)c2nc(CC(=O)N3NC(=O)/C(=C\c4ccccc4)N=C3c3ccccc3)[nH]c(=O)c12,529.560000000001,3.3210200000000016,2,7,125.34,6,5,0.3380684464504688,1,O=C1NN(C(=O)Cc2nc3c(cnn3-c3ccccc3)c(=O)[nH]2)C(c2ccccc2)=N/C1=C/c1ccccc1,CHEMBL4790553,IC50,655.6,nM,6.18,CHEMBL4737325,CHEMBL203,CHEMBL4732181,0.85,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
Cc1oc2ncnc(Nc3cccc(Cl)c3)c2c1C(=O)NCCO,346.77399999999983,2.6503200000000002,3,6,100.28000000000002,7,3,0.6563447162380661,0,c1ccc(Nc2ncnc3occc23)cc1,CHEMBL4292715,IC50,2700.0,nM,5.57,CHEMBL4253971,CHEMBL203,CHEMBL4251615,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cl.NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,427.8659999999999,1.8120000000000005,2,7,141.63,9,2,0.3713091468914256,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL485065,IC50,5000.0,nM,5.3,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cl.NCCc1c[nH]c2ccc(OCCc3ccc(O)cc3)cc12,332.8309999999997,3.418000000000002,3,3,71.27000000000001,8,3,0.6473974944677788,0,c1ccc(CCOc2ccc3[nH]ccc3c2)cc1,CHEMBL1095957,IC50,2070.0,nM,5.68,CHEMBL1105615,CHEMBL203,CHEMBL1157833,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cl.O=C(CCN1CCOCC1)c1ccc(OCc2ccccc2)cc1,361.8689999999997,3.5924000000000023,0,4,38.77,7,2,0.7063118762360023,0,O=C(CCN1CCOCC1)c1ccc(OCc2ccccc2)cc1,CHEMBL542893,IC50,1500.0,nM,5.82,CHEMBL677209,CHEMBL203,CHEMBL1128740,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCNCC4)c23)ccc1OCc1ccccn1,480.95999999999987,3.0079000000000002,3,9,113.11000000000001,9,4,0.33238021223507563,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1,CHEMBL257430,IC50,8.0,nM,8.1,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCOCC4)c23)ccc1OCc1ccccn1,481.9439999999999,3.4349000000000016,2,9,110.31000000000002,9,4,0.3710839276117864,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCOCC5)c34)cc2)nc1,CHEMBL271705,IC50,1.0,nM,9.0,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Clc1ccc(/C=N/c2nnc(-c3cccnc3)o2)cc1,284.70599999999985,3.5356000000000014,0,5,64.17,3,3,0.6901578141767949,0,C(=N/c1nnc(-c2cccnc2)o1)\c1ccccc1,CHEMBL4569755,IC50,1128.9,nM,5.95,CHEMBL4313654,CHEMBL203,CHEMBL4311968,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Clc1nc2ccccc2c2nnc(/N=C/c3ccco3)n12,297.70499999999987,3.2745000000000015,0,6,68.58,2,4,0.42044494982774666,0,C(=N/c1nnc2c3ccccc3ncn12)\c1ccco1,CHEMBL4649213,IC50,740.0,nM,6.13,CHEMBL4619916,CHEMBL203,CHEMBL4619706,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; Aromatic ring count typical
Clc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,336.5799999999999,3.579300000000001,1,5,63.59,2,3,0.7247128546913212,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL53311,IC50,82.0,nM,7.09,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Clc1ncc2ncnc(Nc3ccccc3)c2n1,257.684,2.8168000000000006,1,5,63.59,2,3,0.7154214806893806,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL50027,IC50,2550.0,nM,5.59,CHEMBL679947,CHEMBL203,CHEMBL1130057,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1c(-c2csc(N/N=C\C3CCCN3)n2)nc2ccccc21,326.42899999999975,2.8465000000000007,2,7,67.13,5,3,0.5713672191933311,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\C1CCCN1,CHEMBL4749518,IC50,342.06,nM,6.47,CHEMBL4729710,CHEMBL203,CHEMBL4725379,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1c(-c2csc(N/N=C\c3ccncc3)n2)nc2ccccc21,334.40799999999984,3.5378000000000016,1,7,67.99000000000001,5,4,0.4577522916203799,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccncc1,CHEMBL4796408,IC50,569.41,nM,6.25,CHEMBL4729710,CHEMBL203,CHEMBL4725379,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(N)nc21,321.16699999999986,2.8845,1,5,73.8,3,3,0.7477629290151809,0,O=c1[nH]c2ncncc2cc1-c1ccccc1,CHEMBL49596,IC50,5600.0,nM,5.25,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCN3CCOCC3)nc21,448.3539999999998,3.4365000000000014,1,7,72.28,7,3,0.5830057360670298,0,O=c1[nH]c2nc(NCCCN3CCOCC3)ncc2cc1-c1ccccc1,CHEMBL48172,IC50,5000.0,nM,,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCO)nc21,365.21999999999986,2.7065000000000006,2,6,80.04,6,3,0.7432814482943565,0,O=c1[nH]c2ncncc2cc1-c1ccccc1,CHEMBL111618,IC50,5000.0,nM,,CHEMBL680019,CHEMBL203,CHEMBL1131066,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cncnc21,306.1519999999999,3.3023000000000016,0,4,47.78,2,3,0.6928139360704529,0,O=c1[nH]c2ncncc2cc1-c1ccccc1,CHEMBL50977,IC50,50000.0,nM,,CHEMBL683042,CHEMBL203,CHEMBL1131506,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cn1c(=O)c(/C=C/c2ccccn2)nc2ccccc21,263.2999999999999,2.498900000000001,0,4,47.78,3,3,0.7133787189378079,0,O=c1[nH]c2ccccc2nc1/C=C/c1ccccn1,CHEMBL5197555,IC50,100000.0,nM,,CHEMBL5114128,CHEMBL203,CHEMBL5113380,0.39999999999999997,Contains quinazoline core; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,504.231,1.0747999999999998,3,8,109.38000000000001,8,3,0.4492192273694242,1,O=c1cc(Nc2ccccc2)c2c(=O)[nH]cnc2[nH]1,CHEMBL1615025,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.6,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,388.3739999999998,2.9899000000000013,1,7,78.27000000000001,5,3,0.7404265549201985,0,O=c1[nH]c2nc(NC3CCOCC3)ncc2cc1Oc1ccccc1,CHEMBL1230122,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1c(=O)c2[nH]c(SC/C(=N/O)c3ccc(Cl)cc3)nc2n(C)c1=O,379.8289999999999,1.5842999999999998,2,8,105.26999999999998,7,3,0.3097220019525118,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1,CHEMBL4525168,IC50,400.0,nM,6.4,CHEMBL4396109,CHEMBL203,CHEMBL4393713,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1c([Se][Se]c2c(C(=O)O)c3ccccc3n2C)c(C(=O)O)c2ccccc21,506.2780000000001,1.3405999999999996,2,6,84.46000000000001,7,4,0.40070752816938127,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1,CHEMBL334915,IC50,3500.0,nM,5.46,CHEMBL677206,CHEMBL203,CHEMBL1129933,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O,363.24799999999976,2.9578800000000003,2,4,69.85,1,2,0.7562065095068584,0,O=C1NC2(CCNCC2)Cc2c1[nH]c1ccccc21,CHEMBL1945559,IC50,10000.0,nM,,CHEMBL1948120,CHEMBL203,CHEMBL1944596,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(-c2cc(C(=O)/N=c3\[nH]c4ccccc4n3CC(C)(C)O)ccn2)cn1,390.4469999999997,2.2769000000000004,2,6,101.09,8,4,0.5581074752116042,0,O=C(N=c1[nH]c2ccccc2[nH]1)c1ccnc(-c2cn[nH]c2)c1,CHEMBL4525935,IC50,43.0,nM,7.37,CHEMBL4324122,CHEMBL203,CHEMBL4321840,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(-c2cc(C(=O)/N=c3\[nH]c4ccccc4n3[C@H]3CC[C@H](O)CC3)ccn2)cn1,416.48499999999973,2.982000000000001,2,6,101.09,5,4,0.5360553644258685,0,O=C(/N=c1\[nH]c2ccccc2n1C1CCCCC1)c1ccnc(-c2cn[nH]c2)c1,CHEMBL5195167,IC50,12.0,nM,7.92,CHEMBL5143771,CHEMBL203,CHEMBL5143505,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,359.41799999999984,3.2242000000000006,0,8,73.79,4,5,0.49235603543853707,0,c1cnc2ccc(Sc3nnc4ccc(-c5cn[nH]c5)nn34)cc2c1,CHEMBL1236107,Kd,10000.0,nM,,CHEMBL1908699,CHEMBL203,CHEMBL1908390,0.5,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range
Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1,254.26800000000006,2.6832000000000003,0,4,43.6,3,3,0.7058299861910425,0,c1ccc(-c2n[nH]cc2-c2ccncn2)cc1,CHEMBL1989474,Ki,125.89,nM,6.9,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cn1cc(-c2cnc(Nc3cccc(Cn4nc(-c5cnn(C)c5)ccc4=O)c3)nc2)cn1,439.4829999999998,2.6262000000000008,1,10,108.34,8,5,0.4331953735741563,0,O=c1ccc(-c2cn[nH]c2)nn1Cc1cccc(Nc2ncc(-c3cn[nH]c3)cn2)c1,CHEMBL3759079,IC50,1000.0,nM,,CHEMBL3762060,CHEMBL203,CHEMBL3758137,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,406.3929999999998,3.150400000000001,1,7,77.11,5,4,0.5649267950270337,0,c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1,CHEMBL4550702,IC50,28000.0,nM,4.55,CHEMBL4479715,CHEMBL203,CHEMBL4477252,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,421.52999999999975,2.8580000000000005,2,8,103.13,6,4,0.5273865559203794,0,O=C(NC1CCCCC1)c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1,CHEMBL4568087,IC50,340.0,nM,6.47,CHEMBL4479715,CHEMBL203,CHEMBL4477252,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,471.54199999999986,3.1633000000000013,1,7,106.83999999999999,7,5,0.40770976276043064,0,O=c1c2cc(CS(=O)(=O)NCc3ccccn3)ccc2ccc2ncc(-c3cn[nH]c3)cc12,CHEMBL2323775,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.35000000000000003,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,376.2619999999998,1.9414999999999998,2,7,86.06,4,3,0.7140984069156686,0,c1n[nH]cc1-c1cnn2ccc(C3CCCNC3)nc12,CHEMBL2386889,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1,419.4889999999997,1.9894999999999996,4,7,126.42999999999999,6,2,0.6028646095954698,0,O=C(CC1CCCCC1)Nc1cc2c3c(c1)C(=O)NNC=C3C(c1cn[nH]c1)=N2,CHEMBL3545137,Kd,1722.0,nM,5.76,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21,275.3109999999997,3.0660000000000016,1,3,46.92,2,3,0.6937341432555721,0,O=C1Nc2cccnc2C1=Cc1c[nH]c2ccccc12,CHEMBL1516890,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cn1cc(NC(=O)/C=N/O)c(=O)n1-c1ccccc1,260.25299999999993,0.5744999999999999,2,6,88.62,5,2,0.48023250042963117,0,O=c1cc[nH]n1-c1ccccc1,CHEMBL1944920,IC50,8900.0,nM,5.05,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.5,Activity in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1cc(NC(=O)c2ccc(NS(=O)(=O)c3ccccc3)cc2)cn1,356.4069999999998,2.4732000000000003,2,5,93.09,6,3,0.7343486937318324,0,O=C(Nc1cn[nH]c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1,CHEMBL4522594,IC50,36840.0,nM,4.43,CHEMBL4387504,CHEMBL203,CHEMBL4385653,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(NC(=O)c2cccc(NS(=O)(=O)c3ccc(Cl)cc3)c2)cn1,390.85199999999986,3.1266000000000007,2,5,93.09,6,3,0.6994923134651786,0,O=C(Nc1cn[nH]c1)c1cccc(NS(=O)(=O)c2ccccc2)c1,CHEMBL4455321,IC50,30450.0,nM,4.52,CHEMBL4387504,CHEMBL203,CHEMBL4385653,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1cc(NC(=O)c2cccc(NS(=O)(=O)c3ccccc3)c2)cn1,356.4069999999998,2.4732000000000003,2,5,93.09,6,3,0.7343486937318324,0,O=C(Nc1cn[nH]c1)c1cccc(NS(=O)(=O)c2ccccc2)c1,CHEMBL4552065,IC50,34280.0,nM,4.46,CHEMBL4387504,CHEMBL203,CHEMBL4385653,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1ccc2cc(Nc3ncnc4ccc(N)cc34)ccc21,289.3419999999997,3.447300000000001,2,5,68.76,4,4,0.5545491417650095,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1,CHEMBL5174372,IC50,4020.0,nM,5.4,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1cccc1-c1nc2cc(NC(=O)CCl)ccc2[nH]1,288.7379999999997,2.745700000000001,2,3,62.71,4,3,0.7280287843914386,0,c1c[nH]c(-c2nc3ccccc3[nH]2)c1,CHEMBL1812491,IC50,12070.0,nM,4.92,CHEMBL1817212,CHEMBL203,CHEMBL1811776,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,457.687,3.5256000000000016,3,6,88.41000000000001,8,3,0.38928565430938894,0,c1ccc(Nc2ccc3[nH]cnc3c2)cc1,CHEMBL1614701,Kd,2200.0,nM,5.66,CHEMBL1908704,CHEMBL203,CHEMBL1908390,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,441.23199999999997,3.0113000000000003,3,6,88.41000000000001,8,3,0.40456998279113743,0,c1ccc(Nc2ccc3[nH]cnc3c2)cc1,CHEMBL3187723,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,264.29199999999986,2.0938,2,5,85.41,3,4,0.5509620524440141,0,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1,CHEMBL1240566,IC50,2900.0,nM,5.54,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,275.3149999999997,2.7657,1,5,69.62,3,4,0.5796305661836282,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1,CHEMBL1234815,IC50,388.0,nM,6.41,CHEMBL3223623,CHEMBL203,CHEMBL3217752,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,276.30299999999977,2.1606999999999994,1,6,82.51,3,4,0.5757551934279836,0,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1,CHEMBL1242756,IC50,34000.0,nM,4.47,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,293.2859999999998,1.7188999999999997,1,7,99.83,3,4,0.5732695109250916,0,O=c1ccoc2ccc(-c3n[nH]c4ncncc34)cc12,CHEMBL1242117,IC50,10000.0,nM,5.0,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,265.2799999999998,1.4887999999999997,2,6,98.3,3,4,0.5429791141972599,0,c1ncc2c(-c3cnc4[nH]ccc4c3)n[nH]c2n1,CHEMBL1240565,IC50,15000.0,nM,4.82,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21,317.65399999999994,2.7977000000000007,1,5,60.05,2,3,0.6485892731446846,0,O=c1c2ccccc2[nH]c2[nH]ncc12,CHEMBL207400,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2,431.4999999999998,1.7912999999999988,2,7,119.03000000000002,5,3,0.6500786554077449,0,O=C(c1ccccc1)N1CCC(Nc2ncc3c(n2)-c2[nH]ncc2CC3)CC1,CHEMBL599428,IC50,10000.0,nM,,CHEMBL1072198,CHEMBL203,CHEMBL1157561,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1nc(Nc2nc(-c3cn[nH]c3)nc3c2COC3(C)C)c2cccc(F)c21,379.39899999999983,3.4014000000000024,2,7,93.54,6,4,0.5666455411913535,0,c1ccc2c(Nc3nc(-c4cn[nH]c4)nc4c3COC4)n[nH]c2c1,CHEMBL3758830,Ki,57.0,nM,7.24,CHEMBL3762127,CHEMBL203,CHEMBL3758169,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,429.2539999999998,3.5649000000000015,2,5,86.08,8,3,0.6276675785601484,0,O=C(NCCc1ccccc1)c1cc(-c2ccn[nH]2)co1,CHEMBL3137336,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1ncc2cc(Nc3ncnn4ccc(CN5CCC(N)CC5)c34)ccc21,376.4679999999997,2.2827,2,8,89.30000000000001,6,4,0.5680002975695203,0,c1nc(Nc2ccc3[nH]ncc3c2)c2c(CN3CCCCC3)ccn2n1,CHEMBL1645464,IC50,950.0,nM,6.02,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Cn1ncc2cc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)ccc21,393.45099999999974,1.8645999999999996,2,9,90.53000000000002,7,4,0.5167232768578691,0,c1nc(Nc2ccc3[nH]ncc3c2)c2c(COCC3CNCCO3)ccn2n1,CHEMBL1645463,IC50,1000.0,nM,,CHEMBL1647391,CHEMBL203,CHEMBL1641446,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Cn1nccc1-c1nc(Nc2n[nH]c3ccccc23)c2c(n1)C(C)(C)OC2,361.40899999999976,3.2623000000000015,2,7,93.54,6,4,0.5816628715713582,0,c1ccc2c(Nc3nc(-c4ccn[nH]4)nc4c3COC4)n[nH]c2c1,CHEMBL3759096,Ki,0.5,nM,8.96,CHEMBL3762138,CHEMBL203,CHEMBL3758169,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,440.86599999999976,3.156600000000002,2,8,97.86,8,4,0.47768637639075445,0,O=c1cc(-c2ccnc(Nc3ccn[nH]3)n2)ccn1Cc1ccccc1,CHEMBL3544964,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1,319.2899999999998,3.384400000000001,1,5,55.11,3,3,0.8038861553991189,0,c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1,CHEMBL451964,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1,391.44999999999976,3.564700000000002,1,5,58.97,5,4,0.5651418348340334,0,c1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1,CHEMBL1682558,Ki,17.0,nM,7.77,CHEMBL1685430,CHEMBL203,CHEMBL1681650,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Fc1ccc(Nc2ncnc3nc(NCCN4CCOCC4)sc23)cc1Cl,408.88999999999976,3.366500000000002,2,8,75.2,6,3,0.6472190263964109,0,c1ccc(Nc2ncnc3nc(NCCN4CCOCC4)sc23)cc1,CHEMBL511623,IC50,918.0,nM,6.04,CHEMBL987693,CHEMBL203,CHEMBL1153982,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Fc1ccc(Nc2ncnn3cccc23)cc1Cl,262.67499999999984,3.2654000000000014,1,4,42.22,2,3,0.7707196651611228,0,c1ccc(Nc2ncnn3cccc23)cc1,CHEMBL185637,IC50,110.0,nM,6.96,CHEMBL832893,CHEMBL203,CHEMBL1138664,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)c1,456.5289999999998,3.4152000000000013,2,8,75.31,6,5,0.4079430056965276,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)cc1,CHEMBL231875,IC50,90.0,nM,7.05,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1,487.5389999999999,3.5150000000000015,2,9,90.53000000000002,8,5,0.3461751897121855,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCO6)c45)ccc32)cc1,CHEMBL246284,IC50,61.0,nM,7.21,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6COCCN6)c45)ccc32)c1,487.5389999999999,3.5150000000000015,2,9,90.53000000000002,8,5,0.3461751897121855,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6COCCN6)c45)ccc32)cc1,CHEMBL246492,IC50,640.0,nM,6.19,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@H]6CNCCO6)c45)ccc32)c1,487.5389999999999,3.5150000000000015,2,9,90.53000000000002,8,5,0.3461751897121855,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCO6)c45)ccc32)cc1,CHEMBL428046,IC50,83.0,nM,7.08,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Fc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)c1,440.4749999999998,3.384800000000002,1,8,77.97000000000001,7,3,0.5605646187623498,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1,CHEMBL3804886,IC50,83.88,nM,7.08,CHEMBL3807186,CHEMBL203,CHEMBL3804755,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Fc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,315.2789999999998,3.4228000000000023,1,5,56.27000000000001,2,3,0.7850522287471384,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1,CHEMBL4749501,IC50,18.9,nM,7.72,CHEMBL4730561,CHEMBL203,CHEMBL4725422,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C/C(=O)N1CCC[C@@H](n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)C1)C1CC1,453.5099999999998,2.9752800000000015,2,8,142.39999999999998,5,4,0.3571182047147119,0,O=C(C=CC1CC1)N1CCCC(n2nc(-c3cnc4[nH]ccc4c3)c3cncnc32)C1,CHEMBL5268867,IC50,2.0,nM,8.7,CHEMBL5243477,CHEMBL203,CHEMBL5241118,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C/c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,286.3309999999996,2.4536800000000003,3,4,93.35,5,1,0.45178332269251903,0,O=C(C=Cc1ccccc1)NC1CCCCC1,CHEMBL490774,IC50,2000.0,nM,5.7,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
N#C/C(=C/c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,336.3909999999997,3.143880000000001,3,4,93.35,9,2,0.3132976932308161,0,O=C(C=Cc1ccccc1)NCCCCc1ccccc1,CHEMBL490577,IC50,100.0,nM,7.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C/c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,314.7279999999998,3.2968800000000007,3,4,93.35,5,2,0.4601324601439979,0,O=C(C=Cc1ccccc1)Nc1ccccc1,CHEMBL520493,IC50,10000.0,nM,5.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1cc(O)c(O)c(CSCc2ccccc2)c1)C(N)=O,340.40399999999977,2.9234800000000014,3,5,107.34,8,2,0.42562374122939306,0,c1ccc(CSCc2ccccc2)cc1,CHEMBL432428,IC50,640.0,nM,6.19,CHEMBL677393,CHEMBL203,CHEMBL1126897,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,460.4459999999999,1.6939599999999995,4,8,169.11999999999995,8,2,0.3034452933070109,0,O=C(C=Cc1ccccc1)N1CCN(C(=O)/C=C/c2ccccc2)CC1,CHEMBL358494,IC50,4000.0,nM,5.4,CHEMBL677831,CHEMBL203,CHEMBL1129590,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(c2ccccc2)CC1,349.38999999999976,2.35358,2,5,87.79999999999998,5,2,0.504492063759766,0,O=C(C=Cc1ccccc1)N1CCN(c2ccccc2)CC1,CHEMBL291986,IC50,4300.0,nM,5.37,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCc2ccccc21,306.32099999999974,2.594080000000001,2,4,84.55999999999999,4,2,0.5072116503648679,0,O=C(C=Cc1ccccc1)N1CCc2ccccc21,CHEMBL56542,IC50,2100.0,nM,5.68,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,286.3309999999996,2.4536800000000003,3,4,93.35,5,1,0.45178332269251903,0,O=C(C=Cc1ccccc1)NC1CCCCC1,CHEMBL417941,IC50,1600.0,nM,5.8,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,336.3909999999997,3.143880000000001,3,4,93.35,9,2,0.3132976932308161,0,O=C(C=Cc1ccccc1)NCCCCc1ccccc1,CHEMBL440298,IC50,1100.0,nM,5.96,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1,322.3639999999997,2.753780000000001,3,4,93.35,8,2,0.3298283949017812,0,O=C(C=Cc1ccccc1)NCCCc1ccccc1,CHEMBL53898,IC50,700.0,nM,6.16,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCc1ccccc1,308.3369999999997,2.3636799999999996,3,4,93.35,7,2,0.44889524973579664,0,O=C(C=Cc1ccccc1)NCCc1ccccc1,CHEMBL293749,IC50,616.6,nM,6.21,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccc(O)cc1,310.30899999999974,2.0267799999999996,4,5,113.58,7,2,0.3918286419295438,0,O=C(C=Cc1ccccc1)NCc1ccccc1,CHEMBL143805,IC50,3019.95,nM,5.52,CHEMBL676067,CHEMBL203,CHEMBL1136802,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,294.3099999999997,2.32118,3,4,93.35,6,2,0.4580872044365475,0,O=C(C=Cc1ccccc1)NCc1ccccc1,CHEMBL56543,IC50,100.0,nM,7.0,CHEMBL921076,CHEMBL203,CHEMBL1145498,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,280.28299999999973,2.6434800000000003,3,4,93.35,5,2,0.45747459827558473,0,O=C(C=Cc1ccccc1)Nc1ccccc1,CHEMBL56731,IC50,700.0,nM,6.16,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,314.7279999999998,3.2968800000000007,3,4,93.35,5,2,0.4601324601439979,0,O=C(C=Cc1ccccc1)Nc1ccccc1,CHEMBL56219,IC50,1100.0,nM,5.96,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(F)cc1,283.25799999999975,3.0267800000000014,2,4,81.32,5,2,0.39243949883655077,0,O=C(C=Cc1ccccc1)c1ccccc1,CHEMBL55204,IC50,560.0,nM,6.25,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1,265.26799999999974,2.8876800000000014,2,4,81.32,5,2,0.38673859557473217,0,O=C(C=Cc1ccccc1)c1ccccc1,CHEMBL56132,IC50,1000.0,nM,6.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1Cl,299.71299999999974,3.541080000000001,2,4,81.32,5,2,0.39294854780952837,0,O=C(C=Cc1ccccc1)c1ccccc1,CHEMBL59145,IC50,1540.0,nM,5.81,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1cccs1,271.29699999999974,2.949180000000001,2,5,81.32,5,2,0.3890013883060667,0,O=C(C=Cc1ccccc1)c1cccs1,CHEMBL55994,IC50,3100.0,nM,5.51,CHEMBL763200,CHEMBL203,CHEMBL1125266,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#C/C(=C\c1ccc(O)c(O)c1)S(=O)(=O)/C(C#N)=C/c1ccc(O)c(O)c1,384.3689999999999,2.3529600000000013,4,8,162.63999999999996,8,2,0.460853198527708,0,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1,CHEMBL356324,IC50,380.0,nM,6.42,CHEMBL677831,CHEMBL203,CHEMBL1129590,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#CC(C#N)=C(N)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,331.12899999999985,2.027240000000001,3,6,137.85,5,1,0.43047358018284576,0,c1ccccc1,CHEMBL77803,IC50,500.0,nM,6.3,CHEMBL674643,CHEMBL203,CHEMBL1124610,0.85,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
N#CC(C#N)=C(N)/C(C#N)=C/c1cc(O)c(O)c(O)c1,268.2319999999998,0.9703399999999998,4,7,158.07999999999998,6,1,0.35297402256260646,0,c1ccccc1,CHEMBL78257,IC50,800.0,nM,6.1,CHEMBL674643,CHEMBL203,CHEMBL1124610,0.5,Activity in Type 1 range; Activity in typical Type 1 range
N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)c(O)c1,252.23300000000003,1.2647399999999998,3,6,137.85,5,1,0.4112072679178035,0,c1ccccc1,CHEMBL309334,IC50,2500.0,nM,5.6,CHEMBL674643,CHEMBL203,CHEMBL1124610,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
N#CC1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,434.46299999999985,2.9772800000000013,1,9,126.08999999999999,3,4,0.5102183464598228,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1,CHEMBL3327179,IC50,4800.0,nM,5.32,CHEMBL3375023,CHEMBL203,CHEMBL3352252,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1,380.38499999999993,0.008880000000000055,2,8,141.18,4,3,0.6554856757798307,0,O=c1c(=Cc2ccco2)sc2n1C=CC(c1ccco1)C=2,CHEMBL1989805,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
N#CCC(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,377.3819999999999,-0.6064199999999997,2,7,140.95999999999998,4,1,0.6709478108071814,0,N=C1C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,CHEMBL4282506,IC50,23.0,nM,7.64,CHEMBL4274200,CHEMBL203,CHEMBL4270595,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; H-bond features typical of Type 1
N#CCCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,326.3349999999997,2.6140799999999995,2,7,113.64,7,3,0.6966557723535115,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242470,IC50,11000.0,nM,4.96,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,312.30799999999977,2.22398,2,7,113.64,6,3,0.7139923488816922,0,c1ccc(-c2n[nH]c3ncncc23)cc1,CHEMBL1242469,IC50,18000.0,nM,4.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,414.46899999999977,2.9771800000000015,2,7,103.17,6,3,0.597823059764905,0,c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,CHEMBL1078178,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,306.37299999999965,3.466380000000001,1,5,83.17999999999999,4,3,0.7996787783250496,0,c1nc(-c2cnn(CC3CCCC3)c2)c2cc[nH]c2n1,CHEMBL1789941,Kd,10000.0,nM,,CHEMBL1908693,CHEMBL203,CHEMBL1908390,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1,437.8909999999998,3.1898800000000005,2,8,136.08,6,3,0.5845104608227354,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)nc1,CHEMBL4469663,IC50,15400.0,nM,4.81,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,438.4379999999998,3.4196800000000014,2,7,123.18999999999998,6,3,0.5885997566133526,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)cc1,CHEMBL4560385,IC50,16800.0,nM,4.78,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1,471.44299999999976,3.5552800000000007,2,8,136.08,6,3,0.543154679646104,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)nc1,CHEMBL4456974,IC50,20000.0,nM,,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1,402.45799999999974,3.1414799999999996,2,7,123.18999999999998,6,3,0.6320751041018124,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)cc1,CHEMBL4436118,IC50,1710.0,nM,5.77,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1,455.88099999999986,3.3289800000000014,2,8,136.08,6,3,0.5627459394318793,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)nc1,CHEMBL4462332,IC50,20000.0,nM,,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#CN[C@H]1CCc2ccc(-c3ncnc4[nH]ccc34)cc21,275.3149999999997,2.68288,2,4,77.39,2,3,0.5565417580602893,0,c1nc(-c2ccc3c(c2)CCC3)c2cc[nH]c2n1,CHEMBL4281393,IC50,10000.0,nM,,CHEMBL4265587,CHEMBL203,CHEMBL4261650,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#CN[C@H]1C[C@@H](NS(=O)(=O)c2cccc(F)c2)c2ccc(-c3ncnc4[nH]ccc34)cc21,448.48299999999995,3.299080000000001,3,6,123.56,5,4,0.3179451574624481,0,O=S(=O)(NC1CCc2cc(-c3ncnc4[nH]ccc34)ccc21)c1ccccc1,CHEMBL4277610,IC50,10000.0,nM,,CHEMBL4265587,CHEMBL203,CHEMBL4261650,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1c(NC(=O)CNc2n[nH]c3ncccc23)sc2c1CCCC2,352.42299999999983,2.8204800000000008,3,6,106.49,4,3,0.6692456645882572,0,O=C(CNc1n[nH]c2ncccc12)Nc1cc2c(s1)CCCC2,CHEMBL5221067,IC50,0.47,nM,9.33,CHEMBL5216306,CHEMBL203,CHEMBL5214926,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12,287.6619999999999,1.98445,3,5,113.86999999999999,1,3,0.5484316706552603,0,N=c1oc2ccccc2c2cc[nH]c(=O)c12,CHEMBL1973711,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#Cc1cc2c(N)ncnc2nc1Nc1ccc(S(N)(=O)=O)cc1,341.3559999999999,0.8696799999999998,3,8,160.67,5,3,0.6319039493642986,0,c1ccc(Nc2ccc3cncnc3n2)cc1,CHEMBL1910270,IC50,100000.0,nM,,CHEMBL1912180,CHEMBL203,CHEMBL1909587,0.3,Contains aniline substituent; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1,415.4969999999997,3.405780000000002,1,6,87.06,7,3,0.4656489641391838,0,c1cncc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)c1,CHEMBL398951,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1,387.44299999999976,2.6255800000000002,1,6,87.06,5,3,0.5664598162595956,0,c1cncc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)c1,CHEMBL249282,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1,379.3989999999998,1.9573800000000001,3,6,123.72000000000001,4,3,0.636548901628092,0,c1ccc(N2CCC(Nc3ccnc4[nH]ccc34)CC2)nc1,CHEMBL3593777,IC50,1000.0,nM,,CHEMBL3594868,CHEMBL203,CHEMBL3593212,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc(O)c(-c2nc(NCc3cnccn3)c3ccccc3n2)c1,354.3729999999998,3.276180000000001,2,7,107.61,5,4,0.5788210907771824,0,c1ccc(-c2nc(NCc3cnccn3)c3ccccc3n2)cc1,CHEMBL4218431,IC50,17.0,nM,7.77,CHEMBL4186285,CHEMBL203,CHEMBL4184160,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc(O)c(-c2nc(NCc3ncccn3)c3ccccc3n2)c1,354.3729999999998,3.276180000000001,2,7,107.61,5,4,0.5788210907771824,0,c1ccc(-c2nc(NCc3ncccn3)c3ccccc3n2)cc1,CHEMBL5179288,IC50,630.0,nM,6.2,CHEMBL5143783,CHEMBL203,CHEMBL5143505,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1,334.3789999999997,2.639380000000001,2,5,85.17,4,3,0.768976962384502,0,c1ccc2c(-c3ccc(CN4CCOCC4)cn3)c[nH]c2c1,CHEMBL1969664,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,367.2489999999999,3.242980000000002,0,3,70.28999999999999,1,2,0.7769977143246297,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL2205026,IC50,40000.0,nM,,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#Cc1cccc(NC(=O)Nc2ncnc3nn4ccccc4c23)c1,329.3229999999999,2.7931800000000004,2,6,108.0,2,4,0.587675824951867,0,O=C(Nc1ccccc1)Nc1ncnc2nn3ccccc3c12,CHEMBL178953,IC50,10000.0,nM,5.0,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,304.3089999999998,3.016280000000001,1,6,80.06,2,3,0.7835968269091051,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1,CHEMBL4778159,IC50,24.0,nM,7.62,CHEMBL4730561,CHEMBL203,CHEMBL4725422,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,322.2989999999998,3.155380000000001,1,6,80.06,2,3,0.7804578173177072,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1,CHEMBL4743464,IC50,22.0,nM,7.66,CHEMBL4730561,CHEMBL203,CHEMBL4725422,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1,333.30699999999985,2.84368,3,6,128.0,3,3,0.675855970328892,0,O=C(Nc1ccc2ccccc2c1)Nc1cnccn1,CHEMBL560813,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1cnc2cnc(NCc3cccnc3)cc2c1NC1CC1,316.3679999999997,3.082880000000001,2,6,86.52000000000001,5,3,0.7520040452347413,0,c1cncc(CNc2cc3c(NC4CC4)ccnc3cn2)c1,CHEMBL446633,IC50,40000.0,nM,,CHEMBL898017,CHEMBL203,CHEMBL1149691,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2,391.7709999999998,1.13868,4,8,149.62,2,2,0.5217461017747499,0,O=C1Nc2cncc(n2)OCCCCOc2ccccc2N1,CHEMBL1980802,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2,431.8799999999997,3.512080000000001,3,7,129.39000000000001,4,2,0.6773936171434748,0,O=C1Nc2cncc(n2)OCCCCCOc2ccccc2N1,CHEMBL223367,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2,463.87799999999976,2.31918,4,9,158.85,6,2,0.5331141681915937,0,O=C1Nc2cncc(n2)OCCCCCOc2ccccc2N1,CHEMBL223257,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2,447.87899999999973,3.3483800000000006,3,8,138.62,5,2,0.6061623735512308,0,O=C1Nc2cncc(n2)OCCCCCOc2ccccc2N1,CHEMBL373598,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2,433.8519999999998,2.9582800000000002,3,8,138.62,4,2,0.67091677380022,0,O=C1Nc2cncc(n2)OCCCCCOc2ccccc2N1,CHEMBL413779,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N=c1oc2ccccc2cc1C(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,481.48999999999995,1.0193699999999994,3,8,154.16,4,3,0.4728829794752961,0,N=c1oc2ccccc2cc1C(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,CHEMBL4289728,IC50,205.0,nM,6.69,CHEMBL4274200,CHEMBL203,CHEMBL4270595,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
N=c1scc(-c2ccc(Cl)cc2)n1CC(=O)N1CCOCC1,337.83199999999977,2.2082699999999997,1,5,58.32000000000001,3,2,0.9331484255473841,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCOCC1,CHEMBL2437302,Ki,6640.0,nM,5.18,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N=c1scc(-c2ccccc2)n1CC(=O)N1CCN(c2ccccc2)CC1,378.50099999999975,3.0448700000000013,1,5,52.330000000000005,4,3,0.7586530518387643,0,N=c1scc(-c2ccccc2)n1CC(=O)N1CCN(c2ccccc2)CC1,CHEMBL2437293,Ki,4680.0,nM,5.33,CHEMBL2439370,CHEMBL203,CHEMBL2434944,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)C1=C(N)C(=O)C=C(Nc2ccccc2O)C1=O,273.24799999999976,-0.4620999999999999,4,6,135.51000000000002,5,1,0.33401519399643853,0,O=C1C=CC(=O)C(Nc2ccccc2)=C1,CHEMBL2332119,IC50,2600.0,nM,5.58,CHEMBL2343159,CHEMBL203,CHEMBL2331471,0.5,Activity in Type 1 range; Contains aniline substituent
NC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,352.3979999999997,1.1181999999999999,3,7,123.29,6,3,0.6463495960257767,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL408683,IC50,400.0,nM,6.4,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,366.42499999999967,1.5083,3,7,123.29,6,3,0.6429647259188606,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL263528,IC50,170.0,nM,6.77,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)COCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,445.45799999999986,3.0119000000000007,2,8,112.36000000000001,8,5,0.3797356902702404,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL246694,IC50,140.0,nM,6.85,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
NC(=O)Cc1cccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)c1,387.4429999999997,2.7982000000000005,4,5,116.92000000000002,8,4,0.38899058509305734,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4759127,IC50,0.7,nM,9.15,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,362.4299999999997,2.5266,4,4,96.25,4,2,0.6728586895980048,0,O=C(NC1CCCNC1)c1ccc(-c2ccccc2)s1,CHEMBL2041933,Kd,808.0,nM,6.09,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)Nc1ccc2ncnc(Nc3ccc(Cl)cc3)c2c1,313.7479999999998,3.517400000000001,3,4,92.93,3,3,0.6894103456389604,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL2347231,IC50,61.0,nM,7.21,CHEMBL2351374,CHEMBL203,CHEMBL2346534,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N,497.5019999999998,3.0137,3,7,136.70000000000002,9,3,0.4294237147353248,0,c1ccc(Oc2ccc(-c3ccn(C4CCCNC4)n3)cc2)cc1,CHEMBL4440096,IC50,2910.0,nM,5.54,CHEMBL4385485,CHEMBL203,CHEMBL4382291,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12,263.2999999999999,2.5829000000000004,2,3,82.0,3,3,0.697021280133405,0,c1ccc(-c2ccc3ncccc3c2)cc1,CHEMBL1970314,Ki,316.23,nM,6.5,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl,348.1929999999998,3.1266000000000007,3,4,110.68,4,3,0.6751353896145608,0,c1ccc(-c2ccc(-c3ccncn3)[nH]2)cc1,CHEMBL1965660,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F,331.73799999999983,2.6123000000000003,3,4,110.68,4,3,0.6845750834082229,0,c1ccc(-c2ccc(-c3ccncn3)[nH]2)cc1,CHEMBL1981079,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2,395.42499999999967,2.9227000000000016,1,3,66.64,3,1,0.8558843776430741,0,O=C1c2ccccc2CN1C1CCN(C2CCCCC2)CC1,CHEMBL3606021,IC50,10000.0,nM,,CHEMBL3607957,CHEMBL203,CHEMBL3603755,0.5,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range
NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1,272.3039999999998,3.2013000000000007,1,3,55.980000000000004,2,3,0.7784581528861728,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL1974310,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1,290.2939999999998,3.3404000000000007,1,3,55.980000000000004,2,3,0.7866225436403639,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL1975787,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1,272.3039999999998,3.2013000000000007,1,3,55.980000000000004,2,3,0.7784581528861728,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL1971017,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1cc2c(-c3ccccc3)cncc2s1,254.31400000000008,3.0622000000000016,1,3,55.980000000000004,2,3,0.7637242730102001,0,c1ccc(-c2cncc3sccc23)cc1,CHEMBL1999556,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1,271.70699999999977,2.9822000000000006,2,2,71.77000000000001,2,3,0.7520014710396823,0,c1ccc(-c2c[nH]c3ncccc23)cc1,CHEMBL1982711,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,385.2639999999999,2.4702,1,3,89.59,2,2,0.8613501065944181,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL1917093,IC50,40000.0,nM,,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12,505.55599999999987,2.602000000000001,3,6,147.47999999999996,6,4,0.36694196664419915,1,O=C(Nc1ccc(-c2nc3ccccc3[nH]2)cc1)c1cccc(S(=O)(=O)N2CCOCC2)c1,CHEMBL1986597,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2,289.68199999999985,1.5381999999999998,3,5,110.0,1,2,0.7373349617575983,0,O=C1Nc2ccccc2Nc2nnccc21,CHEMBL1968070,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC(=O)c1sc2c(Br)ccc(Cl)c2c1N,305.5839999999999,2.9983000000000004,2,3,69.11,2,2,0.850073293022941,0,c1ccc2sccc2c1,CHEMBL1998611,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=S)N/N=C(/C=C/c1ccc(Cl)cc1)c1ccccc1,315.8289999999998,3.590700000000002,2,2,50.41,4,2,0.5148091219328398,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830265,IC50,20480.0,nM,4.69,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=S)N/N=C(/C=C/c1ccc([N+](=O)[O-])cc1)c1ccccc1,326.3809999999998,2.8455000000000013,2,4,93.55,5,2,0.3812685233737017,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830269,IC50,1570.0,nM,5.8,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=S)N/N=C(/C=C/c1cccc(F)c1)c1ccccc1,299.37399999999974,3.0764000000000022,2,2,50.41,4,2,0.5180659721364937,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830261,IC50,2080.0,nM,5.68,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=S)N/N=C(/C=C/c1cccc([N+](=O)[O-])c1)c1ccccc1,326.3809999999998,2.8455000000000013,2,4,93.55,5,2,0.3812685233737017,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830263,IC50,3740.0,nM,5.43,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC(=S)N/N=C(/C=C/c1ccccc1)c1ccc(Cl)cc1,315.8289999999997,3.590700000000002,2,2,50.41,4,2,0.5148091219328398,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830276,IC50,590.0,nM,6.23,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=S)N/N=C(/C=C/c1ccccc1)c1ccccc1,281.3839999999997,2.9373000000000014,2,2,50.41,4,2,0.5144890473599206,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830272,IC50,2380.0,nM,5.62,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(=S)N/N=C(/C=C/c1ccccc1Cl)c1ccccc1,315.8289999999998,3.590700000000002,2,2,50.41,4,2,0.5148091219328398,0,N=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL1830258,IC50,23270.0,nM,4.63,CHEMBL1831627,CHEMBL203,CHEMBL1828579,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1,361.44499999999965,3.5699000000000023,1,5,70.26,10,3,0.6308399541223088,0,C(=Cc1cncc(OCCCOCc2ccccc2)c1)c1ccncc1,CHEMBL1993781,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1,331.4189999999997,3.5958000000000023,1,4,61.03,8,3,0.7184756354622281,0,C(=Cc1cncc(OCCCc2ccccc2)c1)c1ccncc1,CHEMBL1991846,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12,416.3589999999998,1.8944999999999996,2,7,101.44999999999999,4,3,0.6764188399093582,0,O=c1ccn(-c2ccccc2)c2nc(N3CC4CC4C3)ccc12,CHEMBL1624529,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1,308.3889999999996,2.7017000000000007,3,5,92.50999999999999,4,3,0.6915740910440961,0,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,CHEMBL1966628,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1,308.3889999999996,2.7017000000000007,3,5,92.50999999999999,4,3,0.6915740910440961,0,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,CHEMBL1995813,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCN(Cc2ccn3ncnc(Nc4ccc(F)c(Cl)c4)c23)CC1,374.8509999999998,3.1885000000000003,2,6,71.48,5,3,0.733447314696991,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645476,IC50,10.0,nM,8.0,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cccc[n+]5[O-])c(Cl)c4)c23)CC1,479.97199999999975,3.261800000000001,2,8,107.65,8,4,0.30915624086370924,0,c1ccc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)[nH+]c1,CHEMBL248322,IC50,70.0,nM,7.16,CHEMBL923201,CHEMBL203,CHEMBL1140690,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cnccn5)c(Cl)c4)c23)CC1,464.96099999999973,3.418400000000001,2,9,106.49000000000001,8,4,0.42819360346157703,0,c1cnc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)cn1,CHEMBL248321,IC50,32.0,nM,7.5,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccn5)c4)c23)CC1,453.55399999999975,3.189000000000001,2,9,102.19000000000001,7,5,0.40703148407633766,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)nc1,CHEMBL247914,IC50,47.0,nM,7.33,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccnc5)c4)c23)CC1,453.55399999999975,3.189000000000001,2,9,102.19000000000001,7,5,0.40703148407633766,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)c1,CHEMBL247915,IC50,190.0,nM,6.72,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccncc5)c4)c23)CC1,453.55399999999975,3.189000000000001,2,9,102.19000000000001,7,5,0.40703148407633766,0,c1cc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)ccn1,CHEMBL247916,IC50,530.0,nM,6.28,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
NC1CCN(Cc2ccn3ncnc(Nc4cccc(Br)c4)c23)CC1,401.31199999999967,3.1585,2,6,71.48,5,3,0.7029759603174021,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645474,IC50,6.0,nM,8.22,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCN(Cc2ccn3ncnc(Nc4cccc(Cl)c4)c23)CC1,356.8609999999997,3.0494000000000003,2,6,71.48,5,3,0.7513856846409553,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645473,IC50,9.0,nM,8.05,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCN(Cc2ccn3ncnc(Nc4cccc(F)c4)c23)CC1,340.40599999999966,2.5351,2,6,71.48,5,3,0.7636058343104557,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645472,IC50,32.0,nM,7.5,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NC1CCN(Cc2ccn3ncnc(Nc4ccccc4)c23)CC1,322.41599999999966,2.395999999999999,2,6,71.48,5,3,0.7715933639145311,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1,CHEMBL1645467,IC50,40.0,nM,7.4,CHEMBL1647391,CHEMBL203,CHEMBL1641446,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21,363.1589999999998,-0.7014,4,7,123.21,8,2,0.5329622740154737,0,c1ncc2cc[nH]c2n1,CHEMBL1975534,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
NCCCNC(=O)c1cccc(Nc2nccc(-c3cccnc3)n2)c1,348.4099999999997,2.3607999999999993,3,6,105.82,8,3,0.5660925632971996,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL59099,IC50,45000.0,nM,4.35,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,391.40499999999986,1.3901999999999994,2,7,141.63,9,2,0.39324735394720944,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL309075,IC50,5400.0,nM,5.27,CHEMBL674640,CHEMBL203,CHEMBL1125600,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1,463.5189999999999,2.0793999999999997,4,6,147.04,8,4,0.32991149396628044,0,O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1ccccc1,CHEMBL2000481,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,431.47499999999974,3.4853000000000005,2,8,95.28999999999999,9,5,0.36537151154245545,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL394333,IC50,90.0,nM,7.05,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
NCCn1c(-c2ccccc2)nc2cc(Cl)ccc2c1=O,299.76099999999974,2.675600000000001,1,4,60.910000000000004,4,3,0.8086121833327193,0,O=c1[nH]c(-c2ccccc2)nc2ccccc12,CHEMBL4074248,IC50,287.0,nM,6.54,CHEMBL4025907,CHEMBL203,CHEMBL4024718,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,313.7879999999997,2.9247000000000005,3,3,74.93,6,3,0.6929884458993375,0,c1ccc(Cc2ccc(-c3cn[nH]c3)cc2)cc1,CHEMBL3544960,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NCc1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1,333.4349999999996,3.4913000000000016,2,4,60.17,5,3,0.7671468392881866,0,c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1,CHEMBL484967,IC50,10000.0,nM,,CHEMBL985021,CHEMBL203,CHEMBL1138455,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NNC(=O)c1csc2nc(CN3CCOCC3)c(-c3ccc(Br)cc3)n12,436.33499999999975,2.261,2,7,84.88999999999999,5,3,0.37251815626662527,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1,CHEMBL5204650,IC50,419.0,nM,6.38,CHEMBL5110647,CHEMBL203,CHEMBL5108025,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NNc1c(Br)cccc1Nc1ncnc2ccncc12,331.1769999999999,2.8165000000000004,3,6,88.75,4,3,0.5051540079268191,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL272634,IC50,7.244,nM,8.14,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,331.17699999999985,2.8165000000000004,3,6,88.75,4,3,0.5051540079268191,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL340508,IC50,7.079,nM,8.15,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1,383.47299999999973,2.6800000000000015,2,5,94.31000000000002,5,3,0.7223155548287568,0,c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1,CHEMBL519693,IC50,10000.0,nM,,CHEMBL985021,CHEMBL203,CHEMBL1138455,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1ccc(NC(=O)c2ccccc2NC(=O)c2ccco2)cc1,385.4009999999999,2.4316000000000004,3,5,131.5,6,3,0.6205607299785049,0,O=C(Nc1ccccc1C(=O)Nc1ccccc1)c1ccco1,CHEMBL1782692,IC50,31.2,nM,7.51,CHEMBL5138527,CHEMBL203,CHEMBL5137005,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc4c(cc23)OCO4)cc1,378.79699999999997,2.4029,2,7,116.43,4,3,0.671833023955039,0,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1,CHEMBL3098318,IC50,34600.0,nM,4.46,CHEMBL3101602,CHEMBL203,CHEMBL3098085,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1ccc(Nc2nc(N3CCOCC3)nc3[nH]cnc23)cc1,375.4139999999998,0.5805000000000002,3,8,139.12,5,3,0.6016540235287179,0,c1ccc(Nc2nc(N3CCOCC3)nc3[nH]cnc23)cc1,CHEMBL1172957,IC50,10000.0,nM,5.0,CHEMBL1177355,CHEMBL203,CHEMBL1177660,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4c(F)cccc4F)c3s2)cc1,434.453,3.499100000000001,3,8,122.89,6,4,0.4392475863240641,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1,CHEMBL513716,IC50,187.0,nM,6.73,CHEMBL987693,CHEMBL203,CHEMBL1153982,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3s2)cc1,483.57899999999995,3.057500000000001,3,10,135.35999999999999,7,4,0.3779416297741782,0,c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3s2)cc1,CHEMBL511449,IC50,17900.0,nM,4.75,CHEMBL987693,CHEMBL203,CHEMBL1153982,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1,398.47299999999996,3.220900000000001,3,8,122.89,6,4,0.4714886706179822,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1,CHEMBL511839,IC50,82.0,nM,7.09,CHEMBL987693,CHEMBL203,CHEMBL1153982,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
NS(=O)(=O)c1ccc(Nc2ncnc3ccc(NC(=S)NCc4ccccc4)cc23)cc1,464.5759999999999,3.5074000000000023,4,6,122.03,7,4,0.3199173324116023,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL4096625,IC50,150.0,nM,,CHEMBL4011053,CHEMBL203,CHEMBL4007489,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NS(=O)(=O)c1ccc(Nc2nncc3ccccc23)cc1,300.3429999999998,2.0208,2,5,97.97,4,3,0.7708144734742159,0,c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3926223,IC50,140.0,nM,6.85,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]c3c(c1CCC(=O)O)CCCC3)C(=O)N2,415.4709999999998,2.0508,4,5,142.35000000000002,6,2,0.5529148045988513,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL86531,IC50,29100.0,nM,4.54,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
NS(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2,343.40799999999973,2.0336000000000003,3,3,105.05000000000001,3,2,0.7265817451538872,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL88483,IC50,100000.0,nM,,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
NS(=O)(=O)c1cccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1,426.5019999999998,2.4478,3,8,122.47,7,3,0.5493289571113837,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,CHEMBL3884240,IC50,100000.0,nM,,CHEMBL3875840,CHEMBL203,CHEMBL3875172,0.39999999999999997,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1,365.41799999999984,2.8115000000000006,2,6,102.89999999999999,5,4,0.5787683939396956,0,c1ccc(Nc2ncc3ccn(-c4ccccc4)c3n2)cc1,CHEMBL1988163,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1,379.4449999999998,2.8706000000000014,2,6,102.89999999999999,6,4,0.5549446381950036,0,c1ccc(Cn2ccc3cnc(Nc4ccccc4)nc32)cc1,CHEMBL1993424,Ki,1258.93,nM,5.9,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
N[C@@H]1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,456.52899999999977,3.543000000000001,2,8,89.30000000000001,7,5,0.4063165592166804,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)cc1,CHEMBL393848,IC50,60.0,nM,7.22,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
N[C@H]1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,456.52899999999977,3.543000000000001,2,8,89.30000000000001,7,5,0.4063165592166804,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)cc1,CHEMBL246687,IC50,50.0,nM,7.3,CHEMBL923201,CHEMBL203,CHEMBL1140690,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
Nc1[nH]cnc2nnc(Nc3cccc(Cl)c3)c1-2,260.68799999999993,2.2837000000000005,3,5,92.51,3,1,0.6573306828711838,0,c1ccc(Nc2nnc3nc[nH]cc2-3)cc1,CHEMBL121190,IC50,160.0,nM,6.8,CHEMBL677832,CHEMBL203,CHEMBL1130217,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
Nc1c(Br)cccc1Nc1ncnc2ccncc12,316.16199999999986,3.1131,2,5,76.72,3,3,0.7104596950005694,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL258598,IC50,10.0,nM,8.0,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1c(Cl)cccc1Nc1ncnc2ccncc12,271.7109999999998,3.0040000000000004,2,5,76.72,3,3,0.7008019622152768,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270975,IC50,120.23,nM,6.92,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1c(F)cccc1Nc1ncnc2ccncc12,255.25600000000009,2.4897,2,5,76.72,3,3,0.6878213825487984,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270924,IC50,851.14,nM,6.07,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1c(Nc2ncnc3ccncc23)cccc1[N+](=O)[O-],282.2629999999998,2.2588,2,7,119.86000000000001,4,3,0.42909501618454077,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL441332,IC50,40.74,nM,7.39,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1c(O)cccc1Nc1ncnc2ccncc12,253.2650000000001,2.0561999999999996,3,6,96.95,4,3,0.47747509136976024,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL402452,IC50,70.79,nM,7.15,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc(Br)ccc1Nc1ncnc2ccncc12,316.16199999999986,3.1131,2,5,76.72,3,3,0.7104596950005694,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL271617,IC50,25.7,nM,7.59,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,410.39999999999975,1.8128000000000002,1,8,89.63,4,2,0.8197353914743168,0,c1cncc(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)c1,CHEMBL2017974,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc(C(F)(F)F)ccc1Nc1ncnc2ccncc12,305.26299999999986,3.3694000000000006,2,5,76.72,3,3,0.7098447598415194,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL408351,IC50,4786.3,nM,5.32,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,316.1619999999998,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL51853,IC50,0.13,nM,9.89,CHEMBL680021,CHEMBL203,CHEMBL1129564,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3ccc(Br)cc3)c2cn1,330.18899999999985,2.981600000000001,2,5,76.72,4,3,0.7719918611556922,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL125949,IC50,2460.0,nM,5.61,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3ccc(C(F)(F)F)cc3)c2cn1,319.2899999999998,3.2379000000000016,2,5,76.72,4,3,0.7748286176739182,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL333041,IC50,8000.0,nM,5.1,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3ccc([N+](=O)[O-])cc3)c2cn1,296.2899999999998,2.1273,2,7,119.86,5,3,0.5584942555230018,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL126097,IC50,10000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(NCc3cccc(Br)c3)c2cn1,330.18899999999985,2.981600000000001,2,5,76.72,4,3,0.7719918611556922,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL121708,IC50,1000.0,nM,6.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3cccc(C(F)(F)F)c3)c2cn1,319.2899999999998,3.2379000000000016,2,5,76.72,4,3,0.7748286176739182,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL124533,IC50,1950.0,nM,5.71,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3cccc([N+](=O)[O-])c3)c2cn1,296.2899999999998,2.1273,2,7,119.86,5,3,0.5584942555230018,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL123676,IC50,10100.0,nM,5.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(NCc3ccccc3)c2cn1,251.2930000000001,2.2191,2,5,76.72,4,3,0.7460080920752574,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL300083,IC50,578.0,nM,6.24,CHEMBL680021,CHEMBL203,CHEMBL1129564,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(NCc3ccccc3Br)c2cn1,330.1889999999998,2.981600000000001,2,5,76.72,4,3,0.7719918611556922,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL331307,IC50,1670.0,nM,5.78,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3ccccc3C(F)(F)F)c2cn1,319.2899999999998,3.2379000000000016,2,5,76.72,4,3,0.7748286176739182,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL126062,IC50,10000.0,nM,5.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(NCc3ccccc3N)c2cn1,266.3079999999998,1.8013,3,6,102.74,5,3,0.6245559693103766,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL332846,IC50,230.0,nM,6.64,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(NCc3ccccc3[N+](=O)[O-])c2cn1,296.2899999999998,2.1273,2,7,119.86,5,3,0.5584942555230018,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL125035,IC50,4250.0,nM,5.37,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3ccc(Br)cc3)c2cn1,316.16199999999986,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL338625,IC50,90.0,nM,7.05,CHEMBL674641,CHEMBL203,CHEMBL1128730,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3ccc(C(F)(F)F)cc3)c2cn1,305.2629999999998,3.3694000000000006,2,5,76.72,3,3,0.7588186415391355,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL339684,IC50,4700.0,nM,5.33,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3ccc([N+](=O)[O-])cc3)c2cn1,282.2629999999998,2.2588,2,7,119.86,4,3,0.5579357856635233,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL333115,IC50,65000.0,nM,4.19,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,330.18899999999985,3.300300000000001,3,5,89.85,4,3,0.6273946826021185,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL328216,IC50,0.12,nM,9.92,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,316.16199999999986,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL52076,IC50,10.0,nM,8.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3cccc(C(F)(F)F)c3)c2cn1,305.2629999999998,3.3694000000000006,2,5,76.72,3,3,0.7588186415391355,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL125810,IC50,15.0,nM,7.82,CHEMBL674641,CHEMBL203,CHEMBL1128730,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3cccc(Cl)c3)c2cn1,271.7109999999998,3.0040000000000004,2,5,76.72,3,3,0.7491519597536833,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL124528,IC50,120.0,nM,6.92,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3cccc(F)c3)c2cn1,255.25600000000006,2.4897,2,5,76.72,3,3,0.7352758189604389,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL340438,IC50,840.0,nM,6.08,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3cccc(I)c3)c2cn1,363.16199999999986,2.9552000000000005,2,5,76.72,3,3,0.6850056610960018,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL125550,IC50,260.0,nM,6.58,CHEMBL674641,CHEMBL203,CHEMBL1128730,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3cccc(O)c3)c2cn1,253.26500000000007,2.0561999999999996,3,6,96.95,4,3,0.6464027121144595,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL123322,IC50,70.0,nM,7.16,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3cccc([N+](=O)[O-])c3)c2cn1,282.2629999999998,2.2588,2,7,119.86,4,3,0.5579357856635233,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL124673,IC50,40.0,nM,7.4,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3ccccc3Br)c2cn1,316.16199999999986,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL122132,IC50,240.0,nM,6.62,CHEMBL674641,CHEMBL203,CHEMBL1128730,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3ccccc3C(F)(F)F)c2cn1,305.2629999999998,3.3694000000000015,2,5,76.72,3,3,0.7588186415391355,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL332879,IC50,10000.0,nM,5.0,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1cc2ncnc(Nc3ccccc3N)c2cn1,252.2810000000001,1.9327999999999999,3,6,102.74,4,3,0.6020846498364862,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL124618,IC50,5250.0,nM,5.28,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cc2ncnc(Nc3ccccc3[N+](=O)[O-])c2cn1,282.2629999999998,2.2588,2,7,119.86,4,3,0.5579357856635233,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL338662,IC50,1250.0,nM,5.9,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(-c2cc(=O)c3c(O)c(N)ccc3o2)cc1,268.2719999999997,2.33,3,5,102.48,4,3,0.464024981699999,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL116051,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2cc(=O)c3c(O)ccc(N)c3o2)cc1,268.2719999999997,2.33,3,5,102.48,4,3,0.464024981699999,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL114578,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2cc(=O)c3cc(N)c(O)cc3o2)cc1,268.2719999999997,2.33,3,5,102.48,4,3,0.464024981699999,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL432416,IC50,14100.0,nM,4.85,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(-c2cc(=O)c3cc(N)cc(N)c3o2)cc1,267.2879999999997,2.2066,3,5,108.27,4,3,0.5855892854252639,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL112422,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2cc(=O)c3cc(N)ccc3o2)cc1,252.27300000000005,2.6244000000000005,2,4,82.25,3,3,0.652059197793744,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL112925,IC50,8700.0,nM,5.06,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(-c2cc(=O)c3cc(O)cc(N)c3o2)cc1,268.2719999999997,2.33,3,5,102.48,4,3,0.587650623042462,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL112421,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2cc(=O)c3ccc(O)c(N)c3o2)cc1,268.2719999999997,2.33,3,5,102.48,4,3,0.464024981699999,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL114568,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2cc(=O)c3cccc(N)c3o2)cc1,252.27300000000005,2.6244000000000005,2,4,82.25,3,3,0.652059197793744,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL323660,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1,450.3799999999999,3.2852000000000015,2,7,119.55000000000001,3,5,0.3985293610060524,0,O=c1[nH]c(=O)n(-c2ccccc2)c2c1cnc1ccc(-c3cccnc3)nc12,CHEMBL3903725,IC50,10000.0,nM,,CHEMBL3888660,CHEMBL203,CHEMBL3886794,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
Nc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,310.3609999999997,2.4784,3,7,115.87,5,3,0.49440631109934724,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1241487,IC50,33.0,nM,7.48,CHEMBL1243977,CHEMBL203,CHEMBL1240340,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ccc(C#Cc2cc(F)c3c(c2)C(=O)N(C(C(=O)Nc2nccs2)c2ncn4c2CCC4)C3)cn1,513.558,3.1377000000000015,2,8,119.03000000000002,5,4,0.40491972094628625,1,O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccc(C#Cc3cccnc3)cc2C1=O,CHEMBL5170278,IC50,116.0,nM,6.94,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(CNc2ncnc3cc(N)ncc23)cc1,266.3079999999998,1.8013,3,6,102.74,5,3,0.6245559693103766,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL124836,IC50,10000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(Nc2ncnc3cc(N)ncc23)cc1,252.2810000000001,1.9327999999999999,3,6,102.74,4,3,0.6020846498364862,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL333272,IC50,5900.0,nM,5.23,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc(O)c(-c2nnc(Cc3nc4ccccc4[nH]3)o2)c1,307.31299999999976,2.4915000000000003,3,6,113.85000000000001,5,4,0.3955941057129645,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4094647,IC50,69984.2,nM,4.16,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
Nc1ccc2c(NCc3ccccc3)ncnc2c1,250.3050000000001,2.8241000000000014,2,4,63.83,4,3,0.7015050601686035,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL330946,IC50,1000.0,nM,,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,316.1619999999998,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3ncccc23)cc1,CHEMBL54474,IC50,940.0,nM,6.03,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ccc2c(Nc3cccc(F)c3)ncnc2c1,254.26800000000006,3.0947000000000005,2,4,63.83,3,3,0.6896342875629906,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL93966,IC50,2.0,nM,8.7,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2c(Nc3cccc(I)c3)ncnc2c1,362.17399999999986,3.560200000000001,2,4,63.83,3,3,0.5406149713457675,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL91980,IC50,0.35,nM,9.46,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(NCc3ccccc3)c2c1,250.3050000000001,2.8241000000000014,2,4,63.83,4,3,0.7015050601686034,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL332096,IC50,508.0,nM,6.29,CHEMBL677833,CHEMBL203,CHEMBL1145114,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4[nH]ccc4c3)c2c1,275.3149999999997,3.4369000000000014,3,4,79.62,3,4,0.4895239921837193,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1,CHEMBL5180251,IC50,0.65,nM,9.19,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4[nH]ncc4c3)c2c1,276.30299999999977,2.831900000000001,3,5,92.51,3,4,0.489480274398786,0,c1ccc2c(Nc3ccc4[nH]ncc4c3)ncnc2c1,CHEMBL5178707,IC50,2.98,nM,8.53,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4c(c3)CCC4)c2c1,276.3429999999997,3.444300000000002,2,4,63.83,3,3,0.7036659903515429,0,c1ccc2c(Nc3ccc4c(c3)CCC4)ncnc2c1,CHEMBL5186969,IC50,251.3,nM,6.6,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4cc[nH]c4c3)c2c1,275.3149999999997,3.4369000000000014,3,4,79.62,3,4,0.4895239921837193,0,c1ccc2c(Nc3ccc4cc[nH]c4c3)ncnc2c1,CHEMBL5199612,IC50,183.7,nM,6.74,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4cn[nH]c4c3)c2c1,276.30299999999977,2.831900000000001,3,5,92.50999999999999,3,4,0.489480274398786,0,c1ccc2c(Nc3ccc4cn[nH]c4c3)ncnc2c1,CHEMBL5191992,IC50,1000.0,nM,,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3ccc4ncccc4c3)c2c1,287.32599999999974,3.503800000000002,2,5,76.72,3,4,0.5516860802357946,0,c1cnc2ccc(Nc3ncnc4ccccc34)cc2c1,CHEMBL5188730,IC50,215.1,nM,6.67,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,316.16199999999986,3.113100000000001,2,5,76.72,3,3,0.759476002540334,0,c1ccc(Nc2ncnc3cccnc23)cc1,CHEMBL300217,IC50,7.6,nM,8.12,CHEMBL680021,CHEMBL203,CHEMBL1129564,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ccc2ncnc(Nc3cccc4[nH]ccc34)c2c1,275.3149999999997,3.4369000000000014,3,4,79.62,3,4,0.4895239921837193,0,c1ccc2c(Nc3cccc4[nH]ccc34)ncnc2c1,CHEMBL5192435,IC50,1000.0,nM,,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccc2ncnc(Nc3cccc4cc[nH]c34)c2c1,275.3149999999997,3.4369000000000014,3,4,79.62,3,4,0.4895239921837193,0,c1cc(Nc2ncnc3ccccc23)c2[nH]ccc2c1,CHEMBL5180325,IC50,25.17,nM,7.6,CHEMBL5161051,CHEMBL203,CHEMBL5154786,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cccc(-c2cc(=O)c3c(N)c(O)c(N)cc3o2)c1,283.28699999999975,1.9121999999999997,4,6,128.5,5,3,0.39862752862313183,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL325949,IC50,7800.0,nM,5.11,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Nc1cccc(-c2cc(=O)c3cc(N)c(O)cc3o2)c1,268.2719999999997,2.33,3,5,102.48,4,3,0.464024981699999,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL115102,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1cccc(-c2cc(=O)c3cc(N)ccc3o2)c1,252.27300000000005,2.6244000000000005,2,4,82.25,3,3,0.652059197793744,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL115103,IC50,100000.0,nM,,CHEMBL674638,CHEMBL203,CHEMBL1127357,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1cccc(CNc2ncnc3cc(N)ncc23)c1,266.3079999999998,1.8013,3,6,102.74,5,3,0.6245559693103766,0,c1ccc(CNc2ncnc3ccncc23)cc1,CHEMBL127763,IC50,10000.0,nM,,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1,263.30399999999986,2.8644000000000007,2,5,76.72,4,3,0.7104285506234564,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL57553,IC50,50000.0,nM,4.3,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cccc(Nc2ncnc3cc(N)ncc23)c1,252.2810000000001,1.9327999999999999,3,6,102.74,4,3,0.6020846498364862,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL124617,IC50,1550.0,nM,5.81,CHEMBL674641,CHEMBL203,CHEMBL1128730,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cccc2c(NCc3ccccc3)ncnc12,250.3050000000001,2.8241000000000014,2,4,63.83,4,3,0.7015050601686034,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL117988,IC50,10000.0,nM,,CHEMBL677205,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1cccc2ncnc(NCc3ccccc3)c12,250.3050000000001,2.8241000000000014,2,4,63.83,4,3,0.7015050601686034,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL119432,IC50,10000.0,nM,,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ccccc1Nc1ncnc2cc(Br)ncc12,316.16199999999986,3.113100000000001,2,5,76.72,3,3,0.5609983790443543,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL273116,IC50,245.47,nM,6.61,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,290.3299999999997,2.4519,2,5,85.41,4,4,0.6066146405721698,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1682346,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12,416.2259999999997,3.0565000000000015,2,5,85.41,4,4,0.5031287456477928,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1975128,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12,288.1479999999998,3.574600000000001,2,2,54.699999999999996,2,3,0.718813900266371,0,c1ccc(-c2cccc3[nH]ncc23)cc1,CHEMBL1990346,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12,287.32599999999974,3.2691000000000017,2,4,80.48,3,4,0.592646114514844,0,c1ccc(-c2nnc3[nH]ncc3c2-c2ccccc2)cc1,CHEMBL260135,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1nc(N)c2c(Nc3cccc(Cl)c3)[nH]nc2n1,275.7029999999998,1.9142999999999997,4,6,118.53,4,3,0.5671971055005091,0,c1ccc(Nc2[nH]nc3ncncc23)cc1,CHEMBL122068,IC50,220.0,nM,6.66,CHEMBL677832,CHEMBL203,CHEMBL1130217,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccccc3)c12,307.38199999999983,3.426700000000001,3,5,93.60999999999999,4,4,0.5272972106711614,0,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1,CHEMBL1093099,IC50,15070.0,nM,4.82,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,346.3499999999998,2.3294000000000006,4,8,144.06,6,4,0.43266451954791146,0,c1ccc(-c2nc3cncnc3nc2-c2ccccc2)cc1,CHEMBL230011,Kd,800.0,nM,6.1,CHEMBL1908703,CHEMBL203,CHEMBL1908390,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1nc(NCCc2ccccc2)c2c(n1)[nH]c1ccc(O)cc12,319.3679999999997,3.0535000000000014,4,5,99.85000000000001,6,4,0.46311419907910834,0,c1ccc(CCNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL4060727,Ki,640.0,nM,6.19,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1nc(NCc2ccccc2)c2c(n1)[nH]c1ccc(O)cc12,305.3409999999997,3.011000000000001,4,5,99.85000000000001,5,4,0.46604608494989974,0,c1ccc(CNc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL3715932,Ki,700.0,nM,6.16,CHEMBL4021780,CHEMBL203,CHEMBL4020756,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1nc(Nc2ccc(F)cc2)c2c(n1)-c1ccccc1C2,292.3169999999997,3.5127000000000015,2,4,63.83,3,3,0.5931673450472457,0,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1,CHEMBL3983639,IC50,300000.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ccc1C(=O)c1c(F)cccc1F,404.39799999999985,2.564,3,6,128.17,7,3,0.5608532212395182,0,O=C(c1ccccc1)c1ccc(Nc2ccccc2)nc1,CHEMBL193643,IC50,100000.0,nM,,CHEMBL827663,CHEMBL203,CHEMBL1144370,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,394.36299999999994,1.217999999999999,3,8,145.98999999999998,6,3,0.6027885397158542,0,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1,CHEMBL191003,Kd,10000.0,nM,,CHEMBL1051286,CHEMBL203,CHEMBL1150977,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F,425.4459999999999,1.774599999999999,4,8,140.95,6,3,0.4636793048771347,0,S=C(Nc1ccccc1)n1cnc(Nc2ccccc2)n1,CHEMBL261720,IC50,10000.0,nM,,CHEMBL829442,CHEMBL203,CHEMBL1139550,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1nc(Nc2cccc(F)c2)c2c(n1)-c1ccccc1C2,292.3169999999997,3.5127000000000015,2,4,63.83,3,3,0.5931673450472457,0,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1,CHEMBL3953855,IC50,300000.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1nc(Nc2ccccc2)c2c(n1)-c1ccccc1C2,274.3269999999997,3.3736000000000015,2,4,63.83,3,3,0.5879496808284025,0,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1,CHEMBL3985894,IC50,232700.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1nc(Nc2ccccc2)c2c(n1)[nH]c1ccccc12,275.3149999999997,3.4369000000000014,3,4,79.62,3,4,0.5232974190477884,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1,CHEMBL2337373,IC50,147.0,nM,6.83,CHEMBL2344596,CHEMBL203,CHEMBL2331095,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1nc2c(c(Nc3ccc(F)cc3)n1)-c1ccccc1C2,292.3169999999997,3.5127000000000015,2,4,63.83,3,3,0.5931673450472457,0,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1,CHEMBL2047241,IC50,276100.0,nM,,CHEMBL2050143,CHEMBL203,CHEMBL2046359,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1nc2c(c(Nc3cccc(F)c3)n1)-c1ccccc1C2,292.3169999999997,3.5127000000000015,2,4,63.83,3,3,0.5931673450472457,0,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1,CHEMBL2047246,IC50,200000.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1nc2c(c(Nc3ccccc3)n1)-c1ccccc1C2,274.3269999999997,3.3736000000000015,2,4,63.83,3,3,0.5879496808284025,0,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1,CHEMBL2047243,IC50,200000.0,nM,,CHEMBL3888922,CHEMBL203,CHEMBL3886207,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
Nc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,317.14999999999986,2.5081000000000007,2,6,89.61,3,3,0.7546729998537474,0,c1ccc(Nc2ncnc3cncnc23)cc1,CHEMBL53831,IC50,1.5,nM,8.82,CHEMBL679947,CHEMBL203,CHEMBL1130057,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,338.38999999999965,2.6529000000000007,2,6,81.64999999999999,4,3,0.7671598820564707,0,c1ccc(-c2ncn(C3CCNCC3)c2-c2ccncn2)cc1,CHEMBL274064,Ki,1258.93,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1,438.7969999999999,3.4019000000000013,4,7,126.05000000000001,7,3,0.4495694886554917,0,c1ccc(-c2cccc(Nc3ncncn3)c2)cc1,CHEMBL2001239,Ki,251.19,nM,6.6,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)NNC(=O)CCN1CCOCC1,525.9970000000005,2.5181000000000004,4,9,143.73,10,3,0.30961107176181196,1,O=C(CCN1CCOCC1)NNC(=O)c1cncnc1Nc1ccc(OCc2ccccc2)cc1,CHEMBL472544,IC50,620.0,nM,6.21,CHEMBL971642,CHEMBL203,CHEMBL1156722,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)OCCN1CCOCC1,483.9559999999998,3.5238000000000023,2,9,111.83,10,3,0.4411735163697707,0,O=C(OCCN1CCOCC1)c1cncnc1Nc1ccc(OCc2ccccc2)cc1,CHEMBL461113,IC50,150.0,nM,6.82,CHEMBL971642,CHEMBL203,CHEMBL1156722,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/N1CCN(CCO)CC1,489.55899999999974,2.2832999999999997,3,10,120.72,10,4,0.3225649892157135,0,C(=N/N1CCNCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1,CHEMBL514566,IC50,9.0,nM,8.05,CHEMBL1007322,CHEMBL203,CHEMBL1155952,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/N1CCOCC1,446.4899999999998,3.005600000000001,2,9,106.48,7,4,0.43863551532530015,0,C(=N/N1CCOCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1,CHEMBL498133,IC50,16.0,nM,7.8,CHEMBL1007322,CHEMBL203,CHEMBL1155952,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCCC1,313.33599999999973,3.035300000000001,2,6,89.85,4,3,0.7586966328312489,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242199,IC50,751.0,nM,6.12,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCC1,360.21499999999986,3.268600000000001,2,6,89.85,4,3,0.7321559148328971,0,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1,CHEMBL1242287,IC50,324.0,nM,6.49,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCC1,315.7639999999998,3.1595000000000013,2,6,89.85,4,3,0.7578036662889716,0,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1,CHEMBL1241580,IC50,1150.0,nM,5.94,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCCC1,329.79099999999977,3.5496000000000016,2,6,89.85,4,3,0.7500093831946224,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1241676,IC50,67.0,nM,7.17,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCN1,344.80599999999976,2.186499999999999,3,7,101.88,5,3,0.6728018027891974,0,c1ccc(-c2nn(CC3CCCN3)c3ncncc23)cc1,CHEMBL1241769,IC50,9380.0,nM,5.03,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCNC1,358.83299999999974,2.4341,3,7,101.88,5,3,0.6642625836751026,0,c1ccc(-c2nn(CC3CCCNC3)c3ncncc23)cc1,CHEMBL1241858,IC50,2720.0,nM,5.57,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNC1,344.80599999999976,2.0439999999999996,3,7,101.88,5,3,0.6717292152794165,0,c1ccc(-c2nn(CC3CCNC3)c3ncncc23)cc1,CHEMBL1241770,IC50,2010.0,nM,5.7,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CCC1CCCNC1,372.85999999999973,2.8242000000000003,3,7,101.88,6,3,0.6504764658322094,0,c1ccc(-c2nn(CCC3CCCNC3)c3ncncc23)cc1,CHEMBL1241943,IC50,20500.0,nM,4.69,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCNC1,330.77899999999977,1.9688999999999997,3,7,101.88,4,3,0.6636705536095824,0,c1ccc(-c2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL1241677,IC50,12400.0,nM,4.91,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCOC1,331.7629999999998,2.3959,2,7,99.08,4,3,0.7477036284321827,0,c1ccc(-c2nn(C3CCOC3)c3ncncc23)cc1,CHEMBL1241768,IC50,1400.0,nM,5.85,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@H]1CCOC1,331.7629999999998,2.3959,2,7,99.08,4,3,0.7477036284321827,0,c1ccc(-c2nn(C3CCOC3)c3ncncc23)cc1,CHEMBL1241678,IC50,1580.0,nM,5.8,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCC1,299.30899999999974,2.6452,2,6,89.85,4,3,0.7589171105290101,0,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1,CHEMBL1242566,IC50,2900.0,nM,5.54,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCC1,313.33599999999973,3.035300000000001,2,6,89.85,4,3,0.7586966328312489,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242568,IC50,318.0,nM,6.5,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CNC1,300.29699999999974,1.0644999999999996,3,7,101.88,4,3,0.653972069714125,0,c1ccc(-c2nn(C3CNC3)c3ncncc23)cc1,CHEMBL1242567,IC50,2900.0,nM,5.54,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCNC1,314.3239999999997,1.4545999999999994,3,7,101.88,4,3,0.6616147856905651,0,c1ccc(-c2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL1242658,IC50,15600.0,nM,4.81,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.4,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCOC1,315.30799999999977,1.8815999999999995,2,7,99.08,4,3,0.7488980361133214,0,c1ccc(-c2nn(C3CCOC3)c3ncncc23)cc1,CHEMBL1242749,IC50,2600.0,nM,5.58,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCNC1,314.3239999999997,1.4545999999999994,3,7,101.88,4,3,0.6616147856905651,0,c1ccc(-c2nn(C3CCNC3)c3ncncc23)cc1,CHEMBL1242657,IC50,8700.0,nM,5.06,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCOC1,315.30799999999977,1.8815999999999995,2,7,99.08,4,3,0.7488980361133214,0,c1ccc(-c2nn(C3CCOC3)c3ncncc23)cc1,CHEMBL1242748,IC50,4800.0,nM,5.32,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCC1,280.3309999999997,3.1111000000000013,2,5,76.96000000000001,4,3,0.7558014715547569,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL166765,IC50,600.0,nM,6.22,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCCC1,294.35799999999966,3.5012000000000016,2,5,76.96000000000001,4,3,0.7580244739154796,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1,CHEMBL169570,IC50,250.0,nM,6.6,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCNC1,295.34599999999966,1.9204999999999997,3,6,88.99000000000001,4,3,0.6718983245135965,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL354033,IC50,2670.0,nM,5.57,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccc3[nH]c(=O)ccc3c1)nn2C1CCCC1,346.3939999999997,3.0321000000000016,2,6,102.47999999999999,3,4,0.5806204621168803,0,O=c1ccc2cc(-c3nn(C4CCCC4)c4ncncc34)ccc2[nH]1,CHEMBL1241864,IC50,1400.0,nM,5.85,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc3[nH]ncc3c1)nn2C1CCCC1,319.37199999999973,3.0669000000000013,2,6,98.30000000000001,3,4,0.5914172603895744,0,c1ncc2c(-c3ccc4[nH]ncc4c3)nn(C3CCCC3)c2n1,CHEMBL1242475,IC50,571.0,nM,6.24,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccc3cn[nH]c3c1)nn2C1CCCC1,319.37199999999973,3.0669000000000013,2,6,98.29999999999998,3,4,0.5914172603895744,0,c1ncc2c(-c3ccc4cn[nH]c4c3)nn(C3CCCC3)c2n1,CHEMBL1242572,IC50,760.0,nM,6.12,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCC1,280.3309999999997,3.1111000000000013,2,5,76.96000000000001,4,3,0.7558014715547569,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL355330,IC50,300.0,nM,6.52,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCCC1,294.35799999999966,3.5012000000000016,2,5,76.96000000000001,4,3,0.7580244739154796,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1,CHEMBL169390,IC50,80.0,nM,7.1,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCN(CCO)CC1,353.42599999999965,2.0153,3,7,100.43,7,3,0.6633654673934989,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1,CHEMBL169780,IC50,2540.0,nM,5.59,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNC1,295.34599999999966,1.9204999999999997,3,6,88.99000000000001,4,3,0.6718983245135965,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL171545,IC50,1530.0,nM,5.82,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,349.43799999999965,3.0429000000000013,2,6,80.2,6,3,0.7566370655080714,0,c1ccc(-c2cn(C3CC(CN4CCC4)C3)c3ncncc23)cc1,CHEMBL3787112,IC50,2300.0,nM,5.64,CHEMBL3789407,CHEMBL203,CHEMBL3784924,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1cccc(O)c1F)nn2C1CCCC1,313.33599999999973,3.035300000000001,2,6,89.85,4,3,0.7586966328312489,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1,CHEMBL1242111,IC50,1770.0,nM,5.75,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CNCCO)cc1,359.4329999999997,2.7516,3,6,88.99,8,4,0.4607574223919307,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL173453,IC50,1400.0,nM,5.85,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CO)cc1,316.36399999999975,3.162000000000001,2,5,76.96,5,4,0.6084663937945756,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL367442,IC50,700.0,nM,6.16,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CNCCO)c1,359.4329999999997,2.7516,3,6,88.99,8,4,0.4607574223919307,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL176702,IC50,3400.0,nM,5.47,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CO)c1,316.36399999999975,3.1620000000000017,2,5,76.96,5,4,0.6084663937945756,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL173478,IC50,600.0,nM,6.22,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CNCCO,359.4329999999997,2.7516000000000003,3,6,88.99,8,4,0.4607574223919307,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL176470,IC50,6400.0,nM,5.19,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CO,316.36399999999975,3.1620000000000013,2,5,76.96,5,4,0.6084663937945756,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1,CHEMBL429057,IC50,1100.0,nM,5.96,CHEMBL674015,CHEMBL203,CHEMBL1133080,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2C(CO)Cc1ccc(O)cc1,360.41699999999975,3.1622000000000012,3,6,97.19,8,4,0.5078493534792574,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1,CHEMBL170438,IC50,13200.0,nM,4.88,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2C(CO)Cc1ccccc1,344.4179999999997,3.4566000000000017,2,5,76.96,7,4,0.581179406034094,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1,CHEMBL171311,IC50,440.0,nM,6.36,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1ccccc1)cn2C1CC(O)C1,280.3309999999997,2.3763000000000005,2,5,76.96,4,3,0.7552467947110149,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL168266,IC50,2820.0,nM,5.55,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccccc1)cn2C1CCC(O)C1,294.35799999999966,2.766400000000001,2,5,76.96,4,3,0.761621617221441,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1,CHEMBL168285,IC50,790.0,nM,6.1,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccccc1)cn2C1CCC1,264.3319999999999,3.4055000000000017,1,4,56.73,3,3,0.7713437318510206,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1,CHEMBL166766,IC50,730.0,nM,6.14,CHEMBL674693,CHEMBL203,CHEMBL1134829,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccccc1)cn2C1CCNC1,279.34699999999964,2.2149,2,5,68.75999999999999,3,3,0.7544090562068937,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1,CHEMBL168829,IC50,13400.0,nM,4.87,CHEMBL677878,CHEMBL203,CHEMBL1134003,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccccc1)nn2-c1ccccc1,287.32599999999974,3.064700000000001,1,5,69.62,3,4,0.6148647558317336,0,c1ccc(-c2nn(-c3ccccc3)c3ncncc23)cc1,CHEMBL122243,IC50,800.0,nM,6.1,CHEMBL677832,CHEMBL203,CHEMBL1130217,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(-c1ccn3ccnc3c1)nn2C1CCCC1,319.37199999999973,2.838300000000001,1,7,86.91999999999999,3,4,0.6136659321671243,0,c1ncc2c(-c3ccn4ccnc4c3)nn(C3CCCC3)c2n1,CHEMBL1241675,IC50,12000.0,nM,4.92,CHEMBL1243977,CHEMBL203,CHEMBL1240340,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,319.37199999999973,3.0669000000000013,2,6,98.29999999999998,3,4,0.5914172603895744,0,c1ncc2c(-c3cnc4[nH]ccc4c3)nn(C3CCCC3)c2n1,CHEMBL1081312,IC50,260.0,nM,6.58,CHEMBL3223623,CHEMBL203,CHEMBL3217752,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Nc1ncnc2c1c(I)nn2C1CCC(O)CC1,359.1709999999999,1.4891,2,6,89.85000000000001,3,2,0.7534017327276684,0,c1ncc2cnn(C3CCCCC3)c2n1,CHEMBL1996791,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O,393.14099999999996,-1.3754000000000006,4,9,139.54000000000002,6,2,0.4583951552821156,0,c1ncc2cnn(C3CCCO3)c2n1,CHEMBL2001288,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; MW in Type 1 range; Aromatic ring count typical
Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,292.3019999999998,1.7727,2,6,102.47999999999999,4,4,0.5601515728848441,0,O=C(Cn1cnc2cncnc21)c1c[nH]c2ccccc12,CHEMBL521155,IC50,35000.0,nM,4.46,CHEMBL949877,CHEMBL203,CHEMBL1137681,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1S,283.3129999999997,-1.0425000000000004,4,9,119.31000000000002,6,2,0.5195054952827158,0,c1ncc2ncn(C3CCCO3)c2n1,CHEMBL14326,Kd,1000.0,nM,6.0,CHEMBL673785,CHEMBL203,CHEMBL1130008,0.6,Activity in Type 1 range; Activity in typical Type 1 range; Aromatic ring count typical
Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,405.39299999999986,3.3469000000000015,4,6,126.44,5,4,0.41417283965420687,0,O=C(Nc1ccccc1)Nc1ccc(NC(=O)c2ccn3ncncc23)cc1,CHEMBL1990583,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1/N=N/c1ccc2c(c1)OCO2,374.3599999999999,3.4159000000000015,2,8,119.36,4,4,0.532580414640389,0,O=c1cc(-c2ccccc2)[nH]c2c(/N=N/c3ccc4c(c3)OCO4)cnn12,CHEMBL2029700,IC50,5300.0,nM,5.28,CHEMBL2034705,CHEMBL203,CHEMBL2029299,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1,386.4219999999999,1.7864000000000004,2,11,137.11,6,4,0.3938136643306979,1,O=C(NN=Cc1cccs1)c1nnn(-c2cnon2)c1-c1cccs1,CHEMBL1975256,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Nc1scc2c1c(Nc1ccc(S(N)(=O)=O)cc1)nc1ncnc(N)c12,387.4499999999999,1.7948999999999997,4,9,162.9,6,4,0.4131736421331956,0,c1ccc(Nc2nc3ncncc3c3cscc23)cc1,CHEMBL1910273,IC50,29500.0,nM,4.53,CHEMBL1912180,CHEMBL203,CHEMBL1909587,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(/C=C/CN1CC(O)C1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,433.89599999999973,3.398600000000001,3,7,90.38000000000001,7,3,0.5160821798293825,0,O=C(/C=C/CN1CCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1,CHEMBL3233782,IC50,38.0,nM,7.42,CHEMBL3238947,CHEMBL203,CHEMBL3233010,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(/C=C/CN1CCOCC1)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,479.60599999999977,2.6099000000000006,2,8,90.82000000000001,8,3,0.5035998332606173,0,O=C(/C=C/CN1CCOCC1)N1CCc2c(sc3ncnc(NCc4ccccc4)c23)C1,CHEMBL1272325,IC50,21.0,nM,7.68,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,442.8819999999998,3.3878000000000004,2,7,92.27000000000001,6,3,0.5651048158359574,0,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL3958006,IC50,2.0,nM,8.7,CHEMBL3854867,CHEMBL203,CHEMBL3853319,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(/C=C/CN1CCS(=O)(=O)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,495.9889999999998,3.4525000000000015,2,8,104.29,6,3,0.5045044131234435,0,O=C(/C=C/CN1CCS(=O)(=O)CC1)Nc1cc2c(Nc3ccccc3)ncnc2s1,CHEMBL3233793,IC50,7.0,nM,8.15,CHEMBL3238948,CHEMBL203,CHEMBL3233010,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1,284.3109999999997,2.8969000000000005,2,4,66.76,7,2,0.5031075138837579,0,O=C(/C=C/c1ccccc1)OCCc1ccccc1,CHEMBL319244,IC50,1005.0,nM,6.0,CHEMBL1909203,CHEMBL203,CHEMBL1909046,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,272.25599999999974,2.4051000000000005,4,5,97.99000000000001,7,2,0.3905384760274634,0,O=C(/C=C/c1ccccc1)c1ccccc1,CHEMBL128000,IC50,8000.0,nM,5.1,CHEMBL970971,CHEMBL203,CHEMBL1157216,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cn1,499.34399999999977,3.334200000000001,2,7,92.27000000000001,5,3,0.520742581073658,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL204638,IC50,1.5,nM,8.82,CHEMBL862512,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,454.89299999999974,3.225100000000001,2,7,92.27000000000001,5,3,0.571641552903816,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL203661,IC50,1.3,nM,8.89,CHEMBL862512,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,440.8659999999998,2.835,2,7,92.27000000000001,4,3,0.6024862522840296,0,O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1,CHEMBL202556,IC50,3.1,nM,8.51,CHEMBL862512,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,439.8779999999998,3.4400000000000004,2,6,79.38,4,3,0.6061699667876943,0,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL202621,IC50,31.0,nM,7.51,CHEMBL862515,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,466.3389999999998,3.410000000000001,2,6,79.38,4,3,0.5743009697891237,0,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL93386,IC50,20.0,nM,7.7,CHEMBL680018,CHEMBL203,CHEMBL1134561,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCO)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,370.7709999999999,3.1001000000000003,3,5,87.14,4,3,0.6165970423486862,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL202411,IC50,1.4,nM,8.85,CHEMBL862512,CHEMBL203,CHEMBL1138126,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(C#CCO)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,397.23199999999986,3.070100000000001,3,5,87.14,4,3,0.5917418443447154,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL94062,IC50,2.0,nM,8.7,CHEMBL680018,CHEMBL203,CHEMBL1134561,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,479.23699999999997,3.497600000000001,1,8,99.25,6,4,0.33400118195149187,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3906330,IC50,300.0,nM,6.52,CHEMBL3854309,CHEMBL203,CHEMBL3853296,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(CCCCCCC(=O)Nc1ccccc1)NO,264.32499999999993,2.4711,3,3,78.43,9,1,0.3832200999836573,0,c1ccccc1,CHEMBL98,IC50,12.0,nM,7.92,CHEMBL5215094,CHEMBL203,CHEMBL5214883,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range
O=C(CCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)NO,376.77499999999975,3.440200000000001,3,6,96.37,7,3,0.4502242526783351,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3930226,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,434.78599999999994,3.3415000000000017,1,8,99.25,6,4,0.36674863209348896,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1,CHEMBL3902295,IC50,4700.0,nM,5.33,CHEMBL3854309,CHEMBL203,CHEMBL3853296,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(CN1CCN(CCO)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,464.9539999999998,2.7758000000000003,3,8,93.62,8,3,0.4946866658446772,0,O=C(CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1,CHEMBL3233766,IC50,770.0,nM,6.11,CHEMBL3238947,CHEMBL203,CHEMBL3233010,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,442.3169999999998,3.406600000000001,2,6,79.38,5,3,0.6308468812763068,0,O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL4177348,IC50,98.0,nM,7.01,CHEMBL4156805,CHEMBL203,CHEMBL4152342,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1,415.85599999999977,3.0245000000000015,2,5,95.0,5,3,0.682555137239297,0,c1ccc(-c2n[nH]c(C3CCNCC3)c2-c2ccncn2)cc1,CHEMBL1614705,Ki,199.53,nM,6.7,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(COc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)NO,362.7479999999998,3.0501000000000005,3,6,96.37,6,3,0.47660898616837855,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3922584,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Cc1c[nH]c2ccccc12)NNC(=S)Nc1ncccc1Br,404.29299999999984,2.8857,4,3,81.84,3,3,0.3988411792211693,0,O=C(Cc1c[nH]c2ccccc12)NNC(=S)Nc1ccccn1,CHEMBL3393072,IC50,8490.0,nM,5.07,CHEMBL3395991,CHEMBL203,CHEMBL3393043,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,431.53599999999966,3.318500000000001,1,5,63.69,9,3,0.5631942375722424,0,O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,CHEMBL571546,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(Br)cc1,433.1209999999999,3.2592000000000017,1,3,63.24,4,2,0.8058294777753774,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828879,IC50,17260.0,nM,4.76,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(Cl)cc1,388.6699999999999,3.150100000000001,1,3,63.24,4,2,0.874929227918568,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828878,IC50,15920.0,nM,4.8,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(F)cc1,372.2149999999999,2.6358000000000006,1,3,63.24,4,2,0.897731660583396,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828877,IC50,14530.0,nM,4.84,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccccc1,354.2249999999999,2.4967000000000006,1,3,63.24,4,2,0.9177331477617516,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828875,IC50,17810.0,nM,4.75,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(Br)cc1,388.66999999999985,3.150100000000001,1,3,63.24,4,2,0.8749292279185681,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828874,IC50,11290.0,nM,4.95,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(Cl)cc1,344.2189999999999,3.0410000000000013,1,3,63.24,4,2,0.9273035218742537,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828873,IC50,10340.0,nM,4.99,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(F)cc1,327.76399999999984,2.526700000000001,1,3,63.24,4,2,0.9382242838405996,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828872,IC50,9590.0,nM,5.02,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccccc1,309.77399999999983,2.387600000000001,1,3,63.24,4,2,0.9429128040280621,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828870,IC50,11910.0,nM,4.92,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2,275.73899999999975,2.7330000000000005,2,2,57.78,3,2,0.904842249329252,0,O=C(Cc1ccccc1)Nc1[nH]nc2c1CCC2,CHEMBL2003482,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(Br)cc1,372.2149999999998,2.6358000000000006,1,3,63.24,4,2,0.8977316605833962,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828869,IC50,6410.0,nM,5.19,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(Cl)cc1,327.76399999999984,2.526700000000001,1,3,63.24,4,2,0.9382242838405996,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828868,IC50,5930.0,nM,5.23,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(F)cc1,311.3089999999998,2.0124,1,3,63.24,4,2,0.9392886673774157,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828867,IC50,5170.0,nM,5.29,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccccc1,293.3189999999998,1.8733,1,3,63.24,4,2,0.9357664044618524,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1828865,IC50,6740.0,nM,5.17,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1ccc(F)cc1)Nc1cc(SC[C@@H](O)CO)cc([N+](=O)[O-])c1,380.3969999999998,2.3604000000000003,3,6,112.70000000000002,10,2,0.3681312998797099,0,O=C(Cc1ccccc1)Nc1ccccc1,CHEMBL2029691,IC50,48600.0,nM,4.31,CHEMBL2034705,CHEMBL203,CHEMBL2029299,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(Br)cc1,433.1209999999999,3.2592000000000017,1,3,63.24,4,2,0.8058294777753774,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1829275,IC50,24330.0,nM,4.61,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(Cl)cc1,388.6699999999999,3.150100000000001,1,3,63.24,4,2,0.874929227918568,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1829274,IC50,21280.0,nM,4.67,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(F)cc1,372.2149999999999,2.6358000000000006,1,3,63.24,4,2,0.897731660583396,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1829273,IC50,18720.0,nM,4.73,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccccc1,354.2249999999999,2.4967000000000006,1,3,63.24,4,2,0.9177331477617516,0,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1,CHEMBL1829271,IC50,24680.0,nM,4.61,CHEMBL1831700,CHEMBL203,CHEMBL1828525,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,437.5689999999997,3.0604000000000005,2,7,79.38000000000001,9,3,0.5011225670998131,0,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,CHEMBL4245507,IC50,1000.0,nM,,CHEMBL4233314,CHEMBL203,CHEMBL4229420,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Cc1csc2nc3ccccc3n12)Nc1cccc(O)c1,323.37699999999984,3.4358000000000013,2,5,66.63000000000001,4,4,0.6068000446869499,0,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1,CHEMBL5185952,IC50,55000.0,nM,4.26,CHEMBL5129114,CHEMBL203,CHEMBL5126578,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1O,323.37699999999984,3.435800000000001,2,5,66.63000000000001,4,4,0.5676373884528724,0,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1,CHEMBL4798627,IC50,55.0,nM,,CHEMBL5096403,CHEMBL203,CHEMBL5096145,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Cn1c(-c2ccccc2)cc(=O)n2ncnc12)NNC(=S)Nc1ccccc1,419.46999999999986,1.5757999999999992,3,7,105.35000000000001,4,4,0.3406536909594055,0,O=C(Cn1c(-c2ccccc2)cc(=O)n2ncnc12)NNC(=S)Nc1ccccc1,CHEMBL2029692,IC50,6800.0,nM,5.17,CHEMBL2034705,CHEMBL203,CHEMBL2029299,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NC(CO)Cc1ccccc1)c1cc2cc(Cl)ccc2[nH]1,328.7989999999997,3.154700000000001,3,2,65.12,6,3,0.6733165732064351,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1,CHEMBL4214496,IC50,800.0,nM,6.1,CHEMBL4196285,CHEMBL203,CHEMBL4196002,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1,332.4029999999996,3.0820000000000016,2,3,62.22,7,3,0.7290681127101363,0,O=C(NCCc1ccccc1)c1ccc(-c2ccncc2)cc1,CHEMBL1998545,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F,350.39299999999963,3.2211000000000016,2,3,62.22,7,3,0.717490448498717,0,O=C(NCCc1ccccc1)c1ccc(-c2ccncc2)cc1,CHEMBL1969755,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1,362.43299999999965,3.095200000000001,3,3,81.25,5,3,0.6670337377514938,0,O=C(NCc1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1,CHEMBL1964937,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NC1=NC2C(=O)NN=C(c3ccc(Br)cc3)C2S1)Nc1ccc(Cl)cc1,478.75899999999996,3.5981000000000014,3,5,94.95,2,2,0.6153942557116784,0,O=C(NC1=NC2C(=O)NN=C(c3ccccc3)C2S1)Nc1ccccc1,CHEMBL5274657,IC50,80.0,nM,7.1,CHEMBL5245316,CHEMBL203,CHEMBL5244229,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,382.2509999999997,2.4505999999999997,4,4,98.91,4,2,0.652926389014013,0,O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1ccccc1,CHEMBL445813,Kd,10000.0,nM,,CHEMBL1908693,CHEMBL203,CHEMBL1908390,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1,384.4839999999996,2.3355999999999995,4,4,108.04,11,2,0.4459837471070609,0,O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1,CHEMBL2003420,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1,356.4299999999996,2.980200000000001,4,4,108.04,9,2,0.5179918751244308,0,O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1,CHEMBL1998193,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NCCCN1CCOCC1)c1ccc(N(CCCl)CCCl)cc1,388.33899999999954,2.4227000000000007,1,4,44.81000000000001,10,1,0.49408495164367433,0,O=C(NCCCN1CCOCC1)c1ccccc1,CHEMBL589846,IC50,50000.0,nM,,CHEMBL1065784,CHEMBL203,CHEMBL1157716,0.55,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,471.35899999999975,3.589600000000001,3,6,91.41000000000001,6,3,0.5092849951094718,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1,CHEMBL3814320,IC50,1.43,nM,8.85,CHEMBL3815405,CHEMBL203,CHEMBL3813636,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NCCO)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,461.88099999999986,3.447400000000001,4,7,117.63000000000001,8,3,0.42536678097007175,0,c1ccc(Nc2ncnc3cc(OC4CCOC4)ccc23)cc1,CHEMBL3092322,IC50,27.0,nM,7.57,CHEMBL3095060,CHEMBL203,CHEMBL3091333,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NCCc1ccccc1)c1cc2ccc(O)c(O)c2cn1,308.33699999999965,2.618500000000002,3,4,82.45,6,3,0.6470642948947863,0,O=C(NCCc1ccccc1)c1cc2ccccc2cn1,CHEMBL49350,IC50,1400.0,nM,5.85,CHEMBL873595,CHEMBL203,CHEMBL1126211,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,431.2049999999997,1.6518999999999995,4,5,94.48,8,2,0.5224357037363528,0,c1ccc(Nc2cccnc2)cc1,CHEMBL2107832,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1,278.2929999999998,2.373,2,5,97.16,4,2,0.662334352605951,0,O=C(NCc1ccccc1)Nc1nccs1,CHEMBL1964644,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NCc1ccccc1)c1cc2cc(O)c(O)cc2cn1,294.30999999999966,2.5760000000000014,3,4,82.45,5,3,0.6483629616969674,0,O=C(NCc1ccccc1)c1cc2ccccc2cn1,CHEMBL296582,IC50,3100.0,nM,5.51,CHEMBL873595,CHEMBL203,CHEMBL1126211,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NCc1ccccc1)c1cc2ccc(O)c(O)c2cn1,294.30999999999966,2.5760000000000014,3,4,82.45,5,3,0.6483629616969674,0,O=C(NCc1ccccc1)c1cc2ccccc2cn1,CHEMBL48436,IC50,1400.0,nM,5.85,CHEMBL873595,CHEMBL203,CHEMBL1126211,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12,329.3409999999998,2.2580999999999998,4,7,119.73,5,3,0.43384015968236406,0,O=C(NN=Cc1ccccc1)Nc1cccc2nsnc12,CHEMBL1999811,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NNC(=O)c1ncc(Cc2ccsc2)s1)Nc1ccccc1,358.44799999999987,3.2619000000000016,3,5,83.12,4,3,0.6260961447563734,0,O=C(NNC(=O)c1ncc(Cc2ccsc2)s1)Nc1ccccc1,CHEMBL1944925,IC50,40900.0,nM,4.39,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1,411.91399999999993,3.593700000000002,4,3,73.39,5,3,0.38978852678161935,0,O=C(NNC(=S)Nc1ccccc1)C(c1ccccc1)c1ccccc1,CHEMBL1966722,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1,395.4589999999999,3.0794000000000015,4,3,73.39,5,3,0.4036753675283982,0,O=C(NNC(=S)Nc1ccccc1)C(c1ccccc1)c1ccccc1,CHEMBL1975138,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NO)c1ccc(-c2cc3c(NCc4ccccc4)ncnc3[nH]2)cc1,359.3889999999997,3.3560000000000016,4,5,102.93,6,4,0.32316764807450526,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL3981584,IC50,100.0,nM,,CHEMBL3881964,CHEMBL203,CHEMBL3881527,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NO)c1ccccc1Nc1nc(Nc2ccc(CN3CCOCC3)cc2)ncc1Cl,454.91799999999984,3.5684000000000022,4,8,111.64,8,3,0.3164828339378033,0,c1ccc(Nc2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cc1,CHEMBL4858714,IC50,4.495,nM,8.35,CHEMBL4832126,CHEMBL203,CHEMBL4831496,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NO)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1Cl,440.8909999999998,3.5728000000000026,4,8,111.64,7,3,0.3397702020979,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,CHEMBL4848234,IC50,116.5,nM,6.93,CHEMBL4832125,CHEMBL203,CHEMBL4831496,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,482.1959999999998,2.4667000000000003,4,5,90.82000000000001,9,2,0.35996032896912883,0,c1ccc(Nc2ccccc2)cc1,CHEMBL507361,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NOCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,380.3999999999998,3.277100000000002,5,6,111.05000000000001,10,3,0.3177580667566984,0,O=C(NOCc1ccccc1)c1cccc(NCc2ccccc2)c1,CHEMBL355294,IC50,50.0,nM,7.3,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccc(Br)cc1)c1ccc(Cl)nc1,375.631,2.616200000000001,1,4,76.13,3,2,0.8367737903991025,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945644,IC50,29070.0,nM,4.54,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Br)cc1)c1cccnc1,341.1859999999999,1.9627999999999999,1,4,76.13,3,2,0.9260410466620501,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1916950,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Br)cc1)c1cccnc1Cl,375.631,2.616200000000001,1,4,76.13,3,2,0.8367737903991026,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945452,IC50,15680.0,nM,4.8,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Br)cc1)c1cncc(Br)c1,420.08199999999994,2.7253000000000007,1,4,76.13,3,2,0.8291890836752285,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945447,IC50,2080.0,nM,5.68,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1ccc(Cl)nc1,331.17999999999984,2.5071000000000003,1,4,76.13,3,2,0.8770266129028955,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945645,IC50,18150.0,nM,4.74,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cccnc1,296.73499999999984,1.8537,1,4,76.13,3,2,0.9376485823356931,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1916949,IC50,25360.0,nM,4.6,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cccnc1Cl,331.17999999999984,2.5071000000000003,1,4,76.13,3,2,0.8770266129028954,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945453,IC50,19830.0,nM,4.7,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cncc(Br)c1,375.63099999999986,2.616200000000001,1,4,76.13,3,2,0.8945048084146764,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945448,IC50,90.0,nM,7.05,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(F)cc1)c1ccc(Cl)nc1,314.7249999999998,1.9928,1,4,76.13,3,2,0.8790759510871322,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945643,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(F)cc1)c1cccnc1,280.2799999999998,1.3394,1,4,76.13,3,2,0.9201232799535233,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1916948,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccc(F)cc1)c1cccnc1Cl,314.7249999999998,1.9928,1,4,76.13,3,2,0.8790759510871322,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945451,IC50,28660.0,nM,4.54,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccc(F)cc1)c1cncc(Br)c1,359.1759999999998,2.1018999999999997,1,4,76.13,3,2,0.9108305548149018,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945446,IC50,3270.0,nM,5.49,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(NS(=O)(=O)c1ccccc1)c1ccc(Cl)nc1,296.73499999999984,1.8537,1,4,76.13,3,2,0.8771330806973779,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945454,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,262.28999999999985,1.2003,1,4,76.13,3,2,0.9013632753608682,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1916947,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccccc1)c1cccnc1Cl,296.7349999999998,1.8537,1,4,76.13,3,2,0.8771330806973779,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945449,IC50,30000.0,nM,,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(NS(=O)(=O)c1ccccc1)c1cncc(Br)c1,341.1859999999998,1.9628,1,4,76.13,3,2,0.9260410466620501,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1,CHEMBL1945444,IC50,20190.0,nM,4.7,CHEMBL1949030,CHEMBL203,CHEMBL1944626,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,381.4399999999997,2.0690999999999997,4,5,110.96000000000001,5,3,0.5406836414671591,0,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,CHEMBL495727,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Nc1cc(N2CCOCC2)ncn1)c1ccc(F)cc1,302.30899999999974,1.7045999999999997,1,5,67.35000000000001,3,2,0.9345457896737078,0,O=C(Nc1cc(N2CCOCC2)ncn1)c1ccccc1,CHEMBL1379917,IC50,63.0,nM,7.2,CHEMBL4267257,CHEMBL203,CHEMBL4265907,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CC(O)C1,473.8919999999999,3.5420000000000016,3,7,108.84,6,3,0.5196790318144405,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OC1CCOC1)N1CCC1,CHEMBL3092318,IC50,543.0,nM,6.26,CHEMBL3095060,CHEMBL203,CHEMBL3091333,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCN(CCO)CC1,530.9880000000009,3.4754000000000023,3,8,112.08,8,3,0.4255629882122226,1,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OC1CCOC1)N1CCNCC1,CHEMBL3092303,IC50,331.0,nM,6.48,CHEMBL3095060,CHEMBL203,CHEMBL3091333,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,444.5389999999997,3.4143000000000017,3,7,91.41000000000001,6,3,0.5366372298871934,0,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,CHEMBL3545328,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1ccc(F)cc1)Nc1ncnc2nn3ccccc3c12,322.3029999999999,3.060600000000001,2,5,84.21,2,4,0.5938761104295742,0,O=C(Nc1ccccc1)Nc1ncnc2nn3ccccc3c12,CHEMBL359830,IC50,10000.0,nM,5.0,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1,271.70699999999977,3.4686000000000012,2,2,57.78,2,3,0.7497210373039224,0,O=C(Nc1ccc2[nH]ncc2c1)c1ccccc1,CHEMBL1973808,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1,271.70699999999977,3.4686000000000012,2,2,57.78,2,3,0.7497210373039224,0,O=C(Nc1ccc2cn[nH]c2c1)c1ccccc1,CHEMBL1972489,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(Nc1cccc(Br)c1)c1c(O)c2ccccc2[nH]c1=O,359.1789999999999,3.248500000000001,3,3,82.19,3,3,0.6570094656800847,0,O=C(Nc1ccccc1)c1cc2ccccc2[nH]c1=O,CHEMBL1944926,IC50,56800.0,nM,4.25,CHEMBL1947771,CHEMBL203,CHEMBL1944545,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=C(Nc1cccc([N+](=O)[O-])c1)Nc1ncnc2nn3ccccc3c12,349.3099999999999,2.8297000000000008,2,7,127.35,3,4,0.4322865074747241,0,O=C(Nc1ccccc1)Nc1ncnc2nn3ccccc3c12,CHEMBL181029,IC50,10000.0,nM,5.0,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1ccccc1)Nc1nnc(-c2cccnc2)o1,281.27499999999975,2.7756,2,5,92.94,3,3,0.7695910454979938,0,O=C(Nc1ccccc1)Nc1nnc(-c2cccnc2)o1,CHEMBL4535881,IC50,275.7,nM,6.56,CHEMBL4313654,CHEMBL203,CHEMBL4311968,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1ccccc1)c1cc2cc(O)c(O)cc2cn1,280.2829999999997,2.8983000000000017,3,4,82.45,4,3,0.6302559049582299,0,O=C(Nc1ccccc1)c1cc2ccccc2cn1,CHEMBL50415,IC50,5600.0,nM,5.25,CHEMBL873595,CHEMBL203,CHEMBL1126211,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1ccccc1)c1cc2ccc(O)c(O)c2cn1,280.2829999999997,2.8983000000000017,3,4,82.45,4,3,0.6302559049582299,0,O=C(Nc1ccccc1)c1cc2ccccc2cn1,CHEMBL48650,IC50,7700.0,nM,5.11,CHEMBL873595,CHEMBL203,CHEMBL1126211,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1ccccc1C(=O)N/N=C/c1ccc(O)cc1O)c1ccco1,365.34499999999986,2.707,4,6,124.16000000000001,7,3,0.4087114840842731,0,O=C(Nc1ccccc1C(=O)N/N=C/c1ccccc1)c1ccco1,CHEMBL5206193,IC50,31.2,nM,7.51,CHEMBL5228560,CHEMBL203,CHEMBL5226338,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O,308.34099999999967,3.016300000000001,2,3,74.33000000000001,2,2,0.8952620495802047,0,O=C(Nc1ccccn1)Nc1cccc2c1C1CCCN1C2=O,CHEMBL141247,IC50,20000.0,nM,,CHEMBL677394,CHEMBL203,CHEMBL1134322,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12,283.2659999999998,2.807900000000001,2,4,79.8,2,3,0.7575303900917083,0,O=C(Nc1cnccn1)Nc1ccnc2ccccc12,CHEMBL1975647,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1cnccn1)Nc1ccnc2ccccc12,265.2759999999998,2.668800000000001,2,4,79.8,2,3,0.746139464534418,0,O=C(Nc1cnccn1)Nc1ccnc2ccccc12,CHEMBL1981720,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,425.5139999999997,1.9751999999999998,1,7,96.67,5,3,0.6714427615145171,0,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,CHEMBL3301607,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1,340.3389999999997,2.5792,2,6,110.29000000000002,7,3,0.5291564475607599,0,O=C(Nc1nc2ccccc2[nH]1)c1ccccc1,CHEMBL210887,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1cc(F)ccc1O)N1Cc2ccccc2C1=O,383.4039999999999,3.3236000000000017,2,5,82.53,5,3,0.724063282969499,0,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O,CHEMBL4214567,IC50,3.0,nM,8.52,CHEMBL5143776,CHEMBL203,CHEMBL5143505,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1cc[nH]n1)N1Cc2ccccc2C1=O,339.3799999999999,2.202,2,5,90.97999999999999,4,3,0.7622318235265105,0,O=C(Nc1nccs1)C(c1cc[nH]n1)N1Cc2ccccc2C1=O,CHEMBL5208369,IC50,938.0,nM,6.03,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O,349.41499999999985,3.478900000000002,1,4,62.300000000000004,4,3,0.784298444969999,0,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O,CHEMBL4284413,IC50,24.0,nM,7.62,CHEMBL5215200,CHEMBL203,CHEMBL5214888,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1n[nH]c2c1CCC2)N1Cc2ccccc2C1=O,379.4449999999999,2.6907000000000005,2,5,90.97999999999999,4,3,0.7291318828271967,0,O=C(Nc1nccs1)C(c1n[nH]c2c1CCC2)N1Cc2ccccc2C1=O,CHEMBL5195669,IC50,23.0,nM,7.64,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2c(Cl)cccc2C1=O,413.88999999999993,3.275000000000002,1,6,80.12,4,3,0.711373254939224,0,O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccccc2C1=O,CHEMBL5173979,IC50,4.0,nM,8.4,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2c(F)cc(C#Cc3cccnc3)cc2C1=O,498.543,3.555500000000002,1,7,93.00999999999999,4,4,0.4346202116686042,0,O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccc(C#Cc3cccnc3)cc2C1=O,CHEMBL5189114,IC50,7.0,nM,8.15,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccc(C#Cc3cccnc3)cc2C1=O,480.553,3.416400000000002,1,7,93.00999999999999,4,4,0.4520648564800475,0,O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccc(C#Cc3cccnc3)cc2C1=O,CHEMBL5171139,IC50,460.0,nM,6.34,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccccc2C1=O,379.4449999999999,2.621600000000001,1,6,80.12,4,3,0.7556700904672818,0,O=C(Nc1nccs1)C(c1ncn2c1CCC2)N1Cc2ccccc2C1=O,CHEMBL5203388,IC50,16.0,nM,7.8,CHEMBL5120428,CHEMBL203,CHEMBL5113538,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(Nc1nccs1)[C@@H](c1cc(F)ccc1O)N1Cc2ccccc2C1=O,383.4039999999999,3.3236000000000017,2,5,82.53,5,3,0.724063282969499,0,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O,CHEMBL4452106,IC50,2.0,nM,8.7,CHEMBL4410887,CHEMBL203,CHEMBL4406912,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)C1CCC2(CC1)OOC1(OO2)C2CC3CC(C2)CC1C3,324.3729999999996,3.0199000000000016,1,6,74.22000000000001,1,0,0.7474300690571328,0,C1CCC2(CC1)OOC1(OO2)C2CC3CC(C2)CC1C3,CHEMBL1830034,IC50,10000.0,nM,,CHEMBL3999847,CHEMBL203,CHEMBL3997839,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C(O)CCC(=O)Nc1cc(Nc2ccc(Cl)cc2)ncn1,320.73599999999976,2.6769000000000007,3,6,104.21,6,2,0.7555616404632333,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4287629,IC50,792.0,nM,6.1,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCCC(=O)Nc1cc(N2CCOCC2)ncn1,294.31099999999964,0.5065999999999997,2,7,104.64999999999999,6,1,0.7870304079853485,0,c1cc(N2CCOCC2)ncn1,CHEMBL4283970,IC50,11.0,nM,7.96,CHEMBL4267257,CHEMBL203,CHEMBL4265907,0.6,Activity in Type 1 range; Activity in typical Type 1 range; H-bond features typical of Type 1
O=C(O)CCCC(=O)Nc1cc(Nc2ccc(Cl)cc2)ncn1,334.76299999999975,3.067,3,6,104.21,7,2,0.7184614475595784,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4289682,IC50,944.0,nM,6.03,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCCC(=O)Nc1cc(Nc2cccc(Br)c2)ncn1,379.21399999999977,3.176100000000001,3,6,104.21,7,2,0.6827506835681117,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4286263,IC50,70.0,nM,7.16,CHEMBL4267255,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCCC(=O)Nc1cc(Nc2cccc(Cl)c2)ncn1,334.76299999999975,3.067,3,6,104.21,7,2,0.7184614475595784,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4282460,IC50,7.0,nM,8.15,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCCC(=O)Nc1cc(Nc2ccccc2)ncn1,300.3179999999997,2.4136000000000006,3,6,104.21,7,2,0.7250628181381438,0,c1ccc(Nc2ccncn2)cc1,CHEMBL4278997,IC50,105.0,nM,6.98,CHEMBL4267257,CHEMBL203,CHEMBL4265907,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCNc1c(Br)cccc1Nc1ncnc2ccncc12,388.2249999999999,3.4175000000000013,3,7,100.03,6,3,0.5950398106876298,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL408399,IC50,0.6166,nM,9.21,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,388.22499999999985,3.4175000000000013,3,7,100.03,6,3,0.5950398106876298,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL163168,IC50,27.0,nM,7.57,CHEMBL674648,CHEMBL203,CHEMBL1131301,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,388.2249999999998,3.4175000000000013,3,7,100.03,6,3,0.5950398106876298,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL127086,IC50,0.6026,nM,9.22,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CCc1c(/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)[nH]c2c1CCCC2,380.39999999999975,3.101600000000002,4,5,119.49000000000001,5,2,0.5943541658077995,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL431996,IC50,56500.0,nM,4.25,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=C(O)CCc1c(/C=C2\C(=O)Nc3ccccc32)[nH]c2c1CCCC2,336.39099999999974,3.403400000000002,3,3,82.19,4,2,0.7484452256217751,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL315753,IC50,100000.0,nM,,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=C(O)CN1Cc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,385.2209999999999,3.5405000000000015,2,6,78.35000000000001,4,3,0.7155153448415007,0,c1ccc(Nc2ncnc3cc4c(cc23)CN4)cc1,CHEMBL489308,IC50,5.129,nM,8.29,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)CNc1c(Br)cccc1Nc1ncnc2ccncc12,374.19799999999987,3.027400000000001,3,7,100.03,5,3,0.6312422422594748,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL405771,IC50,1.514,nM,8.82,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,374.1979999999998,3.027400000000001,3,7,100.03,5,3,0.6312422422594748,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL355816,IC50,0.28,nM,9.55,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,374.19799999999987,3.027400000000001,3,7,100.03,5,3,0.6312422422594748,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL338175,IC50,1.5,nM,8.82,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,287.27099999999973,2.1811000000000003,4,6,110.35000000000001,7,2,0.5086049790016567,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL171000,IC50,35000.0,nM,4.46,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,289.2869999999997,2.0425999999999997,5,6,110.02000000000001,8,2,0.5387678894156656,0,c1ccc(CNc2ccccc2)cc1,CHEMBL171085,IC50,6000.0,nM,5.22,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,398.21999999999986,3.5702000000000016,2,7,92.92999999999999,4,4,0.5461438757446158,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1,CHEMBL36819,IC50,52.48,nM,7.28,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)[C@@H]1O[C@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,429.2299999999999,2.9264,3,7,116.74000000000001,5,3,0.5342725411359199,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CO1,CHEMBL2021575,IC50,0.5,nM,9.3,CHEMBL1072157,CHEMBL203,CHEMBL1157583,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)[C@H]1O[C@@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,429.2299999999999,2.9264,3,7,116.74000000000001,5,3,0.5342725411359199,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CO1,CHEMBL2021576,IC50,0.49,nM,9.31,CHEMBL1072157,CHEMBL203,CHEMBL1157583,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,273.24399999999974,2.2521999999999998,4,6,110.35000000000001,6,2,0.5060934582688746,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL316764,IC50,5000.0,nM,5.3,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1cc(/N=C/c2ccccc2O)ccc1O,257.245,2.546600000000001,3,5,90.12,5,2,0.7368409822338415,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL130694,IC50,20000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)c1cc(CCc2cc(O)ccc2O)ccc1O,274.2719999999997,2.286800000000001,4,5,97.99000000000001,7,2,0.6411474343391759,0,c1ccc(CCc2ccccc2)cc1,CHEMBL103860,IC50,3300.0,nM,5.48,CHEMBL674642,CHEMBL203,CHEMBL1127418,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O,381.3839999999998,3.414000000000002,5,7,121.46000000000001,10,3,0.41484854462874077,0,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1,CHEMBL103552,IC50,4100.0,nM,5.39,CHEMBL674642,CHEMBL203,CHEMBL1127418,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,275.2599999999997,2.1137,5,6,110.02000000000001,7,2,0.5465776520357241,0,c1ccc(CNc2ccccc2)cc1,CHEMBL319620,IC50,30.0,nM,7.52,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1cc(NCc2ccccc2O)ccc1O,259.26099999999997,2.4081000000000006,4,5,89.79,6,2,0.6329821396234662,0,c1ccc(CNc2ccccc2)cc1,CHEMBL131407,IC50,20000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1ccc(Nc2nncc3ccccc23)cc1,265.27199999999976,3.071600000000001,2,5,75.11,3,3,0.7607860678475888,0,c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3937949,IC50,6.2,nM,8.21,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)c(O)c1,365.3189999999999,2.1055,2,8,144.04,7,2,0.4497188730255791,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL77688,IC50,300.0,nM,6.52,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,349.3199999999999,2.3999000000000006,1,7,123.81,6,2,0.4821607948417026,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL76958,IC50,1000.0,nM,6.0,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,365.3189999999999,2.1055000000000006,2,8,144.04,7,2,0.4497188730255791,0,O=S(=O)(Oc1ccccc1)c1ccccc1,CHEMBL449093,IC50,50.0,nM,7.3,CHEMBL941404,CHEMBL203,CHEMBL1150213,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)c1cccc(/N=C/c2cc(O)ccc2O)c1,257.245,2.5465999999999998,3,5,90.12,5,2,0.5818297639619144,0,C(=N/c1ccccc1)\c1ccccc1,CHEMBL130116,IC50,20000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(O)c1cccc(NCc2cc(O)ccc2O)c1,259.26099999999997,2.4081,4,5,89.79,6,2,0.6329821396234662,0,c1ccc(CNc2ccccc2)cc1,CHEMBL129907,IC50,20000.0,nM,,CHEMBL676146,CHEMBL203,CHEMBL1127084,0.4,Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,308.3409999999998,3.278500000000002,3,5,90.9,3,3,0.6904642098444874,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,CHEMBL74645,IC50,25700.0,nM,4.59,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.65,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,346.34999999999974,3.5383000000000004,4,7,115.82,5,4,0.4366141482650092,0,c1ccc(Nc2ccnc(Nc3ccc4[nH]ncc4c3)n2)cc1,CHEMBL396523,Ki,316.23,nM,6.5,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1,346.34999999999974,3.5383000000000004,4,7,115.82000000000001,5,4,0.4366141482650092,0,c1ccc(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)cc1,CHEMBL244378,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,322.3239999999997,3.3676000000000013,4,7,107.37,6,3,0.5701763663392925,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1,CHEMBL243088,Ki,199.53,nM,6.7,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(O)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl,483.9119999999998,3.5530000000000017,3,9,125.91000000000001,8,3,0.4404858974160638,0,O=C(COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)N1CCOCC1,CHEMBL4873830,IC50,81.4,nM,7.09,CHEMBL4832126,CHEMBL203,CHEMBL4831496,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1,312.3289999999997,1.8147999999999995,2,5,95.25,3,3,0.7522645323294177,0,O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1,CHEMBL1997340,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1,448.5019999999997,2.1310000000000002,1,6,95.08,4,3,0.6571747250763352,0,O=C(c1cccc(Cc2n[nH]c(=O)c3c2CCCC3)c1)N1CCN(c2ncccn2)CC1,CHEMBL1986530,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C(c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1)N1CCN(CCO)CC1,503.62799999999964,3.2539000000000016,3,8,101.82,10,4,0.3392760101800254,1,O=C(c1ccc(-c2cc3c(NCc4ccccc4)ncnc3s2)cc1)N1CCNCC1,CHEMBL3416632,IC50,5000.0,nM,,CHEMBL3418213,CHEMBL203,CHEMBL3414443,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,332.40699999999964,2.7787000000000006,2,3,61.02,3,3,0.7752072726994866,0,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,CHEMBL1908397,Kd,560.0,nM,6.25,CHEMBL1908704,CHEMBL203,CHEMBL1908390,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1,307.3529999999997,2.7023,1,3,58.22,2,3,0.7916981840643419,0,O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1,CHEMBL1997872,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12,281.31499999999966,1.9031999999999998,1,3,57.58,2,3,0.7797033053485777,0,O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12,CHEMBL539474,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Contains quinazoline core; LogP in drug-like range; Aromatic ring count typical
O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21,282.2169999999998,3.3308000000000018,0,3,47.28,0,2,0.7442421938718567,0,O=C1CCCc2oc3ccccc3c(=O)c21,CHEMBL2006493,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CCN1,484.53899999999976,3.331900000000002,2,8,92.38,6,5,0.38420783124634555,0,O=C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)CCN1,CHEMBL233324,IC50,240.0,nM,6.62,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CCN1,470.5119999999998,2.9418000000000006,2,8,92.38,6,5,0.3965511988106612,0,O=C1CN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)CCN1,CHEMBL265629,IC50,350.0,nM,6.46,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,484.5389999999999,2.9843,2,9,92.38,6,5,0.38285512716324055,0,O=C1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)C1,CHEMBL234580,IC50,780.0,nM,6.11,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
O=C1COc2cc3ncnc(Nc4ccc(Br)cc4)c3cc2N1CCCN1CCOCC1,498.38099999999986,3.5836000000000015,1,7,79.82,6,3,0.5567594868348797,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774609,IC50,823.9,nM,6.08,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1COc2cc3ncnc(Nc4ccc(Cl)cc4)c3cc2N1CCCN1CCOCC1,453.92999999999984,3.4745000000000017,1,7,79.82,6,3,0.6116567670139196,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3775911,IC50,353.7,nM,6.45,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1COc2cc3ncnc(Nc4ccc(F)cc4)c3cc2N1CCCN1CCOCC1,437.4749999999998,2.9602000000000013,1,7,79.82,6,3,0.6351499321369143,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774471,IC50,434.1,nM,6.36,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1COc2cc3ncnc(Nc4cccc(Br)c4)c3cc2N1CCCN1CCOCC1,498.3809999999998,3.5836000000000015,1,7,79.82,6,3,0.5567594868348797,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774906,IC50,89.6,nM,7.05,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1COc2cc3ncnc(Nc4cccc(Cl)c4)c3cc2N1CCCN1CCOCC1,453.92999999999984,3.4745000000000017,1,7,79.82,6,3,0.6116567670139196,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3774947,IC50,63.1,nM,7.2,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1COc2cc3ncnc(Nc4cccc(F)c4)c3cc2N1CCCN1CCOCC1,437.4749999999998,2.9602000000000013,1,7,79.82,6,3,0.6351499321369143,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3775285,IC50,245.1,nM,6.61,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,419.48499999999973,2.8211000000000013,1,7,79.82,6,3,0.6580951654149289,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,CHEMBL3775148,IC50,518.6,nM,6.29,CHEMBL3776094,CHEMBL203,CHEMBL3774304,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1CS/C(=N/Nc2nncc3ccccc23)N1,259.294,1.1756999999999997,2,6,79.27000000000001,2,2,0.7915331807718758,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1,CHEMBL3938794,IC50,51.0,nM,7.29,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1,335.3919999999999,3.0927000000000016,1,6,70.48,3,3,0.7448981753427978,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1,CHEMBL3982619,IC50,45.0,nM,7.35,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1CSC(N/N=C/c2cc(Br)cc(Br)c2O)=N1,393.0599999999999,2.470100000000001,2,5,74.05,3,1,0.5984626580200634,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL590875,IC50,1240.0,nM,5.91,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C1CSC(N/N=C/c2cc(Br)ccc2O)=N1,314.1639999999999,1.7076,2,5,74.05,3,1,0.6436424253541573,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL592457,IC50,90.0,nM,7.05,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.85,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C1CSC(N/N=C/c2cc(Cl)cc(Cl)c2O)=N1,304.1579999999999,2.2519000000000005,2,5,74.05,3,1,0.6490009998557545,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL592481,IC50,1460.0,nM,5.84,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C1CSC(N/N=C/c2cc(Cl)ccc2O)=N1,269.7129999999998,1.5984999999999998,2,5,74.05,3,1,0.6317096900336168,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL592480,IC50,560.0,nM,6.25,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2cc(F)ccc2O)=N1,253.25800000000004,1.0842,2,5,74.05,3,1,0.6107769253203881,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL602328,IC50,970.0,nM,6.01,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.7,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2ccc(Br)cc2)=N1,298.16499999999985,2.002,1,4,53.82,2,1,0.6709595843048989,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL591910,IC50,1720.0,nM,5.76,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2ccc(Cl)cc2)=N1,253.71400000000006,1.8929,1,4,53.82,2,1,0.646954341778492,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL589823,IC50,1940.0,nM,5.71,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2ccc([N+](=O)[O-])cc2)=N1,264.2659999999998,1.1477,1,6,96.96,3,1,0.501434716096333,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL604671,IC50,6820.0,nM,5.17,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2cccc(Br)c2)=N1,298.16499999999985,2.0020000000000002,1,4,53.82,2,1,0.6709595843048989,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL590524,IC50,7460.0,nM,5.13,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N/N=C/c2cccc([N+](=O)[O-])c2)=N1,264.2659999999998,1.1477,1,6,96.96,3,1,0.501434716096333,0,O=C1CSC(N/N=C/c2ccccc2)=N1,CHEMBL591050,IC50,26610.0,nM,4.58,CHEMBL1064820,CHEMBL203,CHEMBL1157666,0.4,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1
O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,321.40499999999975,3.467100000000002,0,4,45.03,2,2,0.8506225265085757,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,CHEMBL1958019,IC50,3380.0,nM,5.47,CHEMBL1958796,CHEMBL203,CHEMBL1955848,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1,328.16899999999987,3.487000000000001,2,2,57.78,0,3,0.663652306602305,0,O=C1Cc2c([nH]c3ccccc23)-c2ncccc2N1,CHEMBL336961,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,293.28199999999975,3.2377000000000002,2,3,88.03,1,3,0.5329812130059154,0,O=C1Cc2c([nH]c3ccccc23)-c2ccccc2N1,CHEMBL50894,Ki,1000.0,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,257.274,1.9537,1,5,71.95,1,2,0.7904639602378932,0,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,CHEMBL568150,IC50,10000.0,nM,,CHEMBL3778248,CHEMBL203,CHEMBL3774321,0.9999999999999999,Activity in Type 1 range; Contains quinazoline core; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,327.3429999999998,3.216400000000001,3,2,77.75,2,4,0.4943855376376712,0,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,CHEMBL266487,IC50,50000.0,nM,,CHEMBL679549,CHEMBL203,CHEMBL1127678,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccc(O)cc1,308.3369999999997,2.5276000000000005,2,3,69.64,5,2,0.6733826697740056,0,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccccc1,CHEMBL213560,IC50,710.0,nM,6.15,CHEMBL866710,CHEMBL203,CHEMBL1146012,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,369.42399999999975,3.592600000000002,2,3,66.89,2,4,0.5303973124628919,0,O=C1NC(=O)C(c2cn3c4c(cccc24)CCC3)C1c1c[nH]c2ccccc12,CHEMBL2103882,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NC(=O)c2cc(Nc3ccc(O)cc3)c(Nc3ccc(O)cc3)cc21,361.35699999999986,3.4686000000000003,5,6,110.69000000000001,6,3,0.35944773615677444,0,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21,CHEMBL267019,IC50,2500.0,nM,5.6,CHEMBL679549,CHEMBL203,CHEMBL1127678,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NC(=S)N/C1=C\c1ccc2ncsc2c1,261.3309999999999,1.6415,2,4,54.02,1,2,0.6051045256113032,0,O=C1NC(=S)N/C1=C\c1ccc2ncsc2c1,CHEMBL3775754,IC50,10000.0,nM,,CHEMBL3778248,CHEMBL203,CHEMBL3774321,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1NC(=S)S/C1=C\c1ccc2c(c1)CCO2,263.34299999999985,2.1102999999999996,1,4,38.33,1,1,0.6219214163297403,0,O=C1NC(=S)S/C1=C\c1ccc2c(c1)CCO2,CHEMBL3774830,IC50,10000.0,nM,,CHEMBL3778248,CHEMBL203,CHEMBL3774321,0.5,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,272.3539999999998,2.723600000000001,1,4,41.99,1,2,0.6400207136057642,0,O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,CHEMBL3774448,IC50,10000.0,nM,,CHEMBL3778248,CHEMBL203,CHEMBL3774321,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,278.3829999999999,2.785100000000001,1,5,41.99,1,2,0.6431745330376714,0,O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,CHEMBL3775393,IC50,10000.0,nM,,CHEMBL3778248,CHEMBL203,CHEMBL3774321,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21,341.21099999999996,2.2602,2,4,58.2,0,1,0.5614558794060808,0,O=C1NC(=S)SC1=C1C(=O)Nc2ccccc21,CHEMBL2001920,Ki,1584.89,nM,5.8,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.85,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21,307.32799999999975,3.168700000000001,2,2,57.78,2,3,0.7637860751295379,0,O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4)c3)cc21,CHEMBL226471,Ki,630.96,nM,6.2,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21,340.3859999999998,3.5778000000000025,2,3,70.67,2,4,0.5858439252332432,0,O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21,CHEMBL226403,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21,315.3759999999997,3.533000000000002,2,2,57.78,3,3,0.7765610345577946,0,O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21,CHEMBL1997129,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23,344.3739999999998,2.987400000000002,3,3,86.35,3,3,0.682085554565901,0,O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23,CHEMBL1969502,Ki,398.11,nM,6.4,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1N[C@H](C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)CO1,544.9710000000014,3.313900000000001,3,9,126.94000000000001,9,3,0.34759146608393776,1,O=C1NC(C(=O)Nc2cc3c(Nc4ccccc4)ncnc3cc2OCCCN2CCOCC2)CO1,CHEMBL3818289,IC50,0.83,nM,9.08,CHEMBL3820193,CHEMBL203,CHEMBL3817746,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1Nc2ccc(C(=O)O)cc2/C1=C/c1cc2c([nH]1)CCCC2,308.3369999999997,3.0844000000000014,3,3,82.19,2,2,0.7456060359509588,0,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2,CHEMBL89010,IC50,100000.0,nM,,CHEMBL679949,CHEMBL203,CHEMBL1133768,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\O,295.2729999999998,2.7929000000000004,3,4,73.72,1,2,0.39732533538006454,0,N=C1/C(=C2/C(=O)Nc3ccccc32)Nc2ccccc21,CHEMBL1077291,IC50,10000.0,nM,,CHEMBL1106060,CHEMBL203,CHEMBL1155384,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/Nc1ccccc1,386.4329999999998,1.4757999999999996,2,6,100.10000000000001,4,2,0.7755112258273426,0,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/Nc1ccccc1,CHEMBL4281426,IC50,46.0,nM,7.34,CHEMBL4274200,CHEMBL203,CHEMBL4270595,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccc(O)cc1,387.41699999999986,1.486,2,6,108.30000000000001,4,2,0.829453471773599,0,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccccc1,CHEMBL4288648,IC50,751.0,nM,6.12,CHEMBL4274200,CHEMBL203,CHEMBL4270595,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=C1Nc2ccccc2/C1=C/c1ccc(N2CCOCC2)cc1,306.36499999999967,3.015900000000001,1,3,41.57000000000001,2,2,0.8672640568997367,0,O=C1Nc2ccccc2/C1=C/c1ccc(N2CCOCC2)cc1,CHEMBL86480,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=C1Nc2ccccc2Nc2nnc(I)cc21,338.1079999999999,2.3904999999999994,2,4,66.91,0,2,0.7241906210517662,0,O=C1Nc2ccccc2Nc2nnccc21,CHEMBL1977346,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=C1Nc2ncnc(Nc3ccc(F)c(Cl)c3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1,511.94499999999994,2.895500000000001,4,7,124.26999999999998,7,3,0.3594565557908186,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1,CHEMBL302552,IC50,22.0,nM,7.66,CHEMBL674637,CHEMBL203,CHEMBL1134862,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=C1c2ccccc2CN1C(c1nc(=O)c2ccccc2[nH]1)c1cc(F)ccc1O,401.3969999999998,3.5132000000000017,2,4,86.29,4,4,0.5500910104712436,0,O=C1c2ccccc2CN1C(c1ccccc1)c1nc(=O)c2ccccc2[nH]1,CHEMBL5206476,IC50,5300.0,nM,5.28,CHEMBL5215207,CHEMBL203,CHEMBL5214888,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=CN1CCN(c2ccc(/C=C3\C(=O)Nc4ccc(Br)cc43)cc2)CC1,412.28699999999975,3.220200000000002,1,3,52.650000000000006,2,2,0.6224578093693941,0,O=C1Nc2ccccc2/C1=C/c1ccc(N2CCNCC2)cc1,CHEMBL88405,IC50,50000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=CN1CCN(c2ccc(/C=C3\C(=O)Nc4ccccc43)cc2)CC1,333.3909999999997,2.457700000000001,1,3,52.650000000000006,2,2,0.6933648256216971,0,O=C1Nc2ccccc2/C1=C/c1ccc(N2CCNCC2)cc1,CHEMBL315546,IC50,100000.0,nM,,CHEMBL676159,CHEMBL203,CHEMBL1131018,0.3,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical; Very weak activity (penalty)
O=P(O)(O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,325.2569999999998,2.0932,6,7,130.25,10,2,0.3664755988269585,1,c1ccc(CNc2ccccc2)cc1,CHEMBL352876,IC50,3000.0,nM,5.52,CHEMBL680022,CHEMBL203,CHEMBL1127676,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=S(=O)(CCO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,409.2649999999998,2.2969,2,7,105.07000000000001,6,3,0.666313111899485,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL335440,IC50,93.5,nM,7.03,CHEMBL673925,CHEMBL203,CHEMBL1134843,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=S(=O)(CO)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,410.2529999999999,2.2223999999999995,3,7,117.10000000000001,6,3,0.590558758814415,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL503755,IC50,93.33,nM,7.03,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12,446.3699999999999,3.5786000000000024,2,4,71.09,8,3,0.5193465752944636,0,O=S(=O)(NCCNCC=Cc1ccccc1)c1cccc2cnccc12,CHEMBL1987756,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S(=O)(Nc1ccccn1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,428.49499999999995,3.420000000000001,3,6,101.58000000000001,5,3,0.5316143390888373,0,O=S(=O)(Nc1ccccn1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,CHEMBL4778717,IC50,1885.0,nM,5.72,CHEMBL4769431,CHEMBL203,CHEMBL4765304,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=S(=O)(Nc1ccccn1)c1ccc(Nc2nncc3ccccc23)cc1,377.4289999999999,3.569200000000002,2,6,96.87,5,4,0.551835562496766,0,O=S(=O)(Nc1ccccn1)c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3978686,IC50,84.0,nM,7.08,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1,378.4169999999999,2.964200000000001,2,7,109.76,5,4,0.5492210204940257,0,O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1,CHEMBL3908272,IC50,86.0,nM,7.07,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,434.524,3.4815000000000014,3,7,101.58000000000001,5,3,0.5248548090334605,0,O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,CHEMBL4799700,IC50,1623.0,nM,5.79,CHEMBL4769431,CHEMBL203,CHEMBL4765304,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=S(=O)(O)CCNc1c(Br)cccc1Nc1ncnc2ccncc12,424.2799999999999,2.8306000000000004,3,8,117.10000000000001,7,3,0.5175314249027725,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270895,IC50,1.413,nM,8.85,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S(=O)(O)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,424.27999999999986,2.8306000000000004,3,8,117.10000000000001,7,3,0.5175314249027725,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL128467,IC50,1.4,nM,8.85,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S(=O)(O)c1cc(NCc2cc(O)ccc2O)ccc1O,311.31499999999977,1.6621999999999997,5,7,127.09000000000002,8,2,0.4290001756980039,0,c1ccc(CNc2ccccc2)cc1,CHEMBL122785,IC50,10300.0,nM,4.99,CHEMBL677211,CHEMBL203,CHEMBL1159167,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1,307.37499999999966,0.9243999999999999,2,5,82.53,3,2,0.8620863798782131,0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL1233300,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; H-bond features typical of Type 1; Aromatic ring count typical
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,291.3759999999997,1.2187999999999999,1,4,62.300000000000004,2,2,0.9034566339582102,0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL38380,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S1(=O)CC2(OCCO2)c2cc3nccc(Nc4ccc5scnc5c4)c3cc21,425.49099999999993,3.575000000000002,1,8,90.41000000000001,2,4,0.5249368816158787,0,O=S1(=O)CC2(OCCO2)c2cc3nccc(Nc4ccc5scnc5c4)c3cc21,CHEMBL4861646,IC50,10000.0,nM,,CHEMBL4817026,CHEMBL203,CHEMBL4813992,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=S1(=O)N=S(c2ccc(Br)cc2)c2ccc(F)cc21,360.229,3.5104000000000006,0,2,46.5,1,2,0.7814422814835917,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL2205024,IC50,40000.0,nM,,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=S1(=O)N=S(c2ccc(Br)cc2)c2ccncc21,343.227,2.766300000000001,0,3,59.39,1,2,0.8000023753824878,0,O=S1(=O)N=S(c2ccccc2)c2ccncc21,CHEMBL2205030,IC50,5400.0,nM,5.27,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=[N+]([O-])c1cc(NCc2cc(O)ccc2O)ccc1O,276.24799999999976,2.3237,4,6,115.86000000000001,7,2,0.38668074707294436,0,c1ccc(CNc2ccccc2)cc1,CHEMBL123045,IC50,5400.0,nM,5.27,CHEMBL677211,CHEMBL203,CHEMBL1159167,0.7,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
O=[N+]([O-])c1ccc(/C=N/Nc2nnc(-c3ccncc3)o2)cc1,310.27299999999985,2.4858000000000002,1,8,119.34,5,3,0.43640077766120267,0,C(=N/Nc1nnc(-c2ccncc2)o1)\c1ccccc1,CHEMBL4561572,IC50,412.3,nM,6.38,CHEMBL4313654,CHEMBL203,CHEMBL4311968,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1ccc2c(NCc3ccccc3)ncnc2c1,280.2869999999998,3.150100000000001,1,5,80.95,4,3,0.5861537000001423,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL116748,IC50,5900.0,nM,5.23,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1ccc2c(Nc3cccc(F)c3)ncnc2c1,284.24999999999983,3.420700000000002,1,5,80.95,3,3,0.588375517380324,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL329183,IC50,6100.0,nM,5.21,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1ccc2c(Nc3ccccc3)ncnc2c1,266.2599999999998,3.281600000000001,1,5,80.95,3,3,0.5807932854962622,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL91914,IC50,12000.0,nM,4.92,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,387.23599999999993,3.2795000000000014,0,4,89.64,2,2,0.5843360881802505,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21,CHEMBL605161,IC50,22000.0,nM,4.66,CHEMBL2208688,CHEMBL203,CHEMBL2203023,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=[N+]([O-])c1ccc2ncnc(NCc3ccccc3)c2c1,280.28699999999975,3.150100000000001,1,5,80.95,4,3,0.5861537000001423,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL119000,IC50,10000.0,nM,,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1ccc2ncnc(Nc3ccccc3)c2c1,266.25999999999976,3.281600000000001,1,5,80.95,3,3,0.5807932854962622,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL328295,IC50,5000.0,nM,5.3,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1cccc(Nc2nccc(-c3ccccn3)n2)c1,293.2859999999998,3.1904000000000012,1,6,93.84,4,3,0.5861212844966496,0,c1ccc(Nc2nccc(-c3ccccn3)n2)cc1,CHEMBL60816,IC50,100000.0,nM,,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
O=[N+]([O-])c1cccc(Nc2nccc(-c3cccnc3)n2)c1,293.28599999999983,3.1904000000000012,1,6,93.84,4,3,0.5861212844966496,0,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,CHEMBL56081,IC50,100000.0,nM,4.0,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
O=[N+]([O-])c1cccc(Nc2nccc(-c3ccncc3)n2)c1,293.28599999999983,3.1904000000000003,1,6,93.84,4,3,0.5861212844966496,0,c1ccc(Nc2nccc(-c3ccncc3)n2)cc1,CHEMBL55683,IC50,100000.0,nM,,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
O=[N+]([O-])c1cccc2c(NCc3ccccc3)ncnc12,280.28699999999975,3.150100000000001,1,5,80.95,4,3,0.5861537000001423,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL117696,IC50,10000.0,nM,,CHEMBL677205,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=[N+]([O-])c1cccc2ncnc(NCc3ccccc3)c12,280.2869999999998,3.150100000000001,1,5,80.95,4,3,0.5861537000001423,0,c1ccc(CNc2ncnc3ccccc23)cc1,CHEMBL119708,IC50,8000.0,nM,5.1,CHEMBL677204,CHEMBL203,CHEMBL1128536,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1[nH]c(/C=C/c2cccc(F)c2)nc2ccccc12,266.27499999999975,3.2326000000000015,1,2,45.75,2,3,0.7736203112635893,0,O=c1[nH]c(/C=C/c2ccccc2)nc2ccccc12,CHEMBL5267057,IC50,10000.0,nM,,CHEMBL5242930,CHEMBL203,CHEMBL5241106,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,289.72199999999975,2.747200000000001,2,4,70.92,1,3,0.7224683040728446,0,O=c1[nH]c(C2CCCN2)nc2c1oc1ccccc12,CHEMBL3544944,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3,322.3929999999998,3.1781000000000006,1,5,63.05,1,4,0.585269182183457,0,O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3,CHEMBL2007592,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3,323.3809999999998,2.5731,1,6,75.94,1,4,0.5839713742147863,0,O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3,CHEMBL1970806,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3,323.3809999999998,2.5731,1,6,75.94,1,4,0.5839713742147863,0,O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3,CHEMBL1966808,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12,269.2889999999998,1.6942999999999993,1,6,75.94,1,4,0.570288793359232,0,O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12,CHEMBL1968151,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12,371.56499999999994,2.9476000000000013,1,3,50.16,1,3,0.6687885857721445,0,O=c1[nH]ccc2nc(-c3ccccc3)cn12,CHEMBL1982610,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12,413.48099999999977,3.315800000000002,2,5,86.9,5,4,0.5241872922478955,0,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12,CHEMBL461139,IC50,10000.0,nM,,CHEMBL955786,CHEMBL203,CHEMBL1152141,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12,271.12799999999993,3.4446000000000003,1,3,45.75,0,3,0.6802918468805197,0,O=c1[nH]cnc2c1sc1ccccc12,CHEMBL583144,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,270.2399999999998,2.576800000000001,3,5,90.9,4,3,0.6318329361180623,0,O=c1c(-c2ccccc2)coc2ccccc12,CHEMBL44,IC50,600.0,nM,6.22,CHEMBL5131965,CHEMBL203,CHEMBL5131376,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1c(-c2cccc(Cl)c2)coc2cc(O)cc(O)c12,288.6859999999998,3.524600000000001,2,4,70.67,3,3,0.7184898389933716,0,O=c1c(-c2ccccc2)coc2ccccc12,CHEMBL7827,IC50,95.0,nM,7.02,CHEMBL677887,CHEMBL203,CHEMBL1132606,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O,348.1889999999999,3.3401000000000023,2,5,71.09,5,3,0.6922950751930791,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1975900,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O,313.74399999999986,2.6867,2,5,71.09,5,3,0.7086521094581059,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1980489,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O,347.2959999999999,3.052100000000001,2,5,71.09,5,3,0.6943808106738237,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1979252,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O,297.2889999999998,2.1723999999999997,2,5,71.09,5,3,0.7062652339131348,0,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O,CHEMBL1982361,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,302.23799999999983,1.988,5,7,131.36,6,3,0.43419044029909815,0,O=c1cc(-c2ccccc2)oc2ccccc12,CHEMBL50,IC50,900.0,nM,6.05,CHEMBL1029460,CHEMBL203,CHEMBL1158361,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1,270.33599999999973,2.5765000000000002,2,4,70.67,3,2,0.898923594284486,0,O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1,CHEMBL1958401,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1,288.3099999999997,2.980200000000001,2,3,74.43,2,4,0.5951911462428789,0,O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1,CHEMBL526133,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc2n1CCCN1CCOCC1,441.4379999999999,3.2818000000000014,1,8,85.41999999999999,6,4,0.49152086334729955,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064389,IC50,570.0,nM,6.24,CHEMBL2066000,CHEMBL203,CHEMBL2062376,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
O=c1oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc2n1CCCN1CCOCC1,445.48299999999983,2.879900000000001,2,9,114.1,6,5,0.4101308594675628,0,O=c1oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc2n1CCCN1CCOCC1,CHEMBL2064403,IC50,120.0,nM,6.92,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
O=c1oc2cc3ncnc(Nc4ccccc4O)c3cc2n1CCCN1CCOCC1,421.45699999999977,2.7092,2,9,105.65,7,4,0.4579944535579647,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1,CHEMBL2064388,IC50,30000.0,nM,4.52,CHEMBL2066000,CHEMBL203,CHEMBL2062376,0.5,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,334.3999999999998,3.2622000000000018,0,5,44.0,3,4,0.5771029549850707,0,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,CHEMBL3545157,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.30000000000000004,MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OB(O)/C=C/COc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,355.5899999999998,2.9738000000000007,3,6,87.5,8,3,0.5892804577050853,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3347488,IC50,270.0,nM,6.57,CHEMBL3391161,CHEMBL203,CHEMBL3390847,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OB(O)c1ccc(COc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,405.64999999999986,3.2856000000000005,3,6,87.5,8,4,0.4267528099851934,0,c1ccc(COc2ccc3ncnc(Nc4ccccc4)c3c2)cc1,CHEMBL3347498,IC50,850.0,nM,6.07,CHEMBL3391161,CHEMBL203,CHEMBL3390847,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OB(O)c1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,317.51599999999985,1.8456999999999992,3,5,78.27000000000001,5,3,0.6425967376083432,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3219506,IC50,800.0,nM,6.1,CHEMBL3223148,CHEMBL203,CHEMBL3217494,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OB(O)c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,299.52599999999984,1.7065999999999992,3,5,78.27000000000001,5,3,0.6417400828499127,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL3218424,IC50,650.0,nM,6.19,CHEMBL3223148,CHEMBL203,CHEMBL3217494,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1,343.81799999999976,3.388700000000001,3,5,86.72,4,3,0.6344614746232909,0,c1cnc2[nH]cc(-c3nccc(NC4CCCCC4)n3)c2c1,CHEMBL1991674,Ki,630.96,nM,6.2,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,343.81799999999976,3.388700000000001,3,5,86.72,4,3,0.6344614746232909,0,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,CHEMBL1986943,Ki,794.33,nM,6.1,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,495.9709999999998,3.559400000000002,3,9,121.31000000000002,10,4,0.319666645132866,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1,CHEMBL404405,IC50,13.0,nM,7.89,CHEMBL947896,CHEMBL203,CHEMBL1143160,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1,294.35799999999966,2.586000000000001,2,4,65.03999999999999,3,3,0.7622255146626498,0,c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1,CHEMBL1973395,Ki,1584.89,nM,5.8,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCC#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,327.7459999999998,3.5097000000000014,2,4,58.040000000000006,3,3,0.7071791441171912,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL249919,IC50,14.1,nM,7.85,CHEMBL924351,CHEMBL203,CHEMBL1140520,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCC(CO)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,390.24099999999976,2.2959999999999994,4,7,103.19,8,3,0.5122032504279256,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL125568,IC50,14.0,nM,7.85,CHEMBL677387,CHEMBL203,CHEMBL1130246,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12,284.3189999999997,1.3899999999999992,4,5,94.06,7,3,0.5678334235102848,0,c1ccc(-c2c[nH]c3ncncc23)cc1,CHEMBL1992922,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.5,Activity in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCC(Nc1ncnc2sc(Br)cc12)c1ccccc1,350.24099999999993,3.599300000000002,2,5,58.04,5,3,0.7549462243945487,0,c1ccc(CNc2ncnc3sccc23)cc1,CHEMBL3416605,IC50,83.0,nM,7.08,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCC(O)CN1Cc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,401.2639999999998,2.809100000000001,3,6,81.51,7,3,0.6102646177989843,0,c1ccc(Nc2ncnc3cc4c(cc23)CN4)cc1,CHEMBL521572,IC50,1.585,nM,8.8,CHEMBL944276,CHEMBL203,CHEMBL1140899,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCC(O)CNc1c(Br)cccc1Nc1ncnc2ccncc12,390.2409999999999,2.2960000000000003,4,7,103.19,8,3,0.5122032504279255,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270695,IC50,0.9333,nM,9.03,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCC(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,390.2409999999998,2.2959999999999994,4,7,103.19,8,3,0.5122032504279255,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL166093,IC50,0.18,nM,9.74,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCC(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,390.24099999999976,2.2960000000000003,4,7,103.19,8,3,0.5122032504279255,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL126372,IC50,0.912,nM,9.04,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCC(O)Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,413.27499999999975,3.4438000000000013,3,6,83.2,7,4,0.46704755671730575,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1,CHEMBL416611,IC50,1.6,nM,8.8,CHEMBL677389,CHEMBL203,CHEMBL1130030,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCC(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,414.2629999999998,2.8388,3,7,96.09,7,4,0.46498109003281113,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1,CHEMBL37543,IC50,12.0,nM,7.92,CHEMBL677389,CHEMBL203,CHEMBL1130030,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCCNc1cc(-c2ncnc(Nc3cccc(Cl)c3)n2)ccn1,356.8169999999997,3.1249000000000002,3,7,95.85,8,3,0.5594995762578155,0,c1ccc(Nc2ncnc(-c3ccncc3)n2)cc1,CHEMBL191336,IC50,10000.0,nM,,CHEMBL832463,CHEMBL203,CHEMBL1145155,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12,268.31999999999977,2.4192,3,4,73.83,6,3,0.6212397497980424,0,c1ccc(-c2c[nH]c3ncncc23)cc1,CHEMBL2000071,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1,297.3329999999997,3.1336000000000013,1,4,50.94,6,3,0.7868717930074887,0,c1ccc(-c2nc[nH]c2-c2ccncc2)cc1,CHEMBL2004871,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCCn1cnc(-c2ccccc2)c1-c1ccncc1,279.3429999999997,2.9945000000000013,1,4,50.94,6,3,0.7808037151415669,0,c1ccc(-c2nc[nH]c2-c2ccncc2)cc1,CHEMBL2002373,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCN(CCO)CCCNc1c(Br)cccc1Nc1ncnc2ccncc12,461.3639999999998,2.6195000000000004,4,8,106.43,13,3,0.3232046327709588,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL427832,IC50,1.202,nM,8.92,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)CCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,461.36399999999963,2.6194999999999995,4,8,106.43,13,3,0.3232046327709588,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL163369,IC50,0.35,nM,9.46,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)CCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,461.3639999999997,2.6194999999999995,4,8,106.43,13,3,0.3232046327709588,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL127058,IC50,1.2,nM,8.92,CHEMBL677387,CHEMBL203,CHEMBL1130246,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)CCNc1c(Br)cccc1Nc1ncnc2ccncc12,447.33699999999976,2.2294,4,8,106.43,12,3,0.37512894337944075,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL271623,IC50,9.333,nM,8.03,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,447.33699999999965,2.229399999999999,4,8,106.43,12,3,0.37512894337944075,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL165630,IC50,0.93,nM,9.03,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,447.3369999999997,2.229399999999999,4,8,106.43,12,3,0.37512894337944075,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL435993,IC50,9.12,nM,8.04,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,456.34399999999977,3.4038000000000004,4,6,97.3,10,4,0.32466201448397525,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1,CHEMBL36164,IC50,3.467,nM,8.46,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCCN(CCO)c1c(Br)cccc1Nc1ncnc2ccncc12,404.2679999999998,2.3218999999999994,3,7,94.4,9,3,0.5565170138961495,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL406004,IC50,12.02,nM,7.92,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCN(CCO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,404.26799999999974,2.3218999999999994,3,7,94.4,9,3,0.5565170138961495,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL128759,IC50,12.0,nM,7.92,CHEMBL677387,CHEMBL203,CHEMBL1130246,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCNCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,431.47499999999974,3.0919000000000008,3,8,92.30000000000001,9,5,0.32716523325245933,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL391321,IC50,45.0,nM,7.35,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
OCCNc1c(Br)cccc1Nc1ncnc2ccncc12,360.21499999999986,2.9351000000000003,3,6,82.96,6,3,0.6490621421214131,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL270696,IC50,0.2455,nM,9.61,CHEMBL952131,CHEMBL203,CHEMBL1143196,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,360.21499999999986,2.9351000000000003,3,6,82.96,6,3,0.6490621421214132,0,c1ccc(Nc2ncnc3cnccc23)cc1,CHEMBL165864,IC50,0.19,nM,9.72,CHEMBL674648,CHEMBL203,CHEMBL1131301,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCNc1cc2cc(-c3cccnc3)ccc2cn1,265.31599999999986,2.7010000000000005,2,4,58.04,5,3,0.7611917049428282,0,c1cncc(-c2ccc3cnccc3c2)c1,CHEMBL1990912,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCNc1cc2cc(-c3ccsc3)ccc2cn1,270.3569999999997,3.3675000000000015,2,4,45.15,5,3,0.7637409769657582,0,c1cc2cc(-c3ccsc3)ccc2cn1,CHEMBL1973860,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,360.2149999999998,2.9351000000000003,3,6,82.96,6,3,0.6490621421214132,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL127041,IC50,0.2399,nM,9.62,CHEMBL944276,CHEMBL203,CHEMBL1140899,0.95,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCCOc1n[nH]c2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,412.8369999999998,3.0950000000000006,3,8,118.07000000000001,9,4,0.40374480872898216,0,c1ccc(COc2ccc(Nc3ncnc4[nH]ncc34)cc2)nc1,CHEMBL257861,IC50,16.0,nM,7.8,CHEMBL947896,CHEMBL203,CHEMBL1143160,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,334.3789999999997,2.7289000000000003,2,6,83.53,6,3,0.5675095065479836,0,N=C1CCc2cc(-c3c[nH]nc3-c3ccncc3)ccc21,CHEMBL525191,Kd,10000.0,nM,,CHEMBL1908698,CHEMBL203,CHEMBL1908390,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCN(CO)c1c(Br)cccc1Nc1ncnc2ccncc12,376.2139999999998,2.2368999999999994,3,7,94.4,7,3,0.5881804918722464,0,c1ccc(Nc2ncnc3ccncc23)cc1,CHEMBL272477,IC50,14.13,nM,7.85,CHEMBL952131,CHEMBL203,CHEMBL1143196,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC[C@@H](Nc1ncnc2[nH]c(-c3cccnc3)cc12)c1ccccc1,331.37899999999973,3.1654000000000018,3,5,86.72,6,4,0.522783770081518,0,c1ccc(CNc2ncnc3[nH]c(-c4cccnc4)cc23)cc1,CHEMBL4789312,IC50,2.2,nM,8.66,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC[C@@H](Nc1ncnc2[nH]c(-c3ccncc3)cc12)c1ccccc1,331.37899999999973,3.1654000000000018,3,5,86.72,6,4,0.522783770081518,0,c1ccc(CNc2ncnc3[nH]c(-c4ccncc4)cc23)cc1,CHEMBL4780965,IC50,2.0,nM,8.7,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,350.24099999999993,3.599300000000002,2,5,58.04,5,3,0.7549462243945487,0,c1ccc(CNc2ncnc3sccc23)cc1,CHEMBL3416603,IC50,36.0,nM,7.44,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OC[C@@H](Nc1ncnc2sc3c(c12)CCC3)c1ccccc1,311.40999999999974,3.3255000000000017,2,5,58.04,5,3,0.7757936978632793,0,c1ccc(CNc2ncnc3sc4c(c23)CCC4)cc1,CHEMBL1272006,IC50,1090.0,nM,5.96,CHEMBL1273341,CHEMBL203,CHEMBL1269003,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC[C@@H](Nc1ncnc2sc3c(c12)CCNC3)c1ccccc1,326.4249999999997,2.4825,3,6,70.07,5,3,0.6870423084522346,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1,CHEMBL1272060,IC50,20000.0,nM,,CHEMBL1273342,CHEMBL203,CHEMBL1269003,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OC[C@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,350.24099999999993,3.599300000000002,2,5,58.04,5,3,0.7549462243945487,0,c1ccc(CNc2ncnc3sccc23)cc1,CHEMBL3416604,IC50,10000.0,nM,,CHEMBL3418211,CHEMBL203,CHEMBL3414443,0.7,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
OCc1cc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)ccc1F,378.4069999999997,3.4018000000000006,4,5,94.06,8,4,0.41257137326231136,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4748149,IC50,1.6,nM,8.8,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.7999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,360.41699999999963,3.2627000000000006,4,5,94.06,8,4,0.42338852792417936,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4175024,IC50,0.2,nM,9.7,CHEMBL4718840,CHEMBL203,CHEMBL4715760,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F,378.40699999999964,3.4018000000000006,4,5,94.06,8,4,0.41257137326231136,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1,CHEMBL4789027,IC50,0.6,nM,9.22,CHEMBL4718820,CHEMBL203,CHEMBL4715760,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
OCc1ccc(-c2nc3c(NCc4ccccc4)ncnc3[nH]2)cc1,331.3789999999997,3.1243000000000007,3,5,86.72,6,4,0.5229174674556003,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)nc23)cc1,CHEMBL5439143,IC50,24.0,nM,7.62,CHEMBL5323119,CHEMBL203,CHEMBL5321237,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
OCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,388.4059999999999,3.5023000000000017,2,7,80.27000000000001,6,5,0.48170054981613747,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1,CHEMBL246276,IC50,120.0,nM,6.92,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1
O[C@@H]1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,486.55499999999984,2.7760999999999996,3,9,95.53999999999999,7,5,0.3397470608937513,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1,CHEMBL393787,IC50,200.0,nM,6.7,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
O[C@H]1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,486.55499999999984,2.7760999999999996,3,9,95.53999999999999,7,5,0.3397470608937513,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1,CHEMBL233325,IC50,26.0,nM,7.58,CHEMBL893470,CHEMBL203,CHEMBL1147910,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
Oc1c(I)cc(I)c2cccnc12,396.95300000000003,3.1496000000000013,1,2,33.120000000000005,1,2,0.6937765865040759,0,c1ccc2ncccc2c1,CHEMBL86754,IC50,1889.0,nM,5.72,CHEMBL1909203,CHEMBL203,CHEMBL1909046,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2,302.28199999999975,1.3204999999999993,5,6,110.38000000000001,5,2,0.46946133619296915,0,c1ccc2c(c1)CC1COc3ccccc3C21,CHEMBL477197,IC50,3400.0,nM,5.47,CHEMBL986505,CHEMBL203,CHEMBL1155833,0.6,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; Aromatic ring count typical
Oc1cc2ncnc(Nc3cccc(Br)c3)c2cc1O,332.1569999999999,3.5471000000000017,3,5,78.27000000000001,4,3,0.6257271479541843,0,c1ccc(Nc2ncnc3ccccc23)cc1,CHEMBL93032,IC50,0.17,nM,9.77,CHEMBL680017,CHEMBL203,CHEMBL1129291,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Oc1ccc(/C=N/Nc2nc3ccccc3c3nncn23)cc1,304.31299999999976,2.4291,2,7,87.7,4,4,0.44814409005528777,0,C(=N/Nc1nc2ccccc2c2nncn12)\c1ccccc1,CHEMBL4873202,IC50,690.0,nM,6.16,CHEMBL4836513,CHEMBL203,CHEMBL4834460,0.95,Activity in Type 1 range; Activity in typical Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Oc1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1,284.34399999999977,3.0242000000000013,2,6,70.93,3,3,0.7077613879094814,0,c1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1,CHEMBL4251297,IC50,38730.0,nM,4.41,CHEMBL4229651,CHEMBL203,CHEMBL4229324,0.5,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,348.3619999999998,2.980200000000001,1,7,84.51,3,4,0.5959336714692189,0,c1ccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)cc1,CHEMBL573339,Kd,10000.0,nM,,CHEMBL1063797,CHEMBL203,CHEMBL1150977,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
Oc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,280.3309999999997,3.2859000000000007,3,4,73.83,3,3,0.6731601481347781,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,CHEMBL72322,IC50,420.0,nM,6.38,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
Oc1cccc(Nc2nnnc3sc4c(c23)CCC4)c1,284.34399999999977,3.0242000000000004,2,6,70.93,3,3,0.7565915328123728,0,c1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1,CHEMBL4246256,IC50,52110.0,nM,4.28,CHEMBL4229651,CHEMBL203,CHEMBL4229324,0.3,Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; Very weak activity (penalty)
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,447.51999999999987,3.301400000000002,1,7,75.89,3,4,0.4761683339185086,0,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,CHEMBL2103851,Kd,30000.0,nM,,CHEMBL3991696,CHEMBL203,CHEMBL3991601,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
S=C(NNc1ccccc1)Nc1ccc2c(c1)OCO2,287.34399999999977,2.7288000000000006,3,4,54.55,3,2,0.5959836773765761,0,S=C(NNc1ccccc1)Nc1ccc2c(c1)OCO2,CHEMBL4776925,IC50,8264.0,nM,5.08,CHEMBL4769431,CHEMBL203,CHEMBL4765304,0.7999999999999999,Activity in Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
S=C(NNc1nncc2ccccc12)Nc1ccc(Cl)cc1,329.8159999999998,3.596700000000001,3,4,61.870000000000005,3,3,0.5039576496633524,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1,CHEMBL3896476,IC50,64.0,nM,7.19,CHEMBL3870506,CHEMBL203,CHEMBL3870309,1.0,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
S=C(NNc1nncc2ccccc12)Nc1ccccc1,295.3709999999998,2.9433000000000007,3,4,61.870000000000005,3,3,0.5099663239679946,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1,CHEMBL3924500,IC50,65.0,nM,7.19,CHEMBL3870506,CHEMBL203,CHEMBL3870309,0.9999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4,320.42799999999994,2.800580000000001,2,7,66.18,0,4,0.48900163886513603,0,S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4,CHEMBL1969537,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
c1cc(Nc2nccc(-c3cccnc3)n2)cc(OCCn2ccnc2)c1,358.40499999999975,3.5577000000000014,1,7,77.75000000000001,7,4,0.5442245722138513,0,c1cc(Nc2nccc(-c3cccnc3)n2)cc(OCCn2ccnc2)c1,CHEMBL58436,IC50,7100.0,nM,5.15,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.8999999999999999,Activity in Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1,282.34699999999964,3.203800000000001,1,4,57.95,3,3,0.801115915408703,0,c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1,CHEMBL1682360,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1,283.33499999999964,2.248,1,5,68.62,3,3,0.8001434789348157,0,c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1,CHEMBL1969843,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1cc2[nH]ncc2cc1-n1cc(C2CCCC2)nn1,253.3090000000001,2.8012000000000006,1,4,59.39,2,3,0.7635837611268254,0,c1cc2[nH]ncc2cc1-n1cc(C2CCCC2)nn1,CHEMBL1682339,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1cc2[nH]ncc2cc1-n1cc(CC2CCCCC2)nn1,281.3629999999996,3.2664000000000017,1,4,59.39,3,3,0.8012311336546573,0,c1cc2[nH]ncc2cc1-n1cc(CC2CCCCC2)nn1,CHEMBL1682340,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,276.29899999999975,3.2037000000000013,1,4,67.6,3,4,0.6236070621596207,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4068254,IC50,31768.74,nM,4.5,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(CCCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,303.3689999999997,3.318900000000001,1,4,59.39,5,4,0.6150421395891045,0,c1ccc(CCCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1682343,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.75,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
c1ccc(CCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,289.34199999999976,2.9288000000000007,1,4,59.39,4,4,0.6281306922122964,0,c1ccc(CCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1682342,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,275.31499999999977,2.7344,1,4,59.39,3,4,0.6251219094382543,0,c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1682341,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,290.32599999999974,3.1275000000000013,1,4,67.6,4,4,0.6267395220085372,0,c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4095623,IC50,25000.0,nM,4.6,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.30000000000000004,LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,275.31499999999977,2.8697,1,4,59.39,3,4,0.6251373324550802,0,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,CHEMBL1682345,Ki,1800.0,nM,,CHEMBL1685402,CHEMBL203,CHEMBL1681644,0.6,Activity in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical
c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)nc1,470.5369999999998,2.770900000000001,2,10,103.42000000000002,8,5,0.35690702543058384,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCO6)c45)ccc32)nc1,CHEMBL396079,IC50,500.0,nM,6.3,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,264.3319999999999,3.580300000000002,2,3,53.6,2,3,0.7434962752401386,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,CHEMBL433305,IC50,310.0,nM,6.51,CHEMBL677880,CHEMBL203,CHEMBL1129072,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; LogP in drug-like range; Aromatic ring count typical
c1ccc(OCc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,306.32499999999976,3.1157000000000012,1,5,76.83000000000001,5,4,0.6127731546792267,0,c1ccc(OCc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,CHEMBL4087921,IC50,46300.0,nM,4.33,CHEMBL3995335,CHEMBL203,CHEMBL3994595,0.45,MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties
c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1,316.3279999999998,1.9365999999999992,1,7,90.1,3,5,0.549131708894013,0,c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1,CHEMBL1966069,Ki,1995.26,nM,,CHEMBL1963766,CHEMBL203,CHEMBL1201862,0.65,Activity in Type 1 range; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; General kinase inhibitor properties
c1cncc(-c2ccnc(Nc3cccc(-n4ccnc4)c3)n2)c1,314.35199999999975,3.4679,1,6,68.52000000000001,4,4,0.6244606257257385,0,c1cncc(-c2ccnc(Nc3cccc(-n4ccnc4)c3)n2)c1,CHEMBL291963,IC50,100000.0,nM,,CHEMBL675386,CHEMBL203,CHEMBL1130562,0.45,Contains aniline substituent; MW in Type 1 range; LogP in drug-like range; H-bond features typical of Type 1; Aromatic ring count typical; General kinase inhibitor properties; Very weak activity (penalty)
c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1,470.5369999999998,2.770900000000001,2,10,103.42000000000002,8,5,0.35690702543058384,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCO6)c45)ccc32)c1,CHEMBL247127,IC50,810.0,nM,6.09,CHEMBL903494,CHEMBL203,CHEMBL1139130,0.8999999999999999,Activity in Type 1 range; Activity in typical Type 1 range; Contains aniline substituent; MW in Type 1 range; LogP in drug-like range
